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Abstract 
Transglutaminase 2 (TG2) is a multifunctional enzyme possessing transamidating, 
GTPase and protein disulphide isomerase activity. Due to its diverse nature and 
ubiquitous distribution TG2 is implicated in the regulation of many physiological 
processes, includeing cell adhesion, migration, growth, differentiation, survival and 
apoptosis. Recently, TG2 has been shown to be modulated by PKC and PKA and to 
play a role in cardioprotection. However, the precise mechanism(s) of its modulation 
by G-protein coupled receptors coupled to PKC and PKA activation are not fully 
understood. The present study investigated the molecular mechanisms underlying  
TG2 modulation by GPCRs (A1 adenosine receptor (A1R) and β2-adrenoceptor (β2-AR)) 
and its role in cardioprotection. Transglutaminase transamidation activity was 
determined using amine-incorporating (in vitro and in situ) and protein cross-linking 
assays. TG2 phosphorylation was assessed via immunoprecipitation and Western 
blotting. The role of TG2 in A1R- or β2-AR-induced cytoprotection was investigated by 
monitoring hypoxia- and hypoxia/reoxygenation-induced cell death. Novel TG2 
substrates/interacting proteins were identified using SWATH MS. 
Stimulation of the A1R (with the selective agonist CPA and endogenous agonist 
adenosine) and β2-AR (with the selective agonist formoterol and non-selective agonist 
isoprenaline) resulted in activation of TG2 in a time- and concentration-dependent 
manner, which was attenuated by the TG2 inhibitors Z-DON and R283. Responses to 
CPA and adenosine were blocked by pharmacological inhibition of PKC (Ro 31-8220), 
MEK1/2 (PD 98059), p38 MAPK (SB 203580) and JNK1/2 (SP 600125) and by removal 
of extracellular Ca2+. CPA triggered robust increases in the levels of TG2-associated 
phosphoserine and phosphothreonine, which were attenuated by PKC, MEK1/2 and 
JNK1/2 inhibitors. Responses to formoterol, whilst insensitive to pertussis toxin (PTX; 
Gi-protein inactivator), were abolished by PKA (Rp-cAMPs), MEK1/2, and PI-3K (AS 
605240) inhibitors. Responses to isoprenaline were blocked by PTX and inhibitors of 
MEK1/2 and PI-3K. Formoterol triggered robust increases in the levels of TG2-
associated phosphoserine and phosphothreonine, which were attenuated by PKA, 
MEK1/2 PI-3K inhibitors and by removal of extracellular Ca2+. 
Furthermore, the A1R- or β2-AR-mediated TG2 activation (with the exception of 
formoterol-induced TG2 activation) was protective against hypoxia- and 
hypoxia/reoxygenation-induced cell death. Finally, identification of novel TG2 
substrates/interacting proteins using SWATH MS illustrated differential modulation of 
substrates by TG2 upon stimulation of the A1R- or β2-AR which may contribute to 
differences in their cellular/physiological responses. The present study provides the 
first detailed characterisation of the molecular mechanisms underlying the modulation 
of TG2 by the A1R- or β2-AR and describes a role for TG2 in cardioprotection, along 
with identifying novel substrates/interacting proteins which may be involved in 
mediating this protection. 
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CHAPTER I: Introduction 
 
1.1 Cardiovascular diseases. 
Currently, cardiovascular disease is the leading cause of death in the world with 17.5 
million deaths in 2012 worldwide (WHO statistics database; 
http://www.who.int/mediacentre/factsheets/fs317/en/). Of those deaths, 7.4 million 
were due to ischaemic heart disease (WHO statistics database). In 2015, over 70,000 
deaths in the UK were due to ischaemic heart disease (BHF statistics database; 
https://www.bhf.org.uk/research/heart-statistics) and it is predicted if not controlled, 
it will rise by 25% in 2025 (Gaziano et al, 2010). Ischaemic heart disease occurs when 
the coronary artery is blocked, usually by an atherosclerotic plaque. This blockage 
reduces the blood flow to myocardial tissue resulting in angina pectoris (chest pain 
and discomfort) and myocardial infarction (heart attack). There are several risk factors 
that play a role in development of this atherosclerotic plaque such as age, diet, 
obesity, high blood pressure, high levels of cholesterol, smoking and other lifestyle 
choices (Nichols et al, 2014). Even though there is plenty of research regarding 
ischaemic heart diseases and their underlying mechanisms, there are not many 
pharmacological agents that have made it successfully into clinical trials. Therefore, it 
is of utmost necessity to comprehend the pathophysiology of ischaemic heart disease 
in order to develop novel therapeutic strategies and identify potential targets which 
could be manipulated by the use of pharmacological agents to be used in clinical 
studies and scenarios. 
 
1.2 Ischaemia/reperfusion injury. 
Ischaemia is a pathological condition suffered by tissues and organs which are 
deprived of nutrients and oxygen due to inadequate blood supply. This imbalance in 
oxygen demand and supply results in changes in metabolic and cellular responses of 
the cells. Myocardial cells when exposed to ischaemia can show either myocardial 
stunning and/or myocardial hibernation. Myocardial stunning is described as delayed 
return of the contractile function of the heart following ischaemia although complete 
restoration of the blood flow is achieved (Depre and Taegtmeyer, 2000). Myocardial 
hibernation is described as recurring stunning as a result of a chronic ischaemic insult 
(Kim et al, 2003). 
Under normal physiological conditions, cardiac cells generate ATP from metabolites 
and oxidative phosphorylation (aerobic respiration) in order to meet the oxygen supply 
and demand. The heart changes this chemical energy into mechanical energy 
(Carvajal and Moreno-Sanchez, 2003; Solaini and Harris, 2005). During ischaemia, 
mitochondrial respiration is switched from aerobic to anaerobic in order to match the 
oxygen demand and supply. This leads to inhibition of phosphofructokinase, 
accumulation of hydrogen ions and lactate as well as accumulation of sodium ions via 
inhibition of the sodium/potassium pump (Na+/K+-ATPase) and activation of 
sodium/hydrogen exchanger (NHE). Inhibition of phosphofructokinase leads to 
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reduction in sensitivity of Troponin C to calcium resulting in asystole (Di Lisa et al, 
1998). Inhibition of the Na+/K+-ATPase increases efflux of potassium ions and influx of 
sodium and chloride ions as well as water into the cardiac cells, which leads to cell 
swelling. High intracellular sodium ion concentration activates the sodium/calcium 
exchanger (Na+/Ca2+ exchanger), thereby increasing intracellular levels of calcium. 
Normal calcium concentration cannot be restored by the Sarcoplasmic/Endoplasmic 
Reticulum Calcium ATPase (SERCA) due to reduction in ATP levels. This high calcium 
concentration activates calcium dependent proteases such as calpain which results in 
cytoskeletal damage and membrane rupture leading to ischaemic cell death (Schaper 
and Kostin, 2005; for an overview refer to figure 1.1). Ischaemic cell death (apoptosis 
during ischaemia) is characterised by swelling of the cells, increase in membrane 
permeability, non-specific DNA degradation, nuclear chromatin condensation and 
blebbing (Majno and Joris, 1995; Buja, 2005). Apoptosis or programmed cell death is 
characterised by cell shrinkage, nuclear condensation, fragmentation of DNA and 
formation of apoptotic bodies, which are phagocytosed without evoking an 
inflammatory response (Majno and Joris, 1995; Edinger and Thompson, 2004). Cells 
can be rescued from ischaemic cell death, however if not rescued, necrosis sets in. 
Necrosis is characterised by further degradation of cytoplasmic membrane and 
constituents as well as changes in the nucleus and as such represents irreversible cell 
death (for review see Trump and Berezesky, 1996; Adameova et al, 2016). 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.1: Proposed series of events leading from myocardial ischaemia to cell death. 
Anaerobic respiration along with reduced formation of ATP and intracellular acidosis 
causes sarcolemma to rupture and lead to cell death. 
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Reperfusion is the restoration of blood flow following an ischemic insult for more than 
10 min. It was initially thought that reperfusion can rescue the damage caused by 
ischaemia to cells and tissues; however, it is now known that it leads to further 
complications such as arrhythmia, stunning, decrease in contractility and more 
pronounced necrosis (Moens et al, 2005). Neutrophils accumulate surrounding the 
damaged cells and tissues during ischaemia (Hansen, 1995). Upon reoxygenation, 
neutrophils generate more reactive oxygen species (ROS), proteases and cause 
activation of inflammatory cascades (Jordan et al, 1999). Apart from neutrophil 
activation, restoration of oxygen causes mitochondrial respiration to switch back to 
aerobic from anaerobic resulting in additional production of ROS (Korge et al, 2008). 
ROS generation can cause further damage by attacking lipids, proteins and nucleic 
acid components of the cell as well as dysregulating ion transport, fluidity, protein 
synthesis and enzyme activity within the cell (Becker, 2004). ROS generation causes 
activation (opening) of mitochondrial permeability transition pore (mPTP) thereby 
setting off either apoptosis via release of cytochrome c and activation of caspase 
cascade or necrosis via ATP hydrolysis and dysregulation of intracellular calcium 
concentration (Lopez-Neblina and Toledo-Pereyra, 2006). This Ca2+ overload  leads to 
activation of calcium-dependent proteases such as calpains. These proteases degrade 
intracellular proteins and cause cytoskeletal damage leading to cell death (Piper et al, 
2006). Also during reperfusion, Nuclear factor kappa B (NF-кB) activates various cell 
adhesion molecules and adheres leukocytes to the endothelium of the myocardium 
(Baldwin, 2001). This leads to vasoconstriction and microvascular dysfunction 
reducing perfusion resulting in “no-flow” phenomenon which ultimately leads to 
myocardial infarction (Moens et al, 2005; for an overview refer to figure 1.2). 
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Fig 1.2: Proposed series of events leading from myocardial ischaemia/reperfusion 
injury to cell death. Switch from anaerobic respiration to aerobic respiration along with 
rapid formation of ATP and neutrophil activation causes a series of events that lead to 
cell death. 
 
Both ischaemia and ischaemia/reperfusion are known to induce a combination 
apoptosis and necrosis. Apoptosis is the preferred pathway until ATP levels are too low 
to sustain this energy-dependent pathway and then necrosis sets in (Tatsumi et al, 
2003; Otani et al, 2006). This greatly depends on the conditions used to simulate 
ischaemia or ischaemia/reperfusion and model type used in the study. For instance, in 
neonatal and adult rat cardiomyocytes, ischaemia is known to induce apoptosis 
(Tanaka et al, 1994; de Moissac et al, 2000). However, in Langendorff-perfused 
mouse heart, apoptosis was only observed when ischaemia was accompanied with 
reperfusion, hence necrosis dominates (Webster et al, 1999). Also the apoptotic 
pathway stimulated depends on the conditions used to simulate ischaemia or 
ischaemia/reperfusion. For example, in Jurkat cells, a caspase-3 dependent apoptotic 
cascade was activated when ischaemia was simulated in glucose-free medium 
(Malhotra et al, 2001). Similar observations have also been reported in H9c2 
cardiomyoblasts (Ekhterae et al, 1999). However, in Jurkat cells, simulating ischaemia 
in glucose-containing medium (3 mM glucose) activated a caspase-3 independent 
apoptotic cascade (Malhotra et al, 2001). Having said this, overall, there is strong 
evidence that apoptosis is induced in cardiomyocytes during ischaemia (Itoh et al, 
1995; Long et al, 1997; Saraste et al, 1997) or ischaemia/reperfusion injury (Gottlieb 
et al, 1994; Fliss and Gattinger, 1996; Aikawa et al, 1997; Xia et al, 2016). 
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1.3 Ischaemic pre- and post-conditioning. 
The pilot study carried out by Murry and colleagues reported that brief periods of 
discontinuous ischaemia and reperfusion prior to subsequent prolonged lethal 
ischaemia was able to protect against ischaemia/reperfusion damage in a canine 
model (Murry et al, 1986). This is called ischaemic preconditioning or classical/early 
phase preconditioning. There are many clinical limitations to ischaemic preconditioning 
as it is quite difficult to predict the timing of a myocardial infarction. However, this 
phenomenon is very useful in cases of cardiac bypass surgery as well as coronary 
artery bypass graft surgery, where ischaemic events are predicted (Wu et al, 2002; 
Yellon et al, 2005). This preconditioning offers transient benefits for 1-2 hours against 
ischaemic insult. Various survival kinases such as PKA, PKB, PKC and ERK1/2 are 
involved in mediating protection via this mechanism (for reviews see Sanada and 
Kitakaze, 2004; Bolli, 2007). 
Zhao and colleagues were the first to describe the term ischaemic postconditioning 
(Zhao et al, 2003). It is described as brief periods of ischaemia and reperfusion 
following an ischaemic insult but prior to reperfusion (Zhao et al, 2003). It is shown to 
have similar protective effects as pre-conditioning (Hausenloy et al, 2006), however, 
post-conditioning is more clinically relevant as reperfusion following myocardial 
infarction can be predicted. Figure 1.3 represents a basic outline of ischaemic pre- and 
post-conditioning. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.3: Graphical representation of ischaemia/reperfusion injury and pre- /post-
conditioning. Areas in grey indicate ischaemia and white represent normal perfusion. 
Figure adapted from Ferdinandy et al, 2007. 
 
(i) Signalling pathways involved in ischaemic pre- and post-conditioning. 
Both ischaemic pre- and post-conditioning are known to activate several survival 
kinases such as ERK1/2, PKC, PKA, PKB and p38 MAPK, which have well documented 
roles (Hausenloy and Yellon, 2006). During an ischaemic insult, autacoid triggers such 
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as adenosine (Headrick, 1996; Pac-soo et al, 2015), catecholamines (Schomig, 1990; 
Pac-soo et al, 2015) and many others are released from the myocardial tissue. These 
triggers stimulate specific GPCRs which activate signal transduction cascades (for 
reviews see Halestrap and Richardson, 2015; Altamirano et al, 2015; Pac-soo et al, 
2015; Bice et al, 2016). 
The Reperfusion Injury Salvage Kinase (RISK) pathway plays a key role in mediating 
protection. The important targets of the RISK pathway are ERK1/2 and PKB 
(Hausenloy and Yellon, 2006). ERK1/2 phosphorylation is significantly increased 
following pre- and post-conditioning in Langendorff-perfused rat heart (Hausenloy et 
al, 2005) as well as rat (Fryer et al, 2001) and pig hearts in vivo (Schwartz and 
Lagranha, 2006). In order to activate the ERK1/2 pathway, GTP-bound Ras recruits 
and phosphorylates Raf at the cell membrane. Phosphorylated Raf then 
phosphorylates MAPK/ERK Kinase 1 and 2 (MEK1 and MEK2). Phosphorylated MEK1/2 
then phosphorylates ERK1/2. Once ERK1/2 is phosphorylated, it can then activate 
downstream effectors such as p90 ribosomal S6 kinase (p90RSK; Herrera and Sebolt-
leopold, 2002). Figure 1.4 summarises the ERK1/2 pathway. P90RSK inactivates BAD 
and inhibits BAD-mediated cytochrome-c release and caspase activation (Downward, 
1999). The A1 adenosine receptor activation causes phosphorylation of ERK1/2 and its 
role in protecting neonatal rat cardiomyocytes via pre-conditioning is well documented 
(Germack and Dickenson, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.4: The steps leading to activation of ERK1/2. For detailed description, see main 
body of text. 
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Phosphorylation of PKB is significantly increased following pre- and post-conditioning 
in Langendorff-perfused rat and rabbit hearts (Hausenloy et al, 2005; Solenkova et al, 
2006) as well as pig hearts in vivo (Schwartz and Lagranha, 2006). The PKB pathway 
is activated via phosphorylation of PIP2 to PIP3 by PI-3K. PIP3 recruits phosphoinositide 
dependent protein kinase (PDK) to the cell membrane where PKB is phosphorylated at 
Thr308 by PDK1 while Ser473 can be phosphorylated by a number of kinases such as 
PDK2 (Vanhaesebroeck and Alessi, 2000), integrin-linked kinase (ILK; Osaki et al, 
2004), mechanistic target of rapamycin complex (mTORC; Sarbassov et al, 2005) and 
DNA-dependent protein kinase (DNA-PK; Hemmings and Restuccia, 2012). For an 
extensive review on AKT/PKB signalling and regulation, see Bayascas and Alessi, 2005 
and Risso et al, 2015. Phosphatase and tensin homolog (PTEN) counter regulates PI-
3K activity by dephosphorylating PIP3 to PIP2, thereby inhibiting the PKB pathway 
(Carracedo and Pandolfi, 2008). Along with PTEN, the pathway is also modulated by 
protein phosphatase 2A (PP2A) and PH domain and Leucine rich repeat protein 
phosphatases (PHLPP) that dephosphorylate PKB at Thr308 and Ser473 respectively (for 
an extensive review see Carracedo and Pandolfi, 2008). Figure 1.5 summarises the 
PKB pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.5: The steps leading to activation of PKB. For detailed description, see main 
body of text 
 
Phosphorylated PKB is redistributed to the mitochondria (Miyamoto et al, 2008) and/or 
nucleus (Toker and Marmiroli, 2014) where it inhibits BAD-mediated cytochrome-c 
release (Datta et al, 1997). Furthermore, Gottlob and colleagues have reported that 
PKB enhances the interaction between hexokinase and voltage dependent anion 
channel 1 (VDAC-1) thereby preserving the mitochondrial membrane integrity (Gottlob 
et al, 2001; Abu-Hamad et al, 2008). 
There is some evidence that PKA activation prior to an ischaemic insult significantly 
reduces the infarct size in canine heart and that increases in cAMP levels during 
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ischaemia might be necessary to offer protection (Sanada et al, 2004). However, the 
same could not be demonstrated for rat hearts as inhibition of PKA reduced the infarct 
size and improved recovery (Makaula et al, 2005). Another protein kinase involved in 
cardioprotection is PKC. There are 10 isoforms of PKC, however, PKCδ and PKCε are 
dominant in murine heart (Schreiber et al, 2001). While PKCα, PKCβI and PKCβII are 
dominant human ventricles, PKCγ and PKCδ in atria and PKCε and PKCλ are 
distributed equally in both (Simonis et al, 2007). Hence, there is inconsistency in the 
PKC isoform essential to trigger cardioprotection as these depend on the model 
system used. PKCε appears to be somewhat consistently expressed and is essential for 
cardioprotection (Zatta et al, 2006) across various models, for instance, in rabbit and 
human myocardium (Liu et al, 1999; Sivaraman et al, 2009). While inhibition of PKCδ 
has been reported to reduce the infarct size and improve recovery in murine hearts 
(Inagaki et al, 2003). 
Overall, evidence points that cardioprotection via pre- and post-conditioning is 
dependent on protein kinases even though the exact mechanisms are not well 
understood (Hausenloy et al, 2005). Interpretation of the signal transduction cascades 
and their downstream effectors involved in cardioprotection via pre- and post-
conditioning would provide clear understanding and pharmacological tools to exert 
beneficial effects during ischaemia and ischaemia/reperfusion injury. 
1.4 Transglutaminases. 
Transglutaminases (TG) are a family of multifunctional enzymes that catalyse calcium 
dependent post-translational modifications of proteins. Clarke and colleagues provided 
the first data documenting a TG that was obtained from guinea pig liver (Clarke et al, 
1957). The official name ‘transglutaminase’ was coined by Mycek and colleagues in 
1959 (Mycek et al, 1959). Nine proteins have been identified in the TG family. Eight of 
them are enzymatically active (TG1-7 and Factor XIII A), however the ninth one (Band 
4.2) is structurally related to the family but is not enzymatically active due to the fact 
that it lacks a catalytically active site (Grenard et al, 2001; Lorand and Graham, 2003). 
Transglutaminases mainly catalyse an acyl transfer reaction between γ-carboxamides 
of glutamines and ε-amino group of lysine residues. This reaction can form various 
products by incorporation of polyamines into proteins, deamidation of proteins as well 
as protein crosslinks (Lorand and Conrad, 1984; Nurminskaya and Belkin, 2012; 
Eckert et al, 2014). Hence TGs can affect protein structure, signal transduction, 
membrane stabilisation, etc. and these may slightly vary up on kinetics of the reaction 
and differences in substrates (Facchiano and Facchiano, 2009). The family of TGs and 
their physiological impact is summarised in Table 1. 
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Table 1. The family of transglutaminases and their physiological impact. 
Name Alternative names Mol 
wt 
Gene 
name 
Location Function Pathology References 
Factor 
XIIIA 
Plasma transglutaminase, 
fibrin stabilising factor, 
fibrinoligase, Laki-Lorand 
factor 
83 
kDa 
F13A1 Platelets, placenta, 
synovial fluid, 
chondrocytes, astrocytes, 
macrophages, osteoclasts 
and osteoblasts, heart, 
eye, dendritic cells in the 
dermis 
Blood clotting, wound 
healing, bone growth and 
synthesis 
Impaired wound healing, severe 
bleeding tendency, spontaneous 
abortion during pregnancy, 
subcutaneous and intramuscular 
haematomas 
Odii and Coussons, 
2014; Eckert et al, 
2014 
TG1 Keratinocyte 
transglutaminase, 
particulate TG, type 1 TG, 
TGK 
90 
kDa 
TGM1 Cytosol, membrane, 
squamous epithelia, 
keratinocytes 
Cell envelope formation in 
the differentiation of 
keratinocytes, cornified 
envelope assembly in 
surface epithelia, barrier 
function in stratified 
squamous epithelia 
Lamellar ichthyosis Candi et al, 1998; Odii 
and Coussons, 2014; 
Eckert et al, 2005; 
Eckert et al, 2014 
TG2 Tissue transglutaminase, 
type 2 TG, Gαh, cytosolic 
transglutaminase, 
transglutaminase type 
II,liver TG, erythrocyte TG, 
endothelial TG, TGC 
78kDa TGM2 Ubiquitous distribution in 
different tissues, 
membrane, cytosol, 
nucleus, extracellular  
Cell differentiation, matrix 
stabilisation, adhesion 
protein, apoptosis, 
transmembrane signalling, 
GTPase activity, cell 
survival, endocytosis 
Autoimmune diseases, 
neurodegenerative disorders, 
metabolic diseases, malignancies 
Facchianoet al, 2006; 
Eckert et al, 2014; 
Nurminskaya and 
Belkin, 2012; Odii and 
Coussons, 2014 
TG3 Epidermal 
transglutaminase, callus 
TG, hair follicle TG, bovine 
snout TG, type 3 TG, TGE 
77 
kDa 
TGM3 Cytosol, hair follicle, brain, 
epidermis 
Cell envelope formation 
during keratinocyte 
differentiation, terminal 
differentiation of 
keratinocytes and hair 
follicle, GTPase activity 
Human epidermis diseases Odii and Coussons, 
2014, 
Eckert et al, 2014 
TG4 Prostatic transglutaminase, 
androgen-regulated major 
secretory protein, 
vesiculase, dorsal prostate 
protein 1 (DP1), type 4 TG, 
TGP 
77 
kDa 
TGM4 Prostate gland, prostatic 
fluids and seminal plasma 
Reproductive function 
involving semen 
coagulation esp. in rodents, 
cell-matrix adhesion of 
prostate cancer cells 
Prostate cancer progression Odii and Coussons, 
2014; Jiang et al, 
2013; Eckert et al, 
2014 
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TG5 Type 5 TG, TGX 81 
kDa 
TGM5 Ubiquitously expressed but 
predominant in female 
reproductive tissues, foetal 
tissues, cytosol, foreskin 
keratinocytes, skeletal 
muscular striatum, 
epithelial barrier lining 
Keratinocyte differentiation 
and cornified cell envelope 
assembly, adhesion of 
stratum corneum to 
stratum granulosum, 
epidermal differentiation 
Over-expressed or absent in 
different areas of the Dariers’s 
disease lesions, secondarily 
involved in hyperkeratotic 
phenotype in ichthyosis and in 
psoriasis  
Odii and Coussons, 
2014; Candiet al, 
2002; Toone, 2011; 
Eckert et al, 2014 
TG6 Type 6 TG, TGY 78 
kDa 
TGM6 Cytosol, membrane, testis, 
lung, brain 
Development of central 
nervous system, GTPase 
activity, motor function, 
late stage cell envelope 
formation in epidermis and 
hair follicle 
Spinocerebellar ataxias, 
polyglutamine (polyQ) diseases 
Odii and Coussons, 
2014; Wang et al, 
2010; Sailer and 
Houlden, 2012; Guan 
et al, 2013; Thomas et 
al, 2013; Eckert et al, 
2014 
TG7 Type 7 TG, TGZ 81 
kDa 
TGM7 Ubiquitously expressed but 
predominant in testis and 
lungs 
Not characterised Not characterised Odii and Coussons, 
2014; Eckert et al, 
2014 
Band 
4.2 
Erythrocyte membrane 
protein band 4.2, B4.2, 
ATP-binding erythrocyte 
membrane protein band 4.2 
72 
kDa 
EPB42 Erythrocyte membranes, 
spleen, bone marrow, 
foetal liver 
Maintains erythrocyte 
shape and mechanical 
properties, membrane 
integrity, cell attachment, 
signal transduction 
Spherocyticelliptocytosis Odii and Coussons, 
2014; Eckert et al, 
2014; Kalfaet al, 2014 
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1.5 Tissue transglutaminase. 
Tissue transglutaminase or TG2 is an ubiquitously expressed member of the TG family 
(Lorand and Graham, 2003). It is a multifunctional enzyme possessing a 
transamidating activity, GTPase activity, protein disulphide isomerase activity and can 
also function as a scaffolding protein. It is due to its diverse nature and ubiquitous 
distribution that TG2 is implicated in regulation of many physiological processes such 
as cell adhesion and migration, growth and differentiation, survival and apoptosis as 
well as organisation of the extracellular matrix. Given that TG2 has a myriad of 
functions, it is involved in many pathologies such as neurodegenerative disorders, 
coeliac disease, few cancers, inflammation, ischaemia/reperfusion injury, etc. TG2 is 
composed of four domains: N terminal β-sandwich (aa 1-139), catalytic domain (aa 
140-460), β-barrel-1 (aa 461-586) and β-barrel-2 (aa 587-687; see figure 1.6). The 
N-terminus contains a fibronectin binding site that mediates high affinity interaction 
between TG2 and fibronectin, which is involved in cell adhesion (Akimov et al, 2000). 
The catalytic domain contains the catalytic triad (cys277, His335, Asp358) which is 
essential for its transamidating activity (Griffin et al, 2002). The β-barrel-1 contains 
the GTP/GDP-binding domain. However, the catalytic domain also contains 15 residues 
spanning between amino acids 159-173 involved in the GTP/GDP-binding activity. 
Apart from these residues Trp332 and Arg579 have been recently identified as being 
important for GTP binding activity of TG2 (Murthy et al, 2002; Ruan et al 2008; Lai 
and Greenberg, 2013). The β-barrel-2 domain contains 20 residues spanning between 
amino acids 657-677 which are essential to recognise and activate phospholipase C δ1 
(PLCδ1) and promotes α1B adrenoceptor-mediated signal transduction (Das et al, 1993; 
Hwang et al, 1995; Baek et al, 2001; Kang et al, 2002). 
 
 
 
 
 
Fig 1.6: Schematic illustration of the structure of tissue transglutaminase (TG2). TG2 
is composed of four domains: N terminal β-sandwich, catalytic core, β-barrel-1 and 2. 
Figure adapted from Lai and Greenberg, 2012.  
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(i) Functions of TG2. 
(a) GTPase activity: 
In 1990, a novel G-protein was identified, termed Gαh (Im and Graham, 1990). Further 
investigation revealed that Gαh had a 74 kDa α-subunit and a 50 kDa βγ-subunit (Das 
et al, 1993; Baek et al, 1993) which made it atypical to heterotrimeric G-proteins that 
have a 45 kDa α-subunit and a 35-40 kDa βγ-heterodimer (Milligan and Kostenis, 
2006). In 1994, Gαh, was found to be TG2 (Nakoka et al., 1994). It transmits signals 
from α1B and α1D adrenoceptors, thromboxane A2, oxytocin and follicle-stimulating 
hormone receptors. All these receptors activate phospholipase C δ1 (PLC-δ1) which 
leads to increased inositol 1,4,5-trisphosphate (IP3) levels and downstream signalling 
(Baek et al, 1993; Das et al, 1993; Baek et al, 1996; Feng et al, 1996; Im and 
Graham, 1990; Im et al, 1990; Lorand and Graham, 2003; Mhaouty-Kodja, 2004; 
Park et al, 1998; Vezza, 1999). Gαh or TG2 binds and hydrolyses GTP with similar 
affinity and catalytic rate as observed in the classical G-proteins (Begg et al, 2006; 
Begg et al, 2006a). Also, the G-protein cycle is similar to that of the heterotrimeric G-
proteins (Lorand and Graham, 2003; Mhaouty-Kodja, 2004). Extensive 
characterisation of Gαh/TG2 revealed Val
665-Lys672 region in the β-barrel-2 domain as 
the effector contact region required to bind and activate PLC-δ1 (Hwang et al, 1995). 
This is similar to that of heterotrimeric G-protein as C-terminal of the α-subunit 
contains an effector contact region. For instance, Trp263, Leu268 and Arg269 of Gαs are 
the effector contact region required to bind and activate adenylyl cyclase (Itoh and 
Gilman, 1991; Berlot and Bourne, 1992). 
Apart from these TG2 is also known to regulate other signalling pathways. It activates 
ERK1/2 in cardiomyocytes (Lee et al, 2003), increases adenylyl cyclase activity in 
neuroblastoma cells (Tucholski and Johnson, 2003) while inhibits adenylyl cyclase 
activity in fibroblasts and endothelial cells (Gentile et al, 1997). TG2 also promotes 
fibroblast migration (Stephens et al, 2004), however inhibits vascular smooth muscle 
migration by binding to the cytoplasmic tail of α5 integrin (Kang et al, 2004). In 
vascular smooth muscle, TG2 also activates large-conductance Ca2+-activated K+ 
channels (Lee et al, 1997). This implies that regulation of signalling pathways depends 
on the cell background and type (Eckert et al, 2014).  
Regardless of the recent progress in understanding this function of TG2, its role in 
pathophysiology is still poorly understood. In NIH3T3 and HeLa cells, this activity of 
TG2 is prosurvival and cytoprotective independent of its transamidating function 
(Datta et al, 2007). In an ischaemic heart, TG2 GTPase activity is strikingly reduced 
suggesting it is an important factor in cardiac failure (Hwang et al, 1995). However, 
cardiac-specific overexpression of TG2 does not alter PLC-δ1 activity proposing that it 
functions as a TG rather than GTPase (Small et al, 1999) or through a non-PLC-δ1 
pathway such as many outlined above. 
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(b) Kinase activity: 
In 2004, it was reported that TG2 has intrinsic kinase activity (Mishra and Murphy, 
2004). It was found that TG2 phosphorylates insulin-like growth factor binding 
protein-3 (IGFBP-3) and insulin-like growth factor binding protein-5 (IGFBP-5) in 
breast cancer cells. Furthermore, inhibition of TG2 using chemical inhibitors abolished 
phosphorylation of both these proteins (Mishra and Murphy, 2004). This 
phosphorylation was at multiple serine residues in the central domain of these 
proteins. Also, increasing intracellular calcium concentration inhibited TG2 kinase 
activity and enhanced its crosslinking activity in a concentration dependent manner 
(Mishra and Murphy, 2004).  
Furthermore, it was found that the kinase activity of TG2 is responsible for 
phosphorylation of histones H1, H2A, H2B, H3 and H4 (Mishra et al, 2006). This 
phosphorylation occurred at functionally important serine residues such as Ser10, Ser28 
and amino-terminal region of histones, further illustrating the kinase activity of TG2 
(Mishra et al, 2006). TG2 is also responsible for phosphorylating p53 oncoprotein 
(Mishra and Murphy, 2006). TG2 phosphorylates p53 at Ser15 and Ser20 residues which 
reduces the ability of p53 to interact with mouse double minute 2 (Mdm2), thereby 
facilitating apoptosis (Dumaz et al, 2001; Ito et al, 2004; Mishra and Murphy, 2006). 
TG2 phosphorylates retinoblastoma protein (Rb) at Ser780 residue which is important 
for binding of Rb to E2F family of transcription factors (Mishra et al, 2007). Moreover, 
Medina and collegues reported that in FRTL-5 thyroid cells, cAMP-induced proliferation 
involved both phosphorylation of Rb and PKA activation (Medina et al, 2000). It is 
possible that phosphorylation of Rb by TG2 is important however was not investigated 
in these studies. 
TG2 can be phosphorylated by PKA which attenuates its transamidating activity and 
enhances its kinase activity (Mishra et al, 2007). PKA activation by dibutyryl-cAMP 
enhanced TG2 and Rb phosphorylation in mouse embryonic fibroblasts which was 
reversed by PKA inhibitor H-89 (Mishra et al, 2007). Nurminskaya and colleagues 
reported that in differentiation of pre-osteoblasts in the periosteal bone, there is an 
inter-relationship between TG2 and PKA dependent signalling pathways. According to 
this study, TG2 can inhibit PKA-mediated signalling however the underlying 
mechanisms remain unexplored (Nurminskaya et al, 2003). It was recognised that 
TG2 has a Ser216 residue which is phosphorylated by PKA and creates a binding pocket 
for 14-3-3 protein (Mishra and Murphy, 2006). 14-3-3 forms a complex with 
retinoblastoma associated protein RbAp48 (Imhof and Wolffe, 1999). Also, 14-3-3 
protein interacts with various other proteins involved in apoptosis and signalling 
pathways (Mackintosh, 2004; Porter et al, 2006). Hence interaction of 14-3-3 with 
TG2 might be important in regulation of TG2 function as well as for crosstalk amongst 
signalling pathways. 
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Furthermore, phosphorylation of TG2 at Ser216 residue by PKA causes TG2-mediated 
activation of NF-κB, which induces down regulation of PTEN, resulting in activation of 
AKT in mouse embryonic fibroblasts, MCF-7 and T-47D breast cancer cells (Wang et al, 
2012). Use of mutant TG2 lacking the Ser216 residue and H-89 (PKA inhibitor) 
completely blocked activation of NF-κB and down regulation of PTEN (Wang et al, 
2012). Rodolfo and colleagues identified BH3 motif in TG2 which facilitates its 
interaction with Bax but not with Bcl-2 and Bcl-XL (Rodolfo et al, 2004). 
Phosphorylation of Ser112 in BH3 motif of BAD facilitates its interaction with Bcl-XL as 
well as increases accessibility to Ser155 which is phosphorylated by PKA in the BH3 
motif (Macdonald et al, 2006). Phosphoproteomic studies have revealed that TG2 
apart from Ser216 has an additional serine residue Ser212 which is present in PKA 
consensus phosphorylation site (Wang et al, 2012). These potential sites can be 
phosphorylated by many kinases such as calmodulin-dependent protein kinase II, 
casein kinase II, MAPK, PKC, RSK and CDK5 (Rikova et al, 2007; Guo et al, 2008; 
Wang et al, 2012) and once phosphorylated may play a role in interaction of TG2 with 
Bcl-2 which attenuates its pro-apoptotic function and enhances its anti-apoptotic 
function (Wang et al, 2012). 
TG2 has also been shown to play a role in activation of Rho A and MAPK (ERK1/2, 
JNK1/2 and p38 MAPK) pathways (Singh et al, 2003), CREB activation (Tucholski and 
Johnson, 2003) and PLC activation (Nakaoka et al, 1994). It remains unclear if TG2 
kinase activity is necessary for activating these kinases. 
(c) Protein disulphide isomerase activity: 
In 2003, protein disulphide isomerase activity (PDI) of TG2 was reported (Hasegawa 
et al, 2003). PDI’s are enzymes that catalyse formation of disulphide bonds within 
proteins to ensure correct protein folding. Once certain proteins are folded in the 
correct conformation, they can be activated, e.g. inactive RNase A was reported to be 
folded properly into an active form by TG2 (Hasegawa et al, 2003). It is observed that 
TG2 might modulate the respiratory chain by facilitating formation of di-sulphide 
bridges in the mitochondrial complex I (NADH-ubiquinone oxidoreductase), II 
(succinate-ubiquinone oxidoreductase), IV (cytochrome c oxidase) and V (ATP 
synthase) (Mastroberardino et al, 2006). It was also found that there is a reduction in 
ATP production in TG2 knockout mouse cardiomyocytes and skeletal muscles. This 
reduction could be due to lack of di-sulphide bridges formed by TG2 (Krasnikov et al, 
2005). Adenine nucleotide translocator 1 (ANT1) is another target for TG2 PDI activity 
(Malorni et al, 2009). Oligomerisation of ANT1 is necessary for its activity, however 
TG2 knockout mice have increased thiol-dependent ANT1 oligomerisation which results 
in high ANT1 mediated ADP/ATP exchange activity in the cardiac myocyte 
mitochondria (Malorni et al, 2009). It was also found that interaction of Bax and ANT1, 
as well as their co-localisation is dependent on TG2. Overall, this suggests that TG2 
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PDI activity in conjunction with ANT1 might play a role during impairment of 
mitochondrial activity (Malorni et al, 2009; Sarang et al, 2009).  
Overexpression of TG2 in other mitochondrial models resulted in increased cell death 
(Piacentini et al, 2002; Ruan et al, 2007). Piacentini and colleagues have shown that 
there was hyperpolarisation of the mitochondria and increased levels of reactive 
oxygen species (ROS) in TG2 overexpressing cells in response to staurosporine 
treatment (Piacentini et al, 2002). Cyclosporin A (mitochondrial transition pore 
inhibitor) was successful in protecting the cells from apoptosis, however, the 
mitochondria remained hyperpolarised due to overexpression of TG2 (Piacentini et al, 
2002). In a related study using TG2 overexpressing striatal cells reported that 
thapsigargin treatment increased mitochondrial hyperpolarisation and ROS production. 
They also found that this treatment elevated cytochrome c release and caspase-3 
activation which led to increased cell death (Ruan et al, 2007). These studies suggest 
that regulation of TG2 PDI activity is necessary for normal mitochondrial function. It 
should be noted that this activity of TG2 is independent of its transamidating activity 
(Krasnikov et al, 2005). 
(d) Transamidating activity: 
TGs require Ca2+ to catalyse transamidation reactions, however the Ca2+ binding sites 
have not been conclusively identified yet. Kiraly and colleagues have identified six 
putative Ca2+ binding sites on TG2, all of which are located in the catalytic domain (aa 
149, 228, 236, 305, 395 and 432). Mutagenesis studies have shown that mutation of 
any one of the Ca2+ binding site results in complete loss of the transamidating function. 
This suggests that there is some level of co-operation between the Ca2+ binding 
domains to TG2 (Bergamini, 1998; Kiraly et al, 2011). Apart from this, a membrane 
lipid sphingosylphoshocholine (Lyso-Sm) has been shown to modulate TG2 
transamidase activity by enhancing it at 10 µM Ca2+ concentrations. Lyso-Sm induces 
a conformational change in TG2 influencing its Ca2+ binding affinity while not affecting 
its substrate binding affinity (Lai et al, 1997). Another study has shown that the 
transient rise in Ca2+ levels because of tissue injury or other stimuli can reduce TG2’s 
affinity for GTP thereby resulting in activation of its transamidating function (Begg et 
al, 2006a). This rise in intracellular levels of Ca2+ can be induced by a number of 
factors such as rapid ATP production (aerobic metabolism), reactive oxygen species 
(ROS), growth factors (e.g. Insulin-like growth factor binding protein-3, nerve growth 
factor) and chemokines (e.g. CXCL 10, CXCL 12) which can release Ca2+ from 
intracellular stores (De Bernardi et al, 1996; Seurin et al, 2013; Nelson and Gruol, 
2004; Agle et al, 2010). To further support this argument, most of the potential 
substrates of TG2 are primarily cytoplasmic proteins (Facchiano and Facchiano, 2009). 
Stamnaes and colleagues have reported that two intra-molecular disulphide bonds 
(C370-C371 and C370-C270) appear to influence the transamidating activity of TG2 
(Stamnaes et al, 2010). Post-translational modifications such as S-nitrosylation have 
16 
 
also been shown to attenuate TG2 transamidating function (Santhanam et al, 2010). 
These findings indicate that Ca2+ levels are not the only factor regulating the 
transamidating activity of TG2 but it seems that this activity is highly regulated by 
multiple factors (e.g. Ca2+).  
Transglutaminases are capable of catalysing various transamidation reactions. When 
an acyl transfer reaction takes place between γ-carboxamides of glutamines and 
primary amines, it leads to post-translational modification of proteins by amine 
incorporation. When an acyl transfer reaction takes place between γ-carboxamides of 
glutamines and ε-amino group of lysine residues, it leads to formation of an isopeptide 
bond and crosslinks the two proteins (see figure 1.7A). When the same reaction 
occurs between γ-carboxamides of glutamines and primary amines, it leads to 
formation of an amide bond (see figure 1.7B). When an acyl transfer reaction takes 
place between γ-carboxamides of glutamines and a water molecule, deamidation 
occurs (Lorand, 2003; see figure 1.7C). The mechanism of transamidation comprises 
of two steps. Firstly, the acyl acceptor (glutamine residues) binds to the active site 
cys277 of TG2 forming a thioester bond (intermediary step) and releases an ammonia 
molecule. Secondly, the amine donors such as primary amines (free amines) or a 
peptide bound lysine, nucleophilically attacks the thioester bond releasing TG2 to its 
original active form (Folk, 1983). However, if the attacking group is water, then it 
leads to deamidation. 
 
A) 
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Fig 1.7: Transamidation reactions catalysed by TG2. TG2 is capable of catalysing 
various transamidation reactions, which can lead to (A) an isopeptide bond formation, 
(B) an amide bond formation and (C) deamidation. 
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(e) Protein Scaffolding function: 
Apart from the enzymatic functions, protein scaffolding functions of TG2 have also 
been recognised (Park et al., 2010). Interaction of TG2 with fibronectin and β-
integrins (β1, β3 and β5) leads to stronger cell adhesion and stabilisation of the 
extracellular matrix (Akimov et al 2000, Akimov and Belkin, 2001). TG2 also affects 
adhesion-dependent signalling pathways such as constitutive activation of focal 
adhesion kinase (FAK) (Verma and Mehta, 2007) and its ablation causes a decrease in 
renal fibrosis as a result of lower collagen I synthesis and reduced activity of TGFβ 
(Shweke et al, 2008). Another example of TG2 acting as a scaffolding function is in 
cell migration. In EGF-stimulated cancer cells, TG2 binds to actin and recruits proteins 
that aid in actin polymerisation (Antonyak et al, 2009). TG2 functions as a scaffold for 
a variety of non-enzymatic interacting partners and its role has been well documented. 
Few examples include interaction of TG2 with calmodulin and huntingtin (Zainelli et al, 
2004), with calrecticulin and integrin (Coppolino et al, 1997), with small ubiquitin-like 
modifiers (SUMO-1) and E3 SUMO protein ligase (PIASy; Luciani et al, 2009), with 
RhoA, PKA, AKAP13 (Lewis et al, 2005), and with syndecan, fibronectin and integrin 
(Telci et al, 2008). For an extensive review on scaffolding function of TG2, see 
Nurminskaya and Belkin, 2012; Eckert et al, 2014; Kanchan et al, 2015. 
(ii) Role of TG2 in disease. 
(a) Neurodegenerative diseases: 
TG2 has been suggested to contribute to neurodegeneration by generating cytotoxic 
soluble and insoluble protein aggregates (Jeitner et al, 2009; Grosso and Mouradian, 
2012). The activity and expression of TG2 is elevated during Alzheimer’s disease (Kim 
et al, 1999), Parkinson’s disease (Andringa et al, 2004) and Huntington’s disease 
(Karpuj et al, 1999). Alzheimer’s diseases is characterised by the presence of 
extracellular senile plaques formed of aggregated amyloid β protein along with 
intracellular neurofibrillary tangles formed of phosphorylated tau protein (Przedborski 
et al, 2003; Siegel and Khosla, 2007). Amyloid β is a substrate for TG2, crosslinking of 
which resembles the polymers seen in Alzheimer’s disease (Hartley et al, 2008; Martin 
et al, 2011). α-synuclein is a substrate for TG2 in the context of Parkinson’s disease. 
Parkinson’s disease is characterised by degradation of dopaminergic neurons within 
the substantia nigra along with formation of Lewy bodies (α-synuclein protein 
aggregates; Hoffner and Djian, 2005). Crosslinking of α-synuclein monomer leads to 
the aggregation of α-synuclein in Lewy bodies (Andringa et al, 2004).  
Huntington’s disease is characterised by the presence of insoluble huntingtin protein 
aggregates. It is an autosomal dominant disorder caused by expansion of CAG repeats 
which encodes for glutamine and this expansion leads to production of huntingtin 
protein with a poly glutamine N-terminus. Since glutamine is a substrate for TG2, it 
has been highly implicated in formation of insoluble huntingtin protein aggregates 
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(MacDonald et al, 1993; Hoffner and Djian, 2005). During Huntington’s disease, it has 
been recorded that deletion of TG2 extends the life span in mouse models (Bailey and 
Johnson, 2005; Mastroberardino and Piacentini, 2010; Altuntas et al, 2014). These 
studies provide evidence of involvement of TG2 in neurodegenerative disorders and 
that it plays an important role in their progression. 
(b) Coeliac disease: 
It is well established that TG2 acts as a master regulator of coeliac disease. Coeliac 
disease is a systemic autoimmune disorder characterised by villous atrophy and crypt 
hyperplasia of the small intestine due to indigestion of dietary wheat, rye and barley 
derived gluten (Learner et al, 2015; Rauhavirta et al, 2016). The glutamine residues 
in gluten need to be deamidated to provoke an immune response. This is performed 
by TG2 (Schuppan and Hahn, 2002). Previous studies have demonstrated that 
patients suffering from coeliac disease have high levels of anti-TG2 antibody in their 
serum (Sollid and Scott, 1998), higher expression and activity of TG2 in the intestinal 
mucosa (Caputo et al, 2004) and localisation of TG2 in the extracellular matrix and 
small intestinal mucosa as compared to all layers of the small intestinal wall (Hansson 
et al, 2002; Caputo et al, 2004). Despite, having ample evidence of involvement of 
TG2, its role is still being unravelled and new therapeutic strategies are being 
developed for coeliac disease. 
(c) Cancer: 
Elevated levels of TG2 have been reported in malignant melanoma (Fok et al, 2006), 
glioblastoma (Yuan et al, 2007), breast carcinoma (Mehta et al, 2004), ovarian 
carcinoma (Hwang et al, 2008), pancreatic carcinoma (Verma et al, 2006) and lung 
carcinoma (Park et al, 2010). Cancer cells expressing high levels of TG2 show higher 
resistance to chemotherapeutic drugs (Mehta et al, 2006). TG2 has conflicting roles in 
cancer with respect to cell survival or apoptosis. For instance, enhancement in 
adhesion to fibronectin and promotion of cell migration in ovarian carcinoma which 
leads to survival of cancer cells has been observed (Satpathy et al, 2007). However, 
down regulation of TG2 in primary tumours causes metastasis (Verma and Mehta, 
2007). On the other hand, transamidation activity causes apoptosis in some cancer 
cells (Milakovic et al, 2004). These studies illustrate that TG2 can either prevent or 
promote cancer metastasis which greatly depends on cancer cell type and stage.  
(d) Inflammation and wound healing: 
TG2 expression is up-regulated by tumour necrosis factor-α (TNF-α) (Kuncio et al, 
1998), interleukin-1 (IL1) (Johnson et al, 2001), interleukin-6 (IL6) (Suto et al, 1993) 
and tumour growth factor-β1 (TGF-β1) (Quan et al, 2005). Recently, it has also been 
reported that TG2 expression is up-regulated via β2 adrenoceptors in macrophages 
and promotes differentiation of T-helper type 17 cells, thereby promoting 
inflammation (Yanagawa et al, 2014). Reduced kidney injury, renal fibrosis and 
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scarring was observed in TG2-/- mice as compared to wild type mice (Verderio et al, 
2004; Shweke et al, 2008). This effect was due to reduced activation of TGF-β and 
collagen I along with reduced inflammatory response. It was also recently observed 
that deletion of TG2 causes autoimmunity due to impairment of macrophage-mediated 
phagocytosis of apoptotic cells (Toth et al, 2009). TG2 can protect cells by enhancing 
attachment and motility in an inflammatory background as TG2-overexpressing 
fibroblasts show increased cell attachment and migration (Gross et al, 2003). As 
suggested by these studies, TG2 is an important player in cell death mechanisms and 
inflammatory responses.  
(e) Ischaemia/reperfusion injury: 
Elevated expression of TG2 in response to ischaemia has been reported in several 
studies (Tolentino et al, 2004; Filiano et al, 2010). Filiano and colleagues have 
reported neuroprotective effects of TG2 in both primary rat cortical neurons and SH-
SY5Y human neuroblastoma cell line (Filiano et al, 2008; Filiano et al, 2010). This 
protection was observed due to interaction of TG2 with hypoxia inducible factor-1β 
(HIF1β) which results in negative regulation of HIF1 transcriptional activity and 
attenuation of the pro-apoptotic gene, Bnip3. Another study from the same group 
reported that astrocytes from TG2-/- mice showed resistance to ischaemia/reperfusion 
injury and were able to increase survival of neurons (Colak et al, 2012). This conflict 
shows that TG2 differentially modulates ischaemic cell death in neurons and astrocytes. 
Szondy and colleagues in another study have shown that TG2 is cardioprotective 
against ischaemia/reperfusion injury (Szondy et al, 2006). This study suggests that 
TG2 acts at a mitochondrial level and maintains mitochondrial respiratory function by 
ATP synthesis. These studies collectively show that TG2 is involved in cellular 
mechanisms underlying ischaemia/reperfusion injury and that it might have a 
protective role depending on the cell background. 
Overall, looking at these studies we can conclude that TG2 is able to contribute to 
both cell survival and cell death depending on cell background and disease pathology. 
Therefore, it is of great interest and importance to get a better understanding of 
function and role of TG2 in numerous pathological conditions as it represents a 
potential target. 
(iii) Role of TG2 in cell death and cell survival. 
TG2 is a complex enzyme, which is regulated by various factors. Hence, conflicting 
roles in the same pathological and/or physiological system have been reported. These 
opposing roles could be due to differences in the enzymatic as opposed to non-
enzymatic functions (Fesus and Szondy, 2005; Iismaa et al, 2009; Kiraly et al, 2011), 
conformational structure (open verses closed) (Fesus and Szondy, 2005; Iismaa et al, 
2009), genetic variations such as short or truncated form (TG2-S) in comparison with 
long form (TG2-L) (Tee et al, 2010) or single-nucleotide polymorphism (Kiraly et al, 
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2011) as well as the genetic background of cell systems or animal models used during 
the study (Iismaa et al, 2009; Tatsukawa and Kojima, 2010).  
Currently, the role of TG2 in cell survival and cell death is widely acknowledged and 
numerous studies are being focused to identify what triggers TG2 to act in a pro- or 
anti-apoptotic manner (Nurminskaya and Belkin, 2012; Tatsukawa et al, 2016). In 
TG2 overexpressing mice neurons and N2a neuronal cell line, TG2 exerts a protective 
effect against hypoxia-induced cell death (Filiano et al, 2010). This protective effect is 
observed due to overexpression of TG2 and its localisation in the nucleus (Filiano et al, 
2010). On the other hand, TG2 knockout or inhibition of TG2 in transgenic mice 
attenuated the progression of neurodegenerative disorders (Bailey and Johnson, 2005; 
Mastroberardino et al, 2002; Karpuj et al, 2002; Andringa et al, 2004; Dudek and 
Johnson, 1994). TG2 enhances cancer development by increasing EGFR expression in 
glioblastomas (Zhang et al, 2013), attenuation of apoptosis in thapsigargin-treated 
HEK293 cells (Milakovic et al, 2004) and retinoic acid treated NIH3T3 and embryonic 
lung fibroblast cells (Boehm et al, 2002), increasing resistance to chemotherapeutic 
drug in breast cancer metastasis (Mehta et al, 2010; Mangala et al, 2007) and 
stabilising adhesive interactions in melanoma cells for metastasis (Kong and Korthuis, 
1997). However, TG2 can also supress cancer by excessive stabilisation and 
accumulation of ECM crosslinks (Johnson et al, 1994; Shrestha et al, 2015) and can 
also facilitate apoptosis in retinoic acid treated U937 cells and phosphorylation of 
retinoblastoma (Rb) protein in MCF-7 cells (Tatsukawa et al, 2011; Mishra et al, 2007; 
Oliverio et al, 1997).  
TG2-/- mice show impaired glucose-stimulated insulin secretion and glucose intolerance 
compared to control mice (Bungay et al, 1986; Gomis et al, 1983; Sener et al, 1985; 
Bernassola et al, 2002; Porzio et al, 2007). However, it should be noted that inhibition 
of TG2 did not prevent insulin secretion induced by cAMP or phorbol ester and could 
only prevent insulin-secretion induced by calcium (Lindsay et al, 1990; Iismaa et al, 
2013). TG2 can enhance angiogenesis through VEGF signalling in the endothelium 
(Dardik and Inbal, 2006; Haroon et al, 1999). It can also facilitate migration and 
tubule formation of the human umbilical vein endothelial cells (HUVEC) (Wang et al, 
2011). It is observed that inhibition of TG2 causes a reduction in fibronectin deposition 
and matrix-bound VEGFA and therefore promotes angiogenesis in a VEGF-dependent 
manner (Wang et al, 2011). TG2 is also know to enhance angiogenesis by co-
localisation and binding with endostatin- a C-terminal domain of collagen XVIII (Faye 
et al, 2009; Faye et al, 2010), organisation of the cytoskeleton, as well as endothelial 
sprouting and migration of both endothelial and vascular mesenchymal cells (Myrsky 
et al, 2008). 
TG2 is also reported to promote spreading and adhesion of human endothelial cells 
ECV304 via its adhesion/scaffolding activity with fibronectin and/or integrin (Gaudry et 
al, 1999; Jones, et al, 1997). However, TG2 is also known to inhibit angiogenesis by 
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excessive stabilisation and accumulation of ECM crosslinks resulting in a reduction of 
organised vasculature (Jones et al, 2006) and can also cause retinoic acid-mediated 
apoptosis in vascular smooth muscle cells (Ou et al, 2000). TG2 can protect 
hepatocytes against carbon tetrachloride and FAS-induced liver injury through 
dimerization leading to activation of Sp1 (Han and Park, 2000; Nardacci et al, 2003; 
Sarang et al, 2005). However, it can also promote liver injury and fibrosis in alcoholic 
steatohepatitis and non-alcoholic steatohepatitis free fatty acid-treated human 293T 
cells and NZB/W F1 mice (Kuo et al, 2012; D’Argenio et al, 2010; Kojima et al, 2010; 
Hsu et al, 2008). Thus, it is clear that the complex balance between pro- and anti-
apoptotic functions of TG2 need further investigation and that they are dependent on 
numerous factors (Tatsukawa et al, 2016).  
In NIH3T3 fibroblast cells, exposure to LY 294002 (PI-3K inhibitor) causes a 
substantial decrease in the ability of TG2 to bind to GTP. This indicates that PI-3K 
regulates the switch between GTPase and transamidase activity of TG2, along with 
changes in Ca2+ concentration. Also the Ras-ERK1/2 pathway influences the switch 
between pro-apoptotic transamidating function and pro-survival GTPase function 
(Antonyak et al, 2003). There is evidence that is contradictory as to whether TG2 is 
pro or anti-apoptotic. The mechanism by which TG2 modulates apoptosis greatly 
depends on the cell type and stimulus involved (Gundemir et al, 2012). It has been 
shown that there is a role for TG2 transamidase activity in tissue injury/repair 
following ischaemic/reperfusion injury (Gundemir et al, 2013) and during ischaemia or 
hypoxia TG2 binds to hypoxia inducible factor 1β (HIF1β) and suppresses HIF activity 
(Gundemir et al, 2013).  
 
(iv) TG2 and cardioprotection. 
TG2 has been shown to be cardioprotective against ischaemia/reperfusion injury in 
mice (Szondy et al, 2006). Wild type and TG2 knockout mouse hearts were subjected 
to ischaemia/reperfusion injury. It was observed that TG2-/- hearts had significantly 
increased infarct size and ventricular fibrillation when compared to TG2+/+ hearts 
under ischaemia/reperfusion injury. It should be noted that infarct size and ventricular 
fibrillation of both TG2+/+ and TG2-/- ischaemia/reperfused hearts were significantly 
increased as compared to control TG2+/+ and TG2-/- normoxic hearts (Szondy et al, 
2006). It was found that TG2  is necessary for maintenance of intact mitochondrial 
respiration and knockout of TG2 leads to severe failure in ATP production. This failure 
in ATP production was hypothesised to be a result of reduced post-translational 
modifications of mitochondrial regulatory proteins along with abolished action of TG2 
on mitochondrial substrate proteins (Szondy et al, 2006). However, further 
investigation is warranted to identify these mitochondrial substrate proteins and 
elucidate which activity of TG2 (kinase, transamidase, etc.) is vital for ATP production.  
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Recently, it has been shown that TG2 can be activated by PKA and PKC (Almami et al, 
2014). Activation of these pathways by forskolin and phorbol ester, respectively, 
contributed to cytoprotection of H9c2 cardiomyoblasts against hydrogen peroxide-
induced cell death. Inhibition of TG2 using chemical inhibitors attenuated the 
protection offered by forskolin and phorbol ester, suggesting TG2 to have an 
important role in facilitating cytoprotection (Almami et al, 2014). 
These studies suggest a role for TG2 in mediating cellular response to 
ischaemia/reperfusion injury and it could potentially be a pharmacological target for 
treatment for ischaemia-induced pathologies. Since GPCRs are capable of initiating 
pathways which lead to activation of protein kinases such as PKA and PKC, it is 
possible that GPCRs can modulate TG2 activity. However, at present very little is 
known about regulation of TG2 by GPCRs and its role in cardioprotection. 
 
1.6 The G-protein Coupled Receptor (GPCR) family. 
G-protein coupled receptors (GPCRs) are the largest (>1200 GPCRs identified in the 
human genome) and most studied family of membrane proteins (Insel et al, 2012). 
They are widely distributed across various cell and tissue types and are responsible for 
mediating physiological responses by interacting with a wide variety of stimuli such as 
peptides, non-peptides, hormones, light, catecholamines, etc. (Katritch et al, 2013; 
Kingwell, 2016). The prime reason for studying these receptors is due to the fact that 
currently about 40% of therapeutic drugs on the market target one or more GPCRs 
(Cooke et al, 2015; Heifetz et al, 2016). 
(i) Structure of GPCRs: 
GPCRs are characterised by seven α-helical transmembrane spanning domains 
separated by alternating intra- and extra-cellular loops, an intracellular carboxyl 
terminal and an extracellular amino terminal (Rosenbaum et al, 2009). GPCRs also 
undergo post-translational modifications such as glycosylation of the amino terminus 
or extracellular loops, which is often necessary for their localisation; palmitoylation of 
cysteine residues within the intracellular loops and/or carboxyl terminal tail is required 
to strengthen membrane association; reversible phosphorylation of the intracellular 
loops and/or carboxyl terminal tail is important for G-protein anchorage as well as 
desensitisation and internalisation of the receptor (see figure 1.8; Goddard and Watts 
2012). Rhodopsin, the light sensitive receptor was the first to have its crystal 
structure reported which has been extensively used to determine the structure and 
function of other GPCRs (Palczewski, 2006).  
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Fig 1.8: Schematic representation of the basic structure of class A GPCR. Class A 
GPCRs interact with ligands and initiate a cascade of events ultimately leading to an 
intracellular response.   
 
Rhodopsin-like/Class A are the largest sub-group of GPCRs that includes receptors for 
a vast variety of neurotransmitters, peptides, hormones and other small molecules 
such as pheromones, taste, vision and olfactory senses (Alexander et al, 2015). 
Ligands bind to the receptor and cause a conformational change which leads to 
receptor activation and activation of heterotrimeric G-proteins (Hillenbrand et al, 2015; 
for an overview refer to figure 1.9). In the inactive state, there is strong association 
between GDP- bound Gα-subunit and the βγ-dimer. When a ligand binds to the 
receptor, it acts as a guanine nucleotide exchange factor (GEF) catalysing the 
exchange of GDP for GTP. This exchange reduces the affinity of Gα-subunit for the βγ-
dimer, which results in their dissociation. Once dissociated the Gα-bound GTP and βγ-
subunits can act on their downstream effectors and generate a response. Termination 
of this signal occurs via the intrinsic GTPase activity of the Gα-subunit that cleaves 
GTP to GDP. This completes the cycle by re-associating the Gα-subunit and the βγ-
dimer hence impeding interaction with their downstream effectors (Cabrera-Vera et al, 
2003; Sunahara and Insel, 2016). Two of the GPCRs discussed in this thesis 
(adenosine A1 receptors and β2 adrenoceptors) belong to the class A sub-group of 
GPCRs. 
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Fig 1.9: Conformational changes during GPCR activation. (1) In the resting state, the 
heterotrimeric G-protein is bound to GDP. (2) Upon ligand binding, a conformational 
change causes receptor to become active which exposes a catalytic component which 
causes exchange of GDP to GTP. (3) The active Gα-GTP subunit dissociates from 
membrane bound Gβγ subunit and both these subunits exert a downstream effect. (4) 
Termination of the signal by hydrolysis of GTP to GDP by the intrinsic GTPase activity 
of Gα subunit, which causes the receptor and G-protein to return to its inactive/resting 
state. 
 
G-proteins are further classified depending upon their Gα-subunit (see figure 1.10). 
They are broadly categorised into four subtypes: Gαs, Gαi/o, Gαq/11, Gα12/13. Gαs 
proteins have a stimulatory effect on the enzyme adenylyl cyclase while the Gαi/o 
proteins have an inhibitory effect on it. Adenylyl cyclase produces the second 
messenger cAMP and activates PKA-mediated signalling. Gαs proteins are selectively 
activated by cholera toxin while Gαi/o proteins are inhibited by pertussis toxin. Gα12/13 
act on the guanine exchange factors (GEF) of the Rho family of GTPases. The Gαq/11 
proteins activate phospholipase C-β (PLCβ) which cleaves phosphatidylinositol 
bisphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3). DAG 
further activates protein kinase C (PKC) and IP3 modulates intracellular calcium 
concentration. The Gαq/11 proteins are insensitive to cholera and pertussis toxin 
therefore distinguishing them from the other G-proteins (Neves et al, 2002; 
Wettschureck and Offermanns, 2005; Syrovatkina et al, 2016). 
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Fig 1.10: Signalling pathways mediated by main classes of Gα proteins. Gαs, Gαi/o 
proteins have stimulatory and inhibitory effects on adenylyl cyclase and its 
downstream effectors respectively. Gαq/11 protein activates phospholipase C thereby 
activating protein kinase C and calcium signalling while Gα12/13 proteins activate 
guanine nucleotide exchange factors of the Rho family. 
 
Many of these GPCRs are expressed in the heart where they contribute to 
cardioprotection, including the adenosine receptors and the beta-adrenoceptors. 
Hence, studying their signalling mechanisms is of utmost importance in order to 
identify potential pharmacological targets, which could protect against myocardial 
injury.  
1.7 Adenosine receptors. 
Adenosine is a naturally occurring purine molecule which is formed by degradation of 
adenine nucleotides (ATP, ADP and AMP) both intra- and extracellularly. Adenosine 
formation is increased in response to various stimuli such as ischaemic/reperfusion 
injury, necrotic cell death, inflammation (Schulte and Fredholm, 2003; Fredholm, 
2014) and exerts several effects such as vasodilation, negative ionotropic, 
chronotropic and dromotropic effects (Sheth et al, 2014). Adenosine exerts these 
effects via the four cloned and characterised adenosine receptors (A1, A2A, A2B and A3) 
belonging to the GPCR superfamily. Among these the A1 and A3 couple to Gi/o proteins 
which are sensitive to pertussis toxin and inhibit cAMP signalling while A2A and A2B 
couple to Gs proteins and activate cAMP signalling (Fredholm et al, 2011; Headrick et 
al, 2013). Furthermore, A1 and A3 adenosine receptors also activate phospholipase C 
(PLC) signalling via βγ subunits released from Gi-proteins (Smrcka and Sternweis, 
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1993; Rebecchi and Pantyala, 2000; Schulte and Fredholm, 2003). Adenosine is 
known to balance cellular energy supply and demand and has several roles in 
maintaining normal physiological regulation including cardiac impulse generation and 
conduction, contractility and adrenergic responsiveness (Headrick et al, 2011; 
Headrick et al, 2013; Fredholm, 2014). Its physiological range is about 30-200 nM, 
however, during ischaemia or ischaemia/reperfusion injury, extracellular levels of 
adenosine can increase up to 10 µM, a concentration which then exerts its 
cardioprotective effects against ischaemia or ischaemia/reperfusion injury (Ballarin et 
al, 1991; Fryer et al, 2002; Schulte and Fredholm, 2003; Fredholm, 2014).  
All the four adenosine receptor subtypes are expressed in the heart. The majority of 
the A1 adenosine receptor population is distributed in the atrial myocytes, ventricular 
myocytes, AV and SA nodes (Burns, 1990; Germack and Dickenson, 2004; Fredholm 
et al, 2011) while the A3 adenosine receptor population is found in coronary vascular 
smooth muscle cells and ventricular myocytes (Burns, 1990; Auchamp and Bolli, 1999; 
Germack and Dickenson, 2004; Fredholm et al, 2011). The A2A adenosine receptor 
population can be found in the coronary endothelium and coronary vascular smooth 
muscle cells of guinea pigs and mice (Burns, 1990; Auchamp and Bolli, 1999; Hein et 
al, 2001; Fredholm et al, 2011) as well as ventricular myocytes while the A2B 
adenosine receptor population is distributed in the coronary endothelium and coronary 
vascular smooth muscle cells of rats (Burns, 1990; Feoktistov and Biaggioni, 1990; 
Germack and Dickenson, 2004; Fredholm et al, 2011). All four adenosine receptors 
exert cardiovascular effects. which are summarised in table 2 and play a role in 
cardioprotection (Ralevic and Burnstock, 1998; Salvatore et al, 2000; Fredholm et al, 
2011; Headrick et al, 2013). However, the major focus of this thesis will be on the A1 
adenosine receptor and its role in cardioprotection. 
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Table 2. Adenosine receptor subtype and their effects on cardiovascular tissue.  
  
Adenosine 
receptor subtype 
Tissue  
distribution 
G-
protein 
subunits 
Signalling pathways 
modulated 
Physiological effects on 
cardiovascular tissue 
References 
 
A1 
 
Atrial and ventricular 
myocytes, AV and SA 
nodes, cortex, 
cerebellum, 
hippocampus, spinal 
cord, eye, adrenal 
gland, skeletal 
muscle, adipose 
tissue,  bronchi, 
oesophagus, kidney, 
liver, colon, testis, 
pancreas. 
 
Go/i1/2/3 
 
↓cAMP 
↑IP3/DAG (PLC) 
↓ Q, P, N-type Ca2+ channels 
↑K+ channels 
↑choline /DAG (PLD) 
↑ Arachidonic acid (PLA2) 
 
Bradycardia (negative chronotropy), 
A-V nodal conduction slowing 
(negative dromotropy), reduction of 
atrial contractility (negative inotropy), 
inhibition of cardiac pacemaker cells, 
anti-β-adrenergic effect, ischaemic 
pre-conditioning and post-
conditioning (tolerance to hypoxia), 
glycolysis (depending on metabolism 
of ATP can increase or decrease). 
 
Belardinelli and Isenberg, 1983;  
Munshi et al, 1991;  Scholz and 
Miller, 1991;  Freund et al, 1994; 
Jockers et al, 1994; Gerwins and 
Fredholm, 1995;  Shryock and 
Belardinelli, 1997; Dickenson and 
Hill, 1998;  Ralevic and 
Burnstock, 1998; Freissmuth et 
al, 1999;  Salvatore et al, 2000;  
Fredholm et al, 2001; Straiker et 
al, 2002; Ciruela et al, 2010;  
Headrick et al, 2011; Fredholm 
et al, 2011; Headrick et al, 2013. 
 
A2A Coronary 
endothelium, 
coronary vascular 
smooth muscle cells, 
ventricular 
myocytes, thymus, 
leukocytes, platelets, 
blood vessels, 
olfactory bulb, 
GABAergic neurons, 
peripheral nerves, 
eye, lung. 
 
Gs   
 
Golf   
 
G15/16 
 
↑cAMP 
 
↑cAMP  
 
↑IP3,  
↓ Ca2+ channels 
Vasodilation (hypotension), inhibition 
of platelet aggregation to vascular 
endothelium, inhibition of adherence 
of activated neutrophils to vascular 
endothelium, inhibition of superoxide 
release. 
Offermanns and Simon, 1995;  
Olah, 1997; Shryock and 
Belardinelli, 1997; Ralevic and 
Burnstock, 1998; Kull et al, 
2000; Salvatore et al, 2000; 
Corvol et al, 2001;  Fredholm et 
al, 2001; Li et al, 2009; Ciruela 
et al, 2010; Headrick et al, 2011; 
Fredholm et al, 2011; Hasko and 
Pacher, 2012; Headrick et al, 
2013. 
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A2B Coronary 
endothelium, 
coronary vascular 
smooth muscle cells, 
blood vessels, eye, 
adrenal gland, brain, 
pituitary gland, lung, 
mast cells, adipose 
tissue, cecum, colon, 
bladder, ovaries, 
kidney, liver. 
 
Gs   
 
 
Gq/11 
↑cAMP 
↑ Ca2+ channels 
 
↑IP3/DAG (PLC) 
Vasodilation (hypotension), inhibition of 
platelet aggregation to vascular 
endothelium, inhibition of adherence of 
activated neutrophils to vascular 
endothelium, inhibition of superoxide 
release. 
Pierce et al, 1992; Shryock and 
Belardinelli, 1997; Ralevic and 
Burnstock, 1998; Linden et al, 
1999; Gao et al, 1999; Salvatore 
et al, 2000; Fredholm et al, 2001; 
Ciruela et al, 2010;  Headrick et 
al, 2011; Fredholm et al, 2011; 
Headrick et al, 2013. 
A3 Coronary vascular 
smooth muscle cells, 
ventricular 
myocytes, 
cerebellum, 
hippocampus, 
microglia cells, lung, 
mast cells, spleen, 
testis, pineal gland, 
thyroid, adrenal 
gland, liver, kidney, 
intestine. 
 
Gq/11   
 
Gi2/3/o 
↑IP3/DAG (PLC)  
 
↓cAMP 
↑IP3/DAG (PLC) 
↑K+-ATP channels 
↑choline /DAG (PLD) 
↑ Cl- channels 
Ischaemic pre-conditioning (tolerance to 
hypoxia), increase in mast cell activation, 
inhibition of inflammatory pain. 
Abbracchio et al, 1995;  Palmer et 
al, 1995;  Shryock and 
Belardinelli, 1997; Parsons et al, 
2000; Ralevic and Burnstock, 
1998; Tracey et al, 1998; Carre et 
al, 2000; Mitchell et al, 1999; 
Salvatore et al, 2000; Fredholm 
et al, 2001; Ciruela et al, 2010; 
Headrick et al, 2011; Fredholm et 
al, 2011; Headrick et al, 2013. 
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(i) Role of the A1 adenosine receptor in cardioprotection: 
The pilot study undertaken by Liu et al, 1991 reported that ischaemic pre-conditioning 
reduced, infarct size in rabbits and that this protection was lost following infusion of 
non-selective adenosine receptor antagonists (Liu et al, 1991). A subsequent study 
showed that selective antagonism of the A1 adenosine receptor completely abolished 
the protection, indicating that the A1 adenosine receptor appears to have a central role 
in offering protection against ischaemia/reperfusion injury (Thornton et al, 1992). 
Thornton and colleagues also showed that infusion of a selective A1 adenosine receptor 
agonist significantly reduced the infarct size, providing further evidence for the role of 
A1 adenosine receptor in protection (Thornton et al, 1992). Pharmacological post-
conditioning using adenosine was effective in reducing infarct size in canines which 
was abolished in the presence of a selective A1 adenosine receptor antagonist 
indicating a role for the A1 adenosine receptor (Velasco et al, 1991). However, similar 
post-conditioning had no effect in isolated rabbit hearts (Xu et al, 2001). Hochhauser 
and colleagues have shown that in isolated hearts from rats (both normotensive and 
hypertensive), activation of the A1 adenosine receptor triggers early- and late-phases 
of pre-conditioning which results in protection (Hochhauser et al, 2007). Another 
study undertaken in canines found that pre-conditioning with adenosine not only 
reduces the infarct size but also preserves myocardial function. However, this 
treatment also had side effects such as increase in energy requirement and oxygen 
wasting (Phillips and Ko, 2007). There have been many subsequent studies evaluating 
the role of adenosine in cardioprotection (Kersten et al, 1997; Mangoni and Barrere-
lemaire, 2004; Peart and Headrick, 2007; Bonney et al, 2014; Yeung and Kolathuru, 
2015; Contractor et al, 2016; Randhawa and Jaggi, 2016). 
Given that all the four adenosine receptors play a role in cardioprotection, there is a 
lot of synergistic effects amongst them. For instance, Cohen and Downey have shown 
that protection delivered by adenosine during ischaemia or ischaemia/reperfusion 
injury triggers activation of the A1 and A3 adenosine receptors which signal via Gi and 
activate PKC. PKC further activates the A2B adenosine receptor, which then offers 
protection by targeting effector proteins such as mitochondrial permeability transition 
pore (mPTP) (Cohen and Downey, 2008). Another study reported that in H9c2 cells 
adenosine-mediated protection was due to co-operation between A1, A2A and A2B 
receptors (Urmaliya et al, 2009). Boucher and colleagues reported that pre-
conditioning of the A2A adenosine receptor resulted in reduction of the infarct size 
(Boucher et al, 2004). The A2B adenosine receptor exhibits protection via 
pharmacological pre- and/or post-conditioning in rabbit hearts (Kuno et al, 2007; 
Philipp et al, 2006). However, no protection was observed in the A1 adenosine 
receptor knock-out mice (Xi et al, 2008) suggesting that the mechanism of protection 
exhibited by the adenosine receptors greatly depends on the model system used. 
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There appears to be a role for PKB in adenosine-mediated cardioprotection. Qin and 
colleagues demonstrated that protection in isolated rabbit hearts via pre-conditioning 
with adenosine is independent of PI-3K (Qin et al, 2003). However, another similar 
study reported that protection of isolated rabbit hearts by adenosine is through 
phosphorylation of PKB during reperfusion (Solenkova et al, 2006). Furthermore, 
Germack and colleagues have shown that in neonatal rat hearts, PKB phosphorylation 
is involved in adenosine mediated signalling but not in adenosine-mediated 
cardioprotection (Germack et al, 2004). 
From these examples, it is clear that there is a role for adenosine receptors in 
cardioprotection and that understanding the underlying signal transduction mechanism 
is of the utmost importance as it could potentially modulate proteins which exert these 
cardioprotective effects. A1 adenosine receptor-mediated signalling is very well 
documented. Although the A1 adenosine receptor stimulation is traditionally associated 
with inhibition of adenylyl cyclase, it also can trigger the activation of additional 
signalling cascades involving PKB, PKC, ERK1/2 and p38 MAPK (Dickenson et al, 1998; 
Germack and Dickenson, 2000; Robinson and Dickenson, 2001; Germack and 
Dickenson, 2004, Germack et al, 2005; Yang et al, 2009). Since PKC and ERK1/2 are 
also associated with modulation of transglutaminase activity (Mishra et al, 2007; 
Bollag et al, 2005), it is conceivable that the A1 adenosine receptor can modulate 
transglutaminase activity as well. This will form one of the major areas of investigation 
undertaken by this thesis. 
1.8 Adrenoceptors. 
The catecholamines, adrenaline and noradrenaline play dual roles as 
neurotransmitters as well as hormones. They are synthesised from tyrosine by 
tyrosine hydroxylase to produce dihydroxyphenylalanine (L-DOPA) in the 
postganglionic sympathetic nerve ending and chromaffin cells of the adrenal gland 
(Guimaraes and Moura, 2001). The signal provided by these hormones is transduced 
to a cellular response by a family of GPCRs called the adrenoceptors. There are nine 
adrenoceptor subtypes identified, based upon both genetic and functional studies. The 
family is further split into two divisions, α and β, comprising of six alpha (α1A, α1B, α1D, 
α2A, α2B and α2C) and three beta (β1, β2 and β3) adrenoceptors (Brodde et al, 2006; 
Guimaraes and Moura, 2001; McGrath, 2015). The existence of a fourth atypical beta 
adrenoceptor (β4 adrenoceptor) was proposed by various studies and it was suggested 
to mediate glucose uptake in muscle cells and chronotropic and ionotropic functions in 
rat and human cardiac cells (Roberts et al, 1993; Roberts et al, 1995; Kaumann and 
Molenaar, 1997 Sarsero et al, 1999). Few studies demonstrated that in rat aorta the 
β4 adrenoceptor mediated lusitropic effects (Shafiei and Mahmoudian, 1999; Brawley 
et al, 2000a; Brawley et al, 2000b) and that the β4 adrenoceptor is present in rat 
mesenteric arteries (Kozlowska et al, 2003). However, other studies failed to confirm 
these findings (Brahmadevara et al, 2003; Brahmadevara et al, 2004; Briones et al, 
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2005). Follow up studies have shown that β4 adrenoceptor is rather an altered 
conformational state of the β1 or β3 adrenoceptor and this conformational change 
causes it to lose its affinity for specific ligands and gain affinity towards other agonists 
(Konkar et al, 2000; Granneman, 2001; Jost et al, 2002; Lewis et al, 2004; Baker, 
2005). Thus, the existence of β4 adrenoceptor remains unclear. 
The α1 adrenoceptor subtypes couple to Gq/11 protein and activate phospholipase C-β 
(PLCβ) which further activates protein kinase C (PKC) and releases intracellular 
calcium stores (Minneman, 1988; Terzic et al, 1993) while the α2 adrenoceptor 
subtypes couple to Gi and inhibit cAMP signalling (Civantos and Aleixandre, 2001). 
There is evidence that the α1 adrenoceptors are present in the heart, however, no α2 
adrenoceptors are found in the heart (Simpson, 1983; Bylund et al, 1998). There 
appears to be a substantial role for alpha adrenoceptors in the vasculature, where 
stimulation causes constriction of peripheral vessels, thereby controlling blood 
pressure (Guimaraes and Moura, 2001). 
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Table 3. Adrenoceptor subtype and their effects on cardiovascular tissue. 
Adrenoceptor 
subtype 
Tissue  
distribution 
G-protein 
subunits 
Signalling pathways 
modulated 
Physiological effects on 
cardiovascular tissue 
References 
 
α1A 
 
Coronary vascular smooth muscle cells, 
Atrial and ventricular myocytes, cortex, 
glutamatergic neurons, eye, Liver, 
kidney, lung, uterus smooth muscle, 
salivary gland, platelets, stomach and 
intestinal smooth muscle. 
 
Gq/11 
 
↑IP3/DAG (PLC) 
 
Positive chronotropy,  
positive inotropy, 
vasoconstriction 
 
Bristow et al, 1986; Wu et al, 
1995; Reiter, 2004; Zaugg et 
al, 2004; Zaugg and Schaub, 
2005; Rozec and Gauthier, 
2006; Zaugg et al, 2008 ;  
Cotecchia, 2010; Jensen et al, 
2011. 
 
α1B Coronary vascular smooth muscle cells, 
Atrial and ventricular myocytes, cortex, 
glutamatergic neurons, eye, Liver, 
kidney, lung, uterus smooth muscle, 
salivary gland, platelets, stomach and 
intestinal smooth muscle. 
Gq/11 ↑IP3/DAG (PLC) Positive chronotropy,  
positive inotropy, 
vasoconstriction 
Bristow et al, 1986;  Wu et al, 
1995; Reiter, 2004; Zaugg et 
al, 2004;  Zaugg and Schaub, 
2005; Rozec and Gauthier, 
2006; Zaugg et al, 2008 ;  
Cotecchia, 2010; Jensen et al, 
2011. 
 
α1D Coronary vascular smooth muscle cells, 
Atrial and ventricular myocytes, cortex, 
glutamatergic neurons, eye, Liver, 
kidney, lung, uterus smooth muscle, 
salivary gland, platelets, stomach and 
intestinal smooth muscle. 
Gq/11 ↑IP3/DAG (PLC) Positive inotropy, 
vasoconstriction 
Bristow et al, 1986;  Wu et al, 
1995; Reiter, 2004; Zaugg et 
al, 2004;  Zaugg and Schaub, 
2005; Rozec and Gauthier, 
2006; Zaugg et al, 2008.;  
Cotecchia, 2010; Jensen et al, 
2011. 
 
α2A cortex, cerebellum, hippocampus, spinal 
cord, pre- and post-synaptic nerve 
terminals, hypothalamus, coronary 
vascular smooth muscle cells, atrial and 
ventricular myocytes, adipocytes, 
platelets, kidney, intestinal smooth 
muscle, pancreas. 
 
Go/i1/2/3 ↓cAMP 
↑IP3/DAG (PLC) 
 
Lowers BP Bristow et al, 1986; Gesek, 
1996; Schwartz, 1997; Reiter, 
2004; Zaugg et al, 2004; Zaugg 
and Schaub, 2005; Rozec and 
Gauthier, 2006; Zaugg et al, 
2008; Bondar and Lazar, 2017. 
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α2B Coronary vascular smooth muscle cells, 
atrial and ventricular myocytes, 
hippocampus, thalamus, olfactory bulb, 
blood vessels, intestinal smooth muscle, 
pancreas. 
Go/i1/2/3 ↓cAMP 
↑IP3/DAG (PLC) 
 
vasoconstriction Bristow et al, 1986; Gesek, 
1996; Schwartz, 1997; Reiter, 
2004; Zaugg et al, 2004;  
Zaugg and Schaub, 2005; Rozec 
and Gauthier, 2006; Zaugg et 
al, 2008. 
 
α2C Coronary vascular smooth muscle cells, 
atrial and ventricular myocytes, cortex, 
hippocampus, thalamus, olfactory bulb, 
eye, blood vessels, intestinal smooth 
muscle, pancreas. 
Go/i1/2/3 ↓cAMP 
↑IP3/DAG (PLC) 
 
Lowers BP,  vasoconstriction Bristow et al, 1986; Gesek, 
1996; Schwartz, 1997; Reiter, 
2004; Zaugg et al, 2004;  
Zaugg and Schaub, 2005; Rozec 
and Gauthier, 2006; Zaugg et 
al, 2008. 
 
β1 Atrial and ventricular myocytes, AV and 
SA nodes, cortex, salivary gland, kidney, 
adipocytes, vasculature, urinary bladder, 
stomach and intestinal smooth muscle. 
Gs 
 
 
 
Go/i1/2/3 
↑cAMP 
↑L-type Ca2+ opening 
 
↑IP3/DAG (PLC) 
 
Positive inotropy,  positive 
lusitropy,  positive 
chronotropy, positive 
dromotropy 
Bristow et al, 1986;  Martin et 
al, 2004; Reiter, 2004; Zaugg et 
al, 2004; Zaugg and Schaub, 
2005; Rozec and Gauthier, 
2006; Zaugg et al, 2008 ;  
Bernstein et al, 2011. 
 
β2 Atrial and ventricular myocytes, AV and 
SA nodes, coronary vascular smooth 
muscle cells, blood vessels, cerebellum, 
motor nerve terminals, olfactory bulb, 
eye, kidney, lung, vasculature, liver, mast 
cells, salivary glands, pancreas, 
gastrointestinal and uterus smooth 
muscle, striated and skeletal muscle. 
 
Gs 
 
 
Go/i1/2/3 
↑cAMP 
 
 
↑IP3/DAG (PLC) 
↑PI-3K (PKB) 
 
 
Positive inotropy,  positive 
lusitropy,  positive 
chronotropy,  vasodilation 
Bristow et al, 1986; Xiao, 2001; 
Heubach et al, 2004; Reiter, 
2004; Zaugg et al, 2004; Zaugg 
and Schaub, 2005; Rozec and 
Gauthier, 2006; Zaugg et al, 
2008; Galaz-Montoya et al, 
2017 
β3 Adipocytes, lung, gall bladder, urinary 
bladder. 
Gs 
 
Go/i1/2/3 
↑cAMP 
 
↑IP3/DAG (PLC) 
↑eNOS/nNOS 
 
Negative chronotropy,  
negative inotropy,  positive 
lusitropy,  vasodilation 
Bristow et al, 1986; Reiter, 
2004; Zaugg et al, 2004; Zaugg 
and Schaub, 2005 ; Rozec and 
Gauthier, 2006; Zaugg et al, 
2008 ;  Tchivileva et al, 2009 ; 
Cannavo and Koch, 2017. 
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1.9 Beta-adrenoceptors. 
Evidence shows that the human heart consists of both β1 and β2 adrenoceptors. In the 
atria the ratio between β1:β2 adrenoceptors is 70%:30% while in ventricles its 80%:20% 
(Brodde et al, 2006). Both β1 and β2 adrenoceptors can stimulate cardiac contractility 
(positive inotropy) and are involved in vasodilation, while the β2 adrenoceptors can 
also stimulate lusitropy (cardiac relaxation). The β3 adrenoceptors are usually 
associated with decreasing cardiac contractility (negative inotropy; Motomura et al, 
1990; Kaumann and Sanders, 1993; MacDougall et al, 2012). The β1 and β2 
adrenoceptors couple to Gs although under certain circumstances, there is evidence 
that β2 adrenoceptors can couple to Gi proteins (Xiang and Kobilka, 2003). Whereas 
the β3 adrenoceptors consistently couple to Gi proteins (Wallukat, 2002). 
Both β1 and β2 adrenoceptors play a very important role in cardiac contractility. 
Usually, noradrenaline selectively activates β1 adrenoceptors and controls the heart 
rate and contractibility (Brodde et al, 2006). However, during cardiac insult or stress, 
adrenaline is released which stimulates the β2 adrenoceptors, increasing heart rate 
and contractibility thereby increasing the cardiac output, ensuring adequate tissue 
perfusion (Brodde, 1988). Once activated, both β1 and β2 adrenoceptors couple to Gs, 
activating cAMP signalling thereby activating protein kinase A (PKA), which further 
phosphorylates protein targets involved in chronotropy and inotropy (Brodde et al, 
2006). Increases in intracellular calcium concentration leads to contraction (inotropy) 
while decreases in intracellular calcium concentration leads to relaxation (lusitropy). 
The L-type calcium channels (LTCC) are responsible for regulating the calcium 
concentration in cardiomyocytes (Kamp and Hell, 2000). Hulme and colleagues 
demonstrated that stimulation of isolated ventricular myocytes with isoprenaline 
caused a significant increase in intracellular calcium concentration (Hulme et al, 2006). 
This increase was observed as a result of phosphorylation of serine-1928, a residue 
present at the C-terminal end of the L-type calcium channels, via activation of PKA 
(Hulme et al, 2006). They also suggested that activation of β1 adrenoceptors activates 
the L-type calcium channels by increasing cAMP concentrations throughout the cells, 
while β2 adrenoceptors only produce a smaller population of cAMP near the cell surface, 
which regulates cardiac T-tubules and ryanodine receptors (Hulme et al, 2006). This 
assumption was verified by various studies using frog cardiomyocytes, which only 
express β2 adrenoceptors, as well as FRET-based techniques using cAMP-FRET sensor 
called hyperpolarisation activated cyclic nucleotide-gated potassium channel 2 (HCN2-
cAMP; for reviews see Chen-lzu et al, 2000; Skeberdis et al, 1997; Nikolaev et al, 
2006; Nikolaev et al, 2010). 
Ryanodine receptors are involved in a process called Calcium-Induced Calcium Release 
(CICR) and are located on the membrane of the sarcoplasmic reticulum of 
cardiomyocytes. Zhou and colleagues reported that stimulation of isolated ventricular 
myocytes with isoprenaline caused an increase in activation of ryanodine receptors 
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following activation of L-type Ca2+ channels. PKA was shown to be the key player in 
this study as inhibiting PKA with Rp-8-CPT-cAMP resulted in elimination of ryanodine 
receptors being activated (Zhou et al, 2009). The cardiac relaxation (lusitropy) is 
regulated by SERCA, which is responsible for removal of Ca2+ from the cytoplasm and 
back into the sarcoplasmic reticulum. At rest, phospholamban (sarcoplasmic reticulum 
membrane protein) is dephosphorylated and inhibits SERCA. Activation of PKA by β 
adrenoceptors leads to phosphorylation of phospholamban and activation of SERCA 
(Kaumann et al, 1999). Ca2+ is quickly quenched from the cytoplasm to the 
sarcoplasmic reticulum and results in relaxation (positive lusitropy) (Frank et al, 2002; 
see figure 1.11). Furthermore, phosphorylation of troponin I and myosin-binding 
protein C via PKA reduce myofilament sensitivity to Ca2+ causing ventricular relaxation 
(Frank et al, 2002). Apart from cardiac excitation-contraction coupling, β 
adrenoceptors can also activate glycogen phosphorylase kinase, thereby increasing 
glucose available for metabolism necessary due to increased cardiac output (Xiao and 
Lakatta, 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.11: β-adrenoceptor mediated cardiac excitation-contraction coupling. β-
adrenoceptor couples to Gαs activating adenylyl cyclase and cAMP mediated PKA 
activation. PKA phosphorylates phospholamban (PLB) and enhances sarcoplasmic 
reticulum (SR) calcium uptake. Activation of L-type calcium channels (LTCC) are 
responsible for entry of calcium ions, which causes activation of ryanodine receptors 
(RyR) thereby inducing Calcium-Induced Calcium Release (CICR). Figure adapted from 
Champion and Kass, 2004. 
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(i) Biased agonism of the β2 adrenoceptors: 
Recently, the ‘linear efficacy’ of GPCRs has been proven incorrect for many GPCRs 
(Reiter et al, 2012). Many GPCRs via their agonist signalling are ‘biased’ towards 
multiple G-proteins or β arrestin-dependent signalling pathways. This ‘pluridimensional 
efficacy’ occurs when an agonist preferentially activates one or multiple signalling 
pathways from the same receptor (Reiter et al, 2012). β2 adrenoceptors have been 
shown to demonstrate this property in response to multiple agonists. Noradrenaline 
(the endogenous full agonist) can fully activate β2 adrenoceptor-mediated Gs 
signalling/cAMP signalling pathway (Heubach et al, 2003; Wang et al, 2008). Whereas 
Clenbuterol (full agonist) solely activates β2 adrenoceptor mediated Gi signalling/IP3 
signalling pathway (Siedlecka et al, 2008). Similar biased agonist properties have 
been exhibited by isoprenaline and adrenaline (both full agonists; Heubach et al, 2003; 
Wang et al, 2008; Liu et al, 2009). The biased agonism phenomenon for the β2 
adrenoceptor may involve phosphorylation of the receptor by PKA (Daaka et al, 1997) 
or GRK2 (Liu et al, 2009). Once the agonist is bound, the conformational shift in the 
receptor is sufficient to reveal further allosteric sites (Staus et al, 2014). These sites 
are revealed only during adrenaline biased agonism while for noradrenaline these sites 
are not present (Wang et al, 2008). β2 adrenoceptors can be rapidly desensitised and 
re-sensitised and it appears that dual phosphorylation of the receptor by PKA and 
GRK2 is necessary for this (Xin et al, 2008).  
There are several mechanisms produced to explain the phenomenon of biased 
agonism. For instance, the differences in relative efficacy and potency were implied to 
determine ligand bias (Holloway et al, 2002; Sneddon et al, 2004; Gay et al, 2004; 
Urban et al, 2007). For extensive discussion on biased agonism see Kenakin, 2007; 
Kekanin, 2009; Kenakin et al, 2012; Kenakin and Christopoulos, 2013; Rajagopal, 
2013; Brust et al, 2015; Stahl et al, 2015; Rankovic et al, 2016. The currently 
accepted model for biased agonism is the ‘competitive model’ developed by Kenakin et 
al, 2013 and modified to accommodate weak partial agonists by Sthal et al, 2015. Liu 
and colleagues identified conformational change in helix VI for G-protein dependent 
signalling while conformational change in helix VII for arrestin-biased ligands at the β2 
adrenoceptor using one-dimensional 19F NMR spectroscopic studies (Liu et al, 2012). 
Recently, β-adrenoceptor subtypes were quantified in airway smooth muscles of β-
arrestin knockout mice using this competitive model (Hegde et al, 2015). However, 
Onaran and colleagues screened 11  β2 adrenoceptor agonists coupling to Gs, Gi or β-
arrestin with varying efficacy to confirm this competitive model. They found a high 
level of false positive results along with a lack of correlation between the other models 
used in this study (Onaran et al, 2017). Clearly further studies are necessary to 
successfully identify biased agonists at the  β2 adrenoceptor. 
 
38 
 
(ii) β2 adrenoceptor signalling in cardiomyocytes: 
Liu and colleagues have shown that biased agonism phenomenon occurs at β2 
adrenoceptors in cardiomyocytes only at supra-physiological levels of adrenaline and 
isoprenaline (Liu et al, 2009). They reported that adrenaline induces rapid 
desensitisation and re-sensitisation while noradrenaline just induces desensitisation 
(Liu et al, 2009). This could be seen as a further regulation of β2 adrenoceptor-
mediated Gi binding and it is well known that Gi is localised separately to β2 
adrenoceptors (Head et al, 2005). This biased agonism of the β2 adrenoceptor can 
allow the receptor function to switch from being positive inotropy to negative inotropy. 
The βγ subunit of Gi activates downstream effectors such as MAPKs via the Src/Ras 
pathway (Daaka et al, 1997). MAPKs can inhibit PKA induced phosphorylation of 
phospholamban and hence reduce cardiac contractility (Crespo et al, 1995). 
Communal and colleagues have shown that MAPK activation can protect the 
cardiomyocyte from noradrenaline-induced apoptosis (Communal et al, 2000). The β2 
adrenoceptor-mediated Gi binding exerts an anti-apoptotic effect via ERK and AKT 
signalling (Chesley et al, 2000; Shizukuda and Buttrick, 2002). The activation of p38 
MAPK exerts negative inotropic effects in adult cardiomyocytes and its inhibition 
causes strong reversible cardiac inotropy (Liao et al, 2002). Heubach and colleagues 
have shown that β2 adrenoceptor-overexpressing muscle strips from mice represent a 
bell-shaped concentration response curve when stimulated with adrenaline. However, 
this was not observed with noradrenaline. β2 adrenoceptor-mediated Gs signalling 
causes positive inotropy when stimulated with adrenaline; however, at higher 
concentrations, β2 adrenoceptor-mediated Gi signalling kicks in and inhibits this 
positive inotropy, bringing contraction to baseline levels (Heubach et al, 2003). This 
suggests that β2 adrenoceptor-mediated Gi signalling occurs only at higher agonist 
concentrations, while at physiological levels of adrenaline the β2 adrenoceptor couples 
to Gs. 
(iii) Cardioprotective effects of β2 adrenoceptors: 
Cardiovascular effects of the β adrenoceptors lies in their ability to couple to different 
G-proteins. Communal and colleagues (1999) demonstrated that β1 adrenoceptors 
induce apoptosis while β2 adrenoceptors prevent it. This was established by inhibiting 
Gi-proteins by treating the cardiomyocytes with pertussis toxin, which led to a 
significant increase in the number of apoptotic cells (Communal et al, 1999). Based on 
this study it was suggested that β1 adrenoceptors have cardiotoxic effects while β2 
adrenoceptors have cardioprotective effects and that this is based on the ability of 
receptors coupling to different G-proteins. This could explain why prolonged 
stimulation of the β adrenoceptors causes apoptosis (Shizakuda and Buttrick, 2002). 
Activation of phosphoinositide 3 kinase (PI-3K), PKB and ERK1/2 by Gi-proteins 
promotes cell survival (Xiao, 2001; Chesley et al, 2000, Zhu et al, 2003). The β1 
adrenoceptor is also known to promote cardiac hypertrophy and abnormal calcium 
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signalling by activating CAMKII and exchange protein directly activated by cAMP 
(Epac1 and Epac2; Schafer et al, 2000; Morisco et al, 2001; Zhu et al, 2003). Epac 
activation is also known to be associated with pro-hypertrophy by activation of 
NFAT/calcineurin signalling (Metrich et al, 2008; Pereira et al, 2013). Epac2 signalling 
can cause leakage of Ca2+ from intracellular stores resulting in Ca2+ sparks, arrhythmia 
and hypertrophy (Wu et al, 2002; Hothi et al, 2008; Pereira et al, 2013). 
β1 adrenoceptor antagonists are prescribed to prevent cardiotoxic effects of β1 
adrenoceptors, which leads to various cardiovascular diseases such as chronic stable 
angina and hypertrophy (Messerli et al, 2009). The mechanism by which these 
antagonists prevent cardiovascular diseases is by inhibiting the sympathetic activation 
of heart and also limiting the myocardial oxygen demand so that it matches the supply. 
This measure was used in pre-operative and perioperative patients with cardiovascular 
risk factors to decrease myocardial oxygen demand, which conferred cardiac 
protection (Mangano and Goldman, 1995; Poldermans et al, 1999; Messerli et al, 
2009). However, some clinical studies have shown adverse effects, such as increased 
incidence of stroke and mortality (Devereaux et al, 2008; Beattie et al, 2010; Brady et 
al, 2005; Wallace et al, 2011; Yang et al, 2006). Some studies have shown that the β2 
adrenoceptors are cardioprotective (Bernstein et al, 2005; Fajardo et al, 2006; 
Shizukuda and Buttrick, 2002; Chelsey et al, 2000; Devic et al, 2001). For instance, β2 
adrenoceptors protects the heart against doxorubicin-mediated toxicity by activating 
survival pathways (Fajardo et al, 2011). Overall, these studies support the hypothesis 
that β1 adrenoceptors have cardiotoxic effects while β2 adrenoceptors have 
cardioprotective effects. 
Yano and colleagues have reported that in H9c2 cardiomyocytes, the β2 adrenoceptors 
couples to Gi and activates pro-survival kinases such as PI-3K (Yano et al, 2007). PI-
3K is a central compound in the RISK pathway and it has also been demonstrated that 
β2 adrenoceptors can activate the ERK1/2 pathway, which is another key player in the 
RISK pathway (Hausenloy et at, 2005; Galandrin and Bouvier, 2006; Tutor et al, 
2007). A pilot study by Strasser and colleagues reported that in Langendorff-perfused 
rat heart, exposure to ischaemia for short periods resulted in increased levels of β 
adrenoceptors, which led to increased activity of adenylyl cyclase. However, longer 
periods of ischaemia resulted in decreased levels of β adrenoceptors and in turn 
decreased activity of adenylyl cyclase (Strasser et al, 1990). A subsequent study using 
neonatal rat ventricular myocytes reported a similar observation (Rocha-Singh et al, 
1991). These initial studies demonstrated a role for β adrenoceptors during ischaemia.  
Many studies have looked at β adrenoceptors agonists as a potential preventive 
measure against ischaemia. In mouse heart, cardioprotection is mediated via β2 
adrenoceptors and its switching from Gs to Gi-mediated signalling (Tong et al, 2005). 
The β adrenoceptor(s) responsible for cardioprotection in rat heart remain unclear 
(Lange et al, 2006; Lochner et al, 1999; Marais et al, 2001; Moolman et al, 2006a; 
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Moolman et al, 2006c; Nasa et al, 1997; Robinet et al, 2005; Tong et al, 2005; Yabe 
et al, 1998; Yates et al, 2003). In the Langendorff-perfused rat heart, pre-conditioning 
with β adrenoceptors results in decrease in cytokine release, apoptosis and infarct size. 
The key pathways identified as mediating these protective effects are PI-3K, PKA, PKC 
and p38 MAPK (Nasa et al, 1997; Robinet et al, 2005 ; Moolman et al, 2006a; 
Moolman et al, 2006c). However, the β adrenoceptor activating these kinases is yet to 
be identified.  
There is a potential role for β2 adrenoceptors in post-conditioning. β2 adrenoceptors 
can activate PI-3K and ERK1/2, which are both key players of the RISK pathway 
(Galandrin and Bouvier, 2006; Tutor et al, 2007). RISK pathways are activated during 
reperfusion and so it is entirely possible that activation of β2 adrenoceptors could 
mimic post-conditioning. Preliminary evidence exists that activation of β2 
adrenoceptors via post-conditioning in langendoff perfused rat hearts can offer 
cardioprotection (Tota et al, 2012; Tota et al, 2014). 
 
1.10 H9c2 cells as a model system for cardioprotection. 
H9c2 cells are derived from embryonic rat heart tissue and exhibit similar biochemical, 
morphological and electrophysiological properties to primary cardiac cells (Kimes and 
Brandt, 1976; Hescheler et al, 1991). These cells are increasingly being used as an in 
vitro model for studies relating to cardioprotection (see Han et al, 2005; Chen et al, 
2010; Crawford et al, 2003; Sun et al, 2016) and H9c2 cells have been shown to be a 
good model for ischaemia/reperfusion injury (Fretwell and Dickenson, 2009; Urmaliya 
et al, 2009; Zhu et al, 2011; Sun et al, 2015; Hu et al, 2016; Khaliulin et al, 2017; Li 
et al, 2017; Liu et al, 2017; Wang et al, 2017; Xu et al, 2017). Furthermore, recent 
studies have demonstrated that H9c2 cells are energetically more similar to primary 
cardiac myocytes than mouse atrial HL-1 cells and thus represent a viable in vitro 
model to investigate simulated cardiac ischaemia/reperfusion injury (Kuznetsov et al. 
2015). It should also be noted that HL-1 cell medium contains adenosine (a 
cardioprotective agent) and hence cannot be used to assess cardioprotective potential 
especially with the adenosine receptors (Peter et al, 2016). In addition to their 
increasing use in studies exploring cardioprotection, H9c2 cells show hypertrophic 
responses comparable to primary neonatal cardiac myocytes and therefore also 
represent a useful cell model system to study heart disease (Watkins et al. 2011). 
H9c2 cells also contain multiple cytochrome P450 (CYP) genes which are comparable 
to those expressed in primary cardiomyocytes thus offering a unique in vitro model to 
investigate cardiac metabolic activity (Zordoky and El-Kadi, 2007). Zhou and collegues 
have reported that even though H9c2 cells do not have a beating function, they have 
the ability to contract and expand. Therefore, they represent a suitable model for 
investigating contraction and relaxation characteristics of cardiomyocytes as well as 
for pre-assesment for toxicological studies of cardiovascular drugs where high 
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throughput and repitations are required (Zhou et al, 2016). Comparative analysis of 
H9c2 cells with other cardiac cells is summarised in table 4. 
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Table 4. Comparative analysis of H9c2 cells with other cardiac cells (adapted from Peter et al, 2016). 
 
Neonatal 
cardiomyocytes 
(NRVMs/NMVMs) 
Adult cardiomyocytes 
(ARVMs/AMVMs) 
H9c2 cardiomyoblasts 
HL-1 
cardiomyocytes 
Human embryonic 
and pluripotent stem 
cells (ESCs) 
Origin Neonatal ventricular origin Adult ventricular origin Ventricular origin 
 
Derived from AT-1 atrial 
tumour cell lineage 
Ventricular origin 
Isolation Easy isolation 
 
Technically challenging 
isolation 
Immortalised Immortalised Immortalised 
Maintenance 
Can be maintained in a 
serum-free culture 
medium up to 28 days 
after isolation 
Can be maintained in a 
serum-free culture 
medium for a short time 
after isolation 
Media must be 
supplemented with an atrial 
differentiation factor in order 
to differentiate in 
cardiomyocytes and express 
cardiomyocyte lineage 
markers 
Have to be maintained in 
medium containing a 
cardioprotective agent, a 
hypertrophic stimulus, 
and an atrial 
differentiation factor 
Technically challenging to 
maintain in a serum-free 
culture medium. Numerous 
protocols for 
differentiation. 
Phenotype Immature 
Mature sarcomeric 
structure is ideal for 
patch-clamp/ contractility 
studies. Presence of 
mature ion channels are 
ideal for Ca2+ imaging 
studies 
 
Immature Immature 
Immature unless 
maintained in culture for 
12–15 week 
Homogeneity/ 
heterogeneity 
Can produce both 
homogeneous and/or 
heterogeneous cultures 
Can produce both 
homogeneous and/or 
heterogeneous cultures 
 
Homogeneous Homogeneous Heterogeneous 
Transfection/ 
manipulation 
 
Easily transfectable with 
lipid or electroporation 
methodologies 
 
Can only be transfected 
with viral vectors 
Easily manipulated Easily manipulated Easily manipulated 
Contraction in 
culture (beating) 
Spontaneously beat in 
culture 
Do not spontaneously beat 
in culture 
Do not spontaneously beat 
in culture 
Contract spontaneously 
in ideal culture 
conditions 
 
Contract spontaneously in 
ideal culture conditions 
 
 
Respond to 
hypertrophic stimuli 
 
Yes Yes Yes No Yes 
Cost 
 
Cost-effective 
 
Cost-effective Cost-effective Cost-effective Expensive 
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It has been previously shown that pre- and post-conditioning with adenosine via A1 
adenosine receptor protects H9c2 cells against simulated ischaemia (Nagarkitti and 
Shaafi, 1998; Fretwell and Dickenson, 2011; Fretwell and Dickenson, 2009). A recent 
study showed that TG2 can be modulated by PKC and PKA and that it plays a role in 
cardioprotection in H9c2 cells (Almami et al, 2014). However, this study did not 
investigate the GPCR(s) involved in TG2-induced protection as general activators of 
PKA (forskolin) and PKC (PMA) were used. Since PKC and ERK1/2 pathways are also 
associated with modulation of TG activity (Mishra et al, 2007; Bollag et al, 2005), it is 
conceivable that the A1 adenosine receptor could modulate TG2 activity and thereby 
play a role in cardioprotection in these cells. The role of β-adrenoceptors in mediating 
cardioprotection in H9c2 cells has not been uncovered yet. However, since PKA is 
known to be activated by β-adrenoceptors, it is also conceivable that β-adrenoceptors 
could modulate TG2 activity and hence have a role in cardioprotection in H9c2 cells. 
1.11 Aims of this project. 
The main aims of this project are: 
1) To establish functional expression of GPCRs (adenosine receptors and β-
adrenoceptors) and TG2 in H9c2 cells. 
2) To investigate modulation of TG2 activity by the A1 adenosine receptor. 
3) To investigate modulation of TG2 activity by the β2-adrenoceptor. 
4) To identify and validate substrates of TG2 that are modulated by the 
aforementioned GPCRs. 
5) To assess the cardioprotective potential of GPCR-induced TG2 activity. 
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Chapter II: Methods 
2.1 Materials. 
Akt inhibitor XI, AS 605240, BAPTA/AM, forskolin, PD 98059, CGP 20712, Ro-31-8220, 
Rp-8-Cl-cAMPs, N6-cyclopentyladenosine, SB 203580, SP 600125, CL 316243, 
cimaterol, dobutamine, formoterol, ICI 118,551, KT 5720, LY 294002, propranolol, 
thapsigargin and wortmannin were obtained from Tocris Bioscience (Bristol, UK). 
 
Adenosine, casein, DPCPX (1,3-dipropylcyclopentylxanthine), IBMX, IGEPAL, 
Isoprenaline, MTT (3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), 
N’,N’-dimethylcasein, paraformaldehyde, pertussis toxin, protease inhibitor cocktail, 
phosphatase inhibitor cocktail 2 and 3, ExtrAvidin®-HRP and ExtrAvidin®-FITC and 
TritonTM X-100 were obtained from Sigma–Aldrich Co. Ltd. (Gillingham, UK). Fluo-
8/AM was purchased from Stratech Scientific Ltd (Newmarket, UK). 5X MMLV buffer, 
10 mM dNTPs, random primers, RNAsin, MMLV enzyme and 100 bp DNA ladder were 
purchased from Promega® (Southampton, UK). Biomix red taq polymerase was 
obtained from Bioline (London, UK). The TG2 inhibitors Z-DON (Z-ZON-Val-Pro-Leu-
OMe) and R283 along with purified standard guinea-pig liver TG2 were obtained from 
Zedira GmbH (Darmstadt, Germany). Biotin-TVQQEL was purchased from Pepceuticals 
(Enderby, UK). DAPI was from Vector Laboratories Inc (Peterborough, UK). Coomassie 
blue (Instant BlueTM stain) was purchased from Expedeon (Swavesey, UK). Biotin 
cadaverine (N-(5-Aminopentyl) biotinamide) and biotin-X-cadaverine (5-([(N-
(Biotinoyl)amino)hexanoyl]amino)pentylamine) were purchased from Invitrogen UK 
(Loughborough, UK). DMEM (Dulbecco’s modified Eagle’s medium), foetal bovine 
serum, trypsin (10X), L-glutamine (200mM), penicillin (10,000 U/ml)/streptomycin 
(10,000 µg/ml) were purchased from Lonza, (Castleford, UK). All other reagents were 
purchased from Sigma–Aldrich Co. Ltd. (Gillingham, UK) and were of analytical grade.  
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Table 2.1. Primary antibodies employed in this study. 
 
It should be noted that the anti-phosphoserine and anti-phosphothreonine are sold as 
they’re directed towards all phosphoproteins. However, there’s a possibility they might 
not do so due to the protein conformation resulting in epitope not being exposed and 
also there could be a loss in epitope due to harsh reducing conditions of SDS and 
Laemmli. 
 
 
 
Antigen Antibody 
Catalogue 
number 
Company 
Working 
dilution 
(Western 
Blot) 
Working 
dilution 
(Immunofluo
rescence) 
phospho-specific JNK 
(Thr183/Tyr185) 
 
Rabbit 
monoclonal 
9251 
New 
England 
Biolabs, UK 
1:500 N/A 
Total unphosphorylated 
JNK 
 
Rabbit polyclonal 9252 
New 
England 
Biolabs, UK 
1:500 N/A 
phospho-specific PKB 
(Ser473) 
 
Rabbit polyclonal 9271 
New 
England 
Biolabs, UK 
1:500 N/A 
Total unphosphorylated 
PKB 
 
Rabbit polyclonal 9272 
New 
England 
Biolabs, UK 
1:500 N/A 
phospho-specific 
ERK1/2 (Thr202/Tyr204) 
 
Mouse 
monoclonal 
M8159 
Sigma-
Aldrich, UK 
1:1000 N/A 
Total unphosphorylated 
ERK1/2 
 
Mouse 
monoclonal 
9107 
New 
England 
Biolabs, UK 
1:1000 N/A 
phospho-specific p38 
MAPK (Thr180/Tyr182) 
 
Rabbit 
monoclonal 
9216 
New 
England 
Biolabs, UK 
1:500 N/A 
Total unphosphorylated 
p38 MAPK 
 
Rabbit polyclonal 9212 
New 
England 
Biolabs, UK 
1:500 N/A 
Cleaved caspase-3 
(Asp175) 
 
Rabbit 
monoclonal 
9661 
New 
England 
Biolabs, UK 
1:200 N/A 
anti-TG2 (CUB 7402) 
Mouse 
monoclonal 
MA5-12739 
Thermo 
Scientific, 
UK 
1:1000 1:1000 
anti-phosphoserine Rabbit polyclonal 
ab9332 
 
Abcam, UK 1:1000 N/A 
anti-phosphothreonine 
 
Rabbit polyclonal ab9337 Abcam, UK 1:1000 N/A 
anti-TG1 Rabbit polyclonal A018 
Zedira 
GmbH, 
Germany 
1:1000 1:1000 
anti-TG3 Rabbit polyclonal A015 
Zedira 
GmbH, 
Germany 
1:1000 1:1000 
GAPDH 
Rabbit 
monoclonal 
2118 
New 
England 
Biolabs, UK 
1:1000 N/A 
Hexokinase-1 
Rabbit 
monoclonal 
2024 
New 
England 
Biolabs, UK 
1:1000 N/A 
VDAC-1 
Rabbit 
monoclonal 
4661 
New 
England 
Biolabs, UK 
1:1000 N/A 
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Table 2.2. Secondary antibodies employed in this study. 
 
2.2 Cell culture. 
Rat embryonic cardiomyoblast-derived H9c2 cells (European Collection of Animal Cell 
Cultures, Salisbury, UK) were cultured in 75 cm2 flasks in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% (v/v) foetal bovine serum, 2 mM L-
glutamine and 100 U/ml penicillin/streptomycin for the duration of this project. Cells 
were maintained in a humidified incubator (95% air / 5% CO2, 37°C) and grown up to 
70-80% confluency as observed by light microscopy. Beyond 80% confluency, cells 
start to differentiate and hence change their morphology. Typically, H9c2 cells were 
sub-cultured with a 1:10 split using trypsin (0.05% w/v)/EDTA (0.02% w/v). Cells for 
MTT, LDH and functional receptor expression assays were grown in 24 well plates 
and/or 96 well plates (Sarstedt; NÜmbrecht, Germany). 
(i) Differentiation of H9c2 cells: 
H9c2 cells were differentiated by culturing the cells for 7 days in the continued 
presence of 10 nM all-trans retinoic acid in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 1 % (v/v) foetal bovine serum. The differentiation medium was 
replaced every 48 h and to confirm differentiation. The cells were observed under the 
microscope to form cardiomyocyte-like phenotype by the formation of multinucleated 
elongated myotubes as described by Daubney et al, 2015. 
2.3 Tissue transglutaminase activity assays. 
(i) Preparation of cell lysates for tissue transglutaminase activity assays: 
H9c2 cells were grown in T75 cm2 tissue culture flasks. Following the treatments, cells 
were washed twice with ice cold PBS and then subjected to 500 μl of lysis buffer (50 
mM Tris-HCl pH 8.0, 0.5% (w/v) sodium deoxycholate, 0.1% (v/v) protease inhibitor 
cocktail and 1% (v/v) phosphatase inhibitor cocktail 2 and 3). The cells were 
incubated in the lysis buffer on ice for 30 min, scraped and clarified by centrifugation 
Secondary 
antibody 
Catalogue 
number 
Company 
Working dilution 
(Western Blot) 
Working dilution 
(Ex/Em-
Immunofluorescence) 
Horse anti-mouse 
IgG, HRP-linked 
 
7076 
 
New England 
Biolabs, UK 
1:1000 N/A 
Goat anti-rabbit 
IgG, HRP-linked 
 
7074 
New England 
Biolabs, UK 
1:1000 N/A 
FITC conjugated 
goat anti-rabbit 
IgG, H&L 
 
ab6717 Abcam, UK N/A 1:1000 (493/528nm) 
FITC conjugated 
goat anti-mouse 
IgG, H&L 
 
ab6785 Abcam, UK N/A 1:1000 (493/528nm) 
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at 4ºC for 10 min at 14000xg. The supernatant was collected and stored at -80ºC until 
use. 
(ii) Amine incorporating assay: 
The amine incorporating activity of TG2 was measured via biotin-cadaverine 
incorporation into N, N’-dimethylcasein as described by Slaughter et al., (1992) with 
modifications of Lilley et al., (1998). 96-well microtitre plates were coated overnight 
at 4ºC with 250 μl of N, N’-dimethylcasein (10 mg/ml in 100mM Tris-HCl, pH 8.0). 
After incubation, plates were washed twice with distilled water and blocked with 250 μl 
of 3% (w/v) BSA in 100 mM Tris-HCl, pH 8.0 and incubated at room temperature for 1 
h with gentle agitation. The plate was then washed twice with distilled water and 150 
μl of either 6.67 mM calcium chloride (required for enzyme activity) or 13.3 mM EDTA 
(added to identify background activity) containing 225 μM biotin-cadaverine and 2mM 
2-mercaptoethanol was added in the respective wells. The reaction was started by the 
addition of either 50 μl samples or negative or positive controls. 50 ng/well of guinea 
pig liver TG2 was used as a positive control and 100 mM Tris-HCl, pH 8.0 was used as 
a negative control. The plates were incubated at 37ºC for 1 h. After incubation, the 
plates were washed twice with distilled water and 200 μl of 100 mM Tris-HCl, pH 8.0 
containing 1% BSA and 1:5000 dilution of ExtrAvidin®-peroxidase conjugate was 
added to each well. The plates were then incubated at 37ºC for 45 min and washed as 
before. The reaction was developed by the addition of 200 μl of freshly prepared 
developing buffer (7.5 μg ml-1 3, 3’, 5, 5’-tetramethylbenzidine (TMB) and 0.0005% 
(v/v) hydrogen peroxide in 100 mM sodium acetate, pH 6.0) and incubated at room 
temperature for 15 min. The development of colour was terminated using 50 μl of 5.0 
M sulphuric acid and the absorbance read at 450 nm using a standard 96-well plate 
reader. Each experiment was performed in triplicate and the results are expressed as 
specific activity of TG2 in units. One unit of TG2 was defined as a change in 
absorbance at 450nm/1 h. The order of drug treatments on the layout of the plate was 
randomised to avoid experimental design bias. 
(iii) Peptide crosslinking assay: 
The crosslinking activity of TG2 was measured via biotin-TVQQEL peptide 
incorporation into casein as described by Trigwell et al., 2004 with minor modifications. 
96-well microtitre plates were coated overnight at 4ºC with 250 μl of casein (1 mg/ml 
in 100mM Tris-HCl, pH 8.0). After incubation, plates were washed twice with distilled 
water and blocked with 250 μl of 3% (w/v) BSA in 100 mM Tris-HCl, pH 8.0 and 
incubated at room temperature for 1 h with gentle agitation. The plate was then 
washed twice with distilled water and 150 μl of either 6.67 mM calcium chloride 
(required for enzyme activity) or 13.3 mM EDTA (added to detect background activity) 
containing 5 μM biotin-TVQQEL peptide and 2 mM 2-mercaptoethanol was added in 
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the respective wells. The reaction was started by the addition of 50 μl samples or 
negative and positive controls. 50 ng/well of guinea pig liver TG2 was used as a 
positive control and 100 mM Tris-HCl, pH 8.0 was used as a negative control. The 
plates were incubated at 37ºC for 1 h. After incubation, the plates were washed twice 
with distilled water and 200 μl of 100 mM Tris-HCl, pH 8.0 containing 1% BSA and 
1:5000 dilution of ExtrAvidin®-peroxidase conjugate was added to each well. The 
plates were then incubated at 37ºC for 45 min and washed as before. The reaction 
was developed by the addition of 200 μl of freshly prepared developing buffer (7.5 
ug/ml 3, 3’, 5, 5’-tetramethylbenzidine (TMB) and 0.0005% (v/v) hydrogen peroxide 
in 100 mM sodium acetate, pH 6.0) and incubating at room temperature for 15 min. 
The development of colour was terminated using 50 μl of 5.0 M sulphuric acid and the 
absorbance read at 450 nm using a standard 96-well plate reader. Each experiment 
was performed in triplicate and the results are expressed as specific activity of TG2 in 
units. One unit of TG2 was defined as a change in absorbance at 450nm/1 h. The 
order of drug treatments on the layout of the plate was randomised to avoid 
experimental design bias. 
(iv) Visualisation of in-situ TG2 transamidating activity via ExtrAvidin® FITC and    
confocal microscopy: 
H9c2 cells were seeded into 8-well chamber slides (15000 cells/well) and cultured for 
24 h in fully supplemented DMEM. The next day, cells were exposed to fresh fully 
supplemented DMEM containing 1 mM biotin-x-cadaverine and incubated for 6 h 
(Perry et al., 1995). Following incubation, cells were treated as described in Figure 
legends. After treatment(s), cells were washed three times (five min per wash) with 
PBS. 200 μl of 3.7% (w/v) paraformaldehyde in PBS was added into each well and 
incubated at room temperature for 15 min in order to fix cells. The cells were washed 
twice (five min per wash) with PBS. 200 μl of 0.1% (v/v) Triton-X100 in PBS was 
added into each well and incubated at room temperature for 15 min in order to 
permeabilise the cells. The cells were washed again as described previously and 
blocked with 3% (w/v) BSA in PBS for 1 h at room temperature. Transglutaminase 
mediated transamidating activity was detected by FITC-conjugated ExtrAvidin® (1:200 
v/v) in blocking buffer. The slides were incubated overnight at 4ºC. The next day, cells 
were washed as before and nuclei counter-stained using DAPI in Vectorshield 
mounting medium. The slides were sealed with coverslips and secured with nail 
varnish and stored at 4ºC until required. Images were acquired using Leica TCS SP5 II 
confocal microscope (Leica Microsystems, GmbH, Manheim, Germany) equipped with a 
20x air objective. Optical sections were typically 1–2 µm and the highest fluorescence 
intensity was acquired using either forskolin (10 µM) or CPA (100 nM) as a positive 
control. Using the look-up table overlay option, saturation was observed and avoided 
by setting the gain accordingly. The output laser power, acquisition mode, pinhole 
49 
 
diameter, detector gain and amplifier offset were standardised for all samples 
analysed. Images were acquired using a sequential scan to avoid cross-excitation of 
fluorochromes and to distinguish between extracellular, cell surface and intracellular 
TG2. The images were analysed and quantified using Leica LAS AF software from 
minimum of five fields of view per treatment. Each experiment had a negative control 
(no application of FITC) and the FITC fluorescence intensity values of the negative 
control (i.e. background) were subtracted from the FITC fluorescence intensity values 
of each treatment in that experiment. Following this, the value obtained for each 
treatment was divided by the fluorescence intensity of DAPI for that treatment in that 
experiment to get fluorescence per nuclei. This normalised FITC fluorescence intensity 
per nuclei values were plotted and further analysed using GraphPad Prism® software 
(GraphPad Software, Inc., USA). 
2.4 Expression of GPCRs and TGs in H9c2 cells. 
(i) RT-PCR for GPCR expression: 
(a) cDNA synthesis: 
Total RNA was isolated from mitotic and differentiated H9c2 cells, rat heart, rat lung, 
rat brain and rat eye using a GenElute® total RNA isolation kit (Sigma-Aldrich Co. Ltd, 
Gillingham, UK) according to the manufacturer’s instructions. First strand 
complementary DNA (cDNA) was synthesized using 10 µl of 5X MMLV buffer, 10 µl of 
10 mM dNTPs, 1 µl of random primers, 1 µl of RNAsin, 1 µl of MMLV enzyme and 27 µl 
of 2 µg mRNA (Promega®, Southampton, UK). 
 
After gentle mixing of the reagents, each sample was subjected to 42°C for 90 min. 
Following this incubation, residual RNA was preserved in 0.1 vol of 3M sodium acetate 
and 2.5 vol of 100% ethanol. Samples were then gently mixed and stored at -20°C. 
 
(b) PCR: 
PCR was performed using gene-specific primer sequences (Eurofins Genomics, 
Wolverhampton, UK) for adenosine receptors and beta adrenoceptors as well as the 
housekeeping gene GAPDH. The primers used are shown in Table 2.3. 
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Table 2.3.  Primer sequences designed along with melting temperature and product 
sizes. 
Receptor Primer Sequence Tm Product size 
Adenosine A1 Receptor Forward GCTCCATTCTGGCTCTGCT 60°C 
207 
 
Reverse CACTGCCGTTGGCTCTCC 60°C 
 
Adenosine A2A Receptor Forward TTCGCTATCACCATCAGCAC 60°C 
249 
 
Reverse GTTCCAGCCCAGCATGGG 60°C 
 
Adenosine A2B Receptor Forward TTCGCCATCCCCTTTGCCA 60°C 
250 
 
Reverse GGAAAGGAGTCAGTCCAATG 60°C 
 
Adenosine A3 Receptor Forward CCACGCTTCCATCATGTCC 60°C 
237 
 Reverse CCGACCACGGAACGGAAG 60°C  
β1 adrenoceptor Forward TACTCCTGGCGCTCATCGT 60°C 599 
 
Reverse CTCGCAGCTGTCGATCTTC 60°C 
 
β2 adrenoceptor Forward AGCCACACGGGAATGACAG 60°C 323 
 
Reverse CCAGAACTCGCACCAGAA 60°C 
 
β3 adrenoceptor Forward AGTCCTGGTGTGGATCGTG 60°C 724 
 
Reverse ACGCTCACCTTCATAGCCAT 60°C 
 
GAPDH Forward CAAGTTCAACGGCACAGTCA 60°C 392 
 
Reverse GAGTGGCAGTGATGGCATG 60°C 
 
 
Eight thin-walled PCR tubes were prepared consisting of 1 µl forward primer, 1 µl 
reverse primer, 1 µl cDNA, 12.5 µl Biomix red taq polymerase (Bioline, London, UK) 
and 9.5 µl DEPC water. The PCR conditions for the adenosine receptors, beta 
adrenoceptor and GAPDH were 40 cycles of 94oC for 1 min, 59oC for 1.5 min, and 72oC 
for 1 min. Samples were held at 4°C. Negative controls were performed using an 
identical protocol but lacking the cDNA template. 
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(c) Agarose gel electrophoresis: 
1.5% (w/v) agarose gels were cast in Tris-acetate-EDTA (TAE) buffer (40mM Tris, 
20mM acetic acid, 1mM EDTA) supplemented with 0.5 µg/ml of ethidium bromide. 5 µl 
of 100 bp DNA ladder (Promega®, Southampton, UK) and 25 µl of PCR product were 
loaded on the gel. Gels were run at 100 V for 30 min. DNA was visualised under UV 
illumination and images were captured by U:Genius3 (Syngene, Cambridge, UK). 
(ii) Immunofluorescence for TG expression: 
H9c2 cells were seeded into 8-well chamber slides (15,000 cells/well) and cultured for 
24 h in fully supplemented DMEM. The next day, medium was removed and cells were 
washed twice (five min per wash) with PBS. 200 μl of 3.7% (w/v) paraformaldehyde in 
PBS was added into each well and incubated at room temperature for 15 min in order 
to fix cells. The cells were washed three times (five min per wash) with PBS. 200 μl of 
0.1% (v/v) Triton-X100 in PBS was added into each well and incubated at room 
temperature for 15 min in order to permeabilise the cells. The cells were then again 
washed as described above and blocked with 3% (w/v) BSA in PBS for 1 h at room 
temperature. The slides were incubated overnight at 4ºC in blocking buffer with one of 
the following primary antibodies (1:1000 unless otherwise stated): TG1 (A018), TG2 
(CUB 7402) and TG3 (A015). After incubation, the primary antibody was removed and 
the slides washed three times (five min per wash) with PBS. Slides were then 
incubated with appropriate secondary antibody (FITC conjugated goat anti-rabbit/ 
anti-mouse antibody; 1:1000) in blocking buffer for 2 h at room temperature. After 
incubation with secondary antibody, the slides were washed three times (five min per 
wash) with PBS and the nuclei counter stained using DAPI in Vectorshield® mounting 
medium. The slides were sealed with coverslips, secured with nail varnish and stored 
at 4ºC until required. Images were acquired using Leica TCS SP5 II confocal 
microscope (Leica Microsystems, GmbH, Manheim, Germany) and the images were 
analysed and quantified, as described above. 
 
2.5 Functional Expression of GPCRs in H9c2 cells. 
(i) cAMP accumulation assay: 
H9c2 cells (5000 cells/well) were seeded in a white 96 well microtitre plate, with clear-
bottomed wells (Fisher Scientific, Loughborough, UK) and cultured for 24 h in fully 
supplemented DMEM. The medium was removed and the monolayer treated with 
agonists for 20 min in serum-free DMEM (40 µl/well) in the presence of 1 M MgCl2 and 
500 µM 3-isobutyl-1-methylxanthine (IBMX; phosphodiesterase inhibitor). Where 
appropriate, cells were pre-treated with antagonists for 30 min in similar media. 
Following stimulation, cAMP levels within cells were determined using the cAMP-Glo™ 
Max Assay kit (Promega®, Southampton, UK). Briefly, following antagonist/agonist 
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incubation, 10 µl of cAMP detection solution was added to all wells and incubated for 
20 min at room temperature while gently shaking. After incubation, Kinase-Glo® 
reagent (50 µl/well) was added and incubated for 10 min at room temperature under 
shaking conditions, following which luminescence levels across the plate were read 
using a plate-reading FLUOstar Optima luminometer (BMG Labtech Ltd, Aylesbury, 
UK). Forskolin 10 µM was used as a positive control and the luminescence values were 
converted to cAMP levels using a cAMP standard curve (0-100 nM), according to 
manufacturer’s instructions. 
(ii) Measurement of intracellular calcium:  
H9c2 cells were seeded in 24-well flat-bottomed plates (15,000 cells/well) and 
cultured for 24 h in fully supplemented DMEM. Cells were loaded with Fluo-8 AM (5 μM, 
30–40 min) before mounting on the stage of a Leica TCS SP5 II confocal microscope 
(Leica Microsystems, GmbH, Manheim, Germany) equipped with a 20x air objective. 
Cells were incubated at 37°C using a temperature controller and micro incubator (The 
Cube, Life Imaging Services, Basel, Switzerland) in the presence of imaging buffer 
(134 mM NaCl, 6 mM KCl, 1.3 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM 
glucose; pH 7.4). Using an excitation wavelength of 490 nm, emissions over 514 nm 
were collected. Images were collected every 1.7 s for 10 min. Increases in intracellular 
Ca2+ were defined as F/F0 where F was the fluorescence at any given time, and F0 was 
the initial basal level of fluorescence. 
2.6 SDS-PAGE and Western blot analysis. 
(i) Preparation of cell lysates for western blotting: 
H9c2 cells were grown in T25 tissue culture flasks. Following treatments, cells were 
washed twice with PBS (room temperature) and subjected to 300 μl of boiling lysis 
buffer (0.1% SDS in Tris buffered saline). The cells were immediately scraped and 
collected in 1.5 ml Eppendorf™ tubes and boiled for 10 min. The lysates were stored 
at -20ºC until use. 
(ii) BCA protein assay: 
The protein content of samples was assessed using the commercially available kit from 
Sigma-Aldrich based on the bicinchoninic acid (BCA) protocol (Smith et al, 1985) using 
dilutions of bovine serum albumin (BSA) as standard. Protein standards were prepared 
using dilutions of 1 mg/ml BSA to produce a linear standard curve as shown in table 
2.4. 20 μl of standards and samples were added to a 96 well flat-bottomed plate in 
triplicate. 200 μl of working BCA reagent (50 parts of reagent A to 1 part of reagent B) 
was added to each of the wells and the plate incubated at 37ºC for 30 min. 
Absorbance was read at 570 nm using a standard 96-well plate reader. Protein content 
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of samples was obtained by measuring them against the standard curve. The order of 
drug treatments on the layout of the plate was randomised to avoid experimental 
design bias. 
Table 2.4. BSA standard curve. 
Protein concentration (mg/ml) 1 mg/ml BSA (µl) Distilled water (µl) 
0 0 20 
0.2 4 16 
0.4 8 12 
0.6 12 8 
0.8 16 4 
1 20 0 
 
(iii) SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis): 
Once the protein concentration of the samples was estimated, the desired amount of 
protein was dissolved in a 3:1 ratio with 4x reducing Laemmli buffer (125mM Tris-HCl, 
pH 6.8, 20% (v/v) glycerol, 4% (v/v) SDS, 10% (v/v) 2-β-mercaptoethanol and 
0.004% bromophenol blue) (Laemmli et al., 1970) and boiled for 10 min at 95°C to 
denature. The gels were prepared according to manufacturer’s instructions. Briefly, 
1.5 mm thickness 10% acrylamide gel (8.0 ml deionised water, 6.6 ml ProtoGel® 
acrylamide mix (30 % acrylamide solution 37.5:1 ratio, Geneflow Ltd, Staffordshire, 
UK), 5.0 ml 1.5 M Tris-HCl pH 8.8, 200 μl 10% SDS solution (10% (w/v) sodium 
dodecyl sulphate in deionised water), 200 μl APS solution (10% (w/v) ammonium 
persulphate in deionised water), 20 μl TEMED) were cast using the Bio-Rad Mini-
Protean III system. Once the resolving gel was poured to about 75% of the glass 
plates, water was added to ensure level polymerisation of the gel. Once the resolving 
gel had polymerised, water was removed and the stacking gel was poured (12.3 ml 
deionised water, 2.5 ml ProtoGel® acrylamide mix, 5.0 ml 1.0 M Tris-HCl pH 6.8, 200 
μl 10% SDS solution (10% (w/v) sodium dodecyl sulphate in deionised water), 200 μl 
APS solution (10% (w/v) ammonium persulphate in deionised water), 20 μl TEMED). 
Immediately once the stacking gel was poured, a plastic comb was placed to form 
wells. Following polymerisation, the gels were placed in the electrophoretic tank and 
filled with electrophoresis buffer (25mM Tris, 192mM Glycine and 0.1% (w/v) SDS, pH 
8.5). The protein samples (20-50 µg/well; depending on target protein) were loaded 
along with 5 μl of protein ladder. Electrophoresis was conducted at 120 V through the 
stacking gel and then at 160 V through the resolving gel. 
(iv) Coomassie staining of gels: 
Following electrophoresis, the gel was washed twice with distilled water and 20 ml of 
Instant Blue stain (Expedeon, Cambridge, UK) was added. The gel was incubated for 1 
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h at room temperature with gentle agitation. After incubation, the gel was washed 
three times (ten min per wash) with distilled water. Subsequently, the gel was 
visualised and images were captured by LAS 4000 system (GE healthcare life sciences, 
Buckinghamshire, UK). 
(v) Western blotting: 
After electrophoresis, the proteins were transferred to nitrocellulose membranes using 
Bio-Rad Trans-blot system according to previously established protocols (Towbin et al., 
1979). Briefly sponges, filter paper, nitrocellulose membrane and electrophoresed gels 
were soaked in ice-cold transfer buffer (25mM Tris, 192mM glycine, pH 8.3 and 20% 
(v/v) methanol). The western blot sandwich was prepared in the following manner: 
sponge, filter paper, nitrocellulose membrane, gel, filter paper, sponge. A roller was 
used to remove any air bubbles trapped in the sandwich. The layers were clamped 
together and placed in a western blotting cassette and then into the tank along with a 
cooling block. The tank was filled with ice-cold transfer buffer and the transfer was 
performed at 180 mA for 75 min. Following transfer, membranes were stained with 
Ponceau S stain to visualise the protein bands. Once stained the protein bands were 
cut above the predicted molecular weight. Initially, full length blots were used to check 
if there was any non-specific binding of the antibody. However, since no non-specific 
binding was observed, the blots were cut to reduce antibody consumption. The 
membrane strips were destained using Tris-buffered saline Tween-20 (TBST; 0.1% 
(v/v) Tween-20 in 25mM Tris, 150mM NaCl). After destaining, the membrane was 
blocked with 5% (w/v) skimmed milk powder in TBST for 1 h at room temperature 
with gentle agitation. The blots were then incubated overnight with gentle agitation at 
4ºC in blocking buffer with one of the following primary antibodies (1:1000 unless 
otherwise stated): Phospho-specific ERK1/2, phospho-specific JNK (1:500), phospho-
specific p38 MAPK (1:500), phospho-specific PKB (1:500), cleaved active caspase-3 
(1:200), GAPDH, TG1, TG2, TG3,  anti-phosphoserine, anti-phosphothreonine, 
hexokinase-1, VDAC-1. After incubation, the primary antibody was removed and the 
membrane washed three times for 5 min each with TBST. Blots were then incubated 
with appropriate secondary antibody (1:1000) conjugated to horseradish peroxidase 
(New England Biolabs (UK) Ltd) in blocking buffer for 2 h at room temperature with 
gentle agitation. After incubation with secondary antibody, the blots were washed 
three times for 5 min each with TBST and developed using the Enhanced 
Chemiluminescence (ECL) detection system. Digital images of the blots were captured 
by the LAS 4000 system and the bands were quantified by densitometry using 
Advanced Image Data Analysis software (AIDA). Samples were also analysed using 
primary antibodies that recognise total ERK1/2, PKB, p38 MAPK and JNK (1:1000) in 
order to confirm the uniformity of protein loading. 
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2.7 Immunoprecipitation analysis of TG2 phosphorylation. 
H9c2 cells were grown in T175 tissue culture flasks. Following treatments, cells were 
washed twice with ice cold PBS. The cells were then scraped, collected in 5 ml of PBS 
and subjected to centrifugation at 300xg (1000 rpm) at room temperature for 5 min. 
The supernatant was discarded and cell pellet resuspended in 500 μl of ice cold lysis 
buffer (2 mM EDTA, 1.5 mM MgCl2, 10% (v/v) glycerol, 0.5% (v/v) IGEPAL, 0.1% (v/v) 
protease inhibitor cocktail (AEBSF – [4-(2-Aminoethyl)benzenesulfonyl fluoride 
hydrochloride], Aprotinin, Bestatin hydrochloride, E-64 – [N-(trans-Epoxysuccinyl)-L-
leucine 4-guanidinobutylamide], Leupeptin hemisulfate salt, Pepstatin A), and 1% (v/v) 
phosphatase inhibitor cocktail 2 (sodium orthovanadate, sodium molybdate, sodium 
tartrate and imidiazole) and 3 (Cantharidin, (–)-p-Bromolevamisole oxalate, Calyculin 
A) in PBS). The cells were incubated with lysis buffer for 30 min and then clarified by 
centrifugation at 4ºC for 10 min at 14000xg. The supernatant was collected and 
following protein estimation, 500 µg of protein was incubated overnight at 4ºC with 2 
μg of anti-TG2 monoclonal antibody (CUB 7402) or IgG. Immune complexes were 
precipitated using Pierce™ Classic Magnetic IP/Co-IP kit (Thermo Scientific, 
Loughborough, UK). The eluted proteins were resolved by 10% SDS-PAGE and 
western blotting, and then probed using anti-phosphoserine or anti-phosphothreonine 
antibodies (1:1000). The blots were developed using the Enhanced 
Chemiluminescence (ECL) detection system and quantified by densitometry, as 
described above. 
2.8 GPCR-mediated protection against hypoxia- and hypoxia/reoxygenation-
induced cell death. 
(i) Simulation of ischaemia and/or ischaemia/reperfusion injury: 
Ischaemia was simulated by means of hypoxia while ischaemia/reperfusion injury was 
simulated by hypoxia/reoxygenation. Hypoxia was induced by means of Panasonic® 
O2/CO2 incubator. 80% confluent H9c2 cells were placed in glucose- and serum-free 
DMEM and exposed to 8 h (except for time course experiments) hypoxia using a 
hypoxic incubator (5% CO2/1% O2; 37°C) in which O2 was replaced with N2 . Normoxic 
incubation of similar passage numbers were used as controls. Where pharmacological 
pre- or post-conditioning was needed, cells were incubated with GPCR agonists in 200 
μl (96-well microtitre plates), 500 µl (24-well microtitre plates) or 5 ml (T25 tissue 
culture flasks) serum-free DMEM for 10 min (for A1 adenosine receptor) or 20 min (for 
β2 adrenoceptor); this medium was then discarded and replaced with glucose- and 
serum-free DMEM for the hypoxic/normoxic incubation. Where appropriate, cells were 
also treated with GPCR antagonists for 30 min or TG2 inhibitors for 60 min prior to the 
addition of agonist. 
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For hypoxia/reoxygenation experiments, cells were exposed to hypoxia for 8 h as 
described above, and then reoxygenated for 18 h in DMEM containing glucose and 1% 
serum. Preconditioning was performed prior to hypoxia, Postconditioning occurred at 
the start of reoxygenation, treatment protocol as before (see Figure 2.1 for summary). 
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Fig 2.1 Protocol for hypoxia and hypoxia/reoxygenation experiments. Time-matched normoxic and hypoxic controls were performed for each 
experimental condition. 
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(ii) MTT reduction assay: 
H9c2 cells were seeded in 24-well flat-bottomed plates (15,000 cells/well) and 
cultured for 24 h in fully supplemented DMEM. Incubations were performed in 500 μl 
of the relevant media and an hour prior to completion of periods of hypoxia or 
hypoxia/reoxygenation, 0.5 mg/ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) in the relevant media was added to each well. After 
completion of this final hour, the medium was aspirated carefully not disturbing the 
blue insoluble formazan crystals at the bottom of the well. 500 μl of DMSO was added 
to each well and gently agitated to solubilise the formazan product. 200 μl of the 
resulting solution was transferred to 96-well flat-bottomed plates and the absorbance 
read at 570 nm using a standard plate reader. Results are expressed as percentage of 
basal MTT reduction and represent the mean  S.E.M. from four independent 
experiments, each performed in quadruplicate. The order of drug treatments on the 
layout of the plate was randomised to avoid experimental design bias. 
(iii) LDH release assay: 
H9c2 cells were seeded in 96-well flat-bottomed plates (5000 cells/well) and cultured 
for 24 h in fully supplemented DMEM. Incubations were performed in 200 μl of the 
relevant media and the cell death measured using the colorimetric CytoTox 96® non-
radioactive cytotoxicity assay kit (Promega®, Southampton, UK). This kit measures 
lactate dehydrogenase (LDH) leakage from the cell membrane, thereby providing an 
indirect method of measuring cell toxicity. There are two reactions involved. Firstly, 
the LDH released from the cells catalyses lactate and NAD+ to form pyruvate and 
NADH. The second reaction is catalysed by the dehydrogenase enzyme diaphorase 
(present in substrate mix provided in the kit) which involves formation of NAD+ and 
red formazan product which is then measured colorimetrically.  
 
 
 
 
 
 
 
 
Fig 2.2 Reactions involved in detection of cell viability using LDH release assay. 
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Once incubations were finished, the plates were centrifuged at 300xg for 5 min to 
sediment any cell debris. 50 μl of the supernatant was transferred to a new non-sterile 
96-well flat-bottomed plates and 50 μl of reconstituted assay buffer substrate solution 
(10 ml of assay buffer in one bottle of substrate provided in the kit) was added to 
each well. The assay plate was wrapped in foil and incubated for 30 min at room 
temperature with gentle agitation. The reaction was terminated by addition of 50 μl 
stop solution (1 M acetic acid, provided in the kit) to each well and the absorbance 
read at 490 nm using a standard plate reader. Results are expressed as percentage of 
basal LDH release and represent the mean  S.E.M. from four independent 
experiments, each performed in sextuplicate. The order of drug treatments on the 
layout of the plate was randomised to avoid experimental design bias. 
(iv) Caspase-3 activation: 
H9c2 cells were cultured in T25 tissue culture flasks, until 80% confluent, in fully 
supplemented DMEM. Where appropriate, treatments were performed in 5 ml of 
respective media. This was replaced with 5 ml glucose- and serum-free DMEM for the 
8 h incubation under hypoxic conditions and/or DMEM containing glucose and 1% 
serum during reoxygenation. Following incubations, cells were lysed and subjected to 
western blotting as described above to detect cleaved caspase-3. 
2.9 Proteomic analysis of TG2 biotin-X-cadaverine labelled substrates. 
(i) CaptAvidinTM-agarose sedimentation based affinity purification: 
Cellular proteins acting as substrates for endogenous TG2-catalysed polyamine 
incorporation reactions were investigated as described by Singh et al., (1995). Briefly, 
H9c2 cells were grown in T175 tissue culture flasks and cultured until 80% confluent 
in fully supplemented DMEM. Cells were then exposed to fresh fully supplemented 
DMEM containing 1 mM biotin-x-cadaverine and incubated for 6 h (Perry et al., 1995). 
Following incubation, cells were treated as described in Figure legends. Following 
treatments, cells were washed twice with ice cold PBS and subjected to 500 μl of lysis 
buffer (50 mM Tris-HCl pH 8.0, 0.5% (w/v) sodium deoxycholate, 0.1% (v/v) protease 
inhibitor cocktail and 1% (v/v) phosphatise inhibitor cocktail 2 and 3). The cells were 
incubated in the lysis buffer on ice for 30 min, scraped and clarified by centrifugation 
at 4ºC for 10 min at 14000xg. The supernatant was collected and following protein 
estimation, 500 ug of protein was incubated overnight at 4ºC along with 500 µl of 
biotin binding buffer (50 mM citrate phosphate buffer pH 4.0) and 200 µl of 
CaptAvidinTM-agarose sedimentation beads (Life Technologies, UK). The next day, 
protein substrates were eluted according to the manufacturer’s protocol and the 
elution’s subjected to 4-15% gradient SDS–PAGE. The separated proteins were 
stained with Coomassie blue and visualised using LAS 4000 system. The bands were 
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quantified by densitometry using Advanced Image Data Analysis software (AIDA) as 
described previously. 
(ii) Mass spectrometry: 
Following pre-treatment with 1 mM biotin-X-cadaverine, H9c2 cells were treated with 
A1 adenosine receptor or β2 adrenoceptor agonists and lysed as described above. The 
proteins labelled with biotin-X-cadaverine were enriched using CaptAvidinTM-agarose 
and these biotin-X-cadaverine labelled proteins were processed for trypsin digestion 
(Trypsin, proteomics grade; Sigma-Aldrich, UK). For trypsin digestion: samples (~50 
µg protein) were reduced and alkylated (1 µl 0.5 M DTT, 56°C for 20 min; 2.7 µl 0.55 
M iodoacetamide, room temperature 15 min in the dark), dried in a vacuum 
concentrator (Eppendorf, UK) and re-suspended in 100 µl 50 mM tri-ethyl ammonium 
bicarbonate (TEAB). Sigma Trypsin (2 µg) was added in 2 µl of 1 mM HCl, and 
incubated overnight at 37°C in a thermo mixer. Samples were then evaporated to 
dryness in a vacuum concentrator and resuspended in 5% (v/v) acetonitrile/0.1% (v/v) 
formic acid (20 µl) and transferred to a HPLC vial for SWATH MS (Sequential 
Windowed Acquisition of all Theoretical fragment ion Mass Spectra) analysis. For the 
A1 adenosine receptor, samples (3 µl) were directly injected by an autosampler 
(Eksigent nano LC 425 LC system) at 5 µl/min onto a YMC Triart-C18 column (25 cm, 
3 µm, 300 µm inner diameter). For the β2 adrenoceptor, samples (3 µl) were injected 
onto an automated trapelute column prior to injecting onto the column. The column 
was eluted using a gradient elution (2–40% mobile phase B over mobile phase A, 
followed by wash at 80% mobile phase B and re-equilibration at 5% mobile phase B) 
over 120 min run time (for spectral library construction using data/information 
dependent acquisition DDA/IDA) or 60 min run time for SWATH/DIA (Data 
Independent Acquisition) analysis (Huang et al., 2015). Mobile phases consisted of A: 
2% (v/v) acetonitrile, 5% (v/v) DMSO in 0.1% (v/v) formic acid and B: acetonitrile 
containing 5% (v/v) DMSO in 0.1% (v/v) formic acid. A spectral library was 
constructed using the output from ProteinPilot 5 (SCIEX) combining 4 IDA runs per 
group (control and treated) and filtered and aligned to spiked in iRT peptides 
(Biognosys, Switzerland) using PeakView 2.1 SWATH micro app (SCIEX). SWATH data 
extraction, quantitation and fold change analysis were carried out using SCIEX 
OneOmics cloud processing software (https://basespace.illumina.com/home/index; 
Lambert et al., 2013). Further details on this method are given in chapter VII. 
(iii) Bio-informatics analysis of mass spectrometry identified substrates: 
Following identification by SWATH MS, TG2 substrates representing 
increased/decreased levels of proteins in eluates from CaptAvidin™-agarose beads 
following stimulation of either the A1 adenosine receptor and β2 adrenoceptor were 
further analysed using the Database for Annotation, Visualisation and Integrated 
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Discovery (DAVID) v6.8 (https://david.ncifcrf.gov/home.jsp; Dennis et al, 2003). 
Once input of the protein substrates was completed, DEFINE KEGG pathway 
annotation results were chosen. The parameters were set to be stringent by ensuring 
the p value used was <0.05 and that a minimum of two proteins existed in that 
pathway. Fold enrichment values were calculated by the software and used to create a 
graphical representation of the pathway. 
(iv) Validation of mass spectrometry derived substrates of TG2: 
Following pre-treatment with 1 mM biotin-X-cadaverine, H9c2 cells were treated with 
A1 adenosine receptor or β2 adrenoceptor agonists and lysed as described above. The 
proteins labelled with biotin-X-cadaverine were enriched using CaptAvidinTM-agarose 
and subjected to immunoprecipitation as described previously, using specific primary 
antibodies against mass spectrometry-identified proteins. Following 
immunoprecipitation, western blotting was carried out using with ExtrAvidin®-HRP 
(1:5000 dilution) as neither primary antibody nor secondary antibody was used. After 
incubation, the blots were washed three times for 5 min each with TBST and 
developed using the Enhanced Chemiluminescence (ECL) detection system. Digital 
images of the blots were captured by LAS 4000 system and the bands were quantified 
by densitometry using Advanced Image Data Analysis software (AIDA) as described 
previously. 
2.10 Statistical analysis 
All graphs and statistics (one-way ANOVA followed by Dunnett’s multiple comparison 
test and two-way ANOVA followed by Dunnett’s (to compare one mean to other means) 
or Sidak’s (to compare sets of means e.g. normoxia vs hypoxia or 
hypoxia/reoxygenation) multiple comparison test for group comparison) were 
performed using GraphPad Prism® software (GraphPad Software, Inc., USA). Results 
represent mean ± S.E.M. and p values <0.05 were considered statistically significant. 
For all concentration responses, a four-parameter logistic equation was used to fit the 
curve which accounts for top, bottom, slope of the curve and EC50 values. Curve fits 
were performed using GraphPad Prism® software (GraphPad Software, Inc., USA). The 
drug concentrations, particularly antagonist concentrations, were chosen after 
calculating the receptor occupancy for each antagonist using the Hill-
Langmuir equation. As the afftinity (KA) of the ligand for that receptor is known from 
the literature, the proportional occupancy (pA) at a given concentration (xA) of the 
drug was calculated using the Hill-Langmuir equation: 
PA = (xA/KA) / ((xA/KA) + (xB/KB) + 1). 
For example, the affinity of Isoprenaline at the β1-adrenoceptor is 0.871 μM and at the 
β2-adrenoceptor is 0.229 μM and that of the selective β2-adrenoceptor antagonist ICI 
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118551 at the β1-adrenoceptor is 302 nM and at the β2-adrenoceptor is 0.55 nM 
(affinity values obtained from Baker, 2005; Baker, 2010). The receptor occupancies in 
the prescence of both ligands were calculated as follows: 
Proportion occupied (pA) by 100 nM (xA) ICI 118551 (KA) in the presence of 1 μM (xB)  
isoprenaline (KB) for β2-adrenoceptors: 
PA = (xA/KA) / ((xA/KA) + (xB/KB) + 1).  
PA = (100/0.55) / ((100/0.55) + (1/0.229) + 1). 
PA = 181.8/ (181.8 + 4.37 + 1). 
PA = 181.8/ 187.17. 
PA = 0.971. 
The proportion occupied (pA) can be converted to percentage occupied by multiplying 
it by 100. 
PA = 97% 
 
Proportion occupied (pA) by 100 nM (xA) ICI 118551 (KA) in the presence of 1 μM (xB)  
isoprenaline (KB) for β1-adrenoceptors: 
PA = (xA/KA) / ((xA/KA) + (xB/KB) + 1).  
PA = (100/302) / ((100/302) + (1/0.871) + 1). 
PA = 0.33/ (0.33 + 1.15 + 1). 
PA = 0.33/ 2.48. 
PA = 0.133. 
The proportion occupied (pA) can be converted to percentage occupied by multiplying 
it by 100. 
PA = 13% 
All other receptor occupancies were calculated in the same way. 
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CHAPTER III: Functional GPCR and Transglutaminase expression in 
H9c2 cells 
Prior to investigating the modulation of TG2 activity by GPCRs and its cardioprotective 
effects, it is necessary to determine whether TG2 and other TG isoforms along with 
the GPCRs intended to target (adenosine receptors and β-adrenoceptors) are 
functionally expressed in H9c2 cells. Hence, this chapter aims to determine the mRNA 
expression and functional expression of adenosine receptors and β-adrenoceptors via 
RT-PCR analysis, cAMP accumulation and calcium imaging. Subsequently, to determine 
which TG isoforms (TG1, TG2 and TG3) are expressed in these cells via western 
blotting and confocal microscopy. 
3.1. Functional expression of adenosine receptors on H9c2 cells. 
RT-PCR analysis 
A1, A2A, A2B and A3 adenosine receptor mRNA expression in both mitotic and 
differentiated H9c2 cells was determined by RT-PCR analysis. As shown in figure 3.1, 
mRNA encoding for A1 and A3 adenosine receptors was observed in mitotic H9c2 cells, 
whereas only mRNA for the A2A adenosine receptor was present in differentiated H9c2 
cells. Faint expression of the A1 adenosine receptor was observed in differentiated 
H9c2 cells. There was no observable expression of the A2B adenosine receptor in either 
mitotic or differentiated H9c2 cells. 
  
 
 
 
 
 
Fig. 3.1: Adenosine receptor mRNA expression in H9c2 cells. mRNA isolated from 
H9c2 cells was subjected to RT-PCR using intron spanning A1, A2A, A2B and A3 
adenosine receptor gene-specific primers. mRNA sample isolated from rat brain (A1), 
rat eye (A2A and A2B) and rat lung (A3) were used as positive controls. L: 100 bp DNA 
standard; lane 1: no DNA control (DEPC water); lane 2: positive control; lane 3:  
mitotic H9c2 cell-derived mRNA; lane 4: differentiated H9c2 cell-derived mRNA. mRNA 
control using GAPDH primers is shown in the lower panel. The predicted transcript 
sizes for A1, A2A, A2B, A3 adenosine receptor and GAPDH are 207, 2049, 250, 237 and 
392 bp. The results presented are representative of three independent experiments. 
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cAMP accumulation 
Following mRNA assessment, functional expression of adenosine receptors on H9c2 
cells was investigated using a cAMP accumulation assay and calcium imaging. The 
selective A1 adenosine receptor agonist, CPA, revealed substantial inhibition of 
forskolin-induced cAMP accumulation (pEC50 = 9.19  0.16; n=4; figure 3.2) in mitotic 
H9c2 cells. However, 10 μM CPA resulted in beginning of reversal of the inhibition of 
cAMP accumulation observed at lower concentrations suggesting Gs-coupling. CGS 
21680, the selective A2A adenosine receptor agonist, did not generate any cAMP 
accumulation (figure 3.3) suggesting that even though mRNA was detected, this 
receptor is not functionally expressed in differentiated H9c2 cells. 
 
 
 
 
 
 
Fig 3.2 Effect of the selective A1 adenosine receptor agonist CPA on cAMP 
accumulation in H9c2 cells. Cells were pre-treated with the indicated concentrations of 
CPA for 5 min prior to addition of 10 μM forskolin for 10 min. Levels of cAMP were 
determined as described in section 2.5 (i) of chapter II. Data are presented as levels 
of cAMP in nM. The results represent the mean  S.E.M. of four experiments each 
performed in triplicate. *P0.05, **P<0.01, (A) a polynomial curve fit to illustrate Gs-
coupling and (B) sigmoidal four-parameter logistic curve fit to determine the EC50 
values.  
 
 
 
 
 
 
 
Fig 3.3: Effect of the selective A2A adenosine receptor agonist CGS 21680 on cAMP 
accumulation in differentiated H9c2 cells. Cells were pre-treated with the indicated 
concentrations of CGS 21680 for 15 min. Levels of cAMP were determined as 
described in section 2.5 (i) of chapter II. Data are presented as levels of cAMP in nM. 
The results represent the mean  S.E.M. of four experiments each performed in 
triplicate. 
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A1 adenosine receptor-mediated Ca
2+ signalling 
Experiments were performed to assess whether the A1 adenosine receptor triggers 
intracellular Ca2+ responses in H9c2 cells. CPA (100 nM) triggered intracellular Ca2+ 
oscillations (figure 3.4A, B) which were dependent on extracellular Ca2+ (figure 3.4C). 
Furthermore, pertussis toxin (PTX, 100 ng/ml for 16 h; figure 3.4D) and the A1 
adenosine receptor antagonist DPCPX (1 μM; figure 3.4E) blocked CPA-induced Ca2+ 
signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.4: Effect of the A1 adenosine receptor agonist CPA on [Ca
2+]i in H9c2 cells. (A) 
Confocal images of CPA (100 nM)-induced Ca2+ oscillations in the presence of 
extracellular Ca2+ (1.3 mM). The panel letters (a–g) correspond to the time points 
shown in trace B. (B) The A1 adenosine receptor agonist CPA triggered pronounced 
Ca2+ oscillations in the presence of extracellular Ca2+ (1.3 mM). (C) Oscillations 
induced by CPA were absent during experiments performed in nominally Ca2+-free 
buffer and 0.1 mM EGTA. In these experiments, depletion of intracellular Ca2+ stores 
with thapsigargin (5 μM) was still evident which suggested that the intracellular Ca2+ 
stores were still intact. (D) Responses to CPA in the presence of extracellular Ca2+ 
were abolished by the A1 adenosine receptor antagonist DPCPX (1 μM) and (E) 
following treatment with PTX (100 ng/ml for 16 h). ATP (10 μM) was added where 
indicated as a positive control. Similar results were obtained in three other 
experiments, each of several replicates. 
 
Adenosine (100 μM) also triggered intracellular Ca2+ responses  (figure 3.5A, B) which 
were also dependent on extracellular Ca2+ (figure 3.5C). Furthermore, DPCPX (1 μM) 
and PTX (100 ng/ml for 16 h; figure 3.5D, E respectively) blocked adenosine-induced 
Ca2+ signalling confirming the role of Gi/o-proteins and the A1 adenosine receptor in 
adenosine-mediated responses. 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.5: Effect of adenosine on [Ca2+]i in H9c2 cells. (A) Confocal images of adenosine 
(100 μM)-induced Ca2+ responses in the presence of extracellular Ca2+ (1.3 mM). The 
panel letters (a–g) correspond to the time points shown in trace B. (B) Adenosine 
triggered pronounced Ca2+ responses in the presence of extracellular Ca2+ (1.3 mM). 
(C) Responses induced by adenosine were absent during experiments performed in 
nominally Ca2+-free buffer and 0.1 mM EGTA. In these experiments, depletion of 
intracellular Ca2+ stores with thapsigargin (5 μM) was still evident which suggested 
that the intracellular Ca2+ stores were still intact. (D) Responses to adenosine in the 
presence of extracellular Ca2+ were abolished by the A1 adenosine receptor antagonist 
DPCPX (1 μM) and (E) following treatment with PTX (100 ng/ml for 16 h). ATP (10 μM) 
was added where indicated as a positive control. Similar results were obtained in three 
other experiments, each of several replicates. 
These data suggest that mitotic H9c2 cells functionally express the A1 adenosine 
receptors. However, the A2A adenosine receptor mRNA is encoded but is not 
functionally expressed in differentiated H9c2 cells. 
3.2. Functional expression of β-adrenoceptors on H9c2 cells. 
RT-PCR analysis 
β1, β2 and β3 adrenoceptors mRNA expression was determined in mitotic and 
differentiated H9c2 cells by RT-PCR analysis. As shown in figure 3.6, mRNA was 
68 
 
detected in mitotic and differentiated H9c2 cells for all three β-adrenoceptor subtypes 
with a rank order of β2  β1 = β3. 
 
 
 
 
 
 
 
Fig 3.6: β-adrenoceptor mRNA expression in H9c2 cells. mRNA isolated from mitotic 
and differentiated H9c2 cells was subjected to RT-PCR using intron spanning β1, β2 and 
β3-adrenoceptor gene specific primers. mRNA samples isolated from rat heart (β1-
adrenoceptor) and rat lung (β2 and β3-adrenoceptor) were used as positive controls. L: 
100 bp DNA standard; lane 1: no DNA control; lane 2: positive control; lane 3:  
mitotic H9c2 cell-derived mRNA; lane 4: differentiated H9c2 cell-derived mRNA. mRNA 
control using GAPDH primers is shown in the lower panel. The predicted transcript 
sizes for β1, β2 and β3-adrenoceptor and GAPDH are 599, 323, 724 and 392 bp. The 
results presented are representative of three independent experiments.  
 
cAMP accumulation 
Following mRNA assessment, functional expression of β-adrenoceptor subtypes on 
mitotic H9c2 cells was investigated using a cAMP accumulation assay. The selective 
β2-AR agonist formoterol (pEC50 = 8.9  0.1; n=3) stimulated a robust increase in 
cAMP (90% of forskolin max response), confirming the functional expression of the β2-
AR in H9c2 cells (figure 3.7B). Initial experiments using the non-selective β-AR agonist 
isoprenaline revealed only a modest increase in cAMP (figure 3.7A; pEC50 = 7.63  
0.07; n=4; 22% of forskolin max response). However, following treatment of cells 
with PTX (Gi/o-protein in-activator; 100 ng/ml) for 16 h, isoprenaline triggered a near 
maximal cAMP response (figure 3.7A; pEC50 = 8.68  0.09; n=4; 96% of forskolin 
max response). In marked contrast, cAMP accumulation in response to formoterol was 
insensitive to PTX (figure 3.7B; pEC50 = 8.70  0.24; n=4; 89% of forskolin max 
response). These data suggest that in the absence of PTX, isoprenaline-induced cAMP 
accumulation is suppressed due to Gi/o-protein coupling. From here on all isoprenaline-
induced cAMP accumulation was performed in the presence of PTX. The selective β3-
AR agonist CL 316243 did not generate any cAMP accumulation (figure 3.7C) 
suggesting that even though the mRNA is detected, this subtype is not functional in 
H9c2 cells. 
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Fig. 3.7: β-adrenoceptor agonist-induced cAMP accumulation in H9c2 cells. Where 
indicated cells were pre-treated for 16 h with 100 ng/ml PTX. Cells were stimulated for 
20 min with the indicated concentrations of (A) isoprenaline, (B) formoterol and (C) CL 
316243. Levels of cAMP were determined as described in section 2.5 (i) of chapter II. 
Data are presented as mean levels of cAMP (in nM)  S.E.M. of four experiments each 
performed in triplicate. **P<0.01 and ****P<0.0001. 
 
Isoprenaline-induced cAMP responses were abolished by the non-selective β-
adrenoceptor antagonist propranolol (100 nM) and the selective β2-AR antagonist ICI 
118,551 (100 nM), while the selective β1-AR antagonist CGP 20712 (100 nM) part-
inhibited the response (figure 3.8A). This indicates that there is some activity of the 
β1-AR in H9c2 cells. Formoterol-induced cAMP responses were blocked by the non-
selective β-adrenoceptor antagonist propranolol (100 nM) and the selective β2-AR 
antagonist ICI 118,551 (100 nM), whereas the selective β1-AR antagonist CGP 20712 
(100 nM) had no effect (figure 3.8B).  
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Fig. 3.8: Effect of β-adrenoceptor antagonists on isoprenaline and formoterol-induced 
cAMP accumulation in H9c2 cells. Cells were pre-treated for 30 min with propranolol 
(100 nM), CGP 20712 (100 nM), or ICI 118551 (100 nM) prior to 20 min stimulation 
with (A) isoprenaline (10 nM) or (B) formoterol (10 nM). Levels of cAMP were 
determined as described in section 2.5 (i) of chapter II. Data are presented as mean 
levels of cAMP (in nM)  S.E.M. of four experiments each performed in triplicate. 
****P<0.0001, (a) versus control and (b) versus 10 nM isoprenaline or 10 nM 
formoterol alone. 
 
To confirm the functional expression of  β2-AR, cimaterol  (β2-AR selective agonist) 
was investigated. Cimaterol (pEC50 = 7.50  0.06; n=4) stimulated a modest increase 
in cAMP, confirming the functional expression of the β2-AR in H9c2 cells (figure 3.9A). 
Cimaterol-induced cAMP responses were blocked by the non-selective β-adrenoceptor 
antagonist propranolol (100 nM) and the selective β2-AR antagonist ICI 118,551 (100 
nM), whereas the selective β1-AR antagonist CGP 20712 (100 nM) had no effect 
(figure 3.9C). These data support the previous finding suggesting that the β2-AR is 
functionally active in H9c2 cells.  Dobutamine as a partial agonist of the β2-AR 
stimulated only a small cAMP response (pEC50 = 7.40  0.09; n=3; figure 3.9B). Due 
to the lack of a selective β1-AR agonist, the functional expression of this subtype was 
assessed by determining dobutamine-induced cAMP accumulation (non-selective β1 
and β2 agonist). Dobutamine-induced cAMP responses were blocked by the non-
selective β-adrenoceptor antagonist propranolol and the selective β2-AR antagonist ICI 
118,551, whereas the selective β1-AR antagonist CGP 20712 had no effect (figure 
3.9D). Overall these data suggest functional expression of only the β2-AR in mitotic 
H9c2 cells. 
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Fig. 3.9: β-adrenoceptor agonist-induced cAMP accumulation in H9c2 cells. Cells were 
stimulated for 20 min with the indicated concentrations of (A) cimaterol and (B) 
dobutamine. Cells were pre-treated for 30 min with propranolol (100 nM), CGP 20712 
(100 nM), or ICI 118551 (100 nM) prior to 20 min stimulation with (C) cimaterol (1 
µM) and (D) dobutamine (1 µM). Levels of cAMP were determined as described in 
section 2.5 (i) of chapter II. Data are presented as mean levels of cAMP (in nM)  
S.E.M. of four experiments each performed in triplicate. ***P<0.001, and 
****P<0.0001, (a) versus control and (b) versus 1 µM cimaterol or 1 µM dobutamine 
alone. 
 
Since the response generated by cimaterol and dobutamine was modest, it was of 
interest to determine whether these agonists also coupled to Gi/o-protein. To 
determine this, cimaterol and dobutamine along with isoprenaline, formoterol, CL 
316243 and forskolin were used at their maximal concentrations in presence and 
absence of PTX. Also, to verify if the Gi/o-protein coupling observed with isoprenaline 
(and perhaps with the above mentioned agonists) was an event occurring only in H9c2 
cells, BEAS-2B R1 cells (human bronchial epithelial cells) which endogenously express 
the β2-AR (Kelsen et al, 1997) were used as a positive control. Culturing and seeding 
of BEAS-2B R1 cells was similar to H9c2 cells as described in section 2.2 of chapter II. 
Isoprenaline (10 μM) and cimaterol (10 μM) only generated a modest cAMP-response 
in the absence of PTX in H9c2 cells (figure 3.10A), whereas they generated robust 
cAMP-accumulation in the presence of PTX (figure 3.10B). In contrast, responses to 
formoterol (1 μM), CL 316243 (10 μM), dobutamine (10 μM) and forskolin (10 μM) in 
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H9c2 cells were unaffected by PTX pre-treatment. The above mentioned agonists 
(except for CL 316243) generated robust cAMP-accumulation in BEAS-2B R1 cells 
(figure 3.10C) suggesting the β3-AR subtype is not functionally expressed on these 
cells. No significant changes were observed in the cAMP response profiles of these 
agonists following PTX pre-treatment, except for dobutamine which generated slightly 
more cAMP following PTX pre-treatment (figure 3.10D; 68% of forskolin max response 
in presence of PTX as compared to 40% of forskolin max response in absence of PTX) 
suggesting that the Gi/o-protein coupling event is exclusive to H9c2 cells (at least for 
isoprenaline and cimaterol). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10: β-adrenoceptor agonist-induced cAMP accumulation in H9c2 and BEAS-2B 
R1 cells. H9c2 cells were treated with isoprenaline (10 μM), formoterol (1 μM), CL 
316243 (10 μM), cimaterol (10 μM), dobutamine (10 μM) and forskolin (10 μM) for 20 
min in absence of PTX pre-treatment (A) and following 16 h pre-treatment with PTX 
(Gi/o-protein in-activator; 100 ng/ml; B). BEAS-2B R1 cells were treated with 
isoprenaline (10 μM), formoterol (1 μM), CL 316243 (10 μM), cimaterol (10 μM), 
dobutamine (10 μM) and forskolin (10 μM) for 20 min in absence of PTX pre-treatment 
(C) and  following 16 h pre-treatment with PTX (Gi/o-protein in-activator; 100 ng/ml; 
D). Levels of cAMP were determined as described in section 2.5 (i) of chapter II. Data 
are presented as mean levels of cAMP (in nM)  S.E.M. of four experiments each 
performed in triplicate. *P0.05, **P<0.01, and ****P<0.0001 relative to control. 
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Beta-adrenoceptor-mediated Ca2+ signalling 
To determine if formoterol and isoprenaline were able to generate Ca2+ responses in 
H9c2 cells, Ca2+ imaging was performed. Formoterol (1 μM) did not trigger any 
intracellular Ca2+ responses (figure 3.11A; over three independent experiments 18 
wells were observed and no response was observed). Isoprenaline (10 μM) on 
occasion did trigger intracellular Ca2+ responses. Figure 3.11B represents a trace in 
which isoprenaline did not generate any Ca2+ response while figure 3.11C, D represent 
a trace in which isoprenaline did generate a Ca2+ response (over three independent 
experiments 18 wells were observed and in 7 wells isoprenaline generated a response 
i.e. 39%). It is important to note that in all experiments, ATP was used as a positive 
control to check if the Ca2+ stores were still intact. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.11: Effect of β-adrenoceptor agonists on [Ca2+]i responses in H9c2 cells. (A) No 
Ca2+ responses were observed when treated with formoterol (1 μM). (B) Isoprenaline 
triggered no Ca2+ responses on occasion. (C) Isoprenaline on occasion (38.88%) 
triggered pronounced Ca2+ responses in the presence of extracellular Ca2+ (1.3 mM). 
(D) Confocal images of isoprenaline (1 μM)-induced Ca2+ responses in the presence of 
extracellular Ca2+ (1.3 mM). The panel letters (a–f) correspond to the time points 
shown in trace C. ATP (10 μM) was added as a positive control. Similar results were 
obtained in three other experiments. 
 
 
 
 
74 
 
3.3. Characterisation of TG expression pattern in H9c2 cells. 
Western blot analysis was  performed to compare the expression of TG isoforms in 
mitotic and differentiated H9c2 cells. TG1, TG2 and TG3 expression were detected in 
both mitotic and differentiated H9c2 cells (figure 3.12). This indicates that not only 
TG2 but other TG isoforms are present in H9c2 cells. 
 
 
 
 
 
 
 
 
 
 
Fig 3.12: Protein expression of TG isoforms in mitotic and differentiated H9c2 cells. (A) 
cell lysates (20 μg) from mitotic (M) and differentiated (D) H9c2 cells were analysed 
for TG1, TG2 and TG3 expression by western blotting using TG isoform-specific 
antibodies. Loading control using GAPDH is shown in the lower panel. 0.1 ng from 
purified enzymes (C) were used as positive control. (B) Quantified data are expressed 
as the ratio of TG isoform to GAPDH and represent the mean  S.E.M. from three 
independent experiments.  
 
Furthermore, to determine if the levels expressed are localised to a particular area of 
the cell, immunofluorescence by confocal microscopy was performed using TG 
isoform-specific antibodies and counterstained by the nuclear stain DAPI (figure 3.13). 
Immunofluorescence staining indicated that TG1 and TG3 are mainly localised in the 
perinuclear region. TG1 is also sparsely localised in the cytoplasm. TG2 is distributed 
ubiquitously but is predominantly localised in the cytoplasm. 
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Fig 3.13: Protein expression of TG isoforms in mitotic and differentiated H9c2 cells. (A) 
Images acquired from immunofluorescence by confocal microscopy are presented from 
one experiment and are representative of three independent experiments. (B) 
Quantified immunofluorescence data represent the mean ± S.E.M. of fluorescence 
intensity relative to DAPI stain for five fields of view from each of three independent 
experiments. 
 
3.4 Discussion. 
The initial aim of this study was to identify functional expression of adenosine receptor 
and β-adrenoceptor subtypes on H9c2 cells along with characterisation of TG isoforms. 
Functional expression of adenosine receptors on H9c2 cells: 
H9c2 cardiomyoblasts derived from embryonic rat heart myoblasts are widely used as 
an in-vitro model for cardiac cells since they are electrophysiologically and 
biochemically similar to cardiomyocytes (Heschelet et al, 1991). It has been previously 
reported that rat ventricular myocytes  express A1, A2A and A3 adenosine receptors 
(Martens et al, 1987; Linden, 1994; Dixon et al, 1996; Dobson and Fenton, 1997; 
Germack and Dickenson, 2004). Fretwell and Dickenson, reported the functional 
expression of the A1 adenosine receptor on H9c2 cells using cAMP accumulation assay 
(Fretwell and Dickenson, 2009). However, to further investigate, mRNA and functional 
expression of adenosine receptors via RT-PCR analysis, cAMP accumulation and 
calcium imaging was performed. As reported by Fretwell and Dickenson, CPA mediated 
a biphasic modulation of forskolin-stimulated cAMP accumulation in mitotic H9c2 cells 
(figure 3.2). Although CPA-induced inhibition of forskolin-stimulated cAMP 
accumulation was seen at nM concentrations (≤100 nM), at higher concentrations 
(>100 nM) this inhibition was partially reversed. In agreement with previous findings, 
this observation suggests that at higher agonist concentrations, the A1 adenosine 
receptor can also couple to Gs-protein in mitotic H9c2 cells (Fretwell and Dickenson, 
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2009). Due to the extremely low level detection of A1 adenosine receptor mRNA in 
differentiated H9c2 cells, work was performed using mitotic H9c2 cells. 
The selective A2A adenosine receptor agonist, CGS 21680 caused no measurable cAMP 
accumulation (figure 3.3) suggesting that even though the mRNA for A2A adenosine 
receptor is detectable (figure 3.1), this receptor is not functional in differentiated H9c2 
cells. It should be noted that IBMX was implemented in this cAMP accumulation assay 
to inhibit phosphodiesterase activity. However, IBMX also functions as a non-selective 
antagonist of adenosine receptors (Beavo et al, 1970; Morgan et al, 1993). Therefore, 
it is possible that the lack of cAMP response was due to antagonism of CGS 21680 by 
IBMX and hence the use of an alternative phosphodiesterase inhibitor e.g. rolipram 
should be implemented in further studies. The mRNA profile of the adenosine 
receptors shows no expression of A2B adenosine receptor and hence no functional 
studies were undertaken for  this receptor. Although the mRNA profile is positive for 
the A3 adenosine receptor, previous studies have found it not to be functionally 
expressed in these cells (Fretwell and Dickenson, 2009). Hence it was not studied any 
further.  
Convincing evidence exists that the A1 adenosine receptor directly stimulates inositol 
phospholipid hydrolysis through Gi/o-protein βγ subunit-mediated activation of 
phospholipase C in many cell types (White et al, 1992; Dickenson et al, 1995; Murthy 
and Makhlouf, 1995; Tomura et al, 1997; Linden, 2001; Sheth et al, 2014). In this 
study, CPA triggered increases in intracellular Ca2+ levels which were characterised by 
pronounced Ca2+ oscillations (figure 3.4). These responses were eliminated following 
removal of extracellular Ca2+, suggesting that these responses are dependent upon 
extracellular Ca2+ influx as the intracellular stores were still intact. Similar 
observations were made with the endogenous agonist adenosine (figure 3.5). In order 
to clarify the involvement of the A1 adenosine receptor in mediating these Ca
2+ 
responses, the selective A1 adenosine receptor antagonist DPCPX and the Gi/o-protein 
blocker pertussis toxin were used. As expected, intracellular Ca2+ responses observed 
with both CPA and adenosine were blocked when cells were pre-treated with either 
DPCPX and PTX, thus confirming the involvement of the A1 adenosine receptor. 
This influx of extracellular Ca2+ upon stimulation of the A1 adenosine receptor is in 
contrast to previous findings in basal forebrain cholinergic neurons, human bronchial 
smooth muscle cells and the smooth muscle cell line DDT1MF-2 which suggest that the 
A1 adenosine receptor stimulates the release of intracellular Ca
2+ stores (Dickenson 
and Hill, 1993; Basheer et al, 2002; Ethier and Madison, 2006). In relation to the 
current data, it is unlikely that voltage-gated Ca2+ channels are involved as activation 
of the Gi/o-protein coupled A1 adenosine receptor is associated with the inhibition of 
P/Q- and N-type voltage-dependent Ca2+ channels (Gundlfinger et al, 2007). 
Sabourine and colleagues have recently provided an alternative mechanism for the A1 
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adenosine receptor-induced Ca2+ influx in cardiomyocytes which occurs via store-
operated Ca2+ channels (Sabourine et al, 2012). Furthermore, there is some evidence 
that the A1 adenosine receptor can modulate L-type Ca
2+ channels in rat atria (Fassina 
et al, 1991; Braganca et al, 2016). At present the mechanisms associated with the A1 
adenosine receptor-induced Ca2+ influx in H9c2 cells are not established, however it 
would be of interest to investigate the mechanisms underlying this phenomena. 
Collectively, these data sufficiently demonstrate the functional expression of the A1 
adenosine receptor on H9c2 cells. 
Functional expression of β-adrenoceptors on H9c2 cells: 
In contrast to the heart where the β1-AR is the dominant adrenoceptor subtype (Woo 
and Xiao, 2012), previous studies have shown that H9c2 cells have a β-AR subtype 
ratio of 71% β2-AR to 29% β1-AR (Dangel et al, 1996). In this study, RT-PCR analysis 
revealed expression of β1, β2, and β3-AR mRNA in mitotic and differentiated H9c2 cells 
(figure 3.6), with a rank order of β2-AR  β1-AR = β3-AR. Since all of the three β-AR 
subtypes couple to Gs-proteins and activate adenylyl cyclase, their functional 
expression was assessed by measuring cAMP accumulation in mitotic cells. Mitotic 
H9c2 cells were chosen for further investigation even though the mRNA of receptor is 
detected in differentiated cells because it would be more suitable to determine TG2 
activation by GPCRs (adenosine receptors and adrenoceptors) in the same cell 
background. The selective β3-AR agonist CL 316243 did not generate any cAMP 
accumulation (figure 3.7), suggesting that even though the mRNA is detected, this 
subtype is not functionally expressed on H9c2 cells. However, recently it has been 
reported that the β3-AR is functionally active in mouse heart and is involved in 
cardioprotection (Dessy and Balligand, 2010; Niu et al, 2012; Cannavo and Koch, 
2017). 
In this study, the selective β2-AR agonist formoterol revealed a robust increase in 
cAMP accumulation whilst the non-selective β-AR agonist isoprenaline revealed only a 
modest increase in cAMP accumulation (figure 3.7). There is some evidence that in rat 
cardiomyocytes many β2-AR agonists have been shown to activate both Gs and Gi/o 
proteins, with the exception of fenoterol which exclusively activates only Gs protein 
(Xiao et al, 2003). Hence it was of interest to check if isoprenaline were coupling to 
Gi/o-protein in H9c2 cells. Following treatment of cells with PTX for 16 h, isoprenaline 
triggered a robust cAMP response, thus suggesting that in H9c2 cells isoprenaline 
couples to Gi/o-proteins. In contrast, treatment with PTX had no effect on formoterol-
induced robust increase in cAMP accumulation. These data suggest that the cAMP 
responses to isoprenaline were augmented by PTX indicating dual coupling to Gs and 
Gi, whereas responses to formoterol were insensitive to PTX indicating coupling only to 
Gs proteins. There is some evidence that formoterol promotes the receptor to 
exclusively couple to Gs proteins. For instance, in HEK293 cells and isolated rat heart, 
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formoterol-induced cAMP accumulation was insensitive to PTX (Somvanshi et al, 2011; 
Salie et al, 2011). However there are several studies that claim isoprenaline couples to 
Gi/o proteins in mouse cardiomyocytes (for details see Daaka et al, 1997; Davel et al, 
2014; Fu et al, 2014). 
To confirm these results, subtype-selective antagonists were employed. From the data 
shown in figure 3.8, it is clear that the cAMP response to β-AR agonists is via the β2-
AR. Formoterol-induced cAMP responses were blocked by the non-selective β-AR 
antagonist propranolol and the selective β2-AR antagonist ICI 118,551, whereas the 
selective β1-AR antagonist CGP 20712 had no effect. Isoprenaline-induced cAMP 
responses in the presence of PTX were attenuated by the non-selective β-AR 
antagonist propranolol and the selective β2-AR antagonist ICI 118,551, while the 
selective β1-AR antagonist CGP 20712 could only modestly block the response. This 
indicates that there is some activity of the β1-AR in H9c2 cells. The majority of 
evidence is consistent with β2-AR being functionally active, with the exception of 
isoprenaline in presence of the selective β1-AR antagonist CGP 20712. However, it is 
not clear how the response could be dependent up on either β1- or β2-AR. Previous 
studies by Somvanshi and colleagues have implied functional expression of β1-AR in 
H9c2 cells via isoprenaline-induced apoptosis and signalling responses such as CREB 
and ERK1/2 (Somvanshi et al, 2013). However it should be noted that isoprenaline is 
a non-selective β-AR agonist and was reported to induce PI-3K activity which was 
inhibited by the β2-AR antagonist ICI 118,551 but not the β1-AR antagonist CGP 20712 
in H9c2 cells (Yano et al, 2007). Overall, these data suggest functional expression of 
the β2-AR but not β1-AR or β3-AR subtypes in H9c2 cells. 
Due to the slight discrepancy observed in antagonising the isoprenaline- and 
formoterol-induced cAMP accumulation, two additional β-AR agonists were 
implemented. The selective β2-AR agonist cimaterol and the β1/β2 agonist dobutamine 
(figure 3.9) both generated modest cAMP accumulation which was in each case 
blocked by the non-selective β-AR antagonist propranolol and the selective β2-AR 
antagonist ICI 118,551, whereas the selective β1-AR antagonist CGP 20712 had no 
effect. These data confirm the functional expression of the β2-AR but not β1-AR or β3-
AR subtypes in H9c2 cells. Since both of these agonists could only generate a modest 
cAMP response, it became of interest to identify if the cAMP response to these agonists 
is limited by Gi/o-protein-coupling in H9c2 cells, as seen with isoprenaline. Also, to 
identify if the phenomenon of isoprenaline-induced coupling to Gi/o-protein is an effect 
observed only in H9c2 cells, BEAS-2B R1 cells (human bronchial epithelial cells which 
endogenously express β2-AR; Kelsen et al, 1997) were employed as a positive control 
(figure 3.10). Data obtained with H9c2 cells in the presence and absence of PTX, 
suggest that not only isoprenaline but also cimaterol promotes β2-AR coupling to Gi/o-
protein in H9c2 cells. This may explain why cimaterol could only generate a modest 
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cAMP response compared to formoterol. All the other agonists used in this study at 
their maximal concentrations did not have any effect upon treatment with PTX, 
suggesting they do not promote β2-AR coupling to Gi/o-protein in H9c2 cells. 
The data obtained from BEAS-2B R1 cells suggest that the phenomenon of 
isoprenaline and cimaterol coupling to Gi/o-protein is exclusive to H9c2 cells. However, 
it should be noted that there was a slight increase in dobutamine-mediated cAMP 
accumulation in BEAS-2B R1 cells treated with PTX. One reason for these agonists 
coupling to Gi/o-proteins in H9c2 cardiomyocytes could be due to compartmentalisation 
of the β2-AR. Myocytes contain abundant lipid rafts and caveolae with high expression 
of the β2-AR (Patel et al, 2008; Xiang, 2011). This distribution facilitates signalling 
molecules such as cAMP to signal in a location-dependent manner. Using real time 
imaging of live myocytes, it was reported that stimulation of the β2-AR at one end of 
elongated adult myocytes generates a spatially confined cAMP response, whereas, 
similar stimulation of the β1-AR generates a diffused cAMP response reaching inside 
the cells (Nikolaev et al, 2006; Nikolaev et al, 2010). Furthermore, only certain 
isoforms of adenylyl cyclase are enriched in the caveolae (e.g. AC6) and are known to 
couple to the β1-AR more effectively than to the β2-AR (Ostrom et al, 2001). Also, 
disruption of caveolae and lipid rafts causes enhancement of isoprenaline-induced 
cAMP response (Head et al, 2006). Hence, it is plausible that because of the low 
availability of Gs-protein/adenylyl cyclase these agonists couple to Gi/o-protein. 
Apart from this, it is also known that in mouse heart, genetic disruption of β1-AR does 
not alter the function of β2-AR and vice versa (Rohrer et al, 1996; Chruscinski et al, 
1999; Devic et al, 2001; Soto et al, 2009). This suggests that these two receptors 
reside in different compartments in mouse heart. Kuschel and colleagues have 
reported that inhibition of Gi/o-protein using PTX allowed switching of the localised 
cAMP response to a global phenomenon, confirming that β2-AR coupling to Gi/o-protein 
restricts the cAMP response to the sarcolemma of rat ventricular myocytes (Kuschel et 
al, 1999b). Interestingly, some studies have shown that in neonatal cardiac myocytes 
β2-AR coupling to Gi/o-proteins is PKA and GRK phosphorylation dependent and it is 
associated with receptor internalisation and recycling (Xiang et al, 2002; Xiang and 
Kobilka, 2003; Wang et al, 2007; Wang et al, 2008; Liu et al, 2009; Xiang, 2011). 
However, further studies are needed to confirm if this coupling to Gi/o-proteins in H9c2 
cardiomyocytes is due to compartmentalisation. At present, the levels of Gi/o-protein 
and Gs-protein as well as expression of different Gi/o-protein subtypes (Gi1-, Gi2-, Gi3-, 
Go1- and Go2-protein) in H9c2 cells are not known. Furthermore, the different cell 
backgrounds used in various studies could also be a potential reason for these 
agonists to couple to Gi/o-protein. 
To determine if β2-AR activation initiated Ca
2+ responses in H9c2 cells, Ca2+ imaging 
was performed. Formoterol consistently produced no measurable Ca2+ responses, 
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whilst isoprenaline in a proportion of experiments triggered intracellular Ca2+ 
responses (figure 3.11). It can be conceivable that the reason for formoterol not 
triggering any Ca2+ responses could be because it does not promote the β2-AR to 
couple to Gi/o-protein. It is important to note that the concentrations of the agonists 
used to determine intracellular Ca2+ responses are not the same as those used for 
cAMP accumulation studies. This is simply because as shown in Chapter V, modulation 
of TG2 activity occurs at higher concentrations and since TG2 is a calcium dependent 
enzyme, it was necessary to use the same concentration for comparison purposes. As 
for the cAMP accumulation, it was important to use the agonists and antagonists at 
their selective concentrations to be able to determine the subtype functionally 
expressed on H9c2 cells. 
On quantification, it was observed that over three independent experiments 18 wells 
were assessed and in 7 wells isoprenaline generated a response i.e. 39%. The 
intracellular Ca2+ responses observed could be a result of activation of L-type Ca2+ 
channels (LTCCs). LTCCs, along with ryanodine receptors (RyRs) and 
Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase type 2 (SERCA2), are known 
substrates of PKA which are involved in Ca2+ responses and recycling (Kamp and Hell, 
2000; Manni et al, 2008; Kranias and Hajjar, 2012). Convincing evidence exists that 
there is localisation of a subpopulation of LTCCs in caveolae and that activation of β2-
AR coupling causes a localised cAMP response which might be sufficient to spatially 
activate PKA, which leads to activation of caveolar LTCCs (Xiao et al, 1994; Chen-Izu 
et al, 2000; Fu et al, 2013).  
Finally, a number of studies have also shown that activation of β-AR induces activation 
of Ca2+ /calmodulin-dependent kinase II (CaMKII), which causes phosphorylation of 
phospholamban and ryanodine receptors which play a role in myocardial hypertrophy 
(Zhang et al, 2005; Anderson et al, 2011; Swaminathan et al, 2012). This activation 
of CaMKII via β-AR can occur due to PKA-dependent increases in local Ca2+ 
concentrations via LTCCs and RyRs as well as through Gs-protein mediated up-
regulation of LTCCs and cAMP/EPAC-dependent signalling pathways (Lader et al, 1998; 
Oestreich et al, 1998; Ferrero et al, 2007; Soltis and Saucerman, 2010; Fu et al, 
2013). Several studies have shown that activation of the β2-AR following inhibition of 
Gi/o-protein with PTX caused switching of the localised cAMP response to a global 
phenomenon and complete phosphorylation of phospholamban by PKA was observed 
(Xiao et al, 1995; Kuschel et al, 1999b). Furthermore, in rat ventricular myocytes, 
several studies have shown dual coupling of β2-AR to Gs- and Gi/o-proteins and this 
dual coupling leads to reduced cAMP response resulting in highly localised Ca2+ 
responses (Xiao et al, 1995; Daaka et al, 1997; Xiao et al, 1999; Chen-Izu et al, 
2000). These responses appear to be dependent on cAMP/PKA-signalling as inhibition 
of PKA with RpCamps and peptide inhibitors abolished these Ca2+ responses. A similar 
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phenomenon was observed in frog ventricular myocytes which are known to be rich in 
β2-AR (Zhou et al, 1997; Kuschel et al, 1999a; Kuznetsov et al, 1995; Hartzell et al, 
1991; Hartzell and Fischmeister, 1992; Skeberdis et al, 1997b). Together these 
studies show that inhibition of Gi/o-protein caused the β2-AR to signal in a similar 
fashion to the β1-AR. At present it is still not clear if the isoprenaline-induced 
intracellular Ca2+ responses are dependent on Gi/o-protein coupling in H9c2 
cardiomyoblasts and hence further investigation is warranted. Overall, the data 
presented clearly show functional expression of the β2-AR on H9c2 cells.  
Characterisation of TG expression pattern in H9c2 cells: 
At present few studies have shown differential expression of transglutaminase 
isoforms in heart. For instance, Factor XIIIA mRNA and protein levels have been 
identified in mouse heart (Sane et al, 2007; Myneni et al, 2014) and its up-regulation 
in cardiac myxoma (Berrutti and Silverman, 1996). There is also evidence of strong 
mRNA expression for TG3 in mouse heart (Zhang et al, 2005). However, to the 
authors knowledge no studies relating to TG1, TG4, TG5, TG6, TG7 and Band 4.2 have 
been carried out in the cardiovascular field. There are a significant number of studies 
which have reported TG2 mRNA and protein levels in mouse heart (Small et al, 1999; 
Sane et al, 2007; Iismaa et al, 2009; Deasey and Numinskaya, 2013) and neonatal 
rat cardiomyocytes (Li et al, 2009). TG2 is implied in cardiac disorders such as 
atherosclerosis, cardiac hypertrophy and stiffness. The role of TG2 is debatable in 
these disorders as there are contrasting studies suggesting that TG2 does not play a 
role in plaque stability during atherosclerosis (Williams et al, 2010), while another 
study claims that its activity is important in regulating the atherosclerotic plaque 
(Matlung et al, 2012). In an ischaemic heart, TG2 GTPase activity is strikingly reduced 
suggesting that it is an important factor in cardiac failure (Hwang et al, 1995). 
However, cardiac-specific overexpression of TG2 does not alter PLC-δ1 activity, 
suggesting that it functions as a TG rather than a GTPase (Small et al, 1999). TG2 is 
also involved in cardiac hypertrophy (Iismaa and Graham, 2003) and cardiovascular 
stiffness (Jung et al, 2013; Steppan et al, 2014; Steppan et al, 2017), but its role in 
their progression is debatable. All of the above studies were carried out in mouse/rat 
models and hence it was important to determine which TG isoform is expressed in 
H9c2 cardiomyocytes. It is apparent from the data shown in figures 3.12 and 3.13 
that TG1, TG2 and TG3 are expressed in both mitotic and differentiated H9c2 cells. In 
mitotic and differentiated H9c2 cells, TG1 and TG3 are mainly localised in the 
perinuclear region with TG1 being sparsely localised in the cytoplasm. TG2 is 
distributed ubiquitously, however, it is predominantly localised in the cytoplasm. It is 
clear from these data that differentiation of H9c2 cells does not affect the localisation 
of TG1, TG2 and TG3. Although it would have been ideal to check the expression of all 
TG isoforms, this was not technically possible due to lack of specific antibodies and 
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time constraints. However, it should be noted that some of the TG isoforms which 
were not assessed in this study, might not be expressed in H9c2 cardiomyocytes as 
TGs have been named according to their specific localisation. For instance TG4 or 
prostate TG is only expressed in the prostate gland, prostatic fluids and seminal 
plasma. From this study it can be concluded that mitotic and differentiated H9c2 cells 
express TG1, TG2 and TG3. 
In conclusion, these data provide sufficient evidence of functional expression of the A1 
adenosine receptor, β2-adrenoceptor and TG2 in mitotic H9c2 cardiomyocytes. 
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Chapter IV: Modulation of TG2 activity by the A1 adenosine receptor in 
H9c2 cells 
This chapter aims to investigate modulation of TG2 by the A1 adenosine receptor in 
mitotic H9c2 cells via TG2 amine incorporating and peptide crosslinking assays along 
with in-situ TG2 activity. 
4.1 Effect of A1R activation on TG2-mediated biotin cadaverine amine 
incorporation and protein cross-linking activity. 
Initially the effect of the selective A1R agonist CPA on TG2 activity in H9c2 
cardiomyoblasts was investigated. H9c2 cells were treated with CPA (1 μM) for varying 
periods of time and the cell lysates subjected to both biotin cadaverine amine-
incorporation assay (Slaughter et al, 1992) and biotin-labelled peptide (biotin-TVQQEL) 
cross-linking assay (Trigwell et al, 2004). CPA (figure 4.1A) produced time-dependent 
increases in TG2-catalysed biotin-cadaverine incorporation activity, peaking at 10 min. 
In addition, CPA (pEC50 = 8.87  0.17; n=6; figure 4.1C) stimulated concentration-
dependent increases in biotin-cadaverine incorporation activity. CPA also triggered 
time-dependent increases in TG2-mediated protein cross-linking activity peaking at 10 
min (figure 4.1B) along with concentration-dependent increases in protein cross-
linking activity (pEC50 = 8.61  0.20; n=6; figure 4.1D). Similar to CPA, the 
endogenous adenosine receptor agonist adenosine (100 μM) also triggered transient 
increases in TG2 catalysed biotin-cadaverine incorporation and protein cross-linking 
activity, peaking at 10 min (figure 4.2A and B). Furthermore, adenosine stimulated 
concentration-dependent increases in both biotin-amine incorporation activity (figure 
4.2C; pEC50 = 6.90  0.11; n=7) and protein cross-linking activity (figure 4.2D; pEC50 
= 7.08  0.16; n=7). It should be noted that activation of A1R using CPA and 
adenosine reveals a trend towards a decrease in both amine incorporation and protein 
cross-linking activities of TG2 at 1 min.  
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Fig 4.1: Effect of the selective A1 adenosine receptor agonist CPA on TG2 activity in 
H9c2 cells. Cells were stimulated with CPA (1 μM) for the indicated time intervals 
(panels A and B). Concentration-response curves for CPA in cells treated with agonist 
for 10 min (panels C and D). Cell lysates were subjected to biotin-cadaverine 
incorporation (panels A and C) or the peptide cross-linking assay (panels B and D). 
Data points represent the mean ± S.E.M. for TG2 specific activity from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001 versus 
control response. 
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Fig 4.2: Effect of the endogenous adenosine receptor agonist adenosine on TG2 
activity in H9c2 cells. Cells were stimulated with adenosine (100 μM) for the indicated 
time intervals (panels A and B). Concentration-response curves for adenosine in cells 
treated with agonist for 10 min (panels C and D). Cell lysates were subjected to 
biotin-cadaverine incorporation (panels A and C) or the peptide cross-linking assay 
(panels B and D). Data points represent the mean ± S.E.M. for TG2 specific activity 
from four independent experiments. *P0.05, **P<0.01, ***P<0.001 and 
****P0.0001 versus control response. 
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4.2 The effect of selective A1R antagonist and TG2 inhibitors on A1R induced 
TG2 activity. 
To determine if the evoked TG2 activity was via the A1R, H9c2 cells were pre-treated 
for 30 min with the selective A1R antagonist DPCPX (1 µM) prior to stimulation with 
CPA (100 nM) and/or adenosine (100 µM) for 10 min. DPCPX blocked CPA-elicited 
(figure 4.3A and B) and adenosine-induced (figure 4.3C and D) TG2 activity, thus 
confirming that the activity was mediated by the A1R. To confirm that TG2 is 
responsible for the A1R induced transglutaminase activity in H9c2 cells, two 
structurally different cell permeable TG2 specific inhibitors were tested: R283 (a small 
molecule; Freund et al, 1994) and Z-DON (peptide-based; Schaertl et al, 2010). H9c2 
cells were pre-treated for 1 h with Z-DON (150 µM) or R283 (200 µM) prior to 
stimulation with CPA (100 nM) and/or adenosine (100 µM) for 10 min. Both inhibitors 
blocked CPA-induced and adenosine-induced TG-mediated amine incorporation (figure 
4.3A and C) and peptide cross-linking activity (figure 4.3B and D), confirming the 
involvement of TG2. As these are TG2 inhibitors, they are also lowering the basal 
enzyme activity. 
 
4.3 The role of Ca2+ in A1R induced TG2 activity. 
The role of Ca2+ in A1R-induced TG2 activation was determined because TG2 is a Ca
2+-
dependent enzyme. The role of extracellular Ca2+ was assessed by measuring TG2 
responses in the absence of extracellular Ca2+ using nominally Ca2+-free Hanks/HEPES 
buffer containing 0.1 mM EGTA (pH was confirmed). Removal of extracellular Ca2+ 
abolished CPA- and adenosine-induced TG2 activity (figure 4.4A and B). To assess the 
role of intracellular Ca2+, measurements of TG2 activation were also performed using 
cells pre-incubated with the Ca2+ chelator BAPTA-AM (50 µM for 30 min) in the 
absence of extracellular Ca2+. Loading cells with BAPTA in the absence of extracellular 
Ca2+ did not lead to further inhibition of CPA- and adenosine-induced TG2 activation 
(figure 4.4A and B). These observations indicate that the A1R-induced TG2 activation 
is dependent upon the influx of extracellular Ca2+. 
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Fig 4.3: Effect of the A1 adenosine receptor antagonist DPCPX and TG2 inhibitors on 
CPA and adenosine-induced TG2 activity. H9c2 cells were pre-treated for 30 min with 
the selective A1 adenosine receptor antagonist DPCPX (1 µM) or for 1 h with the TG2 
inhibitors Z-DON (150 µM) and R283 (200 µM) prior to 10 min stimulation with CPA 
(100 nM) or adenosine (100 µM). Cell lysates were subjected to biotin cadaverine 
amine incorporation assay (panels A and C) or peptide cross-linking assay (panels B 
and D). Data points represent the mean ± S.E.M for TG2 specific activity from four 
independent experiments. *P0.05, **P0.01, ***P0.001, and ****P0.0001, (a) 
versus control and (b) versus 100 nM CPA or 100 µM adenosine alone. 
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Fig 4.4: The role of extracellular Ca2+ in CPA- and adenosine-induced TG2 activation. 
H9c2 cells were  stimulated for 10 min with CPA (100 nM) or adenosine (100 µM) 
either in the presence of extracellular Ca2+ (1.8 mM) or in its absence using nominally 
Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA. Experiments were also 
performed using cells pre-incubated for 30 min with 50 µM BAPTA/AM and in the 
absence of extracellular Ca2+  (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 
mM EGTA) to chelate intracellular Ca2+. Cell lysates were subjected to biotin-
cadaverine incorporation assay (panel A) or peptide cross-linking assays (panel B). 
Data points represent the mean ± S.E.M for TG specific activity from four independent 
experiments. *P0.05, **P0.01, ***P0.001 and ****P0.0001, (a) versus control in 
presence of extracellular Ca2+, (b) versus 100 nM CPA in the presence of extracellular 
Ca2+, (c) versus 100 µM adenosine in the presence of extracellular Ca
2+. 
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4.4 The effect of pertussis toxin and protein kinase inhibitors on A1 adenosine 
receptor-induced TG2 activity. 
Pre-treatment with the Gi/o-protein inactivating pertussis toxin (100 ng/ml for 16 h) 
completely abolished CPA- and adenosine-induced transglutaminase amine 
incorporation activity and peptide cross-linking activity, confirming the involvement of 
Gi/o-proteins (figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.5: Effect of pertussis toxin on A1 adenosine receptor-induced TG2 activity. H9c2 
cells were pre-treated for 16 h with pertussis toxin (100 ng/ml) prior to 10 min 
stimulation with CPA (100 nM) or adenosine (ADO; 100 µM). Cell lysates were 
subjected to biotin-cadaverine incorporation assay (panels A and C) or peptide cross-
linking assay (panels B and D). Data points represent the mean ± S.E.M for TG2 
specific activity from four independent experiments. *P<0.05, **P0.01, ***P0.001 
and ****P0.0001, (a) versus control and (b) versus 100 nM CPA or 100 µM 
adenosine alone.  
 
It is evident from previous literature that the A1R activates other protein kinases 
including PKB (Germack and Dickenson, 2000; Germack et al, 2005), p38 MAPK 
(Robinson and Dickenson, 2001) and JNK1/2 (Brust et al, 2007). Modulation of ERK1/2, 
p38 MAPK, JNK1/2 and PKB activity following A1R activation was assessed in H9c2 cells 
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by Western blotting using phospho-specific antibodies that recognise phosphorylated 
motifs within activated ERK1/2 (pTEpY), p38 MAPK (pTGpY), JNK1/2 (pTPpY) and PKB 
(pS473). CPA (100 nM for 10 min) and adenosine (100 μM for 10 min) stimulated 
significant increases in ERK1/2 phosphorylation in H9c2 cells (figure 4.6). As expected, 
pre-treatment with the MEK1/2 inhibitor PD 98059 (50 µM) blocked CPA- and 
adenosine-induced activation of ERK1/2 (figure 4.6). Moreover, PD 98059 (50 µM) also 
blocked CPA- and adenosine-induced induced TG-mediated amine incorporation 
activity and peptide cross-linking activity (figure 4.7). As shown in figure 4.7, the PKC 
inhibitor Ro 318220 (10 µM) also blocked CPA- and adenosine-induced TG2 activity 
suggesting the involvement of ERK1/2 and PKC.  
 
 
 
 
 
 
 
 
Fig 4.6: Effect of CPA and adenosine on ERK1/2 phosphorylation in H9c2 cells. H9c2 
cells were pre-treated for 30 min with PD 98059 (50 µM) prior to stimulation with CPA 
(100 nM) or adenosine (100 µM) for 10 min. Cell lysates were analysed by Western 
blotting for activation of ERK1/2 using phospho-specific antibodies. Samples were 
subsequently analysed on separate blots using antibodies that recognize total ERK1/2. 
Data are expressed as the percentage of values for control cells (=100%) in the 
absence of protein kinase inhibitor and represent the mean  S.E.M. of four 
independent experiments. ***P<0.001 and ****P0.0001, (a) versus control and (b) 
versus 100 nM CPA or 100 µM adenosine alone. 
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Fig 4.7: Effect of ERK1/2 and PKC inhibitors on the A1 adenosine receptor-induced TG2 activity. 
H9c2 cells were pre-treated for 30 min with PD 98059 (50 µM) or Ro 31-8220 (10 µM) prior to 
10 min stimulation with CPA (100 nM) or adenosine (ADO; 100 µM). Cell lysates were subjected 
to protein biotin-cadaverine amine incorporation assay (panels A to D) or peptide cross-linking 
assay (panels E and H). Data points represent the mean ± S.E.M for TG2 specific activity from 
four independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) versus 
control and (b) versus 100 nM CPA or 100 µM adenosine alone. 
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CPA (100 nM for 10 min) and adenosine (100 μM for 10 min) also stimulated significant 
increases in p38 MAPK and JNK1/2 phosphorylation in H9c2 cells (figure 4.8). As 
expected, pre-treatment with SB 203580 (20 µM; p38 MAPK inhibitor) and SP 600125 
(20 µM; JNK1/2 inhibitor) blocked CPA- and adenosine-induced activation of p38 MAPK 
and JNK1/2, respectively (figure 4.8). Furthermore, SB 203580 and SP 600125 
blocked  CPA- and adenosine-induced TG-mediated amine incorporation activity and 
peptide cross-linking activity (figure 4.9). On the other hand, no activation of PKB by 
CPA and adenosine was observed in H9c2 cells (figure 4.10). This was confirmed by the 
pan PI-3K inhibitors wortmannin (100 nM) and LY 294002 (30 µM) did not block CPA 
and adenosine-induced TG2 activity (figure 4.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.8: Effect of CPA and adenosine on p38 MAPK and JNK1/2 phosphorylation in 
H9c2 cells. Where indicated, H9c2 cells were pre-treated for 30 min with SB 203580 
(20 µM; panels A and C) or SP 600125 (20 µM; panels B and D) prior to stimulation 
with either CPA (100 nM) or adenosine (100 µM) for 10 min. Cell lysates were 
analysed by Western blotting for activation of p38 MAPK and JNK1/2 using phospho-
specific antibodies. Samples were subsequently analysed on separate blots using 
antibodies that recognise total p38 MAPK and JNK1/2. Data are expressed as the 
percentage of values for control cells (=100%) in the absence of protein kinase 
inhibitor and represent the mean  S.E.M. of four independent experiments. *P<0.05, 
**P0.01, ***P0.001 and ****P0.0001, (a) versus control and (b) versus 100 nM 
CPA or 100 µM adenosine alone. 
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Fig 4.9: Effect of p38 MAPK and JNK1/2 inhibitors on the A1 adenosine receptor-
induced TG2 activity. H9c2 cells were pre-treated for 30 min with SB 203580 (20 µM) 
or SP 600125 (20 µM) prior to 10 min stimulation with CPA (100 nM) or adenosine 
(ADO; 100 µM). Cell lysates were subjected to protein biotin-cadaverine amine 
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incorporation assay (panels A to D) or peptide cross-linking assay (panels E and H). 
Data points represent the mean ± S.E.M for TG2 specific activity from four 
independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) 
versus control and (b) versus 100 nM CPA or 100 µM adenosine alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.10: Effect of CPA and adenosine on PKB phosphorylation in H9c2 cells. Where 
indicated, H9c2 cells were pre-treated for 30 min with LY 294002 (30 µM; panels A 
and C) and wortmannin (100 nM; panels B and D) prior to stimulation with CPA (100 
nM) or adenosine (100 µM) for 10 min. Cell lysates were analysed by Western blotting 
for activation of PKB using phospho-specific antibodies. Samples were subsequently 
analysed on separate blots using antibodies that recognize total PKB. Data are 
expressed as the percentage of values for control cells (=100%) in the absence of 
protein kinase inhibitor and represent the mean  S.E.M. of four independent 
experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) versus control 
and (b) versus 100 nM CPA or 100 μM adenosine alone. 
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Fig 4.11: Effect of pan PI-3K inhibitors on the A1 adenosine receptor-induced TG2 
activity. H9c2 cells were pre-treated for 30 min with wortmannin (100 nM) or LY 
294002 (30 µM) prior to 10 min stimulation with CPA (100 nM) or adenosine (ADO; 
100 µM). Cell lysates were subjected to protein biotin-cadaverine amine incorporation 
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assay (panels A to D) or peptide cross-linking assay (panels E and H). Data points 
represent the mean ± S.E.M for TG2 specific activity from four independent 
experiments. *P<0.05, **P0.01 and ***P0.001, (a) versus control. 
It is important to note that Ro 31-8220, PD 98059, SB 203580, SP 600125, LY 294002, 
wortmannin and other compounds used in this study had no significant effect on 
purified guinea pig liver TG2 activity (table 4.1). Overall, these data suggest that TG2 
activity is modulated in H9c2 cells by the A1 adenosine receptor via a multi protein 
kinase-dependent signalling pathway.  
Table 4.1: Effect of compounds used in this study on purified guinea pig liver TG2 
activity. 
Compound Concentration 
Effect on in-vitro TG2 activity 
(% of control) 
  
Amine 
Incorporation 
Cross linking 
Adenosine 100 µM 102 ± 6 95 ± 2 
CPA 100 nM 94 ± 3 97 ± 4 
DMSO 10 mM 103 ± 2 94 ± 3 
DPCPX 1 µM 89 ± 9 100 ± 1 
Forskolin 10 µM 96 ± 1 99 ± 1 
LY 294002  30 µM 108 ± 8 93 ± 6 
PD 98059  50 µM 100 ± 2 103 ± 2 
PTX 100 ng/ml 109 ± 4 101 ± 5 
Ro 31-8220  10 µM 103 ± 5 97 ± 1 
SB 203580  30 µM 98 ± 3 97 ± 1 
SP 600125  20 µM 90 ± 5 110 ± 1 
Wortmannin  100 nM 103 ± 3 96 ± 6 
 
TG2 amine incorporating and peptide crosslinking assays were carried out using 
purified guinea pig liver TG2 (50 ng/ well). Briefly, 50 ng of purified guinea pig liver 
TG2 was incubated with concentrations of the compounds listen in table 5.1 for 30 min 
prior to 1 h incubation in presence of either 6.67 mM calcium chloride or 13.3 mM 
EDTA containing 225 μM biotin-cadaverine and 2 mM 2-mercaptoethanol. Following 
incubation, the plates were processed as described in section 2.3 (ii) and (iii) of 
chapter II. 
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4.5 Visualisation of in situ TG2 activity following A1R activation. 
Biotin-X-cadaverine, a cell penetrating biotin-labelled primary amine, acts as the acyl-
acceptor during intracellular TG2-mediated transamidating reactions and is 
incorporated into endogenous protein substrates of TG2, which can subsequently be 
visualised by reporters such as FITC- and HRP-ExtrAvidin® (Lee et al, 1993). H9c2 
cells were pre-incubated with 1 mM biotin-X-cadaverine for 6 h at 37°C prior to 
treatment with either CPA or adenosine for 1, 5, 10, 20, 30 and 40 min. After fixation 
and permeabilisation, intracellular proteins with covalently attached biotin-X-
cadaverine were visualised using FITC-ExtrAvidin®. As shown in figure 4.12 and figure 
4.13, CPA (100 nM) and adenosine (100 μM) induced time-dependent increases in the 
incorporation of biotin-X-cadaverine into endogenous protein substrates of TG2. These 
data are comparable to the transient time-dependent increases in TG2 activity 
observed in vitro (see figure 4.1 and 4.2). Surprisingly, given the covalent nature of 
biotin-X-cadaverine incorporation, florescence staining returned to control levels 
following 30 min incubation with CPA or 40 min incubation with adenosine. CPA-
mediated biotin-X-cadaverine incorporation was also concentration-dependent (pEC50 
= 8.07  0.12; n=4; figure 4.12). Similarly, adenosine-mediated biotin-X-cadaverine 
incorporation was also concentration-dependent (pEC50 = 5.94  0.72; n=3; figure 
4.13).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.12: CPA-induced in situ TG2 activity in H9c2 cells. Cells were incubated with 1 
mM biotin-X-cadaverine (BXC) for 6 h, after which they were treated with (A) 1 μM 
CPA for 1, 5, 10, 20, 30 or 40 min or (B) the indicated concentrations (in M) of CPA for 
10 min. TG2-mediated biotin-X-cadaverine incorporation into intracellular proteins was 
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visualized using FITC-ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and 
viewed using a Leica TCS SP5 II confocal microscope (20x objective lens). Images 
presented are from one experiment and representative of three independent 
experiments. Quantified data points for (C) time course and (D) concentration-
response curve experiments represent the mean ± S.E.M. of fluorescence intensity 
relative to DAPI stain for five fields of view each from three independent experiments. 
*P<0.05, **P0.01 and ****P0.0001 versus control response. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.13: Adenosine-induced in situ TG2 activity in H9c2 cells. Cells were incubated 
with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they were treated with (A) 
100 μM adenosine (ADO) for 1, 5, 10, 20, 30 or 40 min or (B) the indicated 
concentrations (in M) of adenosine for 10 min. TG2-mediated biotin-X-cadaverine 
incorporation into intracellular proteins was visualized using FITC-ExtrAvidin® (green). 
Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal 
microscope (20x objective lens). Images presented are from one experiment and 
representative of three independent experiments. Quantified data points for (C) time 
course and (D) concentration-response curve experiments represent the mean ± 
S.E.M. of fluorescence intensity relative to DAPI stain for five fields of view each from 
three independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001 
versus control response. 
 
To confirm the involvement of the A1R and Gi/o-proteins, cells were treated with the 
A1R selective antagonist DPCPX (1 µM) for 30 min and Gi/o-protein inactivating 
pertussis toxin (100 ng/ml) for 16 h prior to incubation with either CPA (100 nM) or 
adenosine (100 μM) for 10 min. Pre-treatment of cells with DPCPX and PTX resulted in 
the complete inhibition of CPA- and adenosine-mediated biotin-X-cadaverine 
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incorporation into protein substrates (figure 4.14), confirming that the induced TG2 
activity was mediated by the A1R.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.14: Effect of the A1 adenosine receptor selective antagonist DPCPX and Gi/o-
protein inactivating pertussis toxin on in situ TG2 activity. H9c2 cells were pre-treated 
for 30 min with the selective A1 adenosine receptor antagonist DPCPX (1 µM) or 16 h 
with Gi/o-protein inactivating pertussis toxin (100 ng/ml) prior to 10 min stimulation 
with CPA (100 nM) or adenosine (100 µM). Cells were subsequently lysed with 0.1 M 
Tris buffer pH 8.0 containing protease and phosphatase inhibitors and cell lysates 
subjected to biotin cadaverine amine incorporation assay (panels A and C) or peptide 
cross-linking assay (panels Band D). Data points represent the mean ± S.E.M for TG2 
specific activity from four independent experiments. ****P0.0001, (a) versus control 
and (b) versus 100 nM CPA or 100 µM adenosine alone.  
 
To confirm the involvement of TG2 activation, cells were treated with the TG2 
inhibitors Z-DON (150 µM) and R283 (200 µM) for 1 h prior to incubation with either 
CPA (100 nM) or adenosine (100 μM) for 10 min. Pre-treatment of cells with Z-DON 
and R283 resulted in the complete inhibition of CPA-mediated biotin-X-cadaverine 
incorporation into protein substrates (figure 4.15A). The in situ responses to CPA were 
also attenuated by inhibitors of PKC (Ro 31-8220; 10 μM), MEK1 (PD 98059, 50 μM), 
p38 MAPK inhibitor (SB 203580; 20 μM), JNK1/2 inhibitor (SP 600125; 20 μM) and 
following removal of Ca2+ (figure 4.15). 
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Fig 4.15: Effects of TG2, PKA, ERK1/2, p38 MAPK, JNK1/2 inhibitors and removal of 
Ca2+ on in situ TG2 activity in H9c2 cells following stimulation with CPA. Cells were 
incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h after which they were treated 
as follows: (A) 1 h with the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM), (B) 30 
min with PD 98059 (50 µM) or Ro 31-8220 (10 µM), (C) 30 min with SB 203580 (20 
µM) or SP 600125 (20 µM), and (D) in the absence of extracellular Ca2+ for 30 min 
(nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) or pre-incubated 
for 30 min with 50 µM BAPTA/AM and in the absence of extracellular Ca2+  (nominally 
Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) to chelate intracellular Ca2+, 
prior to 10 min stimulation with CPA (100 nM). TG2-mediated biotin-X-cadaverine 
incorporation into intracellular proteins was visualized using FITC-ExtrAvidin® (green). 
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Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal 
microscope (20x objective lens). Images presented are from one experiment and are 
representative of three independent experiments. Quantified data points represent the 
mean ± S.E.M. of fluorescence intensity relative to DAPI stain for five fields of view 
from each of three independent experiments. ***P0.001 and ****P<0.0001, (a) 
versus control and (b) versus 100 nM CPA alone.   
 
Similarly, adenosine-mediated biotin-X-cadaverine incorporation into protein 
substrates was sensitive to TG2 (Z-DON; 150 µM and R283; 200 µM), PKC (Ro 31-
8220; 10 µM), MEK1/2 (PD 98059; 50 µM), p38 MAPK (SB 203580; 20 µM), and 
JNK1/2 (SP 600125; 20 µM) inhibitors and following the removal of Ca2+ (figure 4.16). 
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Fig 4.16: Effects of TG2, PKA, ERK1/2, p38 MAPK, JNK1/2 inhibitors and removal of 
Ca2+ on in situ TG2 activity in H9c2 cells following stimulation with adenosine. Cells 
were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h after which they were 
treated as follows: (A) 1 h with the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM), 
(B) 30 min with PD 98059 (50 µM) or Ro 31-8220 (10 µM), (C) 30 min with SB 
203580 (20 µM) or SP 600125 (20 µM), and (D) in the absence of extracellular Ca2+ 
for 30 min (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) or pre-
incubated for 30 min with 50 µM BAPTA/AM and in the absence of extracellular Ca2+  
(nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) to chelate 
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intracellular Ca2+, prior to 10 min stimulation with adenosine (ADO; 100 µM). TG2-
mediated biotin-X-cadaverine incorporation into intracellular proteins was visualized 
using FITC-ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed 
using a Leica TCS SP5 II confocal microscope (20x objective lens). Images presented 
are from one experiment and are representative of three independent experiments. 
Quantified data points represent the mean ± S.E.M. of fluorescence intensity relative 
to DAPI stain for five fields of view from each of three independent experiments. 
***P0.001 and ****P<0.0001, (a) versus control and (b) versus 100 μM adenosine 
alone. 
 
4.6 A1R induced TG2 phosphorylation.    
The effect of CPA on TG2 phosphorylation was examined via immunoprecipitation of 
TG2, followed by SDS-PAGE and Western blot analysis using anti-phosphoserine and 
anti-phosphothreonine antibodies. As shown in figure 4.17 and 4.18, CPA (100 nM) 
enhanced the phosphoserine and phosphothreonine residues within TG2. Pre-
treatment with Ro 318220 (10 µM), PD 98059 (50 µM) and SP 600125 (20 µM) 
attenuated CPA-induced TG2 phosphorylation (figure 4.17 and 4.18). However, SB 
203580 (20 µM) had no significant effect on CPA-induced TG2 phosphorylation (figure 
4.18). 
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Fig 4.17: Effect of PKC and ERK1/2 inhibition on CPA-induced phosphorylation of TG2. 
Where indicated, H9c2 cells were incubated for 30 min with Ro 318220 (10 µM) or PD 
98059 (50 µM) prior to stimulation with CPA (100 nM) for 10 min. Following 
stimulation, cell lysates were subjected to immunoprecipitation using an anti-TG2 
monoclonal antibody as described in section 2.7 of chapter II. The resultant 
immunoprecipitated protein(s) were subjected to SDS-PAGE and analysed via Western 
blotting using (A) anti-phosphoserine and (B) and anti-phosphothreonine antibodies. 
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10% of the input was added to the first lane to show the presence of phosphorylated 
proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with beads or IgG only were included to demonstrate 
the specificity of the bands shown. Quantified data for formoterol-induced increases in 
TG2-associated serine and threonine phosphorylation are expressed as a percentage 
of that observed in control cells (100%). Data points represent the mean  S.E.M. 
from three independent experiments.  *P0.05, **P0.01 and ***P0.001 (a) versus 
control and (b) versus CPA alone. 
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Fig 4.18: Effect of p38 MAPK and JNK1/2 inhibition on CPA-induced phosphorylation of 
TG2. Where indicated, H9c2 cells were incubated for 30 min with SB 203580 (20 µM) 
or SP 600125 (20 µM) prior to stimulation with CPA (100 nM) for 10 min. Following 
stimulation, cell lysates were subjected to immunoprecipitation using an anti-TG2 
monoclonal antibody as described in section 2.7 of chapter II.. The resultant 
immunoprecipitated protein(s) were subjected to SDS-PAGE and analysed via Western 
blotting using (A) anti-phosphoserine and (B) and anti-phosphothreonine antibodies. 
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10% of the input was added to the first lane to show the presence of phosphorylated 
proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with beads or IgG only were included to demonstrate 
the specificity of the bands shown. Quantified data for formoterol-induced increases in 
TG2-associated serine and threonine phosphorylation are expressed as a percentage 
of that observed in control cells (100%). Data points represent the mean  S.E.M. 
from three independent experiments.  *P0.05 and **P0.01 (a) versus control and (b) 
versus CPA alone. 
 
In conclusion, the data shown in this chapter provide sufficient evidence that supports 
the notion that TG2 activity is modulated by the A1 adenosine receptor in mitotic H9c2 
cells via a multi kinase dependent pathway. 
 
4.7 Discussion. 
The aims of this chapter were to identify if TG2 is modulated by the A1 adenosine 
receptor in H9c2 cells and to determine the molecular mechanisms underlying this 
modulation. 
In vitro modulation of TG2 by the A1R: 
Recently Almami and colleagues reported that PMA (a PKC activator) triggers 
increases in TG2-mediated transamidase activity in H9c2 cells (Almami et al, 2014). 
Hence, it was of interest to investigate if the A1R, which couples to PKC, could 
modulate TG2-mediated transamidase activity in rat H9c2 cardiomyoblasts. Activation 
of the A1R with the selective agonist CPA or the endogenous agonist adenosine 
triggered time- and concentration-dependent increases in the amine-incorporating and 
protein cross-linking activity of TG2 (figures 4.1 and 4.2). It was observed that there 
was a trend towards a decrease in both amine incorporation and protein cross-linking 
activities of TG2 at 1 min following activation of A1R using CPA and adenosine. At 
present, it is not known how A1R activation promotes an apparent inhibition of TG2 
amine incorporation activity. Moreover, experiments performed with the selective A1R 
antagonist DPCPX and the Gi/o-protein inactivating pertussis toxin further clarify that 
the responses obtained occur through the A1R and Gi/o-protein-mediated signalling 
(figure 4.3 and 4.5). Finally, involvement of TG2 was confirmed as responses to 
agonists were blocked by R283 and Z-DON, two structurally different TG2 inhibitors 
(Freund et al, 1994; Schaertl et al, 2010; figure 4.3). It should be noted that these 
TG2 inhibitors are poorly cell-permeable and inhibition of cellular TG2 is only 
achievable at concentrations significantly above their IC50 value versus purified 
enzyme (Schaertl et al, 2010; Freund et al, 1994). Hence, from these results, it is 
clear that the A1R is able to modulate TG2 mediated amine- and peptide-incorporating 
activities. 
At present there is insufficient knowledge regarding the regulation of TG2 enzymatic 
activity by GPCRs. Some examples in the literature include muscarinic receptor-
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mediated increases in TG2 activity in SH-SY5Y cells (Zhang et al, 1998) and 5-HT2A 
receptor mediated transamidation (TG-catalysed) of the small G-protein Rac1 in the 
rat A1A1v cells (Dai et al, 2008). Zhang and colleagues (1998) measured in situ TG2 
activity (polyamine incorporation) triggered by the muscarinic agonist carbachol, 
whereas Dai and colleagues (2008) reported TG2-catalysed incorporation of 5-
hydroxytryptamine into Rac1. 5-HT2A receptor-mediated incorporation of 5-HT into the 
small GTPases RhoA and Rab4 was also observed in platelets (Walther et al, 2003). It 
has been suggested that 5-HT2A and muscarinic receptor-mediated release of Ca
2+ 
from intracellular Ca2+ stores might be responsible for triggering TG transamidating 
activity (Zhang et al, 1998; Walther et al, 2003).  
Role of extracellular Ca2+ in A1R-induced TG2 activation: 
The amine- and peptide-incorporating activities of TG2 are dependent upon Ca2+ 
(Slaughter et al, 1992; Trigwell et al, 2004), therefore the role of extracellular and 
intracellular Ca2+ in A1R-induced TG2 activation was investigated. Although coupled to 
Gi/o-proteins, the A1R directly stimulates inositol phospholipid hydrolysis and Ca
2+ 
signalling through G-protein β subunit-mediated activation of phospholipase C in 
DDT1MF-2 cells, rat ventricular myocytes, rat atria and mouse heart (White et al, 1992; 
Dickenson & Hill, 1993, Dickenson et al, 1995; Sterin-Borda et al, 2002; Fenton et al, 
2010). Removal of extracellular Ca2+ inhibited CPA- and adenosine-induced TG2-
mediated amine- and peptide-incorporating activities (figure 4.4). As shown in chapter 
III (see figures 3.4 and 3.5), CPA and adenosine triggered increases in intracellular 
Ca2+ levels in H9c2 cells loaded with Fluo-8 AM which were characterised by 
pronounced Ca2+ oscillations and abolished following removal of extracellular Ca2+. As 
the A1R-induced TG2 activation was also abolished following removal of extracellular 
Ca2+, it suggests that extracellular Ca2+ has an important role in modulation of TG2. 
Further studies are warranted to determine precisely how A1R-induced Ca
2+ influx and 
TG2 activation occur in H9c2 cells. However, it is known that the A1R promotes 
receptor-operated Ca2+ influx in cardiomyocytes via a phospholipase C and PKC-
dependent pathway (Sabourin et al, 2012) and hence the kinase-dependent pathways 
outlined in the present study could be central to these novel aspects of TG2 
modulation by the A1R.  
 
Role of protein kinases in A1R-induced TG2 activity: 
The role of PKC and other protein/lipid kinases in CPA- and adenosine-induced TG2 
activation were investigated using appropriate pharmacological inhibitors. Even though 
TG2 activity can be modulated by intracellular [Ca2+] changes, there is growing 
evidence that TG activity can also be regulated by phosphorylation (Bollag et al, 2005; 
Mishra et al, 2007). PKB was not activated following stimulation of A1R (figure 4.10) 
suggesting that this pathway is not involved. Similarly, the pan PI-3K inhibitors LY 
294002 and wortmannin did not have any effect on A1R induced TG2 activation (figure 
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4.11), further confirming that these protein kinases are not involved. As illustrated in 
figure 4.6, CPA and adenosine induced robust increases in ERK1/2. The broad 
spectrum PKC inhibitor Ro 31-8220 and the MEK1/2 (up-stream activator of ERK1/2) 
inhibitor PD 98059 completely abolished CPA and adenosine-induced TG2 activity 
(figure 4.7), suggesting prominent roles for PKC and ERK1/2. Although ERK1/2 has 
been implicated in regulating the cross-linking activity of TG1 (Bollag et al, 2005) 
there is no prior evidence suggesting a role for this protein kinase in TG2 regulation. It 
is interesting to note that ERK1/2 activation by the A1R is sensitive to PKC inhibition in 
both neonatal rat cardiomyocytes (Germack and Dickenson, 2004) and H9c2 cells 
(Fretwell and Dickenson, 2009) and, therefore, the role of PKC in TG2 activation may 
be up-stream of ERK1/2. 
As indicated in figure 4.8, CPA and adenosine also induced robust activation of p38 
MAPK and JNK1/2. The p38 MAPK and JNK1/2 inhibitors SB 203580 and SP 600125 
blocked CPA and adenosine-induced TG2 activation (figure 4.9), further confirming the 
role of these protein kinases. Previous studies have shown activation of p38 MAPK 
occurs upon stimulation of A1R in adult rat ventricular myocytes, Langendorff-perfused 
rat hearts, isolated rabbit ventricular myocytes and a human cardiomyocyte-derived 
cell line (Carroll and Yellon, 2000; Dana et al, 2000; Mocanu et al, 2000; Liu and 
Hofmann, 2003; Ballard-Croft et al, 2005). In all of these cases, activation of p38 by 
the A1R was crucial for A1R-mediated preconditioning against ischaemia-reperfusion 
injury. Furthermore, activation of JNK1/2 following stimulation of A1R is not known to 
occur in cardiac cells. However, there are several studies reporting activation of 
JNK1/2 following stimulation of A1R in rat hippocampus (Burst et al, 2007; Chen et al, 
2014; Stockwell et al, 2017).  
There appears to be general constitutive activity of the enzyme TG2 in H9c2 cells. This 
activity could be a result of constitutive activity of the A1R or that TG2 is regulated by 
other constitutively active GPCRs. However, this is unlikely as there have been no 
studies investigating constitutive activation of GPCRs in H9c2 cells. There also seems 
to be a trend that the protein kinases assessed in this study can lower TG2 basal 
activity. As mentioned previously, there are some examples of TG2 being modulated 
by GPCRs and therefore, these kinases could be activated by a different GPCR (apart 
from A1R) and modulate the basal activity of TG2. Furthermore, it is possible that TG2 
activity is not only modulated by GPCRs but also by other receptors that activate 
protein kinases e.g. Receptor Tyrosine Kinases (RTKs; Sivaramakrishnan et al, 2013), 
post-translational modifications (phosphorylation; Mishra and Murphy, 2006) and 
direct activation of kinases by intracellular peptides (such as polyubiquitin chains; Xia 
et al, 2009). Therefore it is not surprising that the basal TG2 activity is lowered when 
treated with inhibitors of protein kinases on their own. Overall, these data suggest 
that the A1R regulates TG2 activity in H9c2 cells via a multi-protein kinase dependent 
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pathway. Although protein kinase inhibition and removal of extracellular Ca2+ both 
inhibit A1R-induced TG2 activation, the relationship between the two is yet to be 
explored. 
A1R-induced phosphorylation of TG2: 
Given the apparent role of multiple serine/threonine kinases in modulation of TG2, it 
was of interest to investigate the phosphorylation status of TG2 following A1R 
stimulation. The data obtained demonstrate that TG2 is phosphorylated in response to 
A1R activation (figure 4.17 and 4.18). Hence, the modulation of TG2 phosphorylation 
may represent a prominent downstream target of A1R signalling. Previous studies have 
revealed that TG2 is phosphorylated by PKA at Ser215 and Ser216 (Mishra and Murphy, 
2006) and at an unknown site(s) by PTEN-induced putative kinase 1 (PINK1; Min et al, 
2015). It is also known that phosphorylation of TG2 by PKA at Ser216 inhibits its 
transamidase activity and enhances its kinase activity (Mishra et al, 2007; Wang et al, 
2012). Phosphoproteomic studies have also identified numerous phosphorylation sites 
in human (Ser56, Ser60, Tyr219, Thr368, Tyr369, Ser419, Ser427, Ser538, Ser541 and Ser608; 
Rikova et al, 2007; Imami et al, 2008; Kettenbach et al, 2011; Bian et al, 2014; 
Palacios-Moreno et al, 2015) and rat (Tyr44, Thr58, Ser68 and Ser449; Hoffert et al, 2006; 
Lundby et al, 2012) TG2. Therefore, it is of great interest to identify the specific serine 
and threonine residue(s) within TG2 that are phosphorylated following A1R activation 
as well as the functional consequence(s) of A1R -induced TG2 phosphorylation. 
Given the multiple protein kinases implicated in A1R-induced TG2 activation, the 
influence of protein kinase inhibitors on TG2 phosphorylation were also investigated. 
CPA-induced increases in TG2 serine and threonine phosphorylation were significantly 
reduced following pharmacological inhibition of PKC (Ro 31-8220), MEK1/2 (PD 98059) 
or JNK1/2 (SP 600125). However, further studies are required to confirm whether 
these protein kinases directly catalyse the phosphorylation of TG2. It is notable that 
the p38 MAPK inhibitor SB203580 did not attenuate TG2 phosphorylation despite 
being able to block A1R-induced TG2 activation, suggesting that p38 MAPK modulates 
other targets involved in TG2 activation. Finally, as TG2 possesses kinase activity, it is 
conceivable that CPA-induced increases in TG2-bound serine and threonine 
phosphorylation may involve auto-phosphorylation. However, further work to identify 
the phosphorylation site(s) involved in auto-phosphorylation and phosphorylation 
following A1R activation would be of value and necessary. 
 
In situ A1R-induced polyamine incorporation into protein substrates: 
In situ TG2 activity following A1R stimulation increased in a time- and concentration-
dependent manner, which was comparable to CPA- and adenosine-induced amine 
incorporation activity observed in vitro (figure 4.12 and 4.13). The role of the A1R and 
Gi/o-proteins in inducing in situ TG2 activity was confirmed using the selective A1R 
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antagonist DPCPX and the Gi/o-protein inactivating pertussis toxin, which were able to 
reverse in situ TG2 activity (figure 4.14). However, given the covalent nature of 
biotin-X-cadaverine incorporation into protein substrates, it was surprising to observe 
that in situ TG2 activity returned to basal levels after 40 min. Possible explanations for 
this include reversal of amine incorporation catalysed by TG (Stamnaes et al, 2008), 
targeting of biotin-cadaverine-labelled proteins for degradation or their rapid expulsion 
from the cell. The rapid export of biotin-cadaverine-labelled proteins from PMA- or 
forskolin-stimulated H9c2 cells has been previously observed (Almami et al., 2014), so 
a similar mechanism may be occurring following A1R activation. The role of TG2 in in 
situ A1R-induced polyamine incorporation into protein substrates was confirmed using 
TG2 inhibitors Z-DON and R283, which were able to significantly reverse in situ TG2 
activity (figures 4.15A and 4.16A). A1R-induced in situ TG2 responses were also 
sensitive to pharmacological inhibition of PKC (Ro 31-8220), MEK1/2 (PD 98059), p38 
MAPK (SB203580), JNK1/2 (SP 600125) and removal of Ca2+ (figures 4.15 and 4.16), 
confirming the role of these signalling pathways. In summary, these data demonstrate 
that A1R mediated incorporation of polyamines via TG2 is dependent up on range of 
protein kinases. 
 
In conclusion, this present study has revealed that A1R-mediated activation of TG2 
occurs via a multi-protein kinase pathway in H9c2 cells. Figure 4.19 and table 4.2 
summarises the findings of this chapter.  
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Table 4.2: Summary of the effect of treatments on A1R-induced TG2 activities. 
A1R-induced TG2 activation 
TG2 activity 
Amine 
incorporation 
peptide 
crosslinking 
in-situ 
Treatments CPA ADO CPA ADO CPA ADO 
1 μM DPCPX Y Y Y Y Y Y 
150 μM Z-DON Y Y Y Y Y Y 
200 μM R283 Y Y Y Y Y Y 
Nominally Ca2+-free Hanks/HEPES 
buffer containing 0.1 mM EGTA 
Y Y Y Y Y Y 
50 μM BAPTA-AM in nominally 
Ca2+-free Hanks/HEPES buffer 
containing 0.1 mM EGTA 
Y Y Y Y Y Y 
100 ng/ml PTX Y Y Y Y Y Y 
50 μM PD 98059 Y Y Y Y Y Y 
10 μM Ro 31-8220 Y Y Y Y Y Y 
20 μM SB 208530 Y Y Y Y Y Y 
20 μM SP 600125 Y Y Y Y Y Y 
30 μM LY 294002 N N N N   
100 nM Wortmannin N N N N   
 
Effects of a range of treatments used in this study were investigated for TG2 amine 
incorporating, peptide crosslinking and in-situ activities in H9c2 cells, following 
stimulation with either CPA or adenosine. H9c2 cells were treated with above 
mentioned treatments in presence of CPA (100 nM) or adenosine (ADO; 100 μM) and 
cell lysates subjected to determine TG2 amine incorporating, peptide crosslinking and 
in-situ activities according to the protocols described in chapter II section 2.3. 
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Fig 4.19: Summary of the findings presented in this study. Stimulation of the A1 
adenosine receptor (A1R) by selective and endogenous agonists (CPA and adenosine, 
respectively) triggers activation of protein kinases (PKC, ERK1/2, JNK1/2 and p38 
MAPK) along with influx of extracellular Ca2+ leading to increases in TG2 activity and 
TG2 phosphorylation. Solid black arrows represent findings of this study and grey 
arrows represent published findings (not from the present study). 
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Chapter V: Modulation of TG2 activity by the β2 adrenoceptor in H9c2 
cells 
This chapter aims to investigate modulation of TG2 by the β2 adrenoceptor in mitotic 
H9c2 cells via TG2 amine incorporating and peptide crosslinking assays along with in-
situ TG2 activity. It also investigates the signalling mechanisms underlying its 
modulation. 
5.1 Effect of β2-AR activation on TG2-mediated biotin cadaverine amine 
incorporation and protein cross-linking activity. 
Initially the effect of the selective β2-AR agonist formoterol on TG2 activity in H9c2 
cardiomyoblasts was investigated. H9c2 cells were treated with formoterol (100 nM) 
for varying intervals of time and the cell lysates subjected to both biotin cadaverine 
amine-incorporation assay (Slaughter et al, 1992) and biotin-labelled peptide (biotin-
TVQQEL) cross-linking assay (Trigwell et al, 2004). Formoterol (figure 5.1A) produced 
increases in TG2-catalysed biotin-cadaverine incorporation activity, peaking at 20 min. 
In addition, formoterol (pEC50 = 7.85  0.09; n=4; figure 5.1C) stimulated 
concentration-dependent increases in biotin-cadaverine incorporation activity. 
Formoterol also triggered time-dependent increases in TG2-mediated protein cross-
linking activity peaking at 20 min (figure 5.1B), which was concentration-dependent 
(pEC50 = 7.69  0.15; n=4; figure 5.1D). Even though the β2-AR couples to Gs and Gi 
proteins (Daaka et al, 1997; Zamah et al, 2002), pre-treatment with pertussis toxin 
(Gi/o-protein blocker; 100 ng/ml) for 16 h had no significant effect on formoterol-
induced TG2 activity (figure 5.1E and F). Similar to formoterol, the non-selective β-AR 
agonist isoprenaline (10 μM) also triggered transient increases in TG2 catalysed biotin-
cadaverine incorporation and protein cross-linking activity, peaking at 20 min (figure 
5.2A and B). Furthermore, isoprenaline stimulated concentration-dependent increases 
in both biotin-amine incorporation activity (figure 5.2C; pEC50 = 6.13  0.15; n=4) 
and protein cross-linking activity (figure 5.2D; pEC50 = 7.11  0.17; n=4). It is notable 
that TG2 responses to isoprenaline were blocked by pertussis toxin indicating a role 
for Gi/o-proteins (figure 5.2E and F).  
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Fig 5.1: Effect of the β2-AR agonist formoterol on TG2 activity in H9c2 cells. Cells 
were stimulated with formoterol (100 nM) for the indicated time intervals (panels A 
and B). Concentration-response curves for formoterol in cells treated with agonist for 
20 min (panels C and D). Where indicated H9c2 cells were pre-treated for 16 h with 
100 ng/ml pertussis toxin (PTX) prior to 20 min stimulation with 100 nM formoterol 
(panels E and F). Cell lysates were subjected to the biotin-cadaverine incorporation 
(panels A, C and E) or the peptide cross-linking assay (panels B, D and F). Data points 
represent the mean ± S.E.M. for TG2 specific activity from four independent 
experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) versus control 
response. 
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Fig 5.2: Effect of the non-selective β-AR agonist isoprenaline on TG2 activity in H9c2 
cells. Cells were stimulated with isoprenaline (10 μM) for the indicated time periods 
(panels A and B). Concentration-response curves for isoprenaline in cells treated with 
agonist for 20 min are also shown (panels C and D). Where indicated, H9c2 cells were 
pre-treated for 16 h with 100 ng/ml pertussis toxin (PTX) prior to 20 min stimulation 
with 10 µM isoprenaline (ISO; panels E and F). Cell lysates were subjected to the 
biotin-cadaverine incorporation (panels A, C and E) or the peptide cross-linking assay 
(panels B, D and F). Data points represent the mean ± S.E.M. for TG2 specific activity 
from four independent experiments. *P0.05, **P<0.01, ***P<0.001 and 
****P0.0001, (a) versus control response and (b) versus 10 µM isoprenaline alone. 
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5.2 The effect of β-AR antagonists and TG2 inhibitors on β2-AR induced TG2 
activity. 
To determine whether the formoterol- and isoprenaline-induced TG2 activity occurred 
via activation of the β2-AR, the selective β2-AR antagonist ICI 118,551 and the non-
selective β-adrenoceptor receptor antagonist propranolol were implemented. H9c2 
cells were pre-treated for 30 min with ICI 118,551 (1 µM) or propranolol (1 µM) prior 
to stimulation with formoterol (1 µM) and/or isoprenaline (10 µM) for 20 min. ICI 
118,551 and propranolol blocked formoterol-induced (figure 5.3A and D) and 
isoprenaline-induced (figure 5.4A and D) TG2 activity, thus confirming that the 
induced activity was mediated by the β2-AR. To confirm that TG2 is responsible for the 
β2-AR induced transglutaminase activity in H9c2 cells, two structurally different cell 
permeable TG2 specific inhibitors were tested; R283 (a small molecule; Freund et al, 
1994) and Z-DON (peptide-based; Schaertl et al, 2010). H9c2 cells were pre-treated 
for 1 h with Z-DON (150 µM) or R283 (200 µM) prior to stimulation with formoterol (1 
µM) and/or isoprenaline (10 µM) for 20 min. Both inhibitors blocked formoterol-
induced and isoprenaline-induced TG-mediated amine incorporation (figure 5.3B and 
5.4B) and peptide cross-linking activity (figure 5.3D and 5.4D), confirming the 
involvement of TG2. 
 
5.3 The role of Ca2+ in β2-AR induced TG2 activity. 
The role of Ca2+ in β2-AR-induced TG2 activation was determined because TG2 is a 
Ca2+-dependent enzyme (Kiraly et al, 2011; Nurminskaya and Belkin, 2012; Eckert et 
al, 2014). The role of extracellular Ca2+ was assessed by measuring TG2 responses in 
the absence of extracellular Ca2+ using nominally Ca2+-free Hanks/HEPES buffer 
containing 0.1 mM EGTA. Removal of extracellular Ca2+ partially attenuated 
formoterol- (figure 5.3C and F) and isoprenaline-induced TG2 activity (figure 5.4C and 
F). To assess the role of intracellular Ca2+, measurements of TG2 activation were also 
performed using cells pre-incubated with the Ca2+ chelator BAPTA-AM (50 µM for 30 
min) in the absence of extracellular Ca2+. Loading cells with BAPTA in the absence of 
extracellular Ca2+ did not lead to further inhibition of formoterol-induced (figure 5.3C 
and F) and isoprenaline-induced TG2 activation (figure 5.4C and F). These 
observations indicate that the β2-AR induced TG2 activation is partially dependent 
upon the influx of extracellular Ca2+. 
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Fig 5.3: Effect of β-adrenoceptor antagonists, inhibitors of TG2 and removal of 
extracellular Ca2+ on formoterol-induced TG2 activity in H9c2 cells. H9c2 cells were 
pre-treated for 30 min with the antagonists ICI 118,551 (1 µM; β2-AR selective) and 
propranolol (1 µM; non-selective β-adrenoceptor) or for 1 h with the TG2 inhibitors Z-
DON (150 µM) and R283 (200 µM) prior to stimulation with formoterol (1 µM; 20 min). 
H9c2 cells were also stimulated for 20 min with formoterol (1 µM) either in the 
presence of extracellular Ca2+ (1.8 mM) or in its absence using nominally Ca2+-free 
Hanks/HEPES buffer containing 0.1 mM EGTA. Experiments were also performed using 
cells pre-incubated for 30 min with 50 µM BAPTA/AM and in the absence of 
extracellular Ca2+  (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) 
to chelate intracellular Ca2+. Cell lysates were subjected to the biotin-cadaverine 
incorporation assay (panels A, B and C) or peptide cross-linking assay (panels D, E 
and F). Data points represent the mean ± S.E.M. for TG2 specific activity from four 
independent experiments. *P0.05, **P0.01, ***P0.001 and ****P0.0001, (a) 
versus control and (b) versus 1 µM formoterol in the presence of extracellular Ca2+. 
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Fig 5.4: Effect of β-adrenoceptor antagonists, inhibitors of TG2 and removal of 
extracellular Ca2+ on isoprenaline-induced TG2 activity in H9c2 cells. H9c2 cells were 
pre-treated for 30 min with the antagonists ICI 118,551 (1 µM; β2-AR selective) and 
propranolol (1 µM; non-selective β-adrenoceptor) or for 1 h with the TG2 inhibitors Z-
DON (150 µM) and R283 (200 µM) prior to stimulation with isoprenaline (10 µM; 20 
min). H9c2 cells were also stimulated for 20 min with isoprenaline (10 µM) either in 
the presence of extracellular Ca2+ (1.8 mM) or in its absence using nominally Ca2+-free 
Hanks/HEPES buffer containing 0.1 mM EGTA. Experiments were also performed using 
cells pre-incubated for 30 min with 50 µM BAPTA/AM and in the absence of 
extracellular Ca2+  (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) 
to chelate intracellular Ca2+. Cell lysates were subjected to the biotin-cadaverine 
incorporation assay (panels A, B and C) or peptide cross-linking assay (panels D, E 
and F). Data points represent the mean ± S.E.M. for TG2 specific activity from four 
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independent experiments. *P0.05, **P0.01, ***P0.001 and ****P0.0001, (a) 
versus control and (b) versus 10 µM isoprenaline in the presence of extracellular Ca2+. 
 
 
5.4 The effect of protein and lipid kinase inhibitors on β2-AR induced TG2 
activity. 
The β2-AR activates the cAMP/PKA pathway and therefore the effect of two structurally 
different PKA inhibitors, Rp-cAMPs (de Wit et al, 1984) and KT-5720 (Kase et al, 1987), 
on formoterol-induced and isoprenaline-induced TG2 activity was assessed. As shown 
in figure 5.5, pre-treatment with Rp-cAMPs (50 µM) or KT 5720 (5 µM) partially 
attenuated formoterol-induced TG-mediated amine incorporation and protein cross-
linking activity, suggesting the involvement of PKA. Pre-treatment with Rp-cAMPs (50 
µM) or KT 5720 (5 µM) partially attenuated isoprenaline-induced TG-mediated amine 
incorporation, suggesting the involvement of PKA. It should be noted that the effect of 
Rp-cAMPs on isoprenaline-induced protein cross-linking activity was not statistically 
significant. Moreover, the effect of KT 5720 on formoterol- and isoprenaline-induced 
protein cross-linking activity was also not statistically significant. Overall, these data 
indicate that PKA plays a role in β2-AR induced TG2 activity. 
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Fig 5.5: Effect of PKA inhibitors KT-5720 and Rp-cAMPs on formoterol- and 
isoprenaline-induced TG2 activity. H9c2 cells were pre-treated for 30 min with Rp-
cAMPs (50 µM) or KT-5720 (5 µM) prior to 20 min stimulation with either formoterol 
(1 µM) or isoprenaline (ISO; 10 μM). Cell lysates were subjected to biotin-cadaverine 
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incorporation (panels A to D) or peptide cross-linking assays (panels E to H). Data 
points represent the mean ± S.E.M. for TG2 specific activity from four independent 
experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) versus control 
and (b) versus 1 µM formoterol or 10 μM isoprenaline alone. 
 
 
It is clear from previous studies that the β2-AR triggers the activation of signalling 
cascades involving ERK1/2, p38 MAPK, JNK1/2 and PKB in a variety of cell 
backgrounds (Daaka et al, 1997; Okamoto et al, 1991; Steinberg, 1999; Yano et al, 
2007). Modulation of ERK1/2, p38 MAPK, JNK1/2 and PKB activity following β2-AR 
activation was assessed in H9c2 cells by Western blotting using phospho-specific 
antibodies that recognise phosphorylated motifs within activated ERK1/2 (pTEpY), p38 
MAPK (pTGpY), JNK1/2 (pTPpY)  and PKB (pS473). Formoterol (1 µM for 20 min) and 
isoprenaline (10 µM for 20 min) did not stimulate p38 MAPK or JNK1/2 activation (figure 
5.6). This is consistent with the data showing no significant effect on formoterol- and 
isoprenaline-induced TG2 activity upon treatment with SB 203580 (20 µM; p38 MAPK 
inhibitor) and SP 600125 (20 µM; JNK1/2 inhibitor; figure 5.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.6: Effect of formoterol and isoprenaline on p38 MAPK and JNK1/2 
phosphorylation in H9c2 cells. Where indicated, H9c2 cells were pre-treated for 30 min 
with SB 203580 (20 µM; panels A and C) or SP 600125 (20 µM; panels B and D) prior 
to stimulation with either formoterol (1 µM) or isoprenaline (10 µM) for 20 min. Cell 
lysates were analysed by Western blotting for activation of p38 MAPK and JNK1/2 
using phospho-specific antibodies. Samples were subsequently analysed on separate 
blots using antibodies that recognize total p38 MAPK and JNK1/2. Data are expressed 
as the percentage of values for control cells (=100%) in the absence of protein kinase 
inhibitor and represent the mean  S.E.M. of four independent experiments. 
***P<0.001, (b) versus 1 µM formoterol alone. 
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Fig 5.7: Effect of p38 MAPK and JNK1/2 inhibitors on formoterol and isoprenaline-
induced TG2 activity. H9c2 cells were pre-treated for 30 min with SB 203580 (20 µM) 
or SP 600125 (20 µM) prior to 20 min stimulation with formoterol (1 µM) or 
isoprenaline (ISO; 10 µM). Cell lysates were subjected to the protein biotin-cadaverine 
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amine incorporation assay (panels A to D) or peptide cross-linking assay (panels E to 
H). Data points represent the mean ± S.E.M. TG2 specific activity from four 
independent experiments. *P<0.05, **P0.01 and ****P0.0001, (a) versus control. 
 
Formoterol (1 µM for 20 min) and isoprenaline (10 µM for 20 min) stimulated significant 
increases in ERK1/2 (figure 5.8) and PKB phosphorylation (figure 5.10) in H9c2 cells. As 
expected, pre-treatment with PD 98059 (50 µM; MEK1 inhibitor) blocked formoterol- 
(figure 5.8A) and isoprenaline-induced activation of ERK1/2 (figure 5.8B). 
Furthermore, treatment with PD 98059 (50 µM) also blocked formoterol- and 
isoprenaline-induced TG-mediated amine incorporation and protein cross-linking 
activity, suggesting a role for ERK1/2 in regulating these activities (figure 5.9). Pre-
treatment with wortmannin (100 nM) and LY 294002 (30 µM) blocked formoterol- 
(figure 5.10A and B) and isoprenaline-induced activation of PKB (figure 5.10C and D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.8: Effect of formoterol and isoprenaline on ERK1/2 phosphorylation in H9c2 cells. 
H9c2 cells were pre-treated for 30 min with PD 98059 (50 µM) prior to stimulation 
with formoterol (1 µM) or isoprenaline (10 µM) for 20 min. Cell lysates were analysed 
by Western blotting for activation of ERK1/2 using phospho-specific antibodies. 
Samples were subsequently analysed on separate blots using antibodies that 
recognize total ERK1/2. Data are expressed as the percentage of values for control 
cells (=100%) in the absence of protein kinase inhibitor and represent the mean  
S.E.M. of four independent experiments. *P<0.05, **P<0.01, ***P<0.001 and 
****P0.0001, (a) versus control and (b) versus 1 µM formoterol or 10 µM 
isoprenaline alone. 
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Fig 5.9: Effect of ERK1/2 inhibitor on formoterol- and isoprenaline-induced TG2 
activity. H9c2 cells were pre-treated for 30 min with PD 98059 (50 µM) prior to 20 min 
stimulation with formoterol (1 µM) or isoprenaline (ISO; 10 µM). Cell lysates were 
subjected to the protein biotin-cadaverine amine incorporation assay (panels A and B) 
or peptide cross-linking assay (panels C and D). Data points represent the mean ± 
S.E.M. TG2 specific activity from four independent experiments. *P<0.05, **P0.01 
and ***P0.001, (a) versus control and (b) versus 1 µM formoterol or 10 µM 
isoprenaline alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.10: Effect of formoterol and isoprenaline on PKB phosphorylation in H9c2 cells. 
Where indicated, H9c2 cells were pre-treated for 30 min with wortmannin (100 nM; 
panels A and C) and  LY 294002 (30 µM; panels B and D) prior to stimulation with 
formoterol (1 µM) or isoprenaline (10 µM) for 20 min. Cell lysates were analysed by 
Western blotting for activation of PKB using phospho-specific antibodies. Samples 
were subsequently analysed on separate blots using antibodies that recognize total 
PKB. Data are expressed as the percentage of values for control cells (=100%) in the 
absence of protein kinase inhibitor and represent the mean  S.E.M. of four 
independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) 
versus control and (b) versus 1 µM formoterol or 10 μM isoprenaline alone. 
 
 
 
In this study the pan PI-3K inhibitors wortmannin (100 nM) and LY 294002 (30 µM) 
blocked formoterol and isoprenaline-induced TG2 activity (figure 5.11). Furthermore, 
to determine if PI-3K were involved, the effect of the selective PI-3K inhibitor AS 
605240 was assessed. AS 605240  inhibited PKB phosphorylation (IC50 = 31.84 nM; 
p[IC50] = 7.50  0.03; n=3; figure 5.12A) and ERK1/2 phosphorylation (IC50 = 61.17 
nM; p[IC50] = 7.25  0.10; n=3; figure 5.12B) in a concentration-dependent manner. 
AS 605240 (1 µM) significantly inhibited formoterol and isoprenaline-induced PKB 
phosphorylation (figure 5.12C and D). The selective PI-3K inhibitor AS 605240 (1 µM) 
also blocked formoterol- and isoprenaline-induced TG2 activity (figure 5.13).  
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Fig 5.11: Effect of pan PI-3K inhibitors on formoterol- and isoprenaline-induced TG2 
activity. H9c2 cells were pre-treated for 30 min with wortmannin (100 nM) or LY 
294002 (30 µM) prior to 20 min stimulation with formoterol (1 µM) or isoprenaline 
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(ISO; 10 µM). Cell lysates were subjected to the protein biotin-cadaverine amine 
incorporation assay (panels A to D) or peptide cross-linking assay (panels E to H). 
Data points represent the mean ± S.E.M. TG2 specific activity from four independent 
experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) versus control 
and (b) versus 1 µM formoterol or 10 µM isoprenaline alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.12: Effect of PI-3K inhibitor AS 605240 on formoterol and isoprenaline on PKB 
and ERK1/2 phosphorylation. H9c2 cells were pre-treated for 30 min with indicated 
concentrations of AS 605240 prior to 20 min stimulation with formoterol (1 µM; panels 
A and B). H9c2 cells were pre-treated for 30 min with AS 605240 (1 µM) prior to 20 
min stimulation with formoterol (1 µM) or isoprenaline (ISO; 10 µM; panels C and D). 
Cell lysates were analysed by Western blotting for activation of PKB and ERK1/2 using 
phospho-specific antibodies. Samples were subsequently analysed on separate blots 
using antibodies that recognize total PKB and ERK1/2. Data are expressed as the 
percentage of values for control cells (=100%) in the absence of protein kinase 
inhibitor and represent the mean  S.E.M. of four independent experiments. **P0.01, 
***P0.001 and ****P0.0001, (a) versus control and (b) versus 1 µM formoterol or 
10 μM isoprenaline alone. 
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Fig 5.13: Effect of PI-3K inhibitor (AS 605240) on formoterol- and isoprenaline-
induced TG2 activity. H9c2 cells were pre-treated for 30 min with AS 605240 (1 µM) 
prior to 20 min stimulation with formoterol (1 µM) or isoprenaline (ISO; 10 µM). Cell 
lysates were subjected to the protein biotin-cadaverine amine incorporation assay 
(panels A and B) or peptide cross-linking assay (panels C and D). Data points 
represent the mean ± S.E.M. TG2 specific activity from four independent experiments. 
*P<0.05, **P0.01 and ***P0.001, (a) versus control and (b) versus 1 µM 
formoterol or 10 µM isoprenaline alone. 
 
To assess the role of PKB, Akt inhibitor XI, the selective inhibitor of PKB (Barve et al, 
2006) was employed. Akt inhibitor XI (IC50 = 6.86 nM; p[IC50] = 6.20  0.10; n=3; 
figure 5.14A) inhibited PKB phosphorylation in a concentration-dependent manner. Akt 
inhibitor XI (1 µM) significantly inhibited formoterol- and isoprenaline-induced PKB 
phosphorylation (figure 5.14B and C). However, treatment with Akt inhibitor XI (1 µM) 
had no significant effect on formoterol- and isoprenaline-induced TG2 activity (figure 
5.15). 
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Fig 5.14: Effect of PKB inhibitor on formoterol- and isoprenaline-mediated PKB 
phosphorylation. H9c2 cells were pre-treated for 30 min with indicated concentrations 
of Akt inhibitor XI prior to 20 min stimulation with formoterol (1 µM; panel A). H9c2 
cells were pre-treated for 30 min with Akt inhibitor XI (1 µM) prior to 20 min 
stimulation with formoterol (1 µM) or isoprenaline (ISO; 10 µM; panels B and C). Cell 
lysates were analysed by Western blotting for activation of PKB using phospho-specific 
antibodies. Samples were subsequently analysed on separate blots using antibodies 
that recognize total PKB. Data are expressed as the percentage of values for control 
cells (=100%) in the absence of protein kinase inhibitor and represent the mean  
S.E.M. of four independent experiments. *P<0.05, **P0.01, ***P0.001 and 
****P0.0001, (a) versus control and (b) versus 1 µM formoterol or 10 μM 
isoprenaline alone. 
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Fig 5.15: Effect of PKB inhibitor on formoterol- and isoprenaline-induced TG2 activity. 
H9c2 cells were pre-treated for 30 min with Akt inhibitor XI (1 µM) prior to 20 min 
stimulation with formoterol (1 µM) or isoprenaline (ISO; 10 µM). Cell lysates were 
subjected to the protein biotin-cadaverine amine incorporation assay (panels A and B) 
or peptide cross-linking assay (panels C and D). Data points represent the mean ± 
S.E.M. TG2 specific activity from four independent experiments. *P<0.05, **P0.01 
and ***P0.001, (a) versus control and (b) versus 1 µM formoterol or 10 µM 
isoprenaline alone. 
 
Since formoterol- and isoprenaline-induced TG2 activation is dependent on ERK1/2, 
PI-3K and extracellular Ca2+, it was of interest to determine whether PI-3K and 
extracellular Ca2+ play an up-stream role in ERK1/2 activation. The pan PI-3K 
inhibitors wortmannin and LY 294002, the selective PI-3K inhibitor AS 605240 and 
removal of extracellular Ca2+ attenuated formoterol- and isoprenaline-induced ERK1/2 
activation (figure 5.16 and 5.17) suggesting that they are upstream of ERK1/2.  
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Fig 5.16: Effect of formoterol on ERK1/2 phosphorylation in H9c2 cells. Where 
indicated, H9c2 cells were pre-treated for 30 min with (A) wortmannin (100 nM), (B)  
LY 294002 (30 µM), or (C) AS 605240 (1 µM) prior to stimulation with formoterol (1 
µM) for 20 min. In Panel (D) cells were stimulated for 20 min with formoterol (1 µM) 
either in the presence of extracellular Ca2+ (1.3 mM) or in its absence using nominally 
Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA. Cell lysates were analysed by 
Western blotting for activation of ERK1/2 using phospho-specific antibodies. Samples 
were subsequently analysed on separate blots using antibodies that recognize total 
ERK1/2. Data are expressed as the percentage of values for control cells (=100%) in 
the absence of protein kinase inhibitor and represent the mean  S.E.M. of four 
independent experiments. *P<0.05, **P<0.01 and ***P<0.001, (a) versus control 
and (b) versus 1 µM formoterol alone. 
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Fig 5.17: Effect of isoprenaline on ERK1/2 phosphorylation in H9c2 cells. Where 
indicated, H9c2 cells were pre-treated for 30 min with (A) wortmannin (100 nM), (B)  
LY 294002 (30 µM), or (C) AS 605240 (1 µM) prior to stimulation with isoprenaline 
(10 µM) for 20 min. In Panel (D) cells were stimulated for 20 min with isoprenaline 
(10 µM) either in the presence of extracellular Ca2+ (1.3 mM) or in its absence using 
nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA. Cell lysates were 
analysed by Western blotting for activation of ERK1/2 using phospho-specific 
antibodies. Samples were subsequently analysed on separate blots using antibodies 
that recognize total ERK1/2. Data are expressed as the percentage of values for 
control cells (=100%) in the absence of protein kinase inhibitor and represent the 
mean  S.E.M. of four independent experiments. *P<0.05, **P<0.01, ***P<0.001 
and ****P0.0001, (a) versus control and (b) versus 10 µM isoprenaline alone. 
 
 
Moreover, Rp-cAMPs and pertussis toxin (figure 5.18A and B) had no significant effect 
on formoterol-induced ERK1/2 activation. However, isoprenaline-induced ERK1/2 
activation was inhibited by pertussis toxin and Rp-cAMPs (figure 5.18C and D). These 
data suggest formoterol activates ERK1/2 via a PKA-independent but PI-3K and Ca2+-
dependent pathway while isoprenaline-induced ERK1/2 activation is dependent upon 
Gi-protein, PI-3K, extracellular Ca
2+ and PKA. 
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Fig 5.18: Effect of formoterol and isoprenaline on ERK1/2 phosphorylation in H9c2 
cells. Where indicated, H9c2 cells were pre-treated for 16 h with 100 ng/ml pertussis 
toxin (panels A and C) or 30 min with Rp-cAMPs (50 µM; panels B and D) prior to 20 
min stimulation with formoterol (1 µM) or isoprenaline (10 µM). Cell lysates were 
analysed by Western blotting for activation of ERK1/2 using phospho-specific 
antibodies. Samples were subsequently analysed on separate blots using antibodies 
that recognize total ERK1/2. Data are expressed as the percentage of values for 
control cells (=100%) in the absence of protein kinase inhibitor and represent the 
mean  S.E.M. of four independent experiments. *P<0.05, **P<0.01, ***P<0.001 
and ****P0.0001, (a) versus control and (b) versus 1 µM formoterol or 10 µM 
isoprenaline alone. 
It is important to note that KT-5720, Rp-cAMPs, PD 98059, Akt inhibitor XI, SB 
203580, SP 600125, LY 294002, AS 605240 and other compounds used in this study 
had no significant effect on purified guinea pig liver TG2 activity (table 5.1). H-89 had 
an inhibitory effect on the purified guinea pig liver TG2 activity (table 5.1) and hence 
was not used in this study. Overall, these data suggest that TG2 activity is modulated 
in H9c2 cells by the β2-AR via a pathway involving PKA, ERK1/2 and PI-3K. 
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Table 5.1: Effect of compounds used in this study on purified guinea pig liver TG2 
activity. 
Compound Concentration 
Effect on in-vitro TG2 activity 
(% of control) 
  
Amine 
Incorporation 
Cross linking 
Akt inhibitor  XI 1 µM 87 ± 3 85 ± 3 
AS 605240 1 µM 103 ± 2 88 ± 4 
CGP 20712 1 µM 93 ± 2 96 ± 8 
Cimaterol 10 µM 91 ± 3 86 ± 1 
DMSO 10 mM 103 ± 1 94 ± 3 
Dobutamine 10 µM 90 ± 3 107 ± 4 
Formoterol 1 µM 99 ± 2 108 ± 4 
Forskolin 10 µM 95 ± 1 99 ± 1 
H-89 1 µM 51 ± 5 56 ± 3 
ICI 118,551 1 µM 97 ± 4 81 ± 5 
Isoprenaline 10 µM 98 ± 4 86 ± 4 
KT-5720 2 µM 93 ± 6 93 ± 3 
LY 294002 30 µM 108 ± 8 93 ± 7 
PD 98059 50 µM 100 ± 2 102 ± 2 
Procaterol 10 µM 98 ± 5 108 ± 1 
Propranolol 1 µM 109 ± 2 106 ± 2 
PTX 100 ng/ml 110 ± 4 101 ± 5 
Rp-cAMPs 50 µM 107 ± 3 108 ± 1 
SB 203580 30 µM 98 ± 3 97 ± 1 
SP 600125 20 µM 90 ± 5 110 ± 2 
Wortmannin 100 nM 103 ± 3 96 ± 6 
 
TG2 amine incorporating and peptide crosslinking assays were carried out using 
purified guinea pig liver TG2 (50 ng/ well). Briefly, 50 ng of purified guinea pig liver 
TG2 was incubated with concentrations of the compounds listen in table 5.1 for 30 min 
prior to 1 h incubation in presence of either 6.67 mM calcium chloride or 13.3 mM 
EDTA containing 225 μM biotin-cadaverine and 2mM 2-mercaptoethanol. Following 
incubation, the plates were processed as described in section 2.3 (ii) and (iii) of 
chapter II. H-89 had a significant effect on purified guinea pig liver TG2 activity 
(indicated in red) with **P<0.01 for amine incorporating and *P<0.05 for peptide 
crosslinking activity of TG2 versus control. 
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5.5 Visualisation of in situ TG2 activity following β2-AR activation. 
Biotin-X-cadaverine, a cell penetrating biotin-labelled primary amine, acts as the acyl-
acceptor during intracellular TG2-mediated transamidating reactions and is 
incorporated into endogenous protein substrates of TG2, which can subsequently be 
visualised by reporters such as FITC- and HRP-ExtrAvidin® (Lee et al, 1993). H9c2 
cells were pre-incubated with 1 mM biotin-X-cadaverine for 6 h at 37°C prior to 
treatment with either formoterol or isoprenaline for 1, 5, 10, 20, 30 and 40 min. After 
fixation and permeabilisation, intracellular proteins with covalently attached biotin-X-
cadaverine were visualised using FITC-ExtrAvidin®. As shown in figure 5.19 and figure 
5.20, formoterol (100 nM) and isoprenaline (10 μM) induced a time-dependent 
increase in the incorporation of biotin-X-cadaverine into endogenous protein 
substrates of TG2. These data are comparable to the time-dependent increases in TG2 
activity observed in vitro (see figure 5.1 and 5.2). Formoterol-mediated biotin-X-
cadaverine incorporation was also concentration-dependent (pEC50 = 7.65  0.27; n=4; 
figure 5.19). Similarly, isoprenaline-mediated biotin-X-cadaverine incorporation was 
also concentration-dependent (pEC50 = 6.94  0.14; n=3; figure 5.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.19: Formoterol-induced in situ TG2 activity in H9c2 cells. Cells were incubated 
with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they were treated with (A) 
100 nM formoterol for 1, 5, 10, 20, 30 or 40 min or (B) the indicated concentrations 
(in M) of formoterol for 20 min. TG2-mediated biotin-X-cadaverine incorporation into 
intracellular proteins was visualized using FITC-ExtrAvidin® (green). Nuclei were 
stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal microscope 
(20x objective lens). Images presented are from one experiment and representative of 
three independent experiments. Quantified data points for (C) time course and (D) 
concentration-response curve experiments represent the mean ± S.E.M. of 
fluorescence intensity relative to DAPI stain for five fields of view from each of three 
independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001 versus 
control response. 
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Fig 5.20: Isoprenaline-induced in situ TG2 activity in H9c2 cells. Cells were incubated 
with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they were treated with (A) 
10 μM isoprenaline for 1, 5, 10, 20, 30 or 40 min or (B) the indicated concentrations 
(in M) of isoprenaline for 20 min. TG2-mediated biotin-X-cadaverine incorporation into 
intracellular proteins was visualized using FITC-ExtrAvidin® (green). Nuclei were 
stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal microscope 
(20x objective lens). Images presented are from one experiment and representative of 
three independent experiments. Quantified data points for (C) time course and (D) 
concentration-response curve experiments represent the mean ± S.E.M. of 
fluorescence intensity relative to DAPI stain for five fields of view from each of three 
independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001 versus 
control response. 
 
To confirm the involvement of TG2 activation, cells were treated with the TG2 
inhibitors Z-DON (150 µM) and R283 (200 µM) for 1 h prior to incubation with either 
formoterol (1 µM) or isoprenaline (10 μM) for 20 min. Pre-treatment of cells with Z-
DON and R283 resulted in the complete inhibition of formoterol-mediated biotin-X-
cadaverine incorporation into protein substrates (figure 5.21A). The in situ responses 
to formoterol were also attenuated by inhibitors of PKA (KT 5720 and Rp-cAMPs), PI-
3K (LY 294002 and AS 605240) and MEK1 (PD 98059) and following removal of 
extracellular Ca2+ (figure 5.21).  
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Fig 5.21: Effects of TG2, PKA, ERK1/2, PI-3K inhibitors and removal of extracellular 
Ca2+ on in situ TG2 activity in H9c2 cells following stimulation with formoterol. Cells 
were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h after which they were 
treated as follows: (A) 1 h with the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM), 
(B) 30 min with KT 5720 (5 µM) or Rp-cAMPs (50 µM), (C) 30 min with PD 98059 (50 
µM) or LY 294002 (30 µM) or (D)  30 min with AS 605240 (1 µM) or in the absence of 
extracellular Ca2+ for 30 min (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 
mM EGTA), prior to 20 min stimulation with formoterol (1 µM). TG2-mediated biotin-
X-cadaverine incorporation into intracellular proteins was visualized using FITC-
ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica 
TCS SP5 II confocal microscope (20x objective lens). Images presented are from one 
experiment and are representative of three independent experiments. Quantified data 
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points represent the mean ± S.E.M. of fluorescence intensity relative to DAPI stain for 
five fields of view from each of three independent experiments. *P<0.05, **P0.01, 
***P0.001 and ****P<0.0001, (a) versus control and (b) versus 1 µM formoterol 
alone.   
 
 
Similarly, isoprenaline-mediated biotin-X-cadaverine incorporation into protein 
substrates was sensitive to TG2 (Z-DON and R283), PKA (KT 5720 and Rp-cAMPs), PI-
3K (LY 294002, AS 605240, wortmannin) and MEK1 (PD 98059) inhibitors and 
following removal of extracellular Ca2+ (figure 5.22 and 5.23). 
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Fig 5.22: Effects of TG2, PKA, ERK1/2, PI-3K inhibitors and removal of extracellular 
Ca2+ on in situ TG2 activity in H9c2 cells following stimulation with isoprenaline. Cells 
were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h after which they were 
treated as follows: (A) 1 h with the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM), 
(B) 30 min with KT 5720 (5 µM) or Rp-cAMPs (50 µM), (C) 30 min with PD 98059 (50 
µM) or LY 294002 (30 µM) or (D)  30 min with AS 605240 (1 µM) or in the absence of 
extracellular Ca2+ for 30 min (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 
mM EGTA), prior to 20 min stimulation with isoprenaline (ISO; 10 µM). TG2-mediated 
biotin-X-cadaverine incorporation into intracellular proteins was visualized using FITC-
ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica 
TCS SP5 II confocal microscope (20x objective lens). Images presented are from one 
experiment and are representative of three independent experiments. Quantified data 
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points represent the mean ± S.E.M. of fluorescence intensity relative to DAPI stain for 
five fields of view from each of three independent experiments. *P<0.05, **P0.01, 
***P0.001 and ****P<0.0001, (a) versus control and (b) versus 10 µM isoprenaline 
alone.   
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.23: Effects of pan PI-3K inhibitor wortmannin on in situ TG2 activity in H9c2 
cells following stimulation with formoterol and isoprenaline. Cells were incubated with 
1 mM biotin-X-cadaverine (BXC) for 6 h after which they were treated with 
wortmannin (100 nM) prior to 20 min stimulation with formoterol (1 µM) or 
isoprenaline (ISO; 10 µM). TG2-mediated biotin-X-cadaverine incorporation into 
intracellular proteins was visualized using FITC-ExtrAvidin® (green). Nuclei were 
stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal microscope 
(20x objective lens). Images presented are from one experiment and are 
representative of three independent experiments. Quantified data points represent the 
mean ± S.E.M. of fluorescence intensity relative to DAPI stain for five fields of view 
from each of three independent experiments. **P0.01, ***P0.001 and 
****P<0.0001, (a) versus control and (b) versus 1 µM formoterol or 10 µM 
isoprenaline alone. 
 
To confirm the involvement of the β2-AR, cells were treated with the β2-AR selective 
antagonist ICI 118,551 (1 µM) and non-selective β-AR antagonist propranolol (1 µM) 
for 30 min prior to incubation with either formoterol (1 µM) or isoprenaline (10 μM) for 
20 min. Pre-treatment of cells with ICI 118,551 and propranolol resulted in the 
complete inhibition of formoterol- and isoprenaline-mediated biotin-X-cadaverine 
incorporation into protein substrates (figure 5.24). This confirms that the induced TG2 
activity was mediated by the β2-AR. 
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Fig 5.24: Effect of β-adrenoceptor antagonists on in situ TG2 activity in H9c2 cells 
following stimulation with formoterol and isoprenaline. Cells were incubated with 1 mM 
biotin-X-cadaverine (BXC) for 6 h after which they pre-treated for 30 min with the 
antagonists ICI 118,551 (1 µM; β2-AR selective) and propranolol (1 µM; non-selective 
β-adrenoceptor) prior to 20 min stimulation with formoterol (1 µM) or isoprenaline 
(ISO; 10 µM). TG2-mediated biotin-X-cadaverine incorporation into intracellular 
proteins was visualized using FITC-ExtrAvidin® (green). Nuclei were stained with DAPI 
(blue) and viewed using a Leica TCS SP5 II confocal microscope (20x objective lens). 
Images presented are from one experiment and are representative of three 
independent experiments. Quantified data points represent the mean ± S.E.M. of 
fluorescence intensity relative to DAPI stain for five fields of view from each of three 
independent experiments. **P0.01, ***P0.001 and ****P<0.0001, (a) versus 
control and (b) versus 1 µM formoterol or 10 µM isoprenaline alone. 
 
5.6 β2-AR induced TG2 phosphorylation. 
The effect of formoterol on TG2 phosphorylation was examined via 
immunoprecipitation of TG2, followed by SDS-PAGE and Western blot analysis using 
anti-phosphoserine and anti-phosphothreonine antibodies. As shown in figure 5.25 and 
5.26, formoterol (1 µM) enhanced the phosphoserine and phosphothreonine residues 
within TG2. Pre-treatment with Rp-cAMPs (50 µM), PD 98059 (50 µM) and AS 605240 
(1 µM) attenuated formoterol-induced TG2 phosphorylation (figure 5.25 and 5.26). 
Furthermore, removal of extracellular Ca2+ also resulted in attenuation of formoterol-
induced TG2 activity (figure 5.26). Additionally, formoterol-induced increases in TG2 
phosphorylation were also blocked by the pan PI-3K inhibitors wortmannin and LY 
294002 (figure 5.27). 
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Fig 5.25: Effect of PKA and ERK1/2 inhibition on formoterol-induced phosphorylation 
of TG2. Where indicated, H9c2 cells were incubated for 30 min with Rp-cAMPs (50 µM) 
or PD 98059 (50 µM) prior to stimulation with formoterol (1 µM) for 20 min. Following 
stimulation, cell lysates were subjected to immunoprecipitation using an anti-TG2 
monoclonal antibody as described in section 2.7 of chapter II. The resultant 
immunoprecipitated protein(s) were subjected to  SDS-PAGE and analysed via 
Western blotting using  (A) anti-phosphoserine and (B) and anti-phosphothreonine 
antibodies. 10% of the input was added to the first lane to show the presence of 
phosphorylated proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with beads or IgG only were included to demonstrate 
the specificity of the bands shown. Quantified data for formoterol-induced increases in 
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TG2-associated serine and threonine phosphorylation are expressed as a percentage 
of that observed in control cells (100%). Data points represent the mean  S.E.M. 
from three independent experiments.  *P0.05, **P0.01 and ***P0.001 (a) versus 
control and (b) versus formoterol alone. 
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Fig 5.26: Roles of extracellular Ca2+ and PI-3K in formoterol-induced phosphorylation 
of TG2. Measurements of formoterol-induced TG2 phosphorylation were performed 
either in the absence of extracellular Ca2+ using nominally Ca2+-free Hanks/HEPES 
buffer containing 0.1 mM EGTA, as indicated, or in cells incubated for 30 min with AS 
60540 (1 µM) prior to stimulation with formoterol (1 µM) for 20 min. Following 
stimulation, cell lysates were subjected to immunoprecipitation using an anti-TG2 
monoclonal antibody as described in section 2.7 of chapter II. The resultant 
immunoprecipitated protein(s) were subjected to  SDS-PAGE and Western blot 
analysis using  (A) anti-phosphoserine and (B) and anti-phosphothreonine antibodies. 
10% of the input was added to the first lane to show the presence of phosphorylated 
proteins prior to immunoprecipitation and negative controls with the 
147 
 
immunoprecipitation performed with beads or IgG only were included to demonstrate 
the specificity of the bands shown. Quantified data for formoterol-induced increases in 
TG2-associated serine and threonine phosphorylation are expressed as a percentage 
of that observed in control cells (100%). Data points represent the mean  S.E.M. 
from three independent experiments.  *P0.05 and **P0.01 (a) versus control and (b) 
versus formoterol alone.  
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Fig 5.27: Effect of pan PI-3K inhibitors on formoterol-induced phosphorylation of TG2. 
Where indicated, H9c2 cells were incubated for 30 min with wortmannin (100 nM) or 
LY 294002 (30 µM) prior to stimulation with formoterol (1 µM) for 20 min. Following 
stimulation, cell lysates were subjected to immunoprecipitation using an anti-TG2 
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monoclonal antibody as described in section 2.7 of chapter II. The resultant 
immunoprecipitated protein(s) were subjected to  SDS-PAGE and analysed via 
Western blotting using  (A) anti-phosphoserine and (B) and anti-phosphothreonine 
antibodies. 10% of the input was added to the first lane to show the presence of 
phosphorylated proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with beads or IgG only were included to demonstrate 
the specificity of the bands shown. Quantified data for formoterol-induced increases in 
TG2-associated serine and threonine phosphorylation are expressed as a percentage 
of that observed in control cells (100%). Data points represent the mean  S.E.M. 
from three independent experiments.  *P0.05, **P0.01 and ***P0.001 (a) versus 
control and (b) versus formoterol alone. 
 
In conclusion, the data shown in this chapter provide sufficient evidence which 
supports the notion that TG2 activity is modulated by the β2 adrenoceptor in mitotic 
H9c2 cells via a PKA, PI-3Kγ and ERK1/2 dependent pathway. 
 
5.7 Discussion. 
The aim of this chapter was to identify if TG2 is modulated by the β2 adrenoceptor in 
H9c2 cells along with determining the molecular mechanisms underlying it. 
In vitro modulation of TG2 by the β2-AR 
Recently Almami and colleagues have reported that forskolin (AC activator) triggers 
increases in TG2-mediated transamidase activity in H9c2 cells (Almami et al, 2014). 
Hence it was of interest to investigate if the β2-AR which couples to cAMP/PKA could 
modulate TG2-mediated transamidase activity in rat H9c2 cardiomyoblasts. Activation 
of the β2-AR with either the selective long-acting β2-AR agonist formoterol or the non-
selective β-AR agonist isoprenaline triggered time- and concentration-dependent 
increases in the amine incorporating and protein cross-linking activity of TG2 (figures 
5.1 and 5.2). It is important to note that the potency for both of these agonists in 
mediating biotin-cadaverine incorporation and protein cross-linking is lower than that 
for agonist-stimulated cAMP accumulation. One possible explanation for these 
differences in potency might be due to the top of the curve being different. This could 
be because of less data points on the curve and therefore would need higher 
concentrations of agonist to achieve the top of the curve. These differences may be a 
consequence of biased agonism between agonist-induced cAMP accumulation versus 
TG2 activation (Rajagopal et al, 2011). Alternatively, it could also be a consequence of 
the multiple signalling pathways e.g. PI-3K, ERK1/2 and Ca2+ shown to be required for 
TG2 modulation by the β2-AR. Moreover, administration of the non-selective β-AR 
antagonist propranolol and the selective β2-AR antagonist ICI 118,551 further clarifies 
that the responses obtained are from the β2-AR as the induced TG2 activity was 
completely reversed (figure 5.3 and 5.4). Finally, involvement of TG2 was confirmed 
as responses to agonists were blocked by R283 and Z-DON, two structurally different 
TG2 inhibitors (Freund et al, 1994; Schaertl et al, 2010; figure 5.3 and 5.4). Hence 
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from these results, it is clear that the β2-AR is able to modulate TG2 mediated amine- 
and peptide-incorporating activities. 
 
Role of extracellular Ca2+ in β2-AR induced TG2 activation 
It is well known that the amine- and peptide-incorporating activities of TG2 are 
dependent upon Ca2+ (Slaughter et al, 1992; Trigwell et al, 2004), therefore the role 
of extracellular and intracellular Ca2+ in β2-AR-induced TG2 activation was investigated. 
Removal of extracellular Ca2+ partially inhibited formoterol-induced TG2-mediated 
amine- and peptide-incorporating activities (figure 5.3). As shown in chapter III figure 
3.11, formoterol did not trigger observable increases in intracellular [Ca2+] in H9c2 
cells loaded with Fluo-8 AM. At present the reason(s) for this discrepancy are unclear 
but it may reflect very localized formoterol-induced increases in intracellular [Ca2+] (as 
a consequence of Ca2+ influx) that, whilst sufficient to trigger TG2 activation, were not 
detectable using the methodology employed for imaging. It is important to note that, 
although changes in intracellular [Ca2+] required for TG2 activation are typically in the 
order 3-100 µM (Király et al., 2011), there is growing evidence that intracellular [Ca2+] 
can reach levels sufficient to activate TG2. For instance, interaction of TG2 with 
protein binding partners and/or membrane lipids have been proposed to induce a 
conformational change that promotes activation at lower levels of intracellular [Ca2+] 
(Király et al, 2011). Hence it is possible that formoterol-induced TG2 activation may 
require the sensitization of TG2 to low levels of intracellular [Ca2+]. Interestingly, 
removal of extracellular Ca2+ also partially inhibited isoprenaline-induced TG2-
mediated amine- and peptide-incorporating activities (figure 5.4). As shown in chapter 
III figure 3.11, isoprenaline occasionally did trigger increases in intracellular [Ca2+] in 
H9c2 cells loaded with Fluo-8 AM. This could be a result of isoprenaline coupling to 
Gi/o-proteins as treatment with PTX resulted in reversal of isoprenaline-induced TG2-
mediated amine- and peptide-incorporating activities (figure 5.2) but PTX pre-
treatment had no effect in formoterol-induced TG2-mediated amine- and peptide-
incorporating activities (figure 5.1). Clearly, further studies are warranted to 
determine precisely how β2-AR-induced TG2 activation occurs in the absence of 
detectable increases in intracellular Ca2+ (in case of formoterol) and in case of 
isoprenaline, it is necessary to confirm the isoprenaline-induced intracellular Ca2+ 
responses and their relation with TG2. However, the kinase-dependent pathways 
outlined in the present study could be central to these novel aspects of TG2 
modulation by the β2-AR. Furthermore, many protein kinases (e.g. ERK1/2 and PKC; 
Chuderland and Seger, 2008; Steinberg, 2012) display Ca2+ sensitivity. This Ca2+ 
sensitivity of protein kinases can lead to potential crosstalk and might be crucial in 
modulation of TG2. 
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Role of protein and lipid kinase inhibitors on β2-AR induced TG2 activity 
The role of PKA and other protein/lipid kinases in formoterol- and isoprenaline-induced 
TG2 activation were investigated using the appropriate pharmacological inhibitors. 
There was no activation of p38 MAPK or JNK1/2 following stimulation of β2-AR (figure 
5.6) suggesting that these pathways are not involved. Similarly, the p38 MAPK and 
JNK1/2 inhibitors SB 203580 and SP 600125 did not have any effect on β2-AR-induced 
TG2 activation (figure 5.7) further confirming no involvement of these protein kinases. 
The PKA inhibitors Rp-cAMPs and KT 5720 attenuated formoterol-induced TG2 amine 
incorporating and peptide crosslinking activities, suggesting a role for PKA in β2-AR 
induced TG2 activation (figure 5.5). Interestingly, the PKA inhibitors Rp-cAMPs and KT 
5720 did not inhibit isoprenaline-induced TG2 amine incorporating and peptide 
crosslinking activities, suggesting there might be a different pathway by which 
isoprenaline induces TG2 activation. It has been shown in this study that isoprenaline 
can couple to Gi/o-proteins and hence TG2 activation might occur via a pathway that is 
dependent on Gi/o-proteins. 
As indicated in figure 5.8, formoterol and isoprenaline also induced robust increases in 
ERK1/2. The MEK1/2 (up-stream activator of ERK1/2) inhibitor PD 98059 abolished 
formoterol- and isoprenaline-induced TG2 activation (figure 5.9). Previous studies 
have reported that ERK1/2 activation by the β2-AR involves PKA-dependent activation 
of the small G-protein Rap1 and subsequent activation of B-Raf (Schmitt and Stork, 
2000). However, in H9c2 cells formoterol-induced ERK1/2 activation was insensitive to 
PKA inhibition while isoprenaline-induced ERK1/2 activation was sensitive to PKA 
inhibition. Therefore the role of PKA in TG2 activation remains unclear (figure 5.18).  
In addition to the pathway outlined above, the β2-AR can also trigger ERK1/2 
activation via two other pathways; one Gs/Gi-protein dependent and the other β-
arrestin-dependent but G-protein independent (Shenoy et al, 2006). In H9c2 cells, 
formoterol-induced ERK1/2 and TG2 activation were pertussis toxin insensitive and 
therefore are independent of Gi/o-proteins and suggests involvement of Gs-proteins 
and/or β-arrestin. In contrast, isoprenaline-induced ERK1/2 and TG2 activation were 
sensitive to pertussis toxin suggesting the involvement of Gi/o-proteins (figure 5.1, 5.2 
and 5.18). The fact that removal of extracellular Ca2+ abolished formoterol- and 
isoprenaline-induced ERK1/2 activation, suggests a prominent role for Ca2+ influx 
(figure 5.16 and 5.17). Previous studies have shown that Gs coupled receptors can 
also stimulate ERK1/2 via cAMP-mediated (PKA independent) activation of EPAC 
(exchange protein directly activated by cAMP), which is a guanine nucleotide exchange 
factor for Rap1 (Goldsmith and Dhanasekaran, 2007). Overall, these observations 
suggest that signalling pathways leading to ERK1/2 and TG2 activation by the β2-AR 
appear to be ligand dependent. It would be of interest to investigate further the 
mechanism(s) underlying β2-AR-induced ERK1/2 activation in H9c2 cells. 
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Chesley and colleagues have shown that the β2-AR triggers the activation of PI-3K via 
a Gi-protein dependent pathway (Chesley et al, 2000). Furthermore, PI-3K plays a 
prominent role in the regulation of cardiac contractility by attenuating cAMP levels via 
phosphodiesterase 4 activation (Gregg et al, 2010). It has also been previously 
reported that isoprenaline activates PI-3K via the sequential activation of Gi/Gβ, Src 
and PDGFR in H9c2 cells (Yano et al, 2007) and the β2-AR has been shown to activate 
PI-3K via the transactivation of the platelet-derived growth factor receptor (PDGFR; 
Yano et al, 2007). In the present study we have shown that formoterol- and 
isoprenaline-induced TG2 (figure 5.11 and 5.13) and ERK1/2 (figure 5.16 and 5.17) 
activation are sensitive to the pan PI-3K inhibitors wortmannin and LY 294002 and the 
selective PI-3K inhibitor AS 605240. From these data a substantial role for PI-3Kα in 
β2-AR-induced TG2 activation would seem unlikely. Furthermore, since formoterol-
induced ERK1/2 activation is pertussis toxin insensitive, it is likely that the β2-AR-
induced PI-3K activation proceeds via a Gi-protein independent pathway in H9c2 cells. 
Interestingly, in adult rat cardiomyocytes the β1-AR stimulates PI-3K via a signalling 
pathway involving Gs/PKA and Gsβγ/GRK2 (Leblais et al, 2004). Overall, these 
observations suggest that PI-3K plays a prominent up-stream role in ERK1/2 
stimulation and TG2 activation by the β2-AR in H9c2 cells. Clearly, further studies are 
required to elucidate the mechanism(s) governing β2-AR-induced PI-3K activation in 
H9c2 cells. 
Apart from PI-3K and ERK1/2 activation in H9c2 cells, PKB activation upon 
stimulation of  β2-AR was investigated as PI-3k is closely associated with PKB. It was 
found that the pan PI-3K inhibitors wortmannin and LY 294002 and the selective PI-
3K inhibitor AS 605240 could inhibit PKB phosphorylation (figures 5.10 and 5.12) and 
TG2 activation (figures 5.11 and 5.13) further confirming the role of PI-3K. 
Implementation of the selective PKB inhibitor, Akt inhibitor XI significantly attenuated 
β2-AR-induced PKB activation in H9c2 cells (figure 5.14). In pulmonary vascular 
smooth muscle cells, TG2 promotes Akt signalling by Akt serotonylation i.e. covalent 
attachment of 5-HT via transamidase activity of TG2 (Penumatsa et al, 2014). 
Similarly, in several cancers such as pancreatic cancer cells, HeLa cells, meningioma 
and breast cancer cells, TG2 expression is associated with activation of the PAK/Akt 
survival pathway, inhibition of ROS formation and modulation of tumour suppressor 
phosphatase PTEN which results in cell survival (Bae et al, 2006; Verma et al, 2008; 
Verma et al, 2008; Agnihotri et al, 2013; Huang et al, 2014; Huang et al, 2015). 
However, Akt inhibitor XI had no effect on β2-AR-induced TG2 activation (figure 5.15), 
thus suggesting that even though PKB is being activated, it does not play a role in 
modulation of TG2 activity upon stimulation of the β2-AR.  
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β2-AR-induced phosphorylation of TG2 
Given the apparent role of PKA and ERK1/2 in modulation of TG2, it was of interest to 
investigate the phosphorylation status of TG2 following β2-AR stimulation. The data 
obtained demonstrate that TG2 is phosphorylated in response to β2-AR activation 
(figure 5.25, 5.26 and 5.27). Hence it is conceivable that the modulation of TG2 
phosphorylation represents a downstream target of β2-AR signalling. Previous studies 
have shown that TG2 is phosphorylated by PKA at Ser215 and Ser216  (Mishra and 
Murphy, 2006) and at an unknown site(s) by PTEN-induced putative kinase 1 (PINK1; 
Min et al., 2015). It is also known that phosphorylation of TG2 by PKA at Ser216 
inhibits its transamidase activity and enhances its kinase activity (Mishra et al, 2007; 
Wang et al, 2012). Phosphoproteomic studies have also identified numerous 
phosphorylation sites in human (Ser56, Ser60, Tyr219, Thr368, Tyr369, Ser419, Ser427, 
Ser538, Ser541 and Ser608; Rikova et al, 2007; Imami et al, 2008; Kettenbach et al, 
2011; Bian et al, 2014; Palacios-Moreno et al, 2015) and rat (Tyr44, Thr58, Ser68 and 
Ser449; Hoffert et al, 2006; Lundby et al, 2012) TG2.  
It is interesting to note that PKA-mediated phosphorylation of TG2 has several 
potential consequences, including promotion of protein-protein interactions, 
enhancement of TG2 kinase activity and inhibition of transamidating activity (Mishra 
and Murphy, 2006; Mishra et al, 2007), whereas PINK1-mediated phosphorylation of 
TG2 blocks its proteasomal degradation (Min et al, 2015). In this study β2-AR-induced 
PKA activation promoted TG2 transamidating activity. Mishra and colleagues showed 
using histidine-tagged TG2 immobilized on nickel-agarose and incubated with purified 
PKA that PKA inhibited in vitro TG2 crosslinking activity (Mishra et al, 2007). Hence, in 
vivo regulation of TG2 activity by PKA may be influenced by interaction of TG2 with 
other proteins and/or lipids. Thus, further studies are required to determine the 
consequence(s) of β2-AR induced TG2 phosphorylation. In view of the multiple 
protein/lipid kinases (PKA, ERK1/2, PI-3Kγ) implicated in β2-AR-induced TG2 
activation, investigation of the influence of kinase inhibitors on TG2 phosphorylation 
was carried out. Formoterol-induced increases in TG2 serine and threonine 
phosphorylation were significantly reduced following pharmacological inhibition of PKA 
(Rp-cAMPs), MEK1/2 (PD 98059), PI-3K (AS 605240, wortmannin, LY 294002) and 
removal of extracellular Ca2+. Although the inhibition of TG2 phosphorylation following 
PI-3K inhibition is most likely due to the upstream role of PI-3K in ERK1/2 activation, 
it is possible that the protein kinase activity of PI-3K could directly phosphorylate TG2 
(Hunter 1995; Naga Prasad et al, 2005). Further studies are necessary to establish 
whether PKA, ERK1/2 and/or indeed PI-3K directly catalyse the phosphorylation of 
TG2.  
It is also important to note that removal of extracellular Ca2+ inhibited formoterol-
induced TG2 phosphorylation. The role of extracellular Ca2+ in formoterol-induced 
ERK1/2 activation is apparent from these data. Alternatively, it is also possible that 
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conformational changes in TG2 triggered by Ca2+ facilitate its subsequent 
phosphorylation by PKA and/or ERK1/2. Conversely, it could be that TG2 
phosphorylation sensitizes TG2 to activation in the presence of low intracellular Ca2+ 
levels. Finally, as TG2 possesses kinase activity, it is conceivable that formoterol-
induced increases in TG2-bound serine and threonine phosphorylation may involve 
auto-phosphorylation. However, further work to identify the phosphorylation sites 
involved would be necessary. 
In situ β2-AR-induced polyamine incorporation into protein substrates 
Intracellular polyamines (e.g. spermine, spermidine, and putrescine) play an 
important role the regulation of gene expression, cell proliferation, and the response 
of cells to stress (Miller-Fleming et al, 2015). Polyamines can also be covalently 
attached onto proteins via TG2-mediated transamidation activity, resulting in the 
incorporation of a positively charged group into the target protein. Hence, TG2-
mediated polyamination may promote changes in protein conformation, which could 
lead to alterations in protein function (Yu et al, 2015). For instance, constitutive G-
protein activity is a consequence of TG2-mediated incorporation of polyamines into 
RhoA (Makitie et al, 2009; Shin et al, 2008; Singh et al, 2001), while the incorporation 
of polyamines into phospholipase A2 results in a 2-3 fold increase in its activity which 
causes release of arachidonic acid from membrane phospholipids (Cordella-Miele et al, 
1993). In the present study, in situ TG2 activity increased following stimulation of the 
β2-AR in a time- and concentration-dependent manner which is comparable to amine 
incorporation activity observed in vitro (figures 5.19 and 5.20). The role of TG2 was 
confirmed using TG2 inhibitors Z-DON and R283 which were able to significantly 
reverse in situ TG2 activity (figures 5.21A and 5.22A). These β2-AR induced-TG2 
responses were also sensitive to pharmacological inhibition of PKA (Rp-cAMPs, KT 
5720), MEK1/2 (PD 98059), PI-3K (AS 605240, LY 294002, Wortmannin) and removal 
of extracellular Ca2+ (figures 5.21, 5.22 and 5.23), confirming the role of these 
signalling pathways. The role of β2-AR in inducing TG2 activity was confirmed using 
the selective β2-AR antagonist ICI 118,551 and the non-selective β-AR antagonist 
propranolol which were able to reverse in situ TG2 activity (figure 5.24). From the 
data presented in this study, it could be speculated that β2-AR mediated incorporation 
of polyamines might regulate the function of a range of cellular targets and may 
represent a new paradigm in β2-AR signalling and regulation of cellular function.  
 
In conclusion, this present study has revealed that the activation of TG2 occurs by the 
β2-AR via a PKA, PI-3Kγ and ERK1/2 dependent pathway in H9c2 cells. Figure 5.28 
and table 5.2 summarise the findings of this chapter. 
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Table 5.2: Summary of the effect of treatments on β2-AR-induced TG2 activities. 
β2-AR-induced TG2 activation 
TG2 activity 
Amine 
incorporation 
peptide 
crosslinking 
in-situ 
Treatments FORM ISO FORM ISO FORM ISO 
100 ng/ml PTX N Y N Y   
1 μM ICI 118551 Y Y Y Y Y Y 
1 μM Propranolol Y Y Y Y Y Y 
150 μM Z-DON Y Y Y Y Y Y 
200 μM R283 Y Y Y Y Y Y 
Nominally Ca2+-free Hanks/HEPES buffer 
containing 0.1 mM EGTA 
Y Y Y Y Y N 
50 μM BAPTA-AM in nominally Ca2+-free 
Hanks/HEPES buffer containing 0.1 mM EGTA 
N N N N   
50 μM Rp-cAMPs Y Y Y N Y Y 
5 μM KT 5720 Y N N N N N 
20 μM SB 208530 N N N N   
20 μM SP 600125 N N N N   
50 μM PD 98059 Y Y Y Y Y Y 
30 μM LY 294002 Y Y Y Y Y Y 
100 nM Wortmannin Y Y Y Y Y Y 
1 μM AS 605240 Y Y Y Y Y N 
1 μM AKT XI inhibitor N N N N   
 
Effects of a range of treatments used in this study were investigated for TG2 amine 
incorporating, peptide crosslinking and in-situ activities in H9c2 cells, following 
stimulation with either formoterol or isoprenaline. H9c2 cells were treated with above 
mentioned treatments in presence of formoterol (FORM; 1 μM) or isoprenaline (ISO; 
10 μM) and cell lysates subjected to determine TG2 amine incorporating, peptide 
crosslinking and in-situ activities according to the protocols described in chapter II 
section 2.3. 
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Fig 5.28: Summary of the findings presented in this study. Stimulation of the β2-
adrenoceptor (β2-AR) by selective and non-selective agonists (formoterol and 
isoprenaline, respectively) triggers activation of protein kinases (PKA, PI-3Kγ and 
ERK1/2) along with influx of extracellular Ca2+ leading to increases in TG2 activity and 
TG2 phosphorylation. Solid black arrows represent findings of this study, dashed 
arrows represent findings of this study which need further work or were inconclusive 
and grey arrows represent published findings (not from the present study). 
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Chapter VI: Cardioprotective role of A1 adenosine receptor and β2 
adrenoceptor-induced TG2 activation 
This chapter aims to assess the cardioprotective potential of the A1 adenosine receptor 
and β2 adrenoceptor-induced TG2 activity during simulated hypoxia and hypoxia/re-
oxygenation injury. Cell viability assays and activation of caspase-3 were used to 
investigate if activation of TG2 via the aforementioned receptors is cytoprotective. 
6.1 Determination of time period for hypoxia and hypoxia/re-oxygenation-
induced cell death. 
Initially the effect of hypoxia on cell viability in H9c2 cardiomyoblasts was investigated. 
H9c2 cells were exposed to hypoxia for varying intervals of time and assessed for cell 
viability using reduction in MTT, release of LDH and activation of caspase-3. As shown 
in figure 6.1, ~60% cell death was successfully achieved at 8 h of incubation with 
hypoxia (reduction in MTT was 37 ± 3% of control; n=4; figure 6.1A; release of LDH 
was 543 ± 34% of control; n=4; figure 6.1B; increase in caspase-3 activity was 342 ± 
62% of control; n=4; figure 6.1D) and hence was chosen for further experiments. 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.1: Effect of hypoxia on cell viability in H9c2 cells. Cells were exposed to hypoxia 
for varying intervals of time (1, 2, 4, 6, 8 and 24 h for MTT and LDH assays; 1, 2, 4, 6, 
8, 10 and 24 h for caspase-3 activation). Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into the 
culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P0.05, **P<0.01, ***P<0.001 
and ****P0.0001 versus control. 
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Subsequently the effect of hypoxia/re-oxygenation-induced cell death in H9c2 
cardiomyoblasts was investigated. H9c2 cells were exposed to 8 h of hypoxia followed 
by varying intervals of time of re-oxygenation and assessed for cell viability using 
reduction in MTT, release of LDH and activation of caspase-3. As shown in figure 6.2, 
further reduction in cell viability was successfully achieved at 18 h of re-oxygenation 
(reduction in MTT was 22 ± 2% of control; n=4; figure 6.2A; release of LDH was 637 
± 22% of control; n=4; figure 6.2B; increase in caspase-3 activity was 418 ± 26% of 
control; n=4; figure 6.2D) and was chosen for further experiments so that all 
experiments could be completed in a working day.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.2: Effect of hypoxia/re-oxygenation on cell viability in H9c2 cells. Cells were 
exposed to 8 h of hypoxia followed by re-oxygenation for varying intervals of time 
(0.5, 3, 6, 9, 12, 15, 18, 21 and 24 h; H/R). Cell viability was assessed by measuring 
the metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into 
the culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control (NX) cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P0.05, **P<0.01, ***P<0.001 
and ****P0.0001, (a) versus normoxia control, (b) versus hypoxic control. 
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6.2 Role of TG2 in A1R-induced cell survival against hypoxia-induced cell 
death. 
The A1R agonists CPA and adenosine were both cytoprotective against hypoxic injury. 
Briefly, H9c2 cells were treated with CPA (100 nM) or adenosine (100 μM) for 10 min 
prior to exposure to 8 h of hypoxia. Following hypoxic incubation, cell viability was 
assessed. Both CPA and adenosine were successful in increasing reduction in MTT, 
reducing both release of LDH and activation of caspase-3, thus offering protection 
(figure 6.3, 6.4, 6.5 and 6.6). This protection was abolished when H9c2 cells were 
pre-treated for 30 min with the selective A1R antagonist DPCPX (1 µM) prior to 
stimulation (figure 6.3). Furthermore, pre-treatment with the Gi/o-protein inactivating 
pertussis toxin (100 ng/ml for 16 h) abolished CPA- and adenosine-induced cell 
survival (figure 6.4), confirming the involvement of Gi/o-proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.3: The effect of A1R activation on hypoxia-induced cell death. Where indicated, 
H9c2 cells were pre-treated for 30 min with DPCPX (1 µM) before the addition of CPA 
(100 nM) or adenosine (ADO; 100 µM) for 10 min prior to 8 h hypoxia (H; 1% O2) or 
normoxia (NX). Cell viability was assessed by measuring the metabolic reduction of 
MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Caspase-3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) 
versus normoxia control, (b) versus hypoxic control, (c) versus 100 nM CPA in the 
presence of hypoxia, (d) versus 100 µM ADO in the presence of hypoxia. 
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Fig 6.4: Role of Gi/o-proteins in A1R-induced cell survival versus hypoxia-induced cell 
death. Where indicated, H9c2 cells were pre-treated for 16 h with pertussis toxin (100 
ng/ml) before the addition of CPA (100 nM) or adenosine (ADO; 100 µM) for 10 min 
prior to 8 h hypoxia (H; 1% O2) or normoxia (NX). Cell viability was assessed by 
measuring the metabolic reduction of MTT by cellular dehydrogenases (A) and release 
of LDH into the culture medium (B). Caspase-3 activation was assessed via Western 
blotting using anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) 
are expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P0.05, **P<0.01, ***P<0.001 
and ****P0.0001, (a) versus normoxia control, (b) versus hypoxic control, (c) versus 
100 nM CPA in the presence of hypoxia, (d) versus 100 µM ADO in the presence of 
hypoxia. 
 
To confirm that TG2 is responsible for the A1R-induced cell survival in H9c2 cells, two 
structurally different cell permeable TG2 specific inhibitors were tested; R283 (a small 
molecule; Freund et al, 1994) and Z-DON (peptide-based; Schaertl et al, 2010). H9c2 
cells were pre-treated for 1 h with Z-DON (150 µM) or R283 (200 µM) prior to 
stimulation with CPA (100 nM) and/or adenosine (100 µM) for 10 min. Both inhibitors 
blocked CPA- and adenosine-induced cell survival (figure 6.5 and 6.6), confirming the 
involvement of TG2. 
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Fig 6.5: Role of TG2 in CPA-induced cell survival versus hypoxia-induced cell death. 
Where indicated, H9c2 cells were pre-treated for 1 h with Z-DON (150 µM) or R283 
(200 µM) before the addition of CPA (100 nM) for 10 min prior to 8 h hypoxia (H; 1% 
O2) or normoxia (NX). Cell viability was assessed by measuring the metabolic 
reduction of MTT by cellular dehydrogenases (A) and release of LDH into the culture 
medium (B). Caspase-3 activation was assessed via Western blotting using anti-
activated caspase-3 antibody (C) and quantified caspase-3 data (D) are expressed as 
a percentage of normoxia control cell values (=100%). Data are expressed as a 
percentage of normoxia control cell values (=100%) and represent the mean  S.E.M. 
from four independent experiments. *P0.05, **P<0.01, ***P<0.001 and 
****P0.0001, (a) versus normoxia control, (b) versus hypoxic control, (c) versus 100 
nM CPA in the presence of hypoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.6: Role of TG2 in adenosine-induced cell survival versus hypoxia-induced cell 
death. Where indicated, H9c2 cells were pre-treated for 1 h with Z-DON (150 µM) or 
R283 (200 µM) before the addition of adenosine (ADO; 100 µM) for 10 min prior to 8 h 
hypoxia (H; 1% O2) or normoxia (NX). Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into the 
culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P0.05, **P<0.01, ***P<0.001 
and ****P0.0001, (a) versus normoxia control, (b) versus hypoxic control, (c) versus 
100 µM ADO in the presence of hypoxia. 
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6.3 Role of TG2 in β2-AR-induced cell survival against hypoxia-induced cell 
death. 
To determine the role of TG2 in β2-AR-induced cell survival, H9c2 cells were treated 
with formoterol (1 μM) or isoprenaline (10 μM) for 20 min prior to exposure to 8 h of 
hypoxia. Following hypoxic incubation, cell viability was assessed. Pre-treatment with 
formoterol had no significant effect on hypoxia-induced decrease in MTT reduction or 
release of LDH (figure 6.7). In contrast, isoprenaline significantly attenuated hypoxia-
induced reduction in MTT, release of LDH and activation of caspase-3, thus offering 
protection (figure 6.8, 6.9 and 6.10). This protection was abolished when H9c2 cells 
were pre-treated for 30 min with the β2-AR selective and non-selective β-AR 
antagonists ICI 118551 (1 µM) and propranolol (1 µM), respectively prior to 
stimulation (figure 6.8). Furthermore, pre-treatment with the Gi/o-protein inactivating 
pertussis toxin (100 ng/ml for 16 h) abolished isoprenaline-induced cell survival 
(figure 6.9), suggesting a prominent role for Gi/o-proteins. However, formoterol had no 
significant effect even when cells were pre-treated with pertussis toxin. These 
observations indicate that the β2-AR-induced cell survival is dependent upon Gi/o-
protein and the differences in signalling mapped out in chapter V between isoprenaline 
and formoterol could be a potential cause of formoterol not offering protection. 
Therefore, all further experiments will be performed with isoprenaline. 
 
 
 
 
 
 
 
 
Fig 6.7: The effect of formoterol on hypoxia-induced cell death. Where indicated, 
H9c2 cells were pre-treated for 30 min with ICI 118551 (1 µM) or propranolol (1 µM) 
before the addition of formoterol (1 µM) for 20 min prior to 8 h hypoxia (1% O2) or 
normoxia (NX). Cell viability was assessed by measuring the metabolic reduction of 
MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Data are expressed as a percentage of normoxia control cell values (=100%) and 
represent the mean  S.E.M. from four independent experiments. ***P0.001 and 
****P<0.0001, (a) versus normoxia control. 
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Fig 6.8: The effect of isoprenaline on hypoxia-induced cell death. Where indicated, 
H9c2 cells were pre-treated for 30 min with ICI 118551 (1 µM) or propranolol (1 µM) 
before the addition of isoprenaline (10 µM) for 20 min prior to 8 h hypoxia (H; 1% O2) 
or normoxia (NX). Cell viability was assessed by measuring the metabolic reduction of 
MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Caspase-3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P<0.05 and ****P<0.0001, (a) versus normoxia control, 
(b) versus hypoxic control, (c) versus 10 µM isoprenaline in the presence of hypoxia. 
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Fig 6.9: Role of Gi/o-proteins in β2-AR-induced cell survival versus hypoxia-induced 
cell death. Where indicated, H9c2 cells were pre-treated for 16 h with pertussis toxin 
(100 ng/ml) before the addition of isoprenaline (10 µM) for 20 min prior to 8 h 
hypoxia (H; 1% O2) or normoxia (NX). Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into the 
culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P<0.05, **P0.01, ***P0.001 
and ****P<0.0001, (a) versus normoxia control, (b) versus hypoxic control, (c) 
versus 10 µM isoprenaline in the presence of hypoxia. 
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To confirm that TG2 is responsible for the β2-AR-induced cell survival in H9c2 cells, 
TG2 specific inhibitors R283 and Z-DON were implemented. H9c2 cells were pre-
treated for 1 h with Z-DON (150 µM) or R283 (200 µM) prior to stimulation with 
isoprenaline (10 µM) for 20 min. Both inhibitors blocked isoprenaline-induced cell 
survival (figure 6.10), confirming the involvement of TG2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.10: Role of TG2 in β2-AR-induced cell survival versus hypoxia-induced cell death. 
Where indicated, H9c2 cells were pre-treated for 1 h with Z-DON (150 µM) or R283 
(200 µM) before the addition of isoprenaline (10 µM) for 20 min prior to 8 h hypoxia 
(H; 1% O2) or normoxia (NX). Cell viability was assessed by measuring the metabolic 
reduction of MTT by cellular dehydrogenases (A) and release of LDH into the culture 
medium (B). Caspase-3 activation was assessed via Western blotting using anti-
activated caspase-3 antibody (C) and quantified caspase-3 data (D) are expressed as 
a percentage of normoxia control cell values (=100%). Data are expressed as a 
percentage of normoxia control cell values (=100%) and represent the mean  S.E.M. 
from four independent experiments. *P<0.05, **P0.01, ***P0.001 and 
****P<0.0001, (a) versus normoxia control, (b) versus hypoxic control, (c) versus 10 
µM isoprenaline in the presence of hypoxia. 
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6.4 Role of TG2 in A1R-induced cell survival against hypoxia/re-oxygenation-
induced cell death. 
A1R-induced pre-conditioning 
For pre-conditioning, H9c2 cells were treated with the pharmacological agents prior to 
the onset of hypoxic incubation. Activation of the A1R provided protection against 
hypoxia/re-oxygenation-induced cell death. H9c2 cells were treated with CPA (100 nM) 
or adenosine (100 μM) for 10 min prior to exposure to 8 h of hypoxia followed by 18 h 
re-oxygenation. Both CPA and adenosine significantly attenuated hypoxia/re-
oxygenation-induced decreases in MTT reduction, release of LDH and activation of 
caspase-3, thus offering protection (figure 6.11, 6.12, 6.13 and 6.14). This protection 
was abolished when H9c2 cells were pre-treated for 30 min with the selective A1R 
antagonist DPCPX (1 µM) prior to stimulation (figure 6.11). Moreover, pre-treatment 
with the Gi/o-protein inactivating pertussis toxin (100 ng/ml for 16 h) abolished A1R-
induced-induced cell survival (figure 6.12), confirming the involvement of Gi/o-proteins. 
Finally, pre-treatment for 1 h with Z-DON (150 µM) or R283 (200 µM) prior to 
stimulation attenuated A1R-induced cell survival (figure 6.13 and 6.14), confirming the 
involvement of TG2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.11: The effect of A1R activation on hypoxia/re-oxygenation-induced cell death. 
Where indicated, H9c2 cells were pre-treated for 30 min with DPCPX (1 µM) before the 
addition of CPA (100 nM) or adenosine (ADO; 100 µM) for 10 min prior to 8 h hypoxia 
(1% O2) followed by 18 h re-oxygenation (H/R) or normoxia (NX). Cell viability was 
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assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases (A) 
and release of LDH into the culture medium (B). Caspase-3 activation was assessed 
via Western blotting using anti-activated caspase-3 antibody (C) and quantified 
caspase-3 data (D) are expressed as a percentage of normoxia control cell values 
(=100%). Data are expressed as a percentage of normoxia control cell values 
(=100%) and represent the mean  S.E.M. from four independent experiments. 
*P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) versus normoxia control, (b) 
versus H/R control, (c) versus 100 nM CPA in the presence of H/R, (d) versus 100 µM 
ADO in the presence of H/R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.12: Role of Gi/o-proteins in A1R-induced pre-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated for 16 h 
with pertussis toxin (100 ng/ml) before the addition of CPA (100 nM) or adenosine 
(ADO; 100 µM) for 10 min prior to 8 h hypoxia (1% O2) followed by 18 h re-
oxygenation (H/R) or normoxia (NX). Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into the 
culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P<0.05, **P0.01, ***P0.001 
and ****P<0.0001, (a) versus normoxia control, (b) versus H/R control, (c) versus 
100 nM CPA in the presence of H/R, (d) versus 100 µM ADO in the presence of H/R. 
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Fig 6.13: Role of TG2 in CPA-induced pre-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated for 1 h 
with Z-DON (150 µM) or R283 (200 µM) before the addition of CPA (100 nM) for 10 
min prior to 8 h hypoxia (1% O2) followed by 18 h re-oxygenation (H/R) or normoxia 
(NX). Cell viability was assessed by measuring the metabolic reduction of MTT by 
cellular dehydrogenases (A) and release of LDH into the culture medium (B). Caspase-
3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) 
versus normoxia control, (b) versus H/R control, (c) versus 100 nM CPA in the 
presence of H/R. 
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Fig 6.14: Role of TG2 in adenosine-induced pre-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated for 1 h 
with Z-DON (150 µM) or R283 (200 µM) before the addition of adenosine (ADO; 100 
µM) for 10 min prior to 8 h hypoxia (1% O2) followed by 18 h re-oxygenation (H/R) or 
normoxia (NX). Cell viability was assessed by measuring the metabolic reduction of 
MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Caspase-3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) 
versus normoxia control, (b) versus H/R control, (c) versus 100 μM ADO in the 
presence of H/R. 
 
A1R-induced post-conditioning 
For post-conditioning, H9c2 cells were treated with the pharmacological agents (or 
relevant media for appropriate control experiments) following 8 h hypoxic incubation 
but prior to 18 h of re-oxygenation. H9c2 cells were treated with CPA (100 nM) or 
adenosine (100 μM) for 10 min following exposure to 8 h of hypoxia but prior to 18 h 
re-oxygenation. Both CPA and adenosine significantly attenuated hypoxia/re-
oxygenation-induced decreases in MTT reduction, release of LDH and activation of 
caspase-3, consequently offering protection (figure 6.15, 6.16, 6.17 and 6.18). Pre-
treatment for 30 min with the selective A1R antagonist DPCPX (1 µM) prior to 
stimulation abolished A1R-induced cell survival (figure 6.15). Additionally, pre-
treatment with the Gi/o-protein-inactivating pertussis toxin (100 ng/ml for 16 h) 
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abolished A1R-induced-induced cell survival (figure 6.16), confirming the involvement 
of Gi/o-proteins. Finally, pre-treatment for 1 h with Z-DON (150 µM) or R283 (200 µM) 
prior to stimulation attenuated A1R-induced cell survival (figure 6.17 and 6.18), 
confirming the involvement of TG2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.15: The effect of A1R activation on hypoxia/re-oxygenation-induced cell death. 
Where indicated, H9c2 cells were exposed to 8 h hypoxia (1% O2) followed by 18 h of 
re-oxygenation (H/R) or normoxia (NX). Cells were treated for the first 30 min of re-
oxygenation with DPCPX (1 µM) before the addition of CPA (100 nM) or adenosine 
(ADO; 100 µM) for 10 min, which were then removed for the remainder of the re-
oxygenation period. Cell viability was assessed by measuring the metabolic reduction 
of MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Caspase-3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P<0.0001, (a) 
versus normoxia control, (b) versus H/R control, (c) versus 100 nM CPA in the 
presence of H/R, (d) versus 100 µM ADO in the presence of H/R. 
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Fig 6.16: Role of Gi/o-proteins in A1R-induced post-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were exposed to 8 h 
hypoxia (1% O2) followed by 18 h of re-oxygenation (H/R) or normoxia (NX). Cells 
were treated for the first 16 h of re-oxygenation with pertussis toxin (100 ng/ml) 
before the addition of CPA (100 nM) or adenosine (ADO; 100 µM) for 10 min which 
were then removed for the remainder of re-oxygenation. Cell viability was assessed by 
measuring the metabolic reduction of MTT by cellular dehydrogenases (A) and release 
of LDH into the culture medium (B). Caspase-3 activation was assessed via Western 
blotting using anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) 
are expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P<0.05, **P0.01, ***P0.001 
and ****P<0.0001, (a) versus normoxia control, (b) versus H/R control, (c) versus 
100 nM CPA in the presence of H/R, (d) versus 100 µM ADO in the presence of H/R. 
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Fig 6.17: Role of TG2 in CPA-induced post-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were exposed to 8 h 
hypoxia (1% O2) followed by 18 h of re-oxygenation (H/R) or normoxia (NX). Cells 
were treated for the first 1 h of re-oxygenation with Z-DON (150 µM) or R283 (200 µM) 
before the addition of CPA (100 nM) for 10 min which was then removed for the 
remainder of the re-oxygenation period. Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into the 
culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments.. *P<0.05, **P0.01, ***P0.001 
and ****P<0.0001, (a) versus normoxia control, (b) versus H/R control, (c) versus 
100 nM CPA in the presence of H/R. 
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Fig 6.18: Role of TG2 in adenosine-induced post-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were exposed to 8 h 
hypoxia (1% O2) followed by 18 h of re-oxygenation (H/R) or normoxia (NX). Cells 
were treated for the first 1 h of re-oxygenation with Z-DON (150 µM) or R283 (200 µM) 
before the addition of adenosine (100 μM) for 10 min which was then removed for the 
remainder of the re-oxygenation period. Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into the 
culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P<0.05, **P0.01, ***P0.001 
and ****P<0.0001, (a) versus normoxia control, (b) versus H/R control, (c) versus 
100 µM ADO in the presence of H/R. 
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6.5 Role of TG2 in β2-AR-induced cell survival against hypoxia/ re-
oxygenation-induced cell death. 
β2-AR-induced pre-conditioning 
For pre-conditioning, H9c2 cells were treated with the pharmacological agents prior to 
the onset of hypoxia. Activation of the β2-AR with isoprenaline provided protection 
against hypoxia/re-oxygenation-induced cell death. H9c2 cells were treated with 
isoprenaline (10 μM) for 20 min prior to exposure to 8 h of hypoxia followed by 18 h 
re-oxygenation. Isoprenaline significantly attenuated hypoxia/re-oxygenation-induced 
decrease in MTT reduction, release of LDH and activation of caspase-3, thus offering 
protection (figure 6.19, 6.20 and 6.21) and this protection was reversed when H9c2 
cells were pre-treated for 30 min with the β2-AR selective (ICI 118551; 1 µM) and 
non-selective (propranolol; 1 µM) antagonists prior to stimulation (figure 6.19). 
Furthermore, pre-treatment with the Gi/o-protein-inactivating pertussis toxin (100 
ng/ml for 16 h) abolished isoprenaline-induced cell survival (figure 6.20), suggesting a 
prominent role of Gi/o-proteins. Finally, pre-treatment for 1 h with Z-DON (150 µM) or 
R283 (200 µM) prior to stimulation attenuated isoprenaline-induced cell survival 
(figure 6.21), confirming the involvement of TG2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.19: The effect of isoprenaline on hypoxia/re-oxygenation-induced cell death. 
Where indicated, H9c2 cells were pre-treated for 30 min with ICI 118551 (1 µM) or 
propranolol (1 µM) before the addition of isoprenaline (10 µM) for 20 min, prior to 8 h 
hypoxia (1% O2) followed by 18 h re-oxygenation (H/R) or normoxia (NX). Cell 
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viability was assessed by measuring the metabolic reduction of MTT by cellular 
dehydrogenases (A) and release of LDH into the culture medium (B). Caspase-3 
activation was assessed via Western blotting using anti-activated caspase-3 antibody 
(C) and quantified caspase-3 data (D) are expressed as a percentage of normoxia 
control cell values (=100%). Data are expressed as a percentage of normoxia control 
cell values (=100%) and represent the mean  S.E.M. from four independent 
experiments. *P<0.05 and ****P<0.0001, (a) versus normoxia control, (b) versus 
H/R control, (c) versus 10 µM isoprenaline in the presence of H/R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.20: Role of Gi/o-proteins in β2-AR-induced pre-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated for 16 h 
with pertussis toxin (100 ng/ml) before the addition of isoprenaline (10 µM) for 20 min 
prior to 8 h hypoxia (1% O2) followed by 18 h re-oxygenation (H/R) or normoxia (NX). 
Cell viability was assessed by measuring the metabolic reduction of MTT by cellular 
dehydrogenases (A) and release of LDH into the culture medium (B). Caspase-3 
activation was assessed via Western blotting using anti-activated caspase-3 antibody 
(C) and quantified caspase-3 data (D) are expressed as a percentage of normoxia 
control cell values (=100%). Data are expressed as a percentage of normoxia control 
cell values (=100%) and represent the mean  S.E.M. from four independent 
experiments. *P<0.05, **P0.01, ***P0.001 and ****P<0.0001, (a) versus 
normoxia control, (b) versus H/R control, (c) versus 10 µM isoprenaline in the 
presence of H/R. 
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Fig 6.21: Role of TG2 in β2-AR-induced pre-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated for 1 h 
with Z-DON (150 µM) or R283 (200 µM) before the addition of isoprenaline (10 µM) 
for 20 min prior to 8 h hypoxia (1% O2) followed by 18 h re-oxygenation (H/R) or 
normoxia (NX). Cell viability was assessed by measuring the metabolic reduction of 
MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Caspase-3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P<0.05, **P0.01, ***P0.001 and ****P<0.0001, (a) 
versus normoxia control, (b) versus H/R control, (c) versus 10 µM isoprenaline in the 
presence of H/R. 
 
β2-AR-induced post-conditioning 
For post-conditioning, H9c2 cells were treated with pharmacological agents (or 
relevant media for appropriate control experiments) following 8 h hypoxic incubation 
but prior to 18 h of re-oxygenation. H9c2 cells were treated with isoprenaline (10 μM) 
for 20 min following exposure to 8 h of hypoxia but prior to 18 h re-oxygenation. 
Isoprenaline significantly attenuated the hypoxia/re-oxygenation-induced decrease in 
MTT reduction, release of LDH and activation of caspase-3, therefore offering 
protection (figure 6.22, 6.23 and 6.24). Pre-treatment for 30 min with the β2-AR 
selective (ICI 118551; 1 µM) and non-selective (propranolol; 1 µM) antagonists prior 
to stimulation abolished isoprenaline-induced cell survival (figure 6.22). Moreover, 
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pre-treatment with the Gi/o-protein inactivating pertussis toxin (100 ng/ml for 16 h) 
abolished isoprenaline-induced-induced cell survival (figure 6.23), confirming the 
involvement of Gi/o-proteins. Finally, pre-treatment for 1 h with Z-DON (150 µM) or 
R283 (200 µM) prior to stimulation attenuated isoprenaline-induced cell survival 
(figure 6.24), confirming the involvement of TG2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.22: The effect of isoprenaline on hypoxia/re-oxygenation-induced cell death. 
Where indicated, H9c2 cells were exposed to 8 h hypoxia (1% O2) followed by 18 h of 
re-oxygenation (H/R) or normoxia (NX). Cells were treated for the first 30 min of re-
oxygenation with ICI 118551 (1 µM) or propranolol (1 µM) before the addition of 
isoprenaline (10 µM) for 20 min which were then removed for the remainder of the re-
oxygenation period. Cell viability was assessed by measuring the metabolic reduction 
of MTT by cellular dehydrogenases (A) and release of LDH into the culture medium (B). 
Caspase-3 activation was assessed via Western blotting using anti-activated caspase-3 
antibody (C) and quantified caspase-3 data (D) are expressed as a percentage of 
normoxia control cell values (=100%). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P<0.05 and ****P<0.0001, (a) versus normoxia control, 
(b) versus H/R control, (c) versus 10 µM isoprenaline in the presence of H/R. 
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Fig 6.23: Role of Gi/o-proteins in β2-AR-induced post-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were exposed to 8 h 
hypoxia (1% O2) followed by 18 h of re-oxygenation (H/R) or normoxia (NX). Cells 
were treated for the first 16 h of re-oxygenation with pertussis toxin (100 ng/ml) 
before the addition of isoprenaline (10 µM) for 20 min which were then removed for 
the remainder of the re-oxygenation period. Cell viability was assessed by measuring 
the metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into 
the culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P<0.05 and ****P<0.0001, (a) 
versus normoxia control, (b) versus H/R control, (c) versus 10 µM isoprenaline in the 
presence of H/R. 
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Fig 6.24: Role of TG2 in β2-AR-induced post-conditioning versus hypoxia/re-
oxygenation-induced cell death. Where indicated, H9c2 cells were exposed to 8 h 
hypoxia (1% O2) followed by 18 h of re-oxygenation (H/R) or normoxia (NX). Cells 
were treated for first 1 h of re-oxygenation with Z-DON (150 µM) or R283 (200 µM) 
before the addition of isoprenaline (10 µM) for 20 min which were then removed for 
the remainder of the re-oxygenation period. Cell viability was assessed by measuring 
the metabolic reduction of MTT by cellular dehydrogenases (A) and release of LDH into 
the culture medium (B). Caspase-3 activation was assessed via Western blotting using 
anti-activated caspase-3 antibody (C) and quantified caspase-3 data (D) are 
expressed as a percentage of normoxia control cell values (=100%). Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments. *P<0.05 and ****P<0.0001, (a) 
versus normoxia control, (b) versus H/R control, (c) versus 10 µM isoprenaline in the 
presence of H/R. 
 
In conclusion, the data shown in this chapter provide sufficient evidence to support 
the notion that A1 adenosine receptor- and β2 adrenoceptor-induced TG2 activity is 
cardioprotective during simulated hypoxia and hypoxia/re-oxygenation injury. 
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6.6 Discussion. 
The aim of this chapter was to evaluate the cardioprotective potential of A1 adenosine 
receptor- and β2 adrenoceptor-induced TG2 activity during simulated hypoxia and 
hypoxia/re-oxygenation injury. 
Role of TG2 in A1R-induced cell survival against hypoxia- and hypoxia/re-oxygenation-
induced cell death: 
H9c2 cells are derived from embryonic rat heart tissue and exhibit similar biochemical, 
morphological and electrophysiological properties to primary cardiac cells (Kimes and 
Brandt, 1976; Heschelet et al, 1991). These cells are increasingly being used as an in 
vitro model for studies relating to cardioprotection (see Han et al, 2005; Chen et al, 
2010; Crawford et al, 2003; Sun et al, 2016) and H9c2 cells have been shown to be a 
good model for ischaemia/reperfusion injury (Fretwell and Dickenson, 2009; Urmaliya 
et al, 2009).  
Activation of the Gi/o-coupled A1 adenosine receptor has a well-documented role in 
cardioprotection in many models, including primary rat cardiomyocytes (Safran et al, 
2001; Xiang et al, 2009) and H9c2 cells (Nagarkitti and Shaafi, 1998; Fretwell and 
Dickenson, 2011; Fretwell and Dickenson, 2009). A recent study showed that TG2 can 
be modulated by PKC and PKA and that it plays a role in cardioprotection in H9c2 cells 
(Almami et al, 2014). However, this study did not investigate the GPCR(s) involved in 
TG2-induced protection as non-specific activators of PKA (forskolin) and PKC (PMA) 
were used. It is known that the A1R activates PKC and ERK1/2 and is implicated in 
cardioprotection (Germack and Dickenson, 2004; Li et al, 2006; Dana et al, 2000; 
Kudo et al, 2002). Since PKC and ERK1/2 pathways are also associated with 
modulation of TG activity (Mishra et al, 2007; Bollag et al, 2005), it is conceivable that 
the A1 adenosine receptor could modulate TG2 activity via PKC and ERK1/2,  and 
thereby play a role in cardioprotection in these cells.  
Activation of the A1R with the selective agonist CPA or the endogenous agonist 
adenosine significantly attenuated hypoxia- and hypoxia/re-oxygenation-induced 
decreases in MTT reduction, release of LDH and activation of caspase-3, thus offering 
protection. Loss of mitochondrial membrane integrity is measured by the metabolic 
reduction of MTT by cellular dehydrogenases and release of LDH into the culture 
medium indicates cell death. However, these approaches fail to distinguish between 
apoptosis and necrosis. Hence, activation of caspase-3 (which is specific to apoptosis) 
was also measured to distinguish between apoptosis and necrosis. It was found that 
caspase-3 was significantly activated revealing that the cells were undergoing 
apoptosis which was significantly decreased upon stimulation of A1R. These findings 
suggest a role for the A1R in cardioprotection, which was further confirmed by the use 
of the selective A1R antagonist DPCPX and the Gi/o-protein inactivating pertussis toxin. 
DPCPX and pertussis toxin were able to significantly reverse the protection offered, 
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thus confirming the role of the A1R and Gi/o-protein in cardioprotection. A role for the 
A1R in both apoptosis and necrosis has also been documented in murine hearts over-
expressing the cardiac A1R (Regan et al, 2003). It was reported that, following 
ischaemia/reperfusion, less apoptosis and less necrosis occurred compared to wild-
type controls (Regan et al, 2003).  
The A1R is cardioprotective under both pharmacological pre-conditioning and 
postconditioning in H9c2 cells. Not only was the protection offered by the A1R reversed 
by antagonism and Gi/o-protein blockage but also inhibition of the enzyme TG2. At 
present, whilst the physiological function(s) of TG2 in cardiomyocytes is largely 
unknown, there is evidence for a role in modulating ischaemia/reperfusion injury by 
regulating ATP synthesis (Szondy et al, 2006). TG2 is also known to interact with or 
modulate a number of signalling pathways associated with cell survival against 
hypoxia and glucose deprivation-induced cell death, including hypoxia inducible factor 
1β, NF-κB and PKB (Filiano et al, 2008; Wang et al, 2012). Hence it is of interest to 
identify TG2 protein substrates which are associated with cell survival/apoptosis in 
H9c2 cells. Therefore, chapter VII will be focussed on identification of protein 
substrates of TG2 in H9c2 cells.  
Role of TG2 in β2-AR-induced cell survival against hypoxia and hypoxia/ re-
oxygenation-induced cell death: 
The role of β-AR in cardioprotection remains unclear and varies between different 
models and experimental procedures. In the current study, the selective β2-AR agonist, 
formoterol had no significant effect on hypoxia and hypoxia/re-oxygenation-induced 
decrease in MTT reduction or release of LDH. These observations are in contrast to 
previous studies reporting formoterol-induced cardioprotection in isolated rat hearts 
(Salie et al, 2011). The reason for the discrepancy between the present results and 
work by Salie et al (2011) is unclear but could be due to the use of different models 
(e.g. cell line versus isolated heart) and end points (cell viability assays versus infarct 
size) employed. Furthermore, simultaneous activation of PKA and EPAC in H9c2 cells 
induces cardioprotection against hypoxia/re-oxygenation injury via activation of PKCε 
(Khaliulin et al, 2017). However, this study did not investigate PKA or EPAC activation 
via receptors but through direct activation of PKA using cell permeable cAMP 
analogues (Khaliulin et al, 2017). In marked contrast, the non-selective β-AR agonist, 
isoprenaline, significantly attenuated hypoxia and hypoxia/re-oxygenation-induced 
decrease in MTT reduction, release of LDH and caspase 3 activation. The functional 
studies carried out in chapter III imply that H9c2 cells express β-ARs with a rank order 
of β2-AR  β1-AR = β3-AR. The role of β2-AR in cardioprotection is well documented 
(Tong et al, 2005) and a study by Spear and colleagues reported the cardioprotective 
role of β1-AR (Spear et al, 2007). However, the protection offered by isoprenaline 
appears to occur through the β2-AR, based upon experiments performed with the 
183 
 
selective β2-AR antagonist ICI 118551. As reported in chapter V, isoprenaline 
predominantly signals via Gi/o-proteins. This isoprenaline-induced protection is in good 
agreement with previous studies showing that isoprenaline-induced cell survival 
involved Gi/o-protein coupling (Zhu et al, 2001; Salie et al, 2011). Furthermore, 
treatment with Gi/o-protein inactivating pertussis toxin was able to significantly reverse 
the protection offered, thus confirming involvement of Gi/o-protein in cardioprotection.  
Yano and colleagues have reported that in H9c2 cardiomyocytes, the β2-AR couples to 
Gi/o proteins and activates pro-survival kinases such as PI-3K (Yano et al, 2007). PI-3K 
is a central component of the RISK pathway and it has also been demonstrated that 
β2-AR can activate the ERK1/2 pathway, which is another key player in the RISK 
pathway (Hausenloy et at, 2005; Galandrin and Bouvier, 2006; Tutor et al, 2007). 
From the results obtained in chapter V, it is clear that isoprenaline activates the 
ERK1/2 pathway in a Gi/o-dependent manner while formoterol-induced ERK1/2 
activation is independent of Gi/o-protein. Isoprenaline-induced Gi/o-dependent ERK1/2 
activation could therefore be one of the pathways which offer protection. 
Isoprenaline-induced cell survival is cardioprotective in both pharmacological pre-
conditioning and postconditioning in H9c2 cells. Not only was the protection offered by 
the isoprenaline reversed by antagonism of the β2-AR and Gi/o-protein blockage but 
also inhibition of the enzyme TG2. However, at present it is not clear why formoterol 
does not elicit increased cell survival, despite triggering TG2 and ERK1/2 activation. 
Possible explanations for this include:  (i) only Gi-protein-mediated TG2 stimulation is 
cytoprotective, possibly via the selective activation of alternative enzymic functions of 
TG2 (e.g. protein kinase) not activated via Gs-dependent pathways; or (ii) opposing 
effects of robust formoterol-induced cAMP signalling on cell death which counteract 
TG2-induced cell survival. Overall these data highlight the need to carefully consider 
the signalling profiles (Gs versus Gi) when selecting β2-AR agonists for use in studies 
investigating cardioprotection.  
In conclusion, the present study has revealed that A1 adenosine receptor- and β2 
adrenoceptor-induced TG2 activity has a cardioprotective potential during simulated 
hypoxia and hypoxia/re-oxygenation injury in all the three experimental paradigms of 
preconditioning during hypoxia, preconditioning during hypoxia/re-oxygenation and 
postconditioning during hypoxia/re-oxygenation. 
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Chapter VII: Proteomic identification of agonist-mediated TG2 
substrates and associated proteins 
This chapter aims to identify novel TG2 substrates/interacting proteins in H9c2 cells 
following activation of the A1 adenosine receptor and β2-adrenoceptor using 
CaptAvidin™-agarose affinity chromatography, SWATH mass spectrometry, 
bioinformatics approaches and western blotting. 
7.1 CaptAvidin™-agarose affinity chromatography. 
In order to identify novel protein substrates associated with TG2, H9c2 cells were 
labelled with biotin-x-cadaverine and subsequently treated with CPA (100 nM), 
adenosine (100 µM), formoterol (1 µM) or isoprenaline (10 µM) in the presence or 
absence of TG2 inhibitors (150 μM Z-DON and 200 μM R283). Cell lysates were then 
subjected to CaptAvidin™-agarose affinity chromatography using CaptAvidin™-
agarose sedimentation beads as described in section 2.9 (i) of chapter II and the gels 
stained, imaged and quantified as described in section 2.6 of chapter II. 
Figure 7.1 shows that treatment with either 100 nM CPA or 100 µM adenosine for 10 
min and figure 7.2 shows that treatment with either 1 µM formoterol or 10 µM 
isoprenaline for 20 min significantly increased the incorporation of biotin-X-cadaverine 
into several proteins of different molecular masses. However, it is notable that the 
intensity of several protein bands also decreased following these treatments, 
indicating reduced levels of transamidation and/or altered interactions with TG2 
substrate binding partners. As expected, the incorporation of biotin-X-cadaverine into 
TG2 protein substrates was inhibited by pre-treatment with Z-DON and R283, thus 
signifying that these changes occur via interaction with TG2. 
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Fig. 7.1: Detection of in situ TG2 activity and protein substrates in CPA- and 
adenosine-treated H9c2 cells. Cells were incubated with 1 mM biotin-X-cadaverine for 
6 h, after which they were treated for 1 h with the TG2 inhibitors Z-DON (150 µM) or 
R283 (200 µM) before stimulation with CPA (100 nM) or adenosine (100 μM) for 10 
min. Biotin-X-cadaverine-labelled proteins were enriched using CaptAvidin™ agarose 
sedimentation beads and eluted proteins were subjected to SDS-PAGE on 4-15% 
polyacrylamide gradient gels. (A) Coomassie blue staining of enriched biotin-X-
cadaverine-labelled proteins following SDS-PAGE. (B) Quantification of protein 
substrates detected using Coomassie blue staining. Densitometry of each lane (total 
protein) was carried out using Advanced Image Data Analyser software (Fuji; version 
3.52) and data are expressed as a percentage of basal TG2 protein substrate levels. 
Values are means  S.E.M. from three independent experiments. *P<0.05 and 
**P0.01, (a) versus control response, (b) versus CPA alone, (c) versus adenosine 
alone. 
 
 
 
 
 
 
 
 
 
186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.2: Detection of in situ TG2 activity and protein substrates in formoterol- and 
isoprenaline-treated H9c2 cells. Cells were incubated with 1 mM biotin-X-cadaverine 
for 6 h, after which they were treated for 1 h with the TG2 inhibitors Z-DON (150 µM) 
or R283 (200 µM) before stimulation with formoterol (1 µM) or isoprenaline (10 μM) 
for 20 min. Biotin-X-cadaverine-labelled proteins were enriched using CaptAvidin™ 
agarose sedimentation beads and eluted proteins subjected to SDS-PAGE on 4-15% 
polyacrylamide gradient gels. (A) Coomassie blue staining of enriched biotin-X-
cadaverine-labelled proteins following SDS-PAGE. (B) Quantification of protein 
substrates detected using Coomassie blue staining. Densitometry of each lane (total 
protein) was carried out using Advanced Image Data Analyser software (Fuji; version 
3.52) and data are expressed as a percentage of basal TG2 protein substrate levels. 
Values are means  S.E.M. from three independent experiments. *P<0.05, 
***P<0.001 and ****P0.0001, (a) versus control response, (b) versus formoterol 
alone, (c) versus isoprenaline alone. 
 
7.2 SWATH MS identification of proteins. 
Lysates were digested with trypsin and prepared for SWATH MS (Sequential Windowed 
Acquisition of all Theoretical fragment ion Mass Spectra) analysis as described in 
section 2.9 (ii) of chapter II. SWATH MS is a recent technique which combines the 
advantages of traditional shotgun and selected reaction monitoring (SRM) techniques 
not only in the identification of proteins but also in their quantification following 
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treatments (Wang et al, 2015). The method is best described in two steps, namely: 
data dependent acquisition (DDA), to generate a spectral library; and data 
independent acquisition (DIA) to gather SWATH data. Firstly, all of the samples to be 
analysed (controls and treatments) are pooled together and run through the DDA 
mode (120 min LC run time fragmenting the top 30 proteins per MS cycle, 2.8s cycle 
time). Once the spectral library is constructed, the samples (individually) are then run 
in DIA mode (60 min LC run time, 100 variable window, 25 millisecond accumulation 
time per window, 3s cycle time). Once the DIA run is complete, the peptides are 
aligned in the PeakView 2.1 SWATH micro app (Sciex) with careful consideration of the 
+311.4429 mass shift (unimod.org modification accession number 800) due to 
tagging with biotin-X-cadaverine. The SWATH data is next extracted and quantified 
using OneOmics cloud processing software 
(https://basespace.illumina.com/dashboard; Lambert et al, 2013; for an overview 
refer to fig 7.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.3: SWATH MS protein profiling workflow. Firstly, all the samples were pooled 
and analysed by data-dependent acquisition, followed by SWATH MS/MS. To obtain a 
comprehensive protein coverage in the spectral library, all precursor ions were 
extracted and identified by UniProt database searching. Next, the samples were 
analysed individually by SWATH. The peptides were aligned to the spectral library and 
quantified using OneOmics cloud processing software (SCIEX). Figure adapted from 
Schmidt et al, (2011). 
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The results presented below are shown as agonist-induced fold-changes in proteins 
eluted from CaptAvidin™-agarose, compared to control unstimulated cells. Tables 1-4 
illustrate proteins identified by SWATH-MS whose profile revealed an increase in CPA-, 
adenosine-, formoterol- or isoprenaline-treated cells when compared to untreated 
control cells. Tables 5-8 show proteins identified by SWATH-MS whose profile revealed 
a decrease in CPA-, adenosine-, formoterol- or isoprenaline-treated cells when 
compared to untreated control cells.  
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Table 1. Identification of proteins showing increased levels in eluates from 
CaptAvidin™-agarose columns following A1R activation with 100 nM CPA. 
Protein name 
Uniprot 
accession 
Uniprot 
name 
Absolute fold 
change* 
aAcidic leucine-rich nuclear 
phosphoprotein 32 family member A 
P49911 AN32A_RAT 5.38 
bHexokinase-1 P05708 HXK1_RAT 5.16 
aNischarin Q4G017 NISCH_RAT 4.50 
cTropomyosin alpha-3 chain Q63610 TPM3_RAT 4.34 
dActivated RNA polymerase II 
transcriptional coactivator p15 
Q63396 TCP4_RAT 3.34 
e60S ribosomal protein L13 P41123 RL13_RAT 3.10 
dHistone H4 P62804 H4_RAT 2.76 
eCalcineurin B homologous protein 1 P61023 CHP1_RAT 2.71 
fMyeloid-associated differentiation 
marker 
Q6VBQ5 
MYADM_RA
T 
2.66 
cNestin P21263 NEST_RAT 2.61 
e60S ribosomal protein L30 P62890 RL30_RAT 2.57 
fTransmembrane protein 33 Q9Z142 
TMM33_RA
T 
2.49 
cTubulin alpha-3 chain Q68FR8 TBA3_RAT 2.14 
fHomer protein homolog 3 Q9Z2X5 
HOME3_RA
T 
2.13 
gVoltage-dependent anion-selective 
channel protein 1 
Q9Z2L0 
VDAC1_RA
T 
2.11 
dMIF4G domain-containing protein Q6AXU7 
MI4GD_RA
T 
2.09 
fSerine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A beta 
isoform 
Q4QQT4 2AAB_RAT 2.08 
aPhosphatidylinositol 4-kinase type 2-
alpha 
Q99M64 P4K2A_RAT 2.02 
hExtended synaptotagmin-1 Q9Z1X1 ESYT1_RAT 1.89 
iDolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 2 
P25235 RPN2_RAT 1.85 
dTranslation initiation factor eIF-2B 
subunit delta 
Q63186 EI2BD_RAT 1.78 
hCoatomer subunit delta Q66H80 COPD_RAT 1.74 
dY-box-binding protein 3 Q62764 YBOX3_RAT 1.66 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with CPA 
(100 nM) and biotin-cadaverine-labelled proteins were captured and analysed by 
SWATH MS. *Absolute fold changes in CPA-treated samples versus control (n=4) were 
calculated using SCIEX OneOmics with parameters MLR weight > 0.15, 
confidence >60%, algorithms used described by Lambert et al., (2013). Proposed 
novel TG2 targets not appearing in the TG2 substrate database (Csósz et al., 2009) or 
identified by Yu et al. (2015) or Almami et al. (2014) are indicated in italics. Proteins 
are grouped according to their functions as follows: acell signalling; bmetabolism; 
ccytoskeletal; dtransciption/translation; evesicular trafficking/extracellular matrix 
constituent; fstructural/scaffolding protein; gapoptosis; hlipid/protein transport; 
iprotein glycosylation; jprotein folding. 
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Table 2. Identification of proteins showing increased levels in eluates from 
CaptAvidin™-agarose columns following A1R activation with 100 μM adenosine. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute 
fold change* 
bCitrate synthase, mitochondrial Q8VHF5 CISY_RAT 6.34 
cTropomyosin alpha-3 chain Q63610 TPM3_RAT 5.98 
cTropomyosin alpha-4 chain P09495 TPM4_RAT 5.86 
hGlutathione S-transferase P P04906 GSTP1_RAT 5.63 
gAnnexin A5 P14668 ANXA5_RAT 4.31 
dRNA-binding protein 3 Q925G0 RBM3_RAT 3.81 
cAlpha-actinin-4 Q9QXQ0 ACTN4_RAT 3.58 
d60S ribosomal protein L18a P62718 RL18A_RAT 3.47 
cTransgelin P31232 TAGL_RAT 3.13 
d40S ribosomal protein S28 P62859 RS28_RAT 2.88 
cTropomyosin alpha-1 chain P04692 TPM1_RAT 2.84 
bAspartate aminotransferase, 
mitochondrial 
P00507 AATM_RAT 2.75 
fMyeloid-associated differentiation marker Q6VBQ5 
MYADM_RA
T 
2.72 
eRab GDP dissociation inhibitor beta P50399 GDIB_RAT 2.57 
dHistone H4 P62804 H4_RAT 2.43 
jProtein disulfide-isomerase P04785 PDIA1_RAT 2.21 
hLysosome-associated membrane 
glycoprotein 2 
P17046 LAMP2_RAT 2.06 
bL-lactate dehydrogenase A chain P04642 LDHA_RAT 2.06 
gCytochrome c oxidase subunit 5B, 
mitochondrial 
P12075 
COX5B_RA
T 
1.68 
dEukaryotic translation initiation factor 3 
subunit J 
A0JPM9 EIF3J_RAT 1.38 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with 
adenosine (100 µM) and biotin-cadaverine-labelled proteins were captured and 
analysed by SWATH MS. *Absolute fold changes in adenosine-treated samples versus 
control (n=4) were calculated using SCIEX OneOmics with parameters MLR weight > 
0.15, confidence >60%,  algorithms used described by Lambert et al., (2013). 
Proposed novel TG2 targets not appearing in the TG2 substrate database (Csósz et al., 
2009) or identified by Yu et al. (2015) or Almami et al. (2014) are indicated in italics. 
Proteins are grouped according to their functions as follows: acell signalling; 
bmetabolism; ccytoskeletal; dtransciption/translation; evesicular 
trafficking/extracellular matrix constituent; fstructural/scaffolding protein; gapoptosis; 
hlipid/protein transport; iprotein glycosylation; jprotein folding. 
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Table 3. Identification of proteins showing increased levels in eluates from 
CaptAvidin™-agarose columns following β2-AR activation with 1 μM formoterol. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute fold 
change* 
eCollagen alpha-1(I) chain P02454 CO1A1_RAT 2.64 
aProtein S100-A6 P05964 S10A6_RAT 2.45 
eCollagen alpha-1(III) chain P13941 CO3A1_RAT 2.40 
aProtein SET Q63945 SET_RAT 2.26 
bL-lactate dehydrogenase A chain P04642 LDHA_RAT 1.94 
gAnnexin A5 P14668 ANXA5_RAT 1.91 
eCollagen alpha-2(I) chain P02466 CO1A2_RAT 1.86 
bMalate dehydrogenase, mitochondrial P04636 MDHM_RAT 1.84 
bD-3-phosphoglycerate 
dehydrogenase 
O08651 SERA_RAT 1.65 
gGalectin-1 P11762 LEG1_RAT 1.62 
dRibonuclease inhibitor P29315 RINI_RAT 1.57 
dHistone H1.5 D3ZBN0 H15_RAT 1.46 
e60S ribosomal protein L7 P05426 RL7_RAT 1.32 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with 
formoterol (1 µM) and biotin-cadaverine-labelled proteins were captured and analysed 
by SWATH MS. *Absolute fold changes in formoterol-treated samples versus control 
(n=4) were calculated using SCIEX OneOmics with parameters MLR weight > 0.15, 
confidence >70%,  algorithms used described by Lambert et al., (2013). Proposed 
novel TG2 targets not appearing in the TG2 substrate database (Csósz et al., 2009) or 
identified by Yu et al. (2015) or Almami et al. (2014) are indicated in italics. Proteins 
are grouped according to their functions as follows: acell signalling; bmetabolism; 
ccytoskeletal; dtransciption/translation; evesicular trafficking/extracellular matrix 
constituent; fstructural/scaffolding protein; gapoptosis; hlipid/protein transport; 
iprotein glycosylation; jprotein folding. 
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Table 4. Identification of proteins showing increased levels in eluates from 
CaptAvidin™-agarose columns following β2-AR activation with 10 μM isoprenaline. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute fold 
change* 
bAdenine phosphoribosyltransferase P36972 APT_RAT 2.61 
aProtein S100-A6 P05964 S10A6_RAT 2.46 
eCollagen alpha-1(III) chain P13941 CO3A1_RAT 2.27 
gAnnexin A5 P14668 ANXA5_RAT 2.15 
jProtein disulfide-isomerase A5 Q5I0H9 PDIA5_RAT 2.02 
aProtein SET Q63945 SET_RAT 2.01 
bMalate dehydrogenase, mitochondrial P04636 MDHM_RAT 1.96 
eCollagen alpha-1(I) chain P02454 CO1A1_RAT 1.91 
bAcetyl-CoA carboxylase 1 P11497 ACACA_RAT 1.81 
bL-lactate dehydrogenase A chain P04642 LDHA_RAT 1.75 
gCaspase recruitment domain-
containing protein 9 
Q9EPY0 CARD9_RAT 1.74 
bAldehyde dehydrogenase, 
mitochondrial 
P11884 ALDH2_RAT 1.73 
dRibonuclease inhibitor P29315 RINI_RAT 1.71 
 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with 
isoprenaline (10 µM) and biotin-cadaverine-labelled proteins were captured and 
analysed by SWATH MS. *Absolute fold changes in isoprenaline-treated samples 
versus control (n=4) were calculated using SCIEX OneOmics with parameters MLR 
weight > 0.15, confidence >70%,  algorithms used described by Lambert et al., 
(2013). Proposed novel TG2 targets not appearing in the TG2 substrate database 
(Csósz et al., 2009) or identified by Yu et al. (2015) or Almami et al. (2014) are 
indicated in italics. Proteins are grouped according to their functions as follows: acell 
signalling; bmetabolism; ccytoskeletal; dtransciption/translation; evesicular 
trafficking/extracellular matrix constituent; fstructural/scaffolding protein; gapoptosis; 
hlipid/protein transport; iprotein glycosylation; jprotein folding. 
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Table 5. Identification of proteins showing decreased levels in eluates from 
CaptAvidin™-agarose columns following A1R activation with 100 nM CPA. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute fold 
change* 
e60S ribosomal protein L36 P39032 RL36_RAT -7.71 
d40S ribosomal protein S15 P62845 RS15_RAT -6.32 
fPDZ and LIM domain protein 1 P52944 PDLI1_RAT -5.17 
hGeranylgeranyl transferase type-2 
subunit alpha 
Q08602 PGTA_RAT -4.93 
cCofilin-1 P45592 COF1_RAT -4.35 
cCalponin-1 Q08290 CNN1_RAT -4.12 
d40S ribosomal protein S24 P62850 RS24_RAT -4.08 
cNck-associated protein 1 P55161 NCKP1_RAT -3.67 
d40S ribosomal protein S29 P62275 RS29_RAT -3.05 
hCopper-transporting ATPase 1 P70705 ATP7A_RAT -2.96 
aProtein S100-A4 P05942 S10A4_RAT -2.86 
eGranulins P23785 GRN_RAT -2.54 
dHistone H1.4 P15865 H14_RAT -2.42 
dEukaryotic translation initiation factor 
5 
Q07205 IF5_RAT -2.34 
d60S ribosomal protein L7a P62425 RL7A_RAT -2.31 
dCysteine and glycine-rich protein 1 P47875 CSRP1_RAT -2.27 
bGlyceraldehyde-3-phosphate 
dehydrogenase 
P04797 G3P_RAT -2.11 
hProtein-tyrosine sulfotransferase 2 Q5RJS8 TPST2_RAT -2.10 
gPeroxiredoxin-2 P35704 PRDX2_RAT -1.83 
jHeat shock protein HSP 90-beta P34058 HS90B_RAT -1.82 
e60S ribosomal protein L14 Q63507 RL14_RAT -1.77 
cTubulin beta-5 chain P69897 TBB5_RAT -1.75 
dEukaryotic translation initiation factor 
2 subunit 1 
P68101 IF2A_RAT -1.74 
cTubulin beta-4B chain Q6P9T8 TBB4B_RAT -1.73 
cVacuolar protein sorting-associated 
protein 4A 
Q793F9 VPS4A_RAT -1.69 
bNADPH--cytochrome P450 reductase P00388 NCPR_RAT -1.63 
d40S ribosomal protein S30 P62864 RS30_RAT -1.46 
e60S ribosomal protein L22 P47198 RL22_RAT -1.34 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with CPA (100 nM) 
and biotin-cadaverine-labelled proteins were captured and analysed by SWATH MS. *Absolute 
fold changes in CPA-treated samples versus control (n=4) were calculated using SCIEX 
OneOmics with parameters MLR weight > 0.15, confidence >60%, algorithms used described by 
Lambert et al., (2013). Proposed novel TG2 targets not appearing in the TG2 substrate 
database (Csósz et al., 2009) or identified by Yu et al. (2015) or Almami et al. (2014) are 
indicated in italics. Proteins are grouped according to their functions as follows: acell signalling; 
bmetabolism; ccytoskeletal; dtransciption/translation; evesicular trafficking/extracellular matrix 
constituent; fstructural/scaffolding protein; gapoptosis; hlipid/protein transport; iprotein 
glycosylation; jprotein folding. 
194 
 
Table 6. Identification of proteins showing decreased levels in eluates from 
CaptAvidin™-agarose columns following A1R activation with 100 μM adenosine. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute fold 
change* 
dHistone H2A type 2-A P0CC09 H2A2A_RAT -100.00 
d40S ribosomal protein S29 P62275 RS29_RAT -4.85 
dCysteine-rich protein 2 P36201 CRIP2_RAT -2.59 
cCalponin-1 Q08290 CNN1_RAT -2.50 
dCysteine and glycine-rich protein 1 P47875 CSRP1_RAT -2.49 
fPDZ and LIM domain protein 5 Q62920 PDLI5_RAT -2.42 
gCytochrome c oxidase subunit 6C-2 P11951 CX6C2_RAT -2.39 
cAlpha-centractin P85515 ACTZ_RAT -2.22 
eDynactin subunit 2 Q6AYH5 DCTN2_RAT -2.16 
d40S ribosomal protein S2 P27952 RS2_RAT -2.09 
aIntegrin-linked protein kinase Q99J82 ILK_RAT -2.07 
bD-3-phosphoglycerate dehydrogenase O08651 SERA_RAT -2.06 
cTubulin beta-4B chain Q6P9T8 TBB4B_RAT -1.99 
bGlyceraldehyde-3-phosphate 
dehydrogenase 
P04797 G3P_RAT -1.91 
bPyrroline-5-carboxylate reductase 3 Q5PQJ6 P5CR3_RAT -1.89 
cTubulin beta-2A chain P85108 TBB2A_RAT -1.88 
e60S ribosomal protein L7a P62425 RL7A_RAT -1.87 
d40S ribosomal protein S25 P62853 RS25_RAT -1.81 
cTubulin beta-5 chain P69897 TBB5_RAT -1.77 
f26S protease regulatory subunit 4 P62193 PRS4_RAT -1.74 
dElongation factor 1-alpha 1 P62630 EF1A1_RAT -1.67 
e60S ribosomal protein L10a P62907 RL10A_RAT -1.62 
e60S ribosomal protein L12 P23358 RL12_RAT -1.62 
e60S ribosomal protein L23 P62832 RL23_RAT -1.60 
e60S ribosomal protein L14 Q63507 RL14_RAT -1.58 
dHeterogeneous nuclear 
ribonucleoprotein M 
Q62826 HNRPM_RAT -1.56 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with 
adenosine (100 µM) and biotin-cadaverine-labelled proteins were captured and 
analysed by SWATH MS. *Absolute fold changes in adenosine-treated samples versus 
control (n=4) were calculated using SCIEX OneOmics with parameters MLR weight > 
0.15, confidence >60%,  algorithms used described by Lambert et al., (2013). 
Proposed novel TG2 targets not appearing in the TG2 substrate database (Csósz et al., 
2009) or identified by Yu et al. (2015) or Almami et al. (2014) are indicated in italics. 
Proteins are grouped according to their functions as follows: acell signalling; 
bmetabolism; ccytoskeletal; dtransciption/translation; evesicular 
trafficking/extracellular matrix constituent; fstructural/scaffolding protein; gapoptosis; 
hlipid/protein transport; iprotein glycosylation; jprotein folding. 
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Table 7. Identification of proteins showing decreased levels in eluates from 
CaptAvidin™-agarose columns following β2-AR activation with 1 μM formoterol. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute fold 
change* 
eCalumenin O35783 CALU_RAT -3.27 
eEH domain-containing protein 2 Q4V8H8 EHD2_RAT -2.76 
cMyosin regulatory light polypeptide 9 Q64122 MYL9_RAT -2.65 
dCysteine and glycine-rich protein 1 P47875 CSRP1_RAT -2.46 
eDynactin subunit 2 Q6AYH5 DCTN2_RAT -2.40 
cActin, gamma-enteric smooth muscle P63269 ACTH_RAT -2.36 
dTranscription intermediary factor 1-beta O08629 TIF1B_RAT -2.11 
gLactadherin P70490 MFGM_RAT -2.07 
eDynactin subunit 1 P28023 DCTN1_RAT -2.03 
aFour and a half LIM domains protein 1 Q9WUH4 FHL1_RAT -1.90 
cMyosin light polypeptide 6 Q64119 MYL6_RAT -1.84 
cFilamin-C D3ZHA0 FLNC_RAT -1.80 
cMyosin-9 Q62812 MYH9_RAT -1.73 
fPDZ and LIM domain protein 7 Q9Z1Z9 PDLI7_RAT -1.72 
eAlpha-centractin P85515 ACTZ_RAT -1.72 
aIntegrin beta-1 P49134 ITB1_RAT -1.70 
cTropomyosin alpha-1 chain P04692 TPM1_RAT -1.68 
aTransforming growth factor beta-1-
induced transcript 1 protein 
Q99PD6 TGFI1_RAT -1.65 
aRho-associated protein kinase 2 Q62868 ROCK2_RAT -1.60 
eRas-related protein Rab-7a P09527 RAB7A_RAT -1.53 
jHeat shock protein HSP 90-alpha P82995 HS90A_RAT -1.53 
cLIM and SH3 domain protein 1 Q99MZ8 LASP1_RAT -1.43 
cMyosin regulatory light chain RLC-A P13832 MRLCA_RAT -1.43 
f14-3-3 protein theta P68255 1433T_RAT -1.41 
jEndoplasmin (Heat shock protein HSP 
90-beta 1) 
Q66HD0 ENPL_RAT -1.38 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with 
formoterol (1 µM) and biotin-cadaverine-labelled proteins were captured and analysed 
by SWATH MS. *Absolute fold changes in formoterol-treated samples versus control 
(n=4) were calculated using SCIEX OneOmics with parameters MLR weight > 0.15, 
confidence >70%,  algorithms used described by Lambert et al., (2013). Proposed 
novel TG2 targets not appearing in the TG2 substrate database (Csósz et al., 2009) or 
identified by Yu et al. (2015) or Almami et al. (2014) are indicated in italics. Proteins 
are grouped according to their functions as follows: acell signalling; bmetabolism; 
ccytoskeletal; dtransciption/translation; evesicular trafficking/extracellular matrix 
constituent; fstructural/scaffolding protein; gapoptosis; hlipid/protein transport; 
iprotein glycosylation; jprotein folding. 
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Table 8. Identification of proteins showing decreased levels in eluates from 
CaptAvidin™-agarose columns following β2-AR activation with 10 μM isoprenaline. 
Protein name 
Uniprot 
accession  
Uniprot 
name 
Absolute fold 
change* 
d40S ribosomal protein S24 P62850 RS24_RAT -2.88 
dTranscription intermediary factor 1-beta O08629 TIF1B_RAT -2.87 
fPDZ and LIM domain protein 5 Q62920 PDLI5_RAT -2.60 
dCysteine and glycine-rich protein 1 P47875 CSRP1_RAT -2.47 
gLactadherin P70490 MFGM_RAT -2.24 
eDynactin subunit 2 Q6AYH5 DCTN2_RAT -1.90 
dElongation factor 1-delta Q68FR9 EF1D_RAT -1.88 
aTransforming growth factor beta-1-
induced transcript 1 protein 
Q99PD6 TGFI1_RAT -1.82 
eDynactin subunit 1 P28023 DCTN1_RAT -1.80 
aIntegrin beta-1 P49134 ITB1_RAT -1.79 
cVimentin P31000 VIME_RAT -1.78 
dEukaryotic translation initiation factor 5 Q07205 IF5_RAT -1.68 
eCytoplasmic dynein 1 heavy chain 1 P38650 DYHC1_RAT -1.57 
jHeat shock protein HSP 90-alpha P82995 HS90A_RAT -1.56 
cTubulin beta-4B chain Q6P9T8 TBB4B_RAT -1.52 
bFatty acid synthase P12785 FAS_RAT -1.42 
f14-3-3 protein theta P68255 1433T_RAT -1.42 
f14-3-3 protein zeta/delta P63102 1433Z_RAT -1.38 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with 
isoprenaline (10 µM) and biotin-cadaverine-labelled proteins were captured and 
analysed by SWATH MS. *Absolute fold changes in isoprenaline-treated samples 
versus control (n=4) were calculated using SCIEX OneOmics with parameters MLR 
weight > 0.15, confidence >70%,  algorithms used described by Lambert et al., 
(2013). Proposed novel TG2 targets not appearing in the TG2 substrate database 
(Csósz et al., 2009) or identified by Yu et al. (2015) or Almami et al. (2014) are 
indicated in italics. Proteins are grouped according to their functions as follows: acell 
signalling; bmetabolism; ccytoskeletal; dtransciption/translation; evesicular 
trafficking/extracellular matrix constituent; fstructural/scaffolding protein; gapoptosis; 
hlipid/protein transport; iprotein glycosylation; jprotein folding. 
 
In addition to the tables, figure 7.4 illustrates Venn diagrams representing the number 
of proteins which reveal agonist- and receptor-specific changes in levels of proteins 
eluted from CaptAvidin™-agarose compared to control unstimulated cells. Similar 
colours will be used hereafter to represent proteins showing increased- and/or 
decreased-levels in eluates from CaptAvidin™-agarose columns following receptor 
activation. 
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Fig. 7.4: Venn diagram illustrating number of proteins which reveal agonist- and 
receptor-specific changes in levels of proteins eluted from CaptAvidin™-agarose 
compared to control unstimulated cells. Numbers at the top of the circles represent 
total number of proteins identified, numbers in the brackets represent significant 
number of proteins in that data set as compared to control and the numbers in bold 
represent unique and/or similar proteins. 
 
From the SWATH MS data analysis it can be seen that there are a significant number 
of novel increased and decreased proteins following A1R or β2-AR activation. There is a 
considerable overlap between proteins/substrates identified following treatment with 
selective versus non-selective/endogenous agonists, with changes in these protein 
levels occurring in the same direction. Furthermore, there are several proteins that are 
altered in the same direction in lysates subjected to ligands activating the A1R and β2-
AR. This suggests that there are some common proteins/substrates of TG2 modulated 
by these receptors.  
 
7.3 Pathway analysis. 
Proteins identified from SWATH MS analysis showing increased/decreased levels in 
eluates from CaptAvidin™-agarose beads following stimulation of either A1R and β2-AR 
were further analysed using the Database for Annotation, Visualisation and Integrated 
Discovery (DAVID) v6.8 as described in section 2.9 (iii) of chapter II 
(https://david.ncifcrf.gov/home.jsp; Dennis et al, 2003). Data generated from 
selective/non-selective agonists for either A1R and β2-AR were pooled and processed 
to identify proteins significantly enriched in a pathway following these treatments. 
Figure 7.5 represents pathways identified by DAVID analysis as showing a significant 
enrichment of proteins following activation of the indicated receptor. 
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Fig. 7.5: Identification of pathways associated with the A1R- and β2-AR-induced TG2 
protein substrates. (A, C) Pathways associated with the A1R- and β2-AR-induced TG2 
protein substrates showing increased levels in eluates from CaptAvidin™-agarose 
columns. (B, D) Pathways associated with the A1R- and β2-AR-induced TG2 protein 
substrates showing decreased levels in eluates from CaptAvidin™-agarose columns. 
 
Fold enrichment analysis carried out by the software can be defined as the ratio of two 
proportions. For instance, if 20/200 (i.e. 10%) of the input proteins are involved in 
"contraction of cardiac muscle" and the background information gathered from 
experimental evidence is 100/10000 proteins (i.e. 1%) associated with "contraction of 
cardiac muscle", then there is a 10% / 1% = 10 fold enrichment of the input proteins 
in the “contraction of cardiac muscle” pathway. Since fold enrichment is calculated in 
this manner, several proteins are associated with a number of pathways, as there is 
overlap between pathways. Tables 9-12 illustrate proteins identified by SWATH-MS 
whose profile is enriched in the pathways shown in figure 7.5. 
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Table 9. Identification of proteins significantly enriched in the stated pathways 
showing increased levels in eluates from CaptAvidin™-agarose columns following A1R 
activation. 
 
 
 
 
 
 
 
 
 
 
Proteins identified by SWATH MS analysis showing increased levels in eluates from 
CaptAvidin™-agarose columns following A1R activation were further analysed by 
DAVID bioinformatics software with parameters count per protein > 2 and *P<0.05; 
algorithms used described by Huang et al, (2009). Proposed proteins/substrates of 
TG2 are involved in the corresponding significantly enriched pathway. 
 
Table 10. Identification of proteins significantly enriched in the stated pathway 
showing decreased levels in eluates from CaptAvidin™-agarose columns following 
A1R activation. 
 
 
 
 
 
 
 
 
 
Proteins identified by SWATH MS analysis showing decreased levels in eluates from 
CaptAvidin™-agarose columns following A1R activation were further analysed by 
DAVID bioinformatics software with parameters count per protein > 2 and *P<0.05; 
algorithms used described by Huang et al, (2009). Proposed proteins/substrates of 
TG2 are involved in the corresponding significantly enriched pathway. 
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Table 11. Identification of proteins significantly enriched in the stated pathway 
showing increased levels in eluates from CaptAvidin™-agarose columns following β2-
AR activation. 
 
 
 
 
 
 
 
Proteins identified by SWATH MS analysis showing increased levels in eluates from 
CaptAvidin™-agarose columns following β2-AR activation were further analysed by 
DAVID bioinformatics software with parameters count per protein > 2 and *P<0.05; 
algorithms used described by Huang et al, (2009). Proposed proteins/substrates of 
TG2 are involved in the corresponding significantly enriched pathway. 
Table 12. Identification of proteins significantly enriched in the stated pathway 
showing decreased levels in eluates from CaptAvidin™-agarose columns following β2-
AR activation. 
 
 
 
 
 
 
 
 
 
Proteins identified by SWATH MS analysis showing decreased levels in eluates from 
CaptAvidin™-agarose columns following β2-AR activation were further analysed by 
DAVID bioinformatics software with parameters count per protein > 2 and *P<0.05; 
algorithms used described by Huang et al, (2009). Proposed proteins/substrates of 
TG2 are involved in the corresponding significantly enriched pathway. 
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From the pathway analysis, it can be clearly seen that there are a significant number 
of proteins enriched and allocated to a pathway upon activation of either A1R or β2-AR. 
This also implies a role for TG2 in these pathways, as the proteins analysed are TG2 
substrates/interacting proteins. 
7.4 Western blot confirmation of VDAC1 and HK1. 
Confirmation of proteins identified by SWATH MS (one novel (HK1) and one known 
(VDAC1) substrate of TG2) was investigated using western blotting. Briefly, H9c2 cells 
were labelled with biotin-x-cadaverine and following labelling were treated with 100 
nM CPA and 100 µM adenosine. Cell lysates were then subjected to CaptAvidin™-
agarose affinity chromatography as described in section 2.9 (i) of chapter II. Following 
enrichment, immunoprecipitation of the lysate was carried out as described in section 
2.7 of chapter II using VDAC1- and HK1- specific antibodies. Western blotting was 
carried out as described in section 2.6 of chapter II with minor modifications. Rather 
than using primary and secondary antibodies, blots were incubated overnight at 4°C 
with ExtrAvidin®-HRP (1:5000 dilution) to identify biotinylated proteins. Following 
incubation, the membranes were imaged and quantified.  
Figures 7.6 and 7.7 illustrate that treatment with 100 nM CPA or 100 µM adenosine for 
10 min significantly increased the incorporation of biotin-X-cadaverine into TG2 
substrates, namely HK1 and VDAC1. Incorporation of biotin-X-cadaverine into both 
HK1 and VDAC1 was significantly inhibited by pre-treatment with Z-DON and R283, 
providing evidence that these changes occur via interaction with TG2. 
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Fig. 7.6: Detection of hexokinase 1 as a TG2 protein substrate in CPA- and adenosine-
treated H9c2 cells. Cells were incubated with 1 mM biotin-X-cadaverine for 6 h, after 
which they were treated for 1 h with the TG2 inhibitors Z-DON (150 µM) or R283 (200 
µM) before stimulation with CPA (100 nM) or adenosine (100 μM) for 10 min. Biotin-X-
cadaverine-labelled proteins were enriched using CaptAvidin™ agarose sedimentation 
beads and eluted proteins were subjected to immunoprecipitation using a hexokinase 
1 specific antibody. Samples were subsequently analysed by probing the blots with 
ExtrAvidin®-HRP. Quantified data for CPA- and adenosine-induced increases in HK1 
are expressed as a percentage of that observed in control cells (100%). Values are 
means  S.E.M. from three independent experiments. *P<0.05, **P0.01 and 
***P0.001, (a) versus control response, (b) versus CPA alone, (c) versus adenosine 
alone. 
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Fig. 7.7: Detection of Voltage-Dependent Anion Channel 1 (VDAC1) as a TG2 protein 
substrate in CPA- and adenosine-treated H9c2 cells. Cells were incubated with 1 mM 
biotin-X-cadaverine for 6 h, after which they were treated for 1 h with the TG2 
inhibitors Z-DON (150 µM) or R283 (200 µM) before stimulation with CPA (100 nM) or 
adenosine (100 μM) for 10 min. Biotin-X-cadaverine-labelled proteins were enriched 
using CaptAvidin™ agarose sedimentation beads and eluted proteins were subjected 
to immunoprecipitation using a VDAC1 specific antibody. Samples were subsequently 
analysed by probing the blots with ExtrAvidin®-HRP. Quantified data for CPA- and 
adenosine-induced increases in VDAC1 are expressed as a percentage of that 
observed in control cells (100%). Values are means  S.E.M. from three independent 
experiments. *P<0.05, **P0.01, ***P0.001 and ****P0.0001, (a) versus control 
response, (b) versus CPA alone, (c) versus adenosine alone. 
 
From the data presented in this study, it can be concluded that this novel approach 
can be successfully used to identify and quantify TG2 substrates and to relate them to 
associated pathways. 
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7.5 Discussion. 
This present study represents a novel proteomic approach to the identification of TG2 
substrates. Furthermore, this study not only identifies novel substrates but also 
provides a quantitative analysis of their modification by TG2 in response to GPCR 
activation.  
CaptAvidin™-agarose affinity chromatography 
One recent study investigating TG2 substrates adopted a similar approach of 
enrichment using CaptAvidin™-agarose sedimentation beads followed by 2D-
electrophoresis and MALDI-TOF analysis in H9c2 cells (Almami et al, 2014). However, 
this study used non-specific activators of PKA and PKC (forskolin and PMA) which do 
not target a specific GPCR and might have other effects on signalling/ TG2 and 
therefore the substrates of TG2. The proteomic findings of the present study targeted 
specific GPCRs to amplify responses generated by a single receptor and eliminate the 
possibility of direct activation of signalling pathways, which might have effects on TG2 
and its substrates. However, one of the obvious shortcomings of this study is that 
even though activating one GPCR, signalling profiles can differ significantly between 
agonists at the same receptor (e.g. formoterol versus isoprenaline in chapter V) which 
could account for variability in the substrates identified. Biotin-X-cadaverine labelling 
of cells and its enrichment using CaptAvidin™-agarose sedimentation beads is widely 
used to identify enzyme substrates as well as to purify immunoglobulins (Morag, 1996; 
Bolivar, 2008). CaptAvidin™ has a selective nitrated tyrosine residue in its biotin-
binding site, which reduces the affinity of biotinylated proteins above pH 10. 
Consequently, at acidic or neutral pH biotinylated proteins can be adsorbed 
(association constant Ka = 10
9M-1) and released at pH 10 (Morag, 1996; Bolivar, 
2008). This approach, followed by mass spectrometry has been applied previously to 
identify novel TG2 substrates (Ichikawa et al, 2008; Almami et al, 2014; Sileno et al, 
2014). 
SWATH MS identification of proteins 
Despite providing several advantages over SRM and shotgun techniques, one of the 
obvious limitations of SWATH is that it requires preliminary selection of peptides to 
quantify from i.e. a spectral library generated from pooling samples and not directly 
searched against a database. It also allows monitoring of only a limited number of 
samples per run e.g. better elution of peptides is possible if the LC run is longer, 
however it’s not feasible due to time and expense constraints. However, with this 
small limitation in mind the main advantage of SWATH is that it creates a permanent 
record of all theoretical fragment ion spectra in the sample that can be detected. This 
permanent record can be interrogated at a future date using an improved spectral 
library. 
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It is interesting to note that the confidence level used for the A1R (60%) and β2-AR 
(70%) analysis is different. This compromise in the confidence level can be explained 
by the differences in the injection methods applied, SWATH variable windows and the 
accumulation times used. Even though the instrument (SCIEC TripleTOF® 6600), 
column (YMC Triart C18 150mmX0.3mm 3 μl dam), constant gradient flow rate (5 
μl/min) and LC run times (60 min) were similar, the injection methods were very 
different. The A1R study used direct injection approach (samples directly injected onto 
the column) while during the β2-AR study used an automated trapelute column prior to 
the sample reaching the column (an addition to the existing system). This trapelute 
column adds a desalting step which ensures that the sample is free of salts and 
detergents, which might interfere with the column binding and elution, as well as 
ionisation of the samples. Further differences in these studies were the SWATH 
variable windows and accumulation time. SWATH variable windows are a set of 
precursor acquisition windows, which are typically designed to cover the full mass 
range (400-1200 m /z), within the cycle time (usually 2-4 seconds). These windows 
can be variable, for instance, smaller windows (e.g. 5 Da) for dense m/z regions and 
wider windows (e.g. 25 Da) for lighter m/z regions and require optimisation for 
specific experiments. The A1R study used 40 variable windows and a 50 millisecond 
accumulation time per window while the β2-AR study used 100 variable windows and a 
25 millisecond accumulation time per window. This difference makes the β2-AR study 
much more sensitive as many more peptides were scanned with better precision. 
These more sensitive settings were not available during the A1R study, due to the 
technique being quite novel at the time of these experiments being performed.  
Once the protein lists were retrieved from the OneOmics, the proteins were searched 
against the TRANSDAB database (http://genomics.dote.hu/wiki/index.php/Main_Page; 
Csosz et al, 2009). TRANSDAB is a transglutaminase substrate database that contains 
an entry for each of the substrate proteins identified, source of organism used, 
information about the type of study (e.g. in-vitro/in-vivo) and its location (intracellular 
or extracellular) for the entire transglutaminase family. A significant limitation is that 
this database was last updated in February 2008. Hence, along with searching against 
the database, a manual literature search (using Pubmed) was performed to identify 
whether the given protein was a novel or known TG2 substrate.  
Comparison of proteins either revealing an increase or decrease following treatment 
with selective/non-selective or endogenous agonists of the same receptor highlights 
some interesting similarities as well as differences. This could be explained as follows. 
Firstly, the non-selective/endogenous agonists could trigger TG2-mediated 
incorporation of biotin-X-cadaverine into several proteins via a different receptor 
belonging to the same family and as shown previously (chapter V), there could be a 
difference in the signalling pathway (i.e. Gs versus Gi/o) triggered even when activating 
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just a single receptor. Finally, it is important to bear in mind that only biotin-X-
cadaverine-modified substrates have been considered for this study. TG2 can also 
incorporate other endogenous intracellular proteins (e.g. spermine, spermidine, 
putrescine) which have not been considered. When performing the analysis the mass 
shift (+311.4429) due to tagging with biotin-X-cadaverine was taken into account. 
However, since SWATH MS creates a permanent record of all theoretical fragment ion 
spectra in the sample, these modifications can be considered at a later date. This was 
not possible for this present study due to time and expense constraints. In relation to 
the current data, it is conceivable that the proteins that showed decreased levels in 
eluates from CaptAvidin™-agarose columns following A1R and β2-AR activation 
represent deamidation and/or altered transamidation and/or interactions with TG2 
substrate binding partners. However, further work is necessary to determine the 
mechanism underlying the observed decreases. 
Pathway analysis 
To take an unbiased view of the substrates/interacting proteins identified and to select 
the most biologically relevant targets for further investigation, pathway analysis using 
DAVID bioinformatics software was implemented to examine the pathways where 
these proteins are most likely to function. Although it would have been ideal to 
investigate all of the proteins identified in the list, this was not technically possible due 
to time and expense constraints. For pathway analysis, proteins were pooled as the 
signalling profiles of selective/non-selective agonists are quite different and the 
purpose of this study was to identify substrates of TG2 upon activation of either A1R or 
β2-AR. It is quite clear that some of the substrates identified play significant roles in 
various pathways; for instance tropomyosin plays a role in contraction, hypertrophic 
and dilated cardiomyopathy and adrenergic signalling in cardiomyocytes. This 
illustrates the multifunctional role of a particular substrate in different pathways as 
well as crosstalk between pathways. Even though the software only considers the 
experimental data available for performing pathway analysis, one of the limitations is 
that it considers the organism as a whole and does not allow selection of a particular 
cell/tissue type. Hence, the pathways identified need to be scrutinized for relevance 
depending on the cell/tissue type. This does not mean that the protein is not present 
but simply that it does not perform this function in the given cell/tissue type. It might 
however play a function in the specific given cell type, which is different and is yet to 
be identified. For the purpose of this study only substrates that have been previously 
associated with cellular functions relevant to cardiac cells will be discussed. 
 
i. Hexokinase 1: 
Hexokinase 1 (HK1) is an enzyme involved in glycolysis and plays a key role in 
many metabolic pathways. Hexokinases carry out the first step of glycolysis by 
converting glucose to glucose-6-phosphate. Glucose-6-phosphate can then 
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continue to have either a catabolic or an anabolic fate. Thus, hexokinase acts 
as a gatekeeper for metabolic fates (Depre et al, 1999). Constant ATP 
generation and turnover via metabolism plays a key role in maintaining the 
heart’s mechanical function and hence hexokinase acts as a regulator of 
metabolism (Depre et al, 1999; Calmettes et al, 2015). Apart from their 
metabolic function, hexokinases also have a role in regulating mPTP opening 
directly. HK1 is strongly anti-apoptotic when bound to the outer mitochondrial 
membrane, putatively to VDAC1 (Pastorino and Hoek, 2008; Shoshan-Barmatz 
et al, 2009). It has therefore been implicated in ischaemic preconditioning of 
the heart (Murry et al, 1986). During ischaemia, there is greater energy 
demand for cell survival. HK1 is hence recruited to mitochondria to maximise 
glucose-6-phosphate production to meet this demand. Also, when recruited to 
the mitochondrion, HK1 occupies binding sites which would otherwise be 
occupied by Bax and BAK to initiate apoptosis following this ischaemic insult 
(Southworth et al, 2007). Therefore, HK1 is an important substrate of TG2, 
which has been shown to be significantly increased upon the A1R-induced TG2 
activation (figure 7.6), and hence can be linked with A1R-induced TG2-
mediated cardioprotection seen in chapter VI.  
 
ii. Voltage-Dependent Anion Channel 1 (VDAC1): 
VDAC1, also known as outer mitochondrial membrane protein porin 1, is a 
voltage-dependent anion channel, which allows the flow of metabolites (e.g. 
pyruvate) and ions (e.g. Ca2+) across the outer mitochondrial membrane. It is 
known to interact with many proteins (e.g. BAX, dynein, mitochondrial heat-
shock proteins 70 and 74,  Hexokinases, etc;  Schwarzer et al, 2002; Anflous-
Pharayra et al, 2007; Martel et al, 2014) and is typically considered to be a 
pro-apoptotic protein (Shoshan-Barmatz et al, 2010; Prezma et al, 2013). 
However, recently an anti-apoptotic function of VDAC1 has been reported 
(Abu-Hamad et al, 2009; Shoshan-Barmatz et al, 2009; Arbel et al, 2012; 
Martel et al, 2014; Monaco et al, 2015). It is hypothesised that the protective 
effects of VDAC1 are due to its binding with HK1, which closes the mPTP and 
prevents Bax-induced translocation of cytochrome c and the activation of 
apoptosis (Arzoine et al, 2009; McCommis and Baines, 2012). Moreover, Rosa 
and colleagues recently recognised the neuro-protective effects of hexokinase 
and VDAC1 in several neurological disorders such as Alzheimer’s disease (Rosa 
et al, 2016). TG2 has been extensively implicated in neurodegenerative 
pathologies and it could be speculated that VDAC1 and HK1 serving as its 
substrates mediate this protection. However, it is quite clear that in H9c2 cells 
VDAC1 serves as a substrate for TG2 (Figure 7.7; Almami et al, 2014). Since 
HK1 is a novel target identified in this present study, it suggests that the A1R-
induced TG2-mediated cardioprotection (Chapter VI) could be mediated via 
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HK1 and VDAC1 acting as TG2 substrates. However, further work is warranted 
to confirm this hypothesis. 
 
iii. Protein S100-A6: 
Protein S100-A6, also known as calcyclin, is a Ca2+-binding protein, which is 
known to interact with caldesmon, calponin, tropomyosin, actin and myosin 
(Donato et al, 2013). Its interaction with tropomyosin is well documented 
(Golitsina et al, 1996; Orre et al, 2007) and in fibroblasts it is known that 
depletion of S100-A6 results in disorganisation of tropomyosin-associated 
cytoskeletal filaments (Breen and Tang, 2003). Nedjadi and colleagues have 
also reported that in pancreatic cancer cell lines, depletion of S100-A6 results 
in loss of motility, which is partly caused by S100-A6 interaction with 
tropomyosin. Hence, it is conceivable that TG2-mediated modulation of Protein 
S100-A6 function plays a role in β2-AR-induced regulation of cardiomyocyte 
contractility. It is also suggested that S100-A6 inhibits apoptosis when its 
activation is induced by tumor necrosis factor-α via an NF-κB-dependent 
manner (Tsoporis et al, 2008). When S100-A6 interacts with calcyclin-binding 
protein/Siah-interacting protein (CacyBP/SIP), it exerts cardioprotective effects 
against ischaemia/reperfusion injury (Au et al, 2006; Schneider and Filipek, 
2011). This suggests a possible role for S100A6 in β2-AR induced-
cardioprotection. 
 
iv. Tropomyosin:  
Tropomyosin is a protein that is involved in contraction of muscle cells, 
whereas in non-muscle cells, it is responsible for maintaining cytoskeletal 
architecture. Along with the troponin complex, tropomyosin is associated with 
myosin and actin to regulate contractile functions (Wieczorek, 2016). It is 
therefore interesting to note that Myosin regulatory light polypeptide 9, Myosin 
light polypeptide 6, Myosin-9, Myosin regulatory light chain RLC-A, Actin, 
gamma-enteric smooth muscle, Alpha-actinin-4 are identified in this study. 
There are four isoforms of tropomyosin with further diversity resulting from 
alternative splicing, namely, tropomyosin 1 or α, tropomyosin 2 or β, 
tropomyosin 3 or γ and tropomyosin 4 or δ (Tropomyosin alpha-3 chain, 
Tropomyosin alpha-4 chain, Tropomyosin alpha-1 chain identified in this study), 
however, tropomyosin 3 or γ is not known to be expressed in cardiomyocytes 
(Bai et al, 2013). These isoforms play an important role during development of 
the heart as well as the rate of contraction and relaxation. For instance, in 
transgenic hearts and isolated cardiomyocytes, myofilaments containing 
tropomyosin 2 (β) demonstrate an increase in calcium sensitivity and a 
decrease in the rightward shift of Ca2+-force relation induced by cAMP-
dependent phosphorylation thereby increasing contraction rate (Palmiter et al, 
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1996). In order to fully understand the function of tropomyosin in the heart, a 
number of studies to define the expression and function of these isoforms have 
been undertaken (for reviews see Katz, 1969; Wieczorek et al, 2008; Bai et al, 
2013; Wieczorek, 2016). The presence of tropomyosin in the present study 
demonstrates that H9c2 cells have a cardiomyocyte-like phenotype, as 
tropomyosin is a marker for cardiac muscle. It can also be conceived that TG2-
mediated modulation of tropomyosin plays a role in cardiomyocyte contraction. 
Furthermore, the pathway analysis for increased levels in eluates from 
CaptAvidin™-agarose beads following stimulation of the A1R illustrates cardiac 
muscle contraction, hypertrophic cardiomyopathy (HCM) and dilated 
cardiomyopathy pathways, which all contain the tropomyosin elements 
identified in this study. Convincing evidence exists that dysregulation of 
tropomyosin leads to various cardiomyopathies (Kamisago et al, 2000; Van 
Driest et al, 2002; Marques and De Oliveria, 2016) and hence it is likely that 
the detection of tropomyosin within this study and experimental data from 
previous studies allowed the software to identify these pathways. 
 
v. Acetyl-CoA carboxylase: 
Acetyl-CoA carboxylase and its derivatives are involved in regulation of cardiac 
energy metabolism by playing a key role in metabolic pathways as well as 
influencing the activity of other enzymes (such as carnitine 
palmitoyltransferase 1 and malonyl-CoA decarboxylase) either in an allosteric 
manner or by altering substrate availability (Kolwicz et al, 2013). The heart 
requires a massive rate of ATP production and turnover to maintain its 
continuous mechanical function, which is provided by the mitochondria. The 
cardiac mitochondria are not only responsible for generating ATP but are also 
accountable for maintaining Ca2+ homeostasis, Ca2+ signalling and apoptosis 
(Kolwicz et al, 2013). Although the metabolic network is responsible for 
generating ATP, metabolites generated during the process are known to 
regulate cell function. It is therefore interesting to note that Acetyl-CoA 
carboxylase 1, Adenine phosphoribosyl transferase, Aldehyde dehydrogenase 2 
family (mitochondrial), Lactate dehydrogenase A, Malate dehydrogenase 2, 
Phosphoglycerate dehydrogenase are identified in this study. There have been 
a number of studies involved in identifying the role of metabolites in cardiac 
function as dysregulation of any one of them can cause impairment of cardiac 
function by attenuation of the metabolic pathway (for reviews see Bishop and 
Altschuld, 1969; Kolwicz et al, 2012; Maillet et al, 2013; Doenst et al, 2013; 
Alrob and Lopaschuk, 2014; Pietrocola et al, 2015; Munzel et al, 2015). Ca2+ 
overload during cardiac ischaemia/reperfusion injury is associated with the loss 
of mitochondrial function and opening of the permeability pore resulting in cell 
death. Studies have shown that TG2 knockout (TG2-/-) ischaemia/reperfused 
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isolated hearts have increased infarct size and ventricular fibrillation as 
compared to ischaemia/reperfused wild type hearts (Szondy et al, 2006). 
Further interrogation of the molecular mechanisms underlying this 
phenomenon has led to the understanding that this sensitivity of TG2-/- 
ischaemia/reperfused isolated hearts is not due to impaired adrenoceptor 
signalling but due to low baseline stores of high energy phosphates and defects 
in mitochondrial and ATPase function (Szondy et al, 2006). Piacentini and 
collegues have shown that TG2 co-localizes with mitochondria and TG2 
overexpression leads to mitochondrial hyperpolarization (Piacentini et al, 
2002). Hence, these studies reveal a novel role for TG2 in the maintenance of 
mitochondrial respiratory function. Since most of the metabolic pathways 
identified in this study are associated with the mitochondria and are involved in 
its respiratory function to generate ATP, it is therefore likely that TG2 interacts 
with these metabolites and might play a role in the modulation of their activity. 
From these findings, it is clear that the modulation of TG2 and its substrates by the 
A1R and β2-AR is very complex. Using proteomic approaches several novel TG2 
substrates were identified and assigned to pathways to reveal their biological 
relevance. Two of the substrates were validated, demonstrating the accuracy of the 
new approach. Data presented here therefore supports the notion that TG2 
substrates/interacting proteins show differential modulation upon activation of the A1R 
and β2-AR which can lead to various effects on cellular responses. 
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Chapter VIII: Conclusions and further work 
8.1 General conclusions. 
This present study has provided novel data contributing to the understanding of the 
modulation of tissue transglutaminase (TG2) activity via GPCRs (A1 adenosine receptor 
and β2-adrenoceptor) in H9c2 cardiomyoblasts. This modulation was based upon a 
multi-protein kinase-dependent pathway. Investigation into the cytoprotection offered 
by the A1R and the β2-AR against hypoxia- and hypoxia/re-oxygenation induced cell 
death has revealed that TG2 has a pivotal role in pharmacological pre- and post-
conditioning. Furthermore, identification of novel TG2 substrates/interacting proteins 
has illustrated differential modulation via the A1R and the β2-AR which may contribute 
to differences in their cellular/physiological responses. 
8.2 Further work. 
TG2 regulation by GPCRs 
To extend this body of work, it would be interesting and novel to investigate potential 
GPCR modulation of other TG2 activities such as GTPase activity (Bailey et al, 2004), 
kinase activity (Thangaraju et al, 2016) and/or isopeptidase activity (Oertel et al, 
2007). Assays are available e.g. isopeptidase-fluorogenic assay to evaluate 
isopeptidase activity of TG2  (Zedira, Gmbh), which would enable these activities to be 
explored. Furthermore, since other TG isoforms (TG1 and TG3) are also expressed in 
H9c2 cells (chapter III- figure 3.12 and 3.13), it would be of interest to investigate if 
the activities of these enzymes can also be regulated by GPCRs. Also, it would be 
worthwhile to assess GPCR mediated activation of TG2 in cells derived from transgenic 
animals lacking TG2. 
It would be important to implement another way of inhibiting TG2. The use of siRNA 
would allow silencing of TG2 without using pharmacological/chemical inhibitors which 
may not be 100% TG2 selective and hence would further confirm the findings of this 
study. Preliminary work has been already performed with regards to optimisation of 
TG2 siRNA (appendix 1). It was found that treatment with TG2 siRNA for 72 h could 
knock down ~50% of protein expression. However, further experiments could not be 
performed due to time constraints. 
β2-AR signalling and biased agonism 
An interesting avenue to explore would be to screen numerous β2-AR agonists and 
elucidate the signalling pathway activated by them in H9c2 cardiomyoblasts. The 
possible role of Gi/o and Gs proteins could then be uncovered and perhaps this could be 
linked in with modulation of the enzyme TG2 as well as the cytoprotection offered by 
the β2-AR. It is known that noradrenaline (the endogenous full agonist) can fully 
activate β2-AR-mediated Gs signalling/cAMP signalling pathway (Heubach et al, 2003; 
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Wang et al, 2008) in murine heart and primary cardiomyocytes, whereas clenbuterol 
(full agonist) solely activates β2-AR-mediated Gi signalling/IP3 signalling pathway 
(Siedlecka et al, 2008) in isolated rat ventricular myocytes. Similar properties of 
coupling to different G-proteins (Gs and Gi proteins) have been exhibited by 
isoprenaline and adrenaline (both full agonists; Heubach et al, 2003; Wang et al, 2008; 
Liu et al, 2009) in cardiomyocytes. This study investigated effects of formoterol (long-
acting β2-AR agonist) and isoprenaline (non-selective β-AR agonist). It would be 
interesting to see if other long acting β2-AR agonists (salmeterol) and short acting β2-
AR agonists such as (albuterol, metaproterenol, terbutaline) display similar 
phenomenon of coupling to Gi/o and Gs proteins in H9c2 cardiomyoblasts. 
TG2 phosphorylation 
Another area of interest would be to determine the phosphorylation sites on TG2. 
Phosphoproteomic approaches would reveal which site(s) are being phosphorylated. 
For instance, 32P tagging of ATP followed by strong cation-exchange chromatography 
and high accuracy multi-stage mass spectrometry could be one of the ways of 
identifying phosphoproteins. Previous studies have revealed that TG2 is 
phosphorylated by PKA at Ser215 and Ser216 (Mishra and Murphy, 2006) and at an 
unknown site(s) by PTEN-induced putative kinase 1 (PINK1; Min et al., 2015). It is 
also known that phosphorylation of TG2 by PKA at Ser216 inhibits its transamidase 
activity and enhances its kinase activity (Mishra et al, 2007; Wang et al, 2012). 
Phosphoproteomic studies have also identified numerous phosphorylation sites in 
human TG2 (Ser56, Ser60, Tyr219, Thr368, Tyr369, Ser419, Ser427, Ser538, Ser541 and Ser608; 
Rikova et al, 2007; Imami et al, 2008; Kettenbach et al, 2011; Bian et al, 2014; 
Palacios-Moreno et al, 2015) and rat TG2 (Tyr44, Thr58, Ser68 and Ser449; Hoffert et al, 
2006; Lundby et al, 2012). This study has shown that TG2 is phosphorylated upon 
activation of the A1R and the β2-AR. Inhibition of an individual protein kinase that 
phosphorylates TG2 (e.g. ERK1/2, PKC etc.) and then performing phosphoproteomic 
analysis would reveal exactly which site on TG2 is phosphorylated by which protein 
kinase which is activated upon stimulation of the A1R and the β2-AR. At present the 
relationship between the A1R and the β2-AR-induced TG2 activity and phosphorylation 
is not known. Since the A1R and the β2-AR induce TG2 activity in a time-dependent 
manner, it would be interesting to examine if this time course matches TG2 
phosphorylation induced by these receptors. 
TG2 substrates 
The present study has identified several novel TG2 substrates/interacting proteins 
which illustrate differential modulation upon activation of the A1R and the β2-AR, thus 
leading to various effects on cellular responses. This has uncovered several proteins 
which could make good targets for future work. It would be necessary to validate 
more of the identified substrates/interacting proteins and examine if they are 
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associated with cytoprotection. Moreover, also determine how TG2 modulation could 
potentially alter its biological function, cellular localisation and turnover. This would be 
achieved by using subcellular fractionation (to isolate various compartments) followed 
by functional assays (ELISA). 
TG2 cardioprotection and signalling pathways 
It is known that the A1R activates the RISK pathway (ERK1/2 and PKB) during 
ischaemic and ischaemia/reperfusion conditions (Cohen and Downey, 2015). However, 
it has not been investigated if the β2-AR activates the RISK pathway under these 
conditions and hence would form an area of interest. It is known that the β2-AR 
activates both ERK1/2 and PKB under normal conditions (Yang et al, 2010; Zhang et 
al, 2011). Therefore, it is conceivable that the β2-AR activates both ERK1/2 and PKB 
under hypoxic conditions. As the A1R activates TG2 and RISK pathways, it is possible 
that there could be a link between the protection offered by TG2 and these pathways 
under hypoxia and hypoxia/reoxygenation conditions. Also, it would be interesting to 
check if the switching between Gi/o and Gs proteins by different β2-AR agonists plays a 
role in activation of the RISK pathway. Furthermore, it is known that TG2 binds to 
hypoxia inducible factor 1β (HIF1β) and supresses HIF activity in neurons under 
ischaemic conditions (Filiano et al, 2008). It was later found that nuclear localisation 
of TG2 is necessary for suppression of HIF activity which is not dependent on TG2’s 
interaction with HIF1β (Gundemir et al, 2013). Hence, it would be of interest to assess 
TG2’s interaction with HIF1β and HIF signalling in H9c2 cardiomyocytes. 
Alternative models 
Extending this study to the use of isolated rat cardiomyocytes and ventricle strips 
would be the initial next steps to undertake, closely followed by the use of 
Langendorff-perfused rat heart and in-vivo studies. These approaches represent more 
physiological relevant models for the study of cardiovascular diseases and would 
validate the novel data obtained using H9c2 cardiomyoblasts. It would also be 
interesting to extend this study to neuronal cells as they reflect yet another area that 
is commonly subjected to ischaemic and ischaemic/reperfusion insult during stroke 
and would further add to the current understanding of the cytoprotective mechanism 
of TG2. 
8.3 Concluding remarks. 
In conclusion, this study has shown for the first time that activation of the A1 
adenosine receptor and the β2-adrenoceptor modulates TG2 activity and 
phosphorylation via a multi protein kinase and extracellular Ca2+-dependent pathway 
in H9c2 cells. In addition, cytoprotection offered by the A1R and β2-AR against hypoxia 
and hypoxia/re-oxygenation injury is dependent on TG2. This study has also identified 
novel TG2 substrates/interacting proteins which could be potential therapeutic targets. 
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It is anticipated that this study will lead to further investigation into the modulation of 
TG2 by GPCRs, its role in pathophysiological circumstances such as 
ischaemia/reperfusion injury and potentially lead to novel drug discovery by either 
targeting TG2 or one of its substrates identified. Figure 8.1 summarises the findings of 
this study. 
 
 
 
 
 
 
 
 
 
 
 
Fig 8.1: Summary of the findings in this study. Briefly, stimulation of the A1 adenosine 
receptor (A1R) by selective and endogenous agonists (CPA and adenosine, respectively) 
triggers activation of protein kinases (PKC, ERK1/2, JNK1/2 and p38 MAPK) along with 
influx of extracellular Ca2+ leading to increases in TG2 activity and TG2 
phosphorylation. Similarly, stimulation of the β2-adrenoceptor (β2-AR) by selective and 
non-selective agonists (formoterol and isoprenaline, respectively) triggers activation of 
protein kinases via Gs- and Gi/o- proteins (PKA, PI-3Kγ and ERK1/2) along with influx 
of extracellular Ca2+ leading to increases in TG2 activity and TG2 phosphorylation. 
Cytoprotection against hypoxia and hypoxia/re-oxygenation was offered by the A1R- 
and isoprenaline-mediated pre- and post-conditioning and was dependent on TG2. 
Substrate identification by SWATH-MS revealed several novel TG2 proteins/substrates 
which might be involved in cell survival. Solid black arrows represent findings of this 
study, dashed arrows represent findings of this study which need further work or were 
inconclusive and grey arrows represent published findings (not from the present 
study). 
 
 
 
 
 
215 
 
Bibliography 
Abbracchio MP, Ceruti S, Barbieri D, Franceschi C, Malorni W, Biondo L, Burnstock 
G, Cattabeni F. (1995) A novel action for adenosine: apoptosis of astroglial cells in 
rat brain primary cultures. Biochem Biophys Res Commun. 213(3):908-15. 
Abo Alrob O, Lopaschuk GD. (2014) Role of CoA and acetyl-CoA in regulating 
cardiac fatty acid and glucose oxidation. Biochem Soc Trans. 42(4):1043-51. 
Abu-Hamad S, Arbel N, Calo D, Arzoine L, Israelson A, Keinan N, Ben-Romano R, 
Friedman O, Shoshan-Barmatz V. (2009) The VDAC1 N-terminus is essential both 
for apoptosis and the protective effect of anti-apoptotic proteins. J Cell Sci. 122(Pt 
11):1906-16. 
Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. (2008) 
Hexokinase-I protection against apoptotic cell death is mediated via interaction 
with the voltage-dependent anion channel-1: mapping the site of binding. J Biol 
Chem. 283(19):13482-90. 
Adameova A, Goncalvesova E, Szobi A, Dhalla NS. (2016) Necroptotic cell death in 
failing heart: relevance and proposed mechanisms. Heart Fail Rev. 21(2):213-21. 
Agle KA, Vongsa RA, Dwinell MB. (2010) Calcium mobilization triggered by the 
chemokine CXCL12 regulates migration in wounded intestinal epithelial monolayers. 
J Biol Chem. 285(21):16066-75. 
Agnihotri N, Kumar S, Mehta K. (2013) Tissue transglutaminase as a central 
mediator in inflammation-induced progression of breast cancer. Breast Cancer Res. 
15(1):202. 
Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, Shiojima I, Hiroi Y, 
Yazaki Y. (1997) Oxidative stress activates extracellular signal-regulated kinases 
through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest. 
100(7):1813-21. 
Akimov SS, Belkin AM. (2001) Cell surface tissue transglutaminase is involved in 
adhesion and migration of monocytic cells on fibronectin. Blood. 98(5):1567-76. 
Akimov SS, Krylov D, Fleischman LF, Belkin AM. (2000) Tissue transglutaminase is 
an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol. 148(4):825-38. 
Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, 
Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2015) The 
216 
 
Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J 
Pharmacol. 172(24):5744-869. 
Almami I, Dickenson JM, Hargreaves AJ, Bonner PL. (2014) Modulation of 
transglutaminase 2 activity in H9c2 cells by PKC and PKA signalling: a role for 
transglutaminase 2 in cytoprotection. Br J Pharmacol. 171(16):3946-60. 
Altamirano F, Wang ZV, Hill JA. (2015) Cardioprotection in ischaemia-reperfusion 
injury: novel mechanisms and clinical translation. J Physiol. 593(17):3773-88. 
Altuntas S, D'Eletto M, Rossin F, Hidalgo LD, Farrace MG, Falasca L, Piredda L, 
Cocco S, Mastroberardino PG, Piacentini M, Campanella M. (2014) Type 2 
Transglutaminase, mitochondria and Huntington's disease: menage a trois. 
Mitochondrion. 19(Pt A):97-104. 
Anderson ME, Brown JH, Bers DM. (2011) CaMKII in myocardial hypertrophy and 
heart failure. J Mol Cell Cardiol. 51(4):468-73. 
Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC. (2004) Tissue 
transglutaminase catalyzes the formation of alpha-synuclein crosslinks in 
Parkinson's disease. FASEB J. 18(7):932-4. 
Anflous-Pharayra K, Cai ZJ, Craigen WJ. (2007) VDAC1 serves as a mitochondrial 
binding site for hexokinase in oxidative muscles. Biochim Biophys Acta. 
1767(2):136-42. 
Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA. (2009) Tissue 
transglutaminase is an essential participant in the epidermal growth factor-
stimulated signaling pathway leading to cancer cell migration and invasion. J Biol 
Chem. 284(27):17914-25. 
Antonyak MA, McNeill CJ, Wakshlag JJ, Boehm JE, Cerione RA. (2003) Activation of 
the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue 
transglutaminase expression in NIH3T3 cells. J Biol Chem. 278(18):15859-66. 
Arbel N, Ben-Hail D, Shoshan-Barmatz V. (2012) Mediation of the antiapoptotic 
activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem. 
287(27):23152-61. 
Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V. (2009) Voltage-
dependent anion channel 1-based peptides interact with hexokinase to prevent its 
anti-apoptotic activity. J Biol Chem. 284(6):3946-55. 
217 
 
Au KW, Kou CY, Woo AY, Chim SS, Fung KP, Cheng CH, Waye MM, Tsui SK. (2006) 
Calcyclin binding protein promotes DNA synthesis and differentiation in rat 
neonatal cardiomyocytes. J Cell Biochem. 98(3):555-66. 
Auchampach JA, Bolli R. (1999) Adenosine receptor subtypes in the heart: 
therapeutic opportunities and challenges. Am J Physiol. 276(3 Pt 2):H1113-6. 
Bae J, Lee YS, Jeoung D. (2006) Down-regulation of transglutaminase II leads to 
impaired motility of cancer cells by inactivation of the protein kinase, Akt, and 
decrease of reactive oxygen species. Biotechnol Lett. 28(15):1151-8. 
Baek KJ, Das T, Gray C, Antar S, Murugesan G, Im MJ. (1993) Evidence that the 
Gh protein is a signal mediator from alpha 1-adrenoceptor to a phospholipase C. 
I.Identification of alpha 1-adrenoceptor-coupled Gh family and purification of Gh7 
from bovine heart. J Biol Chem. 268(36):27390-7. 
Baek KJ, Das T, Gray CD, Desai S, Hwang KC, Gacchui R, Ludwig M, Im MJ. (1996) 
A 50 KDa protein modulates guanine nucleotide binding of transglutaminase II. 
Biochemistry. 35(8):2651-7. 
Baek KJ, Kang S, Damron D, Im M. (2001) Phospholipase Cdelta1 is a guanine 
nucleotide exchanging factor for transglutaminase II (Galpha h) and promotes 
alpha 1B-adrenoreceptor-mediated GTP binding and intracellular calcium release. J 
Biol Chem. 276(8):5591-7. 
Bai F, Wang L, Kawai M. (2013) A study of tropomyosin's role in cardiac function 
and disease using thin-filament reconstituted myocardium. J Muscle Res Cell Motil. 
34(3-4):295-310. 
Bailey CD, Graham RM, Nanda N, Davies PJ, Johnson GV. (2004) Validity of mouse 
models for the study of tissue transglutaminase in neurodegenerative diseases. 
Mol Cell Neurosci. 25(3):493-503. 
Bailey CD, Johnson GV. (2005) Tissue transglutaminase contributes to disease 
progression in the R6/2 Huntington's disease mouse model via aggregate-
independent mechanisms. J Neurochem. 92(1):83-92. 
Baker JG. (2005) Evidence for a secondary state of the human beta3-adrenoceptor. 
Mol Pharmacol. 68(6):1645-55. 
Baker JG. (2005) The selectivity of beta-adrenoceptor antagonists at the human 
beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 144(3):317-22.  
218 
 
Baker JG. (2010) The selectivity of beta-adrenoceptor agonists at human beta1-, 
beta2- and beta3-adrenoceptors. Br J Pharmacol. 160(5):1048-61. 
Baldwin AS Jr. (2001) Series introduction: the transcription factor NF-kappaB and 
human disease. J Clin Invest. 107(1):3-6. 
Ballard-Croft C, Kristo G, Yoshimura Y, Reid E, Keith BJ, Mentzer RM Jr, Lasley RD. 
(2005) Acute adenosine preconditioning is mediated by p38 MAPK activation in 
discrete subcellular compartments. Am J Physiol Heart Circ Physiol. 
288(3):H1359-66. 
Ballarín M, Fredholm BB, Ambrosio S, Mahy N. (1991) Extracellular levels of 
adenosine and its metabolites in the striatum of awake rats: inhibition of uptake 
and metabolism. Acta Physiol Scand. 142(1):97-103. 
Barve V, Ahmed F, Adsule S, Banerjee S, Kulkarni S, Katiyar P, Anson CE, Powell 
AK, Padhye S, Sarkar FH. (2006) Synthesis, molecular characterization, and 
biological activity of novel synthetic derivatives of chromen-4-one in human cancer 
cells. J Med Chem. 49(13):3800-8. 
Basheer R, Arrigoni E, Thatte HS, Greene RW, Ambudkar IS, McCarley RW. (2002) 
Adenosine induces inositol 1,4,5-trisphosphate receptor-mediated mobilization of 
intracellular calcium stores in basal forebrain cholinergic neurons. J Neurosci. 
22(17):7680-6. 
Bayascas JR, Alessi DR. (2005) Regulation of Akt/PKB Ser473 phosphorylation. Mol 
Cell. 18(2):143-5. 
Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G, Mitsakakis N, Hare 
GM. (2010) Acute surgical anemia influences the cardioprotective effects of beta-
blockade: a single-center, propensity-matched cohort study. Anesthesiology. 
112(1):25-33. 
Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV. 
(1970) Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-
monophosphate phosphodiesterase activity. Mol Pharmacol. 6(6):597-603. 
Becker LB. (2004) New concepts in reactive oxygen species and cardiovascular 
reperfusion physiology. Cardiovasc Res. 61(3):461-70. 
Begg GE, Carrington L, Stokes PH, Matthews JM, Wouters MA, Husain A, Lorand L, 
Iismaa SE, Graham RM. (2006a) Mechanism of allosteric regulation of 
transglutaminase 2 by GTP. Proc Natl Acad Sci U S A. 103(52):19683-8. 
219 
 
Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM, Iismaa SE. (2006) 
Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 
disinhibits intracellular cross-linking activity. J Biol Chem. 281(18):12603-9. 
Belardinelli L, Isenberg G. (1983) Actions of adenosine and isoproterenol on 
isolated mammalian ventricular myocytes. Circ Res. 53(3):287-97. 
Bergamini CM. (1988) GTP modulates calcium binding and cation-induced 
conformational changes in erythrocyte transglutaminase. FEBS Lett. 239(2):255-8. 
Berlot CH, Bourne HR. (1992) Identification of effector-activating residues of Gs 
alpha. Cell. 68(5):911-22. 
Bernassola F, Federici M, Corazzari M, Terrinoni A, Hribal ML, De Laurenzi V, 
Ranalli M, Massa O, Sesti G, McLean WH, Citro G, Barbetti F, Melino G. (2002) Role 
of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative 
mutation in a MODY patient. FASEB J. 16(11):1371-8.  
Bernstein D, Fajardo G, Zhao M, Urashima T, Powers J, Berry G, Kobilka BK. (2005) 
Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic 
receptor subtypes. Am J Physiol Heart Circ Physiol. 289(6):H2441-9. 
Bernstein D, Fajardo G, Zhao M. (2011) The role of β-adrenergic receptors in heart 
failure: differential regulation of cardiotoxicity and cardioprotection. Prog Pediatr 
Cardiol. 31(1):35-38. 
Berrutti L, Silverman JS. (1996) Cardiac myxoma is rich in factor XIIIa positive 
dendrophages: immunohistochemical study of four cases. Histopathology. 
28(6):529-35. 
Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H. 
(2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver 
phosphoproteome. J Proteomics. 96:253-62. 
Bice JS, Jones BR, Chamberlain GR, Baxter GF. (2016) Nitric oxide treatments as 
adjuncts to reperfusion in acute myocardial infarction: a systematic review of 
experimental and clinical studies. Basic Res Cardiol. 111(2):23. 
Bishop SP, Altschuld RA. (1970) Increased glycolytic metabolism in cardiac 
hypertrophy and congestive failure. Am J Physiol. 218(1):153-9. 
Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. (2002) Tissue 
transglutaminase protects against apoptosis by modifying the tumor suppressor 
protein p110 Rb. J Biol Chem. 277(23):20127-30. 
220 
 
Bollag WB, Zhong X, Dodd ME, Hardy DM, Zheng X, Allred WT. (2005) 
Phospholipase d signaling and extracellular signal-regulated kinase-1 and -2 
phosphorylation (activation) are required for maximal phorbol ester-induced 
transglutaminase activity, a marker of keratinocyte differentiation. J Pharmacol 
Exp Ther. 312(3):1223-31. 
Bolli R. (2007) Preconditioning: a paradigm shift in the biology of myocardial 
ischemia. Am J Physiol Heart Circ Physiol. 292(1):H19-27. 
Bondar A, Lazar J. (2017) G protein Gi1 exhibits basal coupling but not 
preassembly with G protein-coupled receptors. J Biol Chem. pii: jbc.M116.768127. 
doi: 10.1074/jbc.M116.768127. [Epub ahead of print]. 
Bonney S, Hughes K, Eckle T. (2014) Anesthetic cardioprotection: the role of 
adenosine. Curr Pharm Des. 20(36):5690-5. 
Boucher M, Pesant S, Falcao S, de Montigny C, Schampaert E, Cardinal R, 
Rousseau G. (2004) Post-ischemic cardioprotection by A2A adenosine receptors: 
dependent of phosphatidylinositol 3-kinase pathway. J Cardiovasc Pharmacol. 
43(3):416-22. 
Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR; (2005) POBBLE trial 
investigators. Perioperative beta-blockade (POBBLE) for patients undergoing 
infrarenal vascular surgery: results of a randomized double-blind controlled trial. J 
Vasc Surg. 41(4):602-9. 
Bragança B, Oliveira-Monteiro N, Ferreirinha F, Lima PA, Faria M, Fontes-Sousa AP, 
Correia-de-Sá P. (2016) Ion Fluxes through KCa2 (SK) and Cav1 (L-type) Channels 
Contribute to Chronoselectivity of Adenosine A1 Receptor-Mediated Actions in 
Spontaneously Beating Rat Atria. Front Pharmacol. 7:45. 
Brahmadevara N, Shaw AM, MacDonald A. (2004) ALpha1-adrenoceptor antagonist 
properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against 
beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol. 142(4):781-7. 
Brahmadevara N, Shaw AM, MacDonald A. (2003) Evidence against beta 3-
adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in 
rat isolated aorta. Br J Pharmacol. 138(1):99-106. 
Brawley L, Shaw AM, MacDonald A. (2000a) Beta 1-, beta 2- and atypical beta-
adrenoceptor-mediated relaxation in rat isolated aorta. Br J Pharmacol. 
129(4):637-44. 
221 
 
Brawley L, Shaw AM, MacDonald A. (2000b) Role of endothelium/nitric oxide in 
atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Eur J 
Pharmacol. 398(2):285-96. 
Breen EC, Tang K. (2003) Calcyclin (S100A6) regulates pulmonary fibroblast 
proliferation, morphology, and cytoskeletal organization in vitro. J Cell Biochem. 
88(4):848-54. 
Briones AM, Daly CJ, Jimenez-Altayo F, Martinez-Revelles S, Gonzalez JM, McGrath 
JC, Vila E. (2005) Direct demonstration of beta1- and evidence against beta2- and 
beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J 
Pharmacol. 146(5):679-91. 
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, 
Menlove R, Shah P, Jamieson S, et al. (1986) Beta 1- and beta 2-adrenergic-
receptor subpopulations in nonfailing and failing human ventricular myocardium: 
coupling of both receptor subtypes to muscle contraction and selective beta 1-
receptor down-regulation in heart failure. Circ Res. 59(3):297-309. 
Brodde OE, Bruck H, Leineweber K. (2006) Cardiac adrenoceptors: physiological 
and pathophysiological relevance. J Pharmacol Sci. 100(5):323-37. 
Brodde OE. (1988) The functional importance of beta 1 and beta 2 adrenoceptors 
in the human heart. Am J Cardiol. 62(5):24C-29C. 
Bruns RF. (1990) Adenosine receptors. Roles and pharmacology. Ann N Y Acad Sci. 
603:211-25; discussion 225-6. 
Brust TB, Cayabyab FS, MacVicar BA. (2007) C-Jun N-terminal kinase regulates 
adenosine A1 receptor-mediated synaptic depression in the rat hippocampus. 
Neuropharmacology. 53(8):906-17. 
Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ. (2015) Bias analyses of 
preclinical and clinical D2 dopamine ligands: studies with immediate and complex 
signaling pathways. J Pharmacol Exp Ther. 352(3):480-93. 
Buja LM. (2005) Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 
14(4):170-5. 
Bungay PJ, Owen RA, Coutts IC, Griffin M. (1986) A role for transglutaminase in 
glucose-stimulated insulin release from the pancreatic beta-cell. Biochem J. 
235(1):269-78. 
222 
 
Bylund, D.B., Bond, R.A., Clarke, D.E., Eikenburg, D.C., Hieble, J.P., Langer, S.Z., 
et al. (1998) Adrenoceptors. The IUPHAR compendium of receptor characterization 
and classification. London: IUPHAR Media. 58–74. 
Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, 
Hamm HE. (2003) Insights into G protein structure, function, and regulation. 
Endocr Rev. 24(6):765-81. 
Calmettes G, Ribalet B, John S, Korge P, Ping P, Weiss JN. (2015) Hexokinases and 
cardioprotection. J Mol Cell Cardiol. 78:107-15. 
Candi E, Melino G, Lahm A, Ceci R, Rossi A, Kim IG, Ciani B, Steinert PM. (1998) 
Transglutaminase 1 mutations in lamellar ichthyosis. Loss of activity due to failure 
of activation by proteolytic processing. J Biol Chem. 273(22):13693-702. 
Candi E, Oddi S, Paradisi A, Terrinoni A, Ranalli M, Teofoli P, Citro G, Scarpato S, 
Puddu P, Melino G. (2002) Expression of transglutaminase 5 in normal and 
pathologic human epidermis. J Invest Dermatol. 119(3):670-7. 
Cannavo A, Koch WJ. (2017) Targeting β3-Adrenergic Receptors in the Heart: 
Selective Agonism and β-Blockade. J Cardiovasc Pharmacol. 69(2):71-78. 
Caputo I, D'Amato A, Troncone R, Auricchio S, Esposito C. (2004) 
Transglutaminase 2 in celiac disease: minireview article. Amino Acids. 26(4):381-6. 
Carracedo A, Pandolfi PP. (2008) The PTEN-PI3K pathway: of feedbacks and cross-
talks. Oncogene. 27(41):5527-41. 
Carré DA, Mitchell CH, Peterson-Yantorno K, Coca-Prados M, Civan MM. (2000) 
Similarity of A(3)-adenosine and swelling-activated Cl(-) channels in nonpigmented 
ciliary epithelial cells. Am J Physiol Cell Physiol. 279(2):C440-51. 
Carroll R, Yellon DM. (2000) Delayed cardioprotection in a human cardiomyocyte-
derived cell line: the role of adenosine, p38MAP kinase and mitochondrial KATP. 
Basic Res Cardiol. 95(3):243-9. 
Carvajal K, Moreno-Sánchez R. (2003) Heart metabolic disturbances in 
cardiovascular diseases. Arch Med Res. 34(2):89-99.  
Champion HC, Kass DA. (2004) Calcium handler mishandles heart. Nat Med. 
10(3):239-40. 
223 
 
Chen SL, Yang CT, Yang ZL, Guo RX, Meng JL, Cui Y, Lan AP, Chen PX, Feng JQ. 
(2010) Hydrogen sulphide protects H9c2 cells against chemical hypoxia-induced 
injury. Clin Exp Pharmacol Physiol. 37(3):316-21. 
Chen Z, Xiong C, Pancyr C, Stockwell J, Walz W, Cayabyab FS. (2014) Prolonged 
adenosine A1 receptor activation in hypoxia and pial vessel disruption focal cortical 
ischemia facilitates clathrin-mediated AMPA receptor endocytosis and long-lasting 
synaptic inhibition in rat hippocampal CA3-CA1 synapses: differential regulation of 
GluA2 and GluA1 subunits by p38 MAPK and JNK. J Neurosci. 34(29):9621-43. 
Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. (2000) 
G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type 
Ca(2+) channels. Biophys J. 79(5):2547-56. 
Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, Crow MT. (2000) 
The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac 
myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ 
Res. 87(12):1172-9. 
Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK. (1999)  
Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem. 
274(24):16694-700. 
Chuderland D, Seger R. (2008) Calcium regulates ERK signaling by modulating its 
protein-protein interactions. Commun Integr Biol. 1(1):4-5. 
Ciruela F, Albergaria C, Soriano A, Cuffí L, Carbonell L, Sánchez S, Gandía 
J,Fernández-Dueñas V. (2010) Adenosine receptors interacting proteins (ARIPs): 
Behind the biology of adenosine signaling. Biochim Biophys Acta. 1798(1):9-20. 
Civantos Calzada B, Aleixandre de Artiñano A. (2001) Alpha-adrenoceptor 
subtypes. Pharmacol Res. 44(3):195-208. 
Clarke, D.D., Mycek, M.J., Neidle, A., Waelsch, H. (1957) The incorporation of 
amines into proteins. Arch. Biochem. Biophys. 79, 338-354. 
Cohen MV, Downey JM. (2008) Adenosine: trigger and mediator of cardioprotection. 
Basic Res Cardiol. 103(3):203-15. 
Cohen MV, Downey JM. (2015) Signalling pathways and mechanisms of protection 
in pre- and postconditioning: historical perspective and lessons for the future. Br J 
Pharmacol. 172(8):1913-32. 
224 
 
Colak G, Johnson GV. (2012) Complete transglutaminase 2 ablation results in 
reduced stroke volumes and astrocytes that exhibit increased survival in response 
to ischemia. Neurobiol Dis. 45(3):1042-50. 
Communal C, Colucci WS, Singh K. (2000) p38 mitogen-activated protein kinase 
pathway protects adult rat ventricular myocytes against beta –adrenergic receptor-
stimulated apoptosis. Evidence for Gi-dependent activation. J Biol Chem. 
275(25):19395-400. 
Communal C, Singh K, Sawyer DB, Colucci WS. (1999) Opposing effects of 
beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a 
pertussis toxin-sensitive G protein. Circulation. 100(22):2210-2.  
Contractor, Hussain, Rasmus Haarup Lie, Colin Cunnington, Jing Li, Nicolaj B. 
Støttrup, Cedric Manlhiot, Hans Erik Bøtker, Michael R. Schmidt, J. Colin Forfar, 
Houman Ashrafian, Andrew Redington, and Rajesh K. Kharbanda. (2016) 
"Adenosine Receptor Activation in the “Trigger” Limb of Remote Pre-Conditioning 
Mediates Human Endothelial Conditioning and Release of Circulating 
Cardioprotective Factor(s)." JACC: Basic to Translational Science 1.6: 461-71. 
Cooke RM, Brown AJ, Marshall FH, Mason JS. (2015) Structures of G protein-
coupled receptors reveal new opportunities for drug discovery. Drug Discov Today. 
20(11):1355-64. 
Cordella-Miele E, Miele L, Beninati S, Mukherjee AB. (1993) Transglutaminase-
catalyzed incorporation of polyamines into phospholipase A2. J Biochem. 
113(2):164-73. 
Corvol JC, Studler JM, Schonn JS, Girault JA, Hervé D. (2001) Galpha(olf) is 
necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J 
Neurochem. 76(5):1585-8. 
Cotecchia S. (2010) The α1-adrenergic receptors: diversity of signaling networks 
and regulation. J Recept Signal Transduct Res. 30(6):410-9. 
Crawford RM, Jovanović S, Budas GR, Davies AM, Lad H, Wenger RH, Robertson 
KA, Roy DJ, Ranki HJ, Jovanović A. (2003) Chronic mild hypoxia protects heart-
derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression 
of the SUR2A subunit of the ATP-sensitive K+ channel. J Biol Chem. 
278(33):31444-55. 
Csosz E, Meskó B, Fésüs L. (2009) Transdab wiki: the interactive transglutaminase 
substrate database on web 2.0 surface. Amino Acids. 36(4):615-7. 
225 
 
Daaka Y, Luttrell LM, Lefkowitz RJ. (1997) Switching of the coupling of the beta2-
adrenergic receptor to different G proteins by protein kinase A. Nature. 
390(6655):88-91. 
Dai Y, Dudek NL, Patel TB, Muma NA. (2008) Transglutaminase-catalyzed 
transamidation: a novel mechanism for Rac1 activation by 5-hydroxytryptamine2A 
receptor stimulation. J Pharmacol Exp Ther. 326(1):153-62. 
Dana A, Skarli M, Papakrivopoulou J, Yellon DM. (2000) Adenosine A(1) receptor 
induced delayed preconditioning in rabbits: induction of p38 mitogen-activated 
protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and 
protein kinase C-dependent mechanism. Circ Res. 86(9):989-97. 
Dangel V, Giray J, Ratge D, Wisser H. (1996) Regulation of beta-adrenoceptor 
density and mRNA levels in the rat heart cell-line H9c2. Biochem J. 317 (Pt3):925-
31. 
Dardik R, Inbal A. (2006) Complex formation between tissue transglutaminase II 
(tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed 
mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res. 
312(16):2973-82. 
D'Argenio G, Amoruso DC, Mazzone G, Vitaglione P, Romano A, Ribecco MT, 
D'Armiento MR, Mezza E, Morisco F, Fogliano V, Caporaso N. (2010) Garlic extract 
prevents CCl(4)-induced liver fibrosis in rats: The role of tissue transglutaminase. 
Dig Liver Dis. 42(8):571-7. 
Das T, Baek KJ, Gray C, Im MJ. (1993) Evidence that the Gh protein is a signal 
mediator from alpha 1-adrenoceptor to a phospholipase C. II. Purification and 
characterization of a Gh-coupled 69-kDa phospholipase C and reconstitution of 
alpha 1-adrenoceptor, Gh family, and phospholipase C. J Biol Chem. 
268(36):27398-405. 
Datta S, Antonyak MA, Cerione RA. (2007) GTP-binding-defective forms of tissue 
transglutaminase trigger cell death. Biochemistry. 46(51):14819-29. 
Daubney J, Bonner PL, Hargreaves AJ, Dickenson JM. (2015) Cardioprotective and 
cardiotoxic effects of quercetin and two of its in vivo metabolites on differentiated 
h9c2 cardiomyocytes. Basic Clin Pharmacol Toxicol. 116(2):96-109. 
Davel AP, Brum PC, Rossoni LV. (2014) Isoproterenol induces vascular oxidative 
stress and endothelial dysfunction via a Giα-coupled β2-adrenoceptor signaling 
pathway. PLoS One. 9(3):e91877. 
226 
 
De Bernardi MA, Rabins SJ, Colangelo AM, Brooker G, Mocchetti I. (1996) TrkA 
mediates the nerve growth factor-induced intracellular calcium accumulation. J Biol 
Chem. 271(11):6092-8. 
de Moissac D, Gurevich RM, Zheng H, Singal PK, Kirshenbaum LA. (2000) Caspase 
activation and mitochondrial cytochrome C release during hypoxia-mediated 
apoptosis of adult ventricular myocytes. J Mol Cell Cardiol. 32(1):53-63. 
de Wit RJ, Hekstra D, Jastorff B, Stec WJ, Baraniak J, Van Driel R, Van Haastert PJ. 
(1984) Inhibitory action of certain cyclophosphate derivatives of cAMP on cAMP-
dependent protein kinases. Eur J Biochem. 142(2):255-60. 
Deasey S, Shanmugasundaram S, Nurminskaya M. (2013) Tissue-specific 
responses to loss of transglutaminase 2. Amino Acids. 44(1):179-87. 
Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 
(2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. 
Genome Biol. 4(5):P3. 
Depre C, Taegtmeyer H. (2000) Metabolic aspects of programmed cell survival and 
cell death in the heart. Cardiovasc Res. 45(3):538-48. 
Depre C, Vanoverschelde JL, Taegtmeyer H. (1999) Glucose for the heart. 
Circulation. 99(4):578-88. 
Dessy C, Balligand JL. (2010) Beta3-adrenergic receptors in cardiac and vascular 
tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 59:135-
63.  
Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius 
S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, 
Montori VM, Jacka M, Choi P. (2008) Effects of extended-release metoprolol 
succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised 
controlled trial. Lancet. 371(9627):1839-47. 
Devic E, Xiang Y, Gould D, Kobilka B. (2001) Beta-adrenergic receptor subtype-
specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor 
knockout mice. Mol Pharmacol. 60(3):577-83. 
Devic E, Xiang Y, Gould D, Kobilka B. (2001) Beta-adrenergic receptor subtype-
specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor 
knockout mice. Mol Pharmacol. 60(3):577-83. 
227 
 
Di Lisa F, Menabò R, Canton M, Petronilli V. (1998) The role of mitochondria in the 
salvage and the injury of the ischemic myocardium. Biochim Biophys Acta. 
1366(1-2):69-78. 
Dickenson JM, Blank JL, Hill SJ. (1998) Human adenosine A1 receptor and P2Y2-
purinoceptor-mediated activation of the mitogen-activated protein kinase cascade 
in transfected CHO cells. Br J Pharmacol. 124(7):1491-9. 
Dickenson JM, Camps M, Gierschik P, Hill SJ. (1995) Activation of phospholipase C 
by G-protein beta gamma subunits in DDT1MF-2 cells. Eur J Pharmacol. 
288(3):393-8. 
Dickenson JM, Hill SJ. (1993) Adenosine A1-receptor stimulated increases in 
intracellular calcium in the smooth muscle cell line, DDT1MF-2. Br J Pharmacol. 
108(1):85-92. 
Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. (1996) Tissue 
distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol. 118(6):1461-
8. 
Dobson JG Jr, Fenton RA. (1997) Adenosine A2 receptor function in rat ventricular 
myocytes. Cardiovasc Res. 34(2):337-47. 
Doenst T, Nguyen TD, Abel ED. (2013) Cardiac metabolism in heart failure: 
implications beyond ATP production. Circ Res. 113(6):709-24. 
Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. (2013) 
Functions of S100 proteins. Curr Mol Med. 13(1):24-57. 
Downward J. (1999) How BAD phosphorylation is good for survival. Nat Cell Biol. 
1(2):E33-5. 
Dudek SM, Johnson GV. (1994) Transglutaminase facilitates the formation of 
polymers of the betaamyloid peptide. Brain Res 651:129–133 
Dumaz N, Milne DM, Jardine LJ, Meek DW. (2001) Critical roles for the serine 20, 
but not the serine 15, phosphorylation site and for the polyproline domain in 
regulating p53 turnover. Biochem J. 359(Pt 2):459-64. 
Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta 
K. (2014) Transglutaminase regulation of cell function. Physiol Rev. 94(2):383-417. 
Eckert RL, Sturniolo MT, Broome AM, Ruse M, Rorke EA. (2005) Transglutaminase 
function in epidermis. J Invest Dermatol. 124(3):481-92. 
228 
 
Edinger AL, Thompson CB. (2004) Death by design: apoptosis, necrosis and 
autophagy. Curr Opin Cell Biol. 16(6):663-9. 
Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC 3rd, Núñez G. (1999) ARC 
inhibits cytochrome c release from mitochondria and protects against hypoxia-
induced apoptosis in heart-derived H9c2 cells. Circ Res. 85(12):e70-7. 
Ethier MF, Madison JM. (2006) Adenosine A1 receptors mediate mobilization of 
calcium in human bronchial smooth muscle cells. Am J Respir Cell Mol Biol. 
35(4):496-502. 
Facchiano A, Facchiano F. (2009) Transglutaminases and their substrates in 
biology and human diseases: 50 years of growing. Amino Acids. 36(4):599-614. 
Facchiano F, Facchiano A, Facchiano AM. (2006) The role of transglutaminase-2 
and its substrates in human diseases. Front Biosci. 11:1758-73. 
Fajardo G, Zhao M, Berry G, Wong LJ, Mochly-Rosen D, Bernstein D. (2011) β2-
adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial 
cell death pathways. J Mol Cell Cardiol. 51(5):781-9. 
Fajardo G, Zhao M, Powers J, Bernstein D. (2006) Differential 
cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in 
myocytes and fibroblasts in doxorubicin cardiomyopathy. J Mol Cell Cardiol. 
40(3):375-83. 
Fassina G, de Biasi M, Ragazzi E, Caparrotta L. (1991) Adenosine: a natural 
modulator of L-type calcium channels in atrial myocardium? Pharmacol Res. 
23(4):319-26. 
Faye C, Chautard E, Olsen BR, Ricard-Blum S. (2009) The first draft of the 
endostatin interaction network. J Biol Chem. 284(33):22041-7. 
Faye C, Inforzato A, Bignon M, Hartmann DJ, Muller L, Ballut L, Olsen BR, Day AJ, 
Ricard-Blum S. (2010) Transglutaminase-2: a new endostatin partner in the 
extracellular matrix of endothelial cells. Biochem J. 427(3):467-75.  
Feng JF, Rhee SG, Im MJ. (1996) Evidence that phospholipase delta1 is the 
effector in the Gh (transglutaminase II)-mediated signaling. J Biol Chem. 
271(28):16451-4. 
Fenton RA, Shea LG, Doddi C, Dobson JG Jr. (2010) Myocardial adenosine A(1)-
receptor-mediated adenoprotection involves phospholipase C, PKC-epsilon, and 
p38 MAPK, but not HSP27. Am J Physiol Heart Circ Physiol. 298(6):H1671-8. 
229 
 
Feoktistov I, Biaggioni I. (1997) Adenosine A2B receptors. Pharmacol Rev. 
49(4):381-402. 
Ferdinandy P, Schulz R, Baxter GF. (2007) Interaction of cardiovascular risk factors 
with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. 
Pharmacol Rev. 59(4):418-58. 
Ferrero P, Said M, Sánchez G, Vittone L, Valverde C, Donoso P, Mattiazzi 
A,Mundiña-Weilenmann C. (2007) Ca2+/calmodulin kinase II increases ryanodine 
binding and Ca2+-induced sarcoplasmic reticulum Ca2+ release kinetics during 
beta-adrenergic stimulation. J Mol Cell Cardiol. 43(3):281-91. 
Fésüs L, Szondy Z. (2005) Transglutaminase 2 in the balance of cell death and 
survival. FEBS Lett. 579(15):3297-302. 
Filiano A, Tucholski J, Dolan P, Colak G, Johnson G. (2010) Transglutaminase 2 
protects against ischemic stroke. Neurobiology of disease. 39(3):334-343. 
Filiano AJ, Bailey CD, Tucholski J, Gundemir S, Johnson GV. (2008) 
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and 
attenuates HIF1 signaling. FASEB J. 22(8):2662-75. 
Fliss H, Gattinger D. (1996) Apoptosis in ischemic and reperfused rat myocardium. 
Circ Res. 79(5):949-56. 
Fok JY, Ekmekcioglu S, Mehta K. (2006) Implications of tissue transglutaminase 
expression in malignant melanoma. Mol Cancer Ther. 5(6):1493-503. 
Folk JE. (1983) Mechanism and basis for specificity of transglutaminase-catalyzed 
epsilon-(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol 
Biol. 54:1-56. 
Frank KF, Bölck B, Brixius K, Kranias EG, Schwinger RH. (2002) Modulation of 
SERCA: implications for the failing human heart. Basic Res Cardiol. 97 Suppl 
1:I72-8. 
Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. (2001) International 
Union of Pharmacology. XXV. Nomenclature and classification of adenosine 
receptors. Pharmacol Rev. 53(4):527-52. 
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. (2011) International 
Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification 
of adenosine receptors--an update. Pharmacol Rev. 63(1):1-34. 
230 
 
Fredholm BB. (2014) Adenosine--a physiological or pathophysiological agent? J Mol 
Med(Berl). 92(3):201-6. 
Freissmuth M, Waldhoer M, Bofill-Cardona E, Nanoff C. (1999) G protein 
antagonists. Trends Pharmacol Sci. 20(6):237-45. 
Fretwell L, Dickenson JM. (2009) Role of large-conductance Ca(2+) –activated 
potassium channels in adenosine A(1) receptor-mediated pharmacological 
preconditioning in H9c2 cells. Eur J Pharmacol. 618(1-3):37-44. 
Fretwell L, Dickenson JM. (2011) Role of large-conductance Ca²+-activated K+ 
channels in adenosine A₁ receptor-mediated pharmacological postconditioning in 
H9c2 cells. Can J Physiol Pharmacol. 89(1):24-30. 
Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger 
SM, Stern AM. (1994) Transglutaminase inhibition by 2-[(2-
oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. 
Biochemistry. 33(33):10109-19. 
Freund S, Ungerer M, Lohse MJ. (1994) A1 adenosine receptors expressed in CHO-
cells couple to adenylyl cyclase and to phospholipase C. Naunyn Schmiedebergs 
Arch Pharmacol. 350(1):49-56. 
Fryer RM, Auchampach JA, Gross GJ. (2002) Therapeutic receptor targets of 
ischemic preconditioning. Cardiovasc Res. 55(3):520-5. 
Fryer RM, Pratt PF, Hsu AK, Gross GJ. (2001) Differential activation of extracellular 
signal regulated kinase isoforms in preconditioning and opioid-induced 
cardioprotection. J Pharmacol Exp Ther. 296(2):642-9. 
Fu Q, Chen X, Xiang YK. (2013) Compartmentalization of β-adrenergic signals in 
cardiomyocytes. Trends Cardiovasc Med. 23(7):250-6. 
Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y, Zhang Y, Riehle C, Zhu Y, Rawlings T, Shi Q, 
Clark RB, Chen X, Abel ED, Xiang YK. (2014) Insulin inhibits cardiac contractility by 
inducing a Gi-biased β2-adrenergic signaling in hearts. Diabetes. 63(8):2676-89. 
Galandrin S, Bouvier M. (2006) Distinct signaling profiles of beta1 and beta2 
adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein 
kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 70(5):1575-84. 
Galaz-Montoya M, Wright SJ, Rodriguez GJ, Lichtarge O, Wensel TG. (2017) Beta-2 
Adrenergic Receptor Activation Mobilizes Intracellular Calcium via a Non-Canonical 
231 
 
cAMP-Independent Signaling Pathway. J Biol Chem. pii:jbc.M117.787119. doi: 
10.1074/jbc.M117.787119. [Epub ahead of print]. 
Gao Z, Ni Y, Szabo G, Linden J. (1999) Palmitoylation of the recombinant human 
A1 adenosine receptor: enhanced proteolysis of palmitoylation-deficient mutant 
receptors. Biochem J. 342 ( Pt 2):387-95. 
Gaudry CA, Verderio E, Jones RA, Smith C, Griffin M. (1999) Tissue 
transglutaminase is an important player at the surface of human endothelial cells: 
evidence for its externalization and its colocalization with the beta(1) integrin. Exp 
Cell Res. 252(1):104-13. 
Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. (2004) Functional 
selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: 
evidence for induction of ligand-specific receptor states. Mol Pharmacol. 66(1):97-
105. 
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. (2010) Growing 
epidemic of coronary heart disease in low- and middle-income countries. Curr Probl 
Cardiol. 35(2):72-115. 
Gentile V, Porta R, Chiosi E, Spina A, Valente F, Pezone R, Davies PJ, Alaadik A, 
Illiano G. (1997) tTGase/G alpha h protein expression inhibits adenylate cyclase 
activity in Balb-C 3T3 fibroblasts membranes. Biochim Biophys Acta. 1357(1):115-
22. 
Germack R, Dickenson JM. (2000) Activation of protein kinase B by the A(1)-
adenosine receptor in DDT(1)MF-2 cells. Br J Pharmacol. 130(4):867-74. 
Germack R, Dickenson JM. (2005) Adenosine triggers preconditioning through 
MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat 
cardiomyocytes. J Mol Cell Cardiol. 39(3):429-42. 
Germack R, Dickenson JM. (2004) Characterization of ERK1/2 signalling pathways 
induced by adenosine receptor subtypes in newborn rat cardiomyocytes. Br J 
Pharmacol. 141(2):329-39. 
Germack R, Griffin M, Dickenson JM. (2004) Activation of protein kinase B by 
adenosine A1 and A3 receptors in newborn rat cardiomyocytes. J Mol Cell Cardiol. 
37(5):989-99. 
Gerwins P, Fredholm BB. (1995) Activation of adenosine A1 and bradykinin 
receptors increases protein kinase C and phospholipase D activity in smooth 
muscle cells. Naunyn Schmiedebergs Arch Pharmacol. 351(2):186-93. 
232 
 
Gesek FA. (1996) Alpha 2-adrenergic receptors activate phospholipase C in renal 
epithelial cells. Mol Pharmacol. 50(2):407-14. 
Glynn Dennis Jr., Brad T. Sherman, Douglas A. Hosack, Jun Yang, Michael W. 
Baseler, H. Clifford Lane, Richard A. Lempicki.  DAVID: Database for Annotation, 
Visualization, and Integrated Discovery. Genome Biology 2003 4(5): P3. 
Goddard AD, Watts A. (2012) Regulation of G protein-coupled receptors by 
palmitoylation and cholesterol. BMC Biol. 10:27. 
Goldsmith ZG, Dhanasekaran DN. (2007) G protein regulation of MAPK networks. 
Oncogene. 26(22):3122-42. 
Golitsina NL, Kordowska J, Wang CL, Lehrer SS. (1996) Ca2+-dependent binding 
of calcyclin to muscle tropomyosin. Biochem Biophys Res Commun.220(2):360-5. 
Gomis R, Sener A, Malaisse-Lagae F, Malaisse WJ. (1983) Transglutaminase 
activity in pancreatic islets. Biochim Biophys Acta. 760(3):384-8. 
Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. (1994) Reperfusion 
injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 94(4):1621-8. 
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. (2001) Inhibition 
of early apoptotic events by Akt/PKB is dependent on the first committed step of 
glycolysis and mitochondrial hexokinase. Genes Dev. 15(11):1406-18. 
Granneman JG. (2001) The putative beta4-adrenergic receptor is a novel state of 
the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab. 280(2):E199-202. 
Gregg CJ, Steppan J, Gonzalez DR, Champion HC, Phan AC, Nyhan D, Shoukas AA, 
Hare JM, Barouch LA, Berkowitz DE. (2010) β2-adrenergic receptor-coupled 
phosphoinositide 3-kinase constrains cAMP-dependent increases in cardiac inotropy 
through phosphodiesterase 4 activation. Anesth Analg. 111(4):870-7. 
Grenard P, Bates MK, Aeschlimann D. (2001) Evolution of transglutaminase genes: 
identification of a transglutaminase gene cluster on human chromosome 
15q15.Structure of the gene encoding transglutaminase X and a novel gene family 
member, transglutaminase Z. J Biol Chem. 276(35):33066-78. 
Griffin M, Casadio R, Bergamini CM. (2002) Transglutaminases: nature's biological 
glues. Biochem J. 368(Pt 2):377-96. 
233 
 
Gross SR, Balklava Z, Griffin M. (2003) Importance of tissue transglutaminase in 
repair of extracellular matrices and cell death of dermal fibroblasts after exposure 
to a solarium ultraviolet A source. J Invest Dermatol. 121(2):412-23. 
Grosso H, Mouradian MM. (2012) Transglutaminase 2: biology, relevance to 
neurodegenerative diseases and therapeutic implications. Pharmacol Ther. 
133(3):392-410. 
Guan WJ, Xia KD, Ma YT, Liu YT, Shi YT, Jiang H, Shen L, Xia K, Li JD, Tang BS, 
Wang JL. (2013) Transglutaminase 6 interacts with polyQ proteins and promotes 
the formation of polyQ aggregates. Biochem Biophys Res Commun. 437(1):94-
100. 
Guimarães S, Moura D. (2001) Vascular adrenoceptors: an update. Pharmacol Rev. 
53(2):319-56. 
Gundemir S, Colak G, Feola J, Blouin R, Johnson GV. (2013) Transglutaminase 2 
facilitates or ameliorates HIF signaling and ischemic cell death depending on its 
conformation and localization. Biochim Biophys Acta. 1833(1):1-10. 
Gundemir S, Colak G, Tucholski J, Johnson GV. (2012) Transglutaminase 2: a 
molecular Swiss army knife. Biochim Biophys Acta. 1823(2):406-19. 
Gundlfinger A, Bischofberger J, Johenning FW, Torvinen M, Schmitz D, Breustedt J. 
(2007) Adenosine modulates transmission at the hippocampal mossy fibre synapse 
via direct inhibition of presynaptic calcium channels. J Physiol. 582(Pt1):263-77. 
Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone 
J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, 
Polakiewicz RD, Comb MJ. (2008) Signaling networks assembled by oncogenic 
EGFR and c-Met. Proc Natl Acad Sci U S A. 105(2):692-7. 
Halestrap AP, Richardson AP. (2015) The mitochondrial permeability transition: a 
current perspective on its identity and role in ischaemia/reperfusion injury. J Mol 
Cell Cardiol. 78:129-41. 
Han JA, Park SC. (2000) Transglutaminase-dependent modulation of transcription 
factor Sp1 activity. Mol Cells. 10(6):612-8. 
Han XJ, Chae JK, Lee MJ, You KR, Lee BH, Kim DG. (2005) Involvement of 
GADD153 and cardiac ankyrin repeat protein in hypoxia-induced apoptosis of H9c2 
cells. J Biol Chem. 280(24):23122-9. 
234 
 
Hansen PR. (1995) Role of neutrophils in myocardial ischemia and reperfusion. 
Circulation. 91(6):1872-85. 
Hansson T, Ulfgren AK, Lindroos E, DannAEus A, Dahlbom I, Klareskog L. (2002) 
Transforming growth factor-beta (TGF-beta) and tissue transglutaminase 
expression in the small intestine in children with coeliac disease. Scand J Immunol. 
56(5):530-7. 
Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS. (1999) Tissue 
transglutaminase is expressed, active, and directly involved in rat dermal wound 
healing and angiogenesis. FASEB J. 13(13):1787-95. 
Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, Li Z, Walz T. (2008) 
Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are 
protease-resistant and inhibit long-term potentiation. J Biol Chem. 
283(24):16790-800. 
Hartzell HC, Fischmeister R. (1992) Direct regulation of cardiac Ca2+ channels by 
G proteins: neither proven nor necessary? Trends Pharmacol Sci. 13(10):380-5. 
Hartzell HC, Méry PF, Fischmeister R, Szabo G. (1991) Sympathetic regulation of 
cardiac calcium current is due exclusively to cAMP-dependent phosphorylation. 
Nature. 351(6327):573-6. 
Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, Kikuchi M, Sato Y, Saito 
Y. (2003) A novel function of tissue-type transglutaminase: protein disulphide 
isomerase. Biochem J. 373(Pt 3):793-803. 
Haskó G, Pacher P. (2012) Regulation of macrophage function by adenosine. 
Arterioscler Thromb Vasc Biol. 32(4):865-9. 
Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. (2005) Ischemic preconditioning 
protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ 
Physiol. 288(2):H971-6. 
Hausenloy DJ, Tsang A, Yellon DM. (2005) The reperfusion injury salvage kinase 
pathway: a common target for both ischemic preconditioning and postconditioning. 
Trends Cardiovasc Med. 15(2):69-75. 
Hausenloy DJ, Yellon DM. (2006) Survival kinases in ischemic preconditioning and 
postconditioning. Cardiovasc Res. 70(2):240-53. 
Head BP, Patel HH, Roth DM, Lai NC, Niesman IR, Farquhar MG, Insel PA. (2005) 
G-protein-coupled receptor signaling components localize in both sarcolemmal and 
235 
 
intracellular caveolin-3-associated microdomains in adult cardiac myocytes. J Biol 
Chem. 280(35):31036-44. 
Head BP, Patel HH, Roth DM, Murray F, Swaney JS, Niesman IR, Farquhar MG, 
Insel PA. (2006) Microtubules and actin microfilaments regulate lipid raft/caveolae 
localization of adenylyl cyclase signaling components. J Biol Chem. 
281(36):26391-9. 
Headrick JP, Ashton KJ, Rose'meyer RB, Peart JN. (2013) Cardiovascular adenosine 
receptors: expression, actions and interactions. Pharmacol Ther. 140(1):92-111. 
Headrick JP, Peart JN, Reichelt ME, Haseler LJ. (2011) Adenosine and its receptors 
in the heart: regulation, retaliation and adaptation. Biochim Biophys Acta. 
1808(5):1413-28. 
Headrick JP. (1996) Ischemic preconditioning: bioenergetic and metabolic changes 
and the role of endogenous adenosine. J Mol Cell Cardiol. 28(6):1227-40. 
Hegde A, Strachan RT, Walker JK. (2015) Quantification of beta adrenergic 
receptor subtypes in beta-arrestin knockout mouse airways. PLoS One. 
10(2):e0116458. 
Heifetz A, James T, Morao I, Bodkin MJ, Biggin PC. (2016) Guiding lead 
optimization with GPCR structure modeling and molecular dynamics. Curr Opin 
Pharmacol. 30:14-21. 
Hein TW, Wang W, Zoghi B, Muthuchamy M, Kuo L. (2001) Functional and 
molecular characterization of receptor subtypes mediating coronary microvascular 
dilation to adenosine. J Mol Cell Cardiol. 33(2):271-82. 
Hemmings BA, Restuccia DF. (2012) PI3K-PKB/Akt pathway. Cold Spring Harb 
Perspect Biol. 4(9):a011189. 
Herrera R, Sebolt-Leopold JS. (2002) Unraveling the complexities of the Raf/MAP 
kinase pathway for pharmacological intervention. Trends Mol Med. 8(4Suppl):S27-
31. 
Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. (1991) 
Morphological, biochemical, and electrophysiological characterization of a clonal 
cell (H9c2) line from rat heart. Circ Res. 69(6):1476-86. 
Heubach JF, Blaschke M, Harding SE, Ravens U, Kaumann AJ. (2003) 
Cardiostimulant and cardiodepressant effects through overexpressed human 
236 
 
beta2-adrenoceptors in murine heart: regional differences and functional role of 
beta1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 367(4):380-90. 
Hillenbrand M, Schori C, Schöppe J, Plückthun A. (2015) Comprehensive analysis 
of heterotrimeric G-protein complex diversity and their interactions with GPCRs in 
solution. Proc Natl Acad Sci U S A. 112(11):E1181-90. 
Hochhauser E, Leshem D, Kaminski O, Cheporko Y, Vidne BA, Shainberg A. (2007) 
The protective effect of prior ischemia reperfusion adenosine A1 or A3 receptor 
activation in the normal and hypertrophied heart. Interact Cardiovasc Thorac Surg. 
6(3):363-8. 
Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA. (2006) Quantitative 
phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 
phosphorylation at two sites. Proc Natl Acad Sci U S A. 103(18):7159-64. 
Hoffner G, Djian P. (2005) Transglutaminase and diseases of the central nervous 
system. Front Biosci. 10:3078-92. 
Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, 
Thomas WG. (2002) Side-chain substitutions within angiotensin II reveal different 
requirements for signaling, internalization, and phosphorylation of type 1A 
angiotensin receptors. Mol Pharmacol. 61(4):768-77. 
Hothi SS, Gurung IS, Heathcote JC, Zhang Y, Booth SW, Skepper JN, Grace AA, 
Huang CL. (2008) Epac activation, altered calcium homeostasis and ventricular 
arrhythmogenesis in the murine heart. Pflugers Arch. 457(2):253-70. 
Hsu TC, Huang CY, Chiang SY, Lai WX, Tsai CH, Tzang BS. (2008) 
Transglutaminase inhibitor cystamine alleviates the abnormality in liver from 
NZB/W F1 mice. Eur J Pharmacol. 579(1-3):382-9.  
Hu L, Wang J, Zhu H, Wu X, Zhou L, Song Y, Zhu S, Hao M, Liu C, Fan Y, Wang Y, 
Li Q. (2016) Ischemic postconditioning protects the heart against ischemia-
reperfusion injury via neuronal nitric oxide synthase in the sarcoplasmic reticulum 
and mitochondria. Cell Death Dis. 7:e2222. 
Huang da W, Sherman BT, Lempicki RA. (2009) Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. Nucleic 
Acids Res. 37(1):1-13. 
Huang da W, Sherman BT, Lempicki RA. (2009) Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 
4(1):44-57. 
237 
 
Huang Q, Yang L, Luo J, Guo L, Wang Z, Yang X, Jin W, Fang Y, Ye J, Shan B, 
Zhang Y. (2015) SWATH enables precise label-free quantification on proteome 
scale. Proteomics. 15(7):1215-23. 
Huang YC, Wei KC, Chang CN, Chen PY, Hsu PW, Chen CP, Lu CS, Wang HL, 
Gutmann DH, Yeh TH. (2014) Transglutaminase 2 expression is increased as a 
function of malignancy grade and negatively regulates cell growth in meningioma. 
PLoS One. 9(9):e108228. 
Huang, L., Xu, A.-M., & Liu, W. (2015). Transglutaminase 2 in cancer. American 
Journal of Cancer Research. 5(9), 2756–2776. 
Hulme JT, Westenbroek RE, Scheuer T, Catterall WA. (2006) Phosphorylation of 
serine 1928 in the distal C-terminal domain of cardiac CaV1.2 channels during 
beta1-adrenergic regulation. Proc Natl Acad Sci U S A. 103(44):16574-9. 
Hunter T. (1995) When is a lipid kinase not a lipid kinase? When it is a protein 
kinase. Cell. 83(1):1-4. 
Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, 
Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta 
K, Sood AK. (2008) Clinical and biological significance of tissue transglutaminase in 
ovarian carcinoma. Cancer Res. 68(14):5849-58. 
Hwang KC, Gray CD, Sivasubramanian N, Im MJ. (1995) Interaction site of GTP 
binding Gh (transglutaminase II) with phospholipase C. J Biol Chem. 
270(45):27058-62. 
Ichikawa A, Ishizaki J, Morita M, Tanaka K, Ikura K. (2008) Identification of new 
amine acceptor protein substrate candidates of transglutaminase in rat liver 
extract: use of 5-(biotinamido) pentylamine as a probe. Biosci Biotechnol Biochem. 
72(4):1056-62. 
Iismaa SE, Aplin M, Holman S, Yiu TW, Jackson K, Burchfield JG, Mitchell CJ, 
O'Reilly L, Davenport A, Cantley J, Schmitz-Peiffer C, Biden TJ, Cooney GJ, Graham 
RM. (2013) Glucose homeostasis in mice is transglutaminase 2 independent. PLoS 
One. 8(5):e63346. 
Iismaa SE, Graham RM. (2003) Dissecting cardiac hypertrophy and signaling 
pathways: evidence for an interaction between multifunctional g proteins and 
prostanoids. Circ Res. 92(10):1059-61. 
238 
 
Iismaa SE, Mearns BM, Lorand L, Graham RM. (2009) Transglutaminases and 
disease: lessons from genetically engineered mouse models and inherited 
disorders. Physiol Rev. 89(3):991-1023. 
Im MJ, Graham RM. (1990) A novel guanine nucleotide-binding protein coupled to 
the alpha 1-adrenergic receptor. I. Identification by photolabeling or membrane 
and ternary complex preparation. J Biol Chem. 265(31):18944-51. 
Im MJ, Riek RP, Graham RM. (1990) A novel guanine nucleotide-binding protein 
coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and 
reconstitution. J Biol Chem. 265(31):18952-60. 
Imami K, Sugiyama N, Kyono Y, Tomita M, Ishihama Y. (2008) Automated 
phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS 
using a calcined titania/C18 biphasic column. Anal Sci. 24(1):161-6. 
Imhof A, Wolffe AP. (1999) Purification and properties of the Xenopus Hat1 
acetyltransferase: association with the 14-3-3 proteins in the oocyte nucleus. 
Biochemistry. 38(40):13085-93. 
Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, 
Murphy E, Mochly-Rosen D. (2003) Inhibition of delta-protein kinase C protects 
against reperfusion injury of the ischemic heart in vivo. Circulation. 108(19):2304-
7. 
Insel PA, Snead A, Murray F, Zhang L, Yokouchi H, Katakia T, Kwon O, Dimucci D, 
Wilderman A. (2012) GPCR expression in tissues and cells: are the optimal 
receptors being used as drug targets? Br J Pharmacol. 165(6):1613-6. 
Ito K, Nakazato T, Yamato K, Miyakawa Y, Yamada T, Hozumi N, Segawa K, Ikeda, 
Y, Kizaki M. (2004) Induction of apoptosis in leukemic cells by homovanillic acid 
derivative, capsaicin, through oxidative stress: implication of phosphorylation of 
p53 at Ser-15 residue by reactive oxygen species. Cancer Res. 64(3):1071-8. 
Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura M, Jie T, Ito K. 
(1995) DNA fragmentation of human infarcted myocardial cells demonstrated by 
the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol. 
146(6):1325-31. 
Itoh H, Gilman AG. (1991) Expression and analysis of Gs alpha mutants with 
decreased ability to activate adenylylcyclase. J Biol Chem. 266(24):16226-31. 
Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJ. (2009) 
Transglutaminases and neurodegeneration. J Neurochem. 109 Suppl 1:160-6. 
239 
 
Jensen BC, O'Connell TD, Simpson PC. (2011) Alpha-1-adrenergic receptors: 
targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 51(4):518-28. 
Jiang WG, Ye L, Sanders AJ, Ruge F, Kynaston HG, Ablin RJ, Mason MD. (2013) 
Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate 
cancer cells to extracellular matrix, the potential role of TGase-core domain. J 
Transl Med. 11:269. 
Jockers R, Linder ME, Hohenegger M, Nanoff C, Bertin B, Strosberg AD, Marullo S, 
Freissmuth M. (1994) Species difference in the G protein selectivity of the human 
and bovine A1-adenosine receptor. J Biol Chem. 269(51):32077-84. 
Johnson K, Hashimoto S, Lotz M, Pritzker K, Terkeltaub R. (2001) Interleukin-1 
induces pro-mineralizing activity of cartilage tissue transglutaminase and factor 
XIIIa. Am J Pathol. 159(1):149-63. 
Johnson TS, Knight CR, el-Alaoui S, Mian S, Rees RC, Gentile V, Davies PJ, Griffin 
M. (1994) Transfection of tissue transglutaminase into a highly malignant hamster 
fibrosarcoma leads to a reduced incidence of primary tumour growth. Oncogene. 
9(10):2935-42. 
Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, Griffin M. (2006) 
Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis 
and tumor growth. Cell Death Differ. 13(9):1442-53. 
Jones RA, Nicholas B, Mian S, Davies PJ, Griffin M. (1997) Reduced expression of 
tissue transglutaminase in a human endothelial cell line leads to changes in cell 
spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci. 110 
(Pt 19):2461-72. 
Jordan JE, Zhao ZQ, Vinten-Johansen J. (1999) The role of neutrophils in 
myocardial ischemia-reperfusion injury. Cardiovasc Res. 43(4):860-78. 
Jost P, Fasshauer M, Kahn CR, Benito M, Meyer M, Ott V, Lowell BB, Klein HH, 
Klein J. (2002) Atypical beta-adrenergic effects on insulin signaling and action in 
beta(3)-adrenoceptor-deficient brown adipocytes. Am J Physiol Endocrinol Metab. 
283(1):E146-53. 
Jung SM, Jandu S, Steppan J, Belkin A, An SS, Pak A, Choi EY, Nyhan D, Butlin M, 
Viegas K, Avolio A, Berkowitz DE, Santhanam L. (2013) Increased tissue 
transglutaminase activity contributes to central vascular stiffness in eNOS 
knockout mice. Am J Physiol Heart Circ Physiol. 305(6):H803-10. 
240 
 
Kalfa TA, Connor JA, Begtrup AH. EPB42-Related Hereditary Spherocytosis. 2014 
Mar 13 [updated 2016 Nov 10]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, 
Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens 
K,editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, 
Seattle; 1993-2017. Available from 
http://www.ncbi.nlm.nih.gov/books/NBK190102/ 
Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, 
Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE. (2000) 
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl 
J Med. 343(23):1688-96. 
Kamp TJ, Hell JW. (2000) Regulation of cardiac L-type calcium channels by protein 
kinase A and protein kinase C. Circ Res. 87(12):1095-102. 
Kanchan K, Fuxreiter M, Fésüs L. (2015) Physiological, pathological, and structural 
implications of non-enzymatic protein-protein interactions of the multifunctional 
human transglutaminase 2. Cell Mol Life Sci. 72(16):3009-35. 
Kang SK, Kim DK, Damron DS, Baek KJ, Im MJ. (2002) Modulation of intracellular 
Ca(2+) via alpha(1B)-adrenoreceptor signaling molecules, G alpha(h) 
(transglutaminase II) and phospholipase C-delta 1. Biochem Biophys Res Commun. 
293(1):383-90. 
Kang SK, Yi KS, Kwon NS, Park KH, Kim UH, Baek KJ, Im MJ. (2004) Alpha1B-
adrenoceptor signaling and cell motility: GTPase function of Gh/transglutaminase 2 
inhibits cell migration through interaction with cytoplasmic tail of integrin alpha 
subunits. J Biol Chem. 279(35):36593-600. 
Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, 
Steinman L. (2002) Prolonged survival and decreased abnormal movements in 
transgenic model of Huntington disease, with administration of the 
transglutaminase inhibitor cystamine. Nat Med. 8(2):143-9. 
Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L. (1999) 
Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its 
enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad 
Sci U S A. 96(13):7388-93. 
Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M, Murakata C, 
Sato A, Kaneko M. (1987) K-252 compounds, novel and potent inhibitors of protein 
kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res 
Commun. 142(2):436-40. 
241 
 
Katritch V, Cherezov V, Stevens RC. (2013) Structure-function of the G protein-
coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 53:531-56. 
Katz AM. (1970) Contractile proteins of the heart. Physiol Rev. 50(1):63-158. 
Kaumann A, Bartel S, Molenaar P, Sanders L, Burrell K, Vetter D, Hempel P, 
Karczewski P, Krause EG. (1999) Activation of beta2-adrenergic receptors hastens 
relaxation and mediates phosphorylation of phospholamban, troponin I, and C-
protein in ventricular myocardium from patients with terminal heart failure. 
Circulation. 99(1):65-72. 
Kaumann AJ, Molenaar P. (1997) Modulation of human cardiac function through 4 
beta-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol. 
355(6):667-81. 
Kaumann AJ, Sanders L. (1993) Both beta 1- and beta 2-adrenoceptors mediate 
catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn 
Schmiedebergs Arch Pharmacol. 348(5):536-40. 
Kelsen SG, Anakwe OO, Aksoy MO, Reddy PJ, Dhanesekaran N, Penn R, Benovic JL. 
(1997) Chronic effects of catecholamines on the beta 2-adrenoreceptor system in 
cultured human airway epithelial cells. Am J Physiol. 272(5 Pt 1):L916-24. 
Kenakin T, Christopoulos A. (2013) Signalling bias in new drug discovery: 
detection, quantification and therapeutic impact. Nat Rev Drug Discov. 12(3):205-
16. 
Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S. (2012) A simple 
method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci. 
3(3):193-203. 
Kenakin T. (2009) Biased agonism. F1000 Biol Rep. 1:87. 
Kenakin T. (2007) Functional selectivity through protean and biased agonism: who 
steers the ship? Mol Pharmacol. 72(6):1393-401. 
Kersten JR, Orth KG, Pagel PS, Mei DA, Gross GJ, Warltier DC. (1997) Role of 
adenosine in isoflurane-induced cardioprotection. Anesthesiology. 86(5):1128-39. 
Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. 
(2011) Quantitative phosphoproteomics identifies substrates and functional 
modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal. 
4(179):rs5. 
242 
 
Khaliulin I, Bond M, James AF, Dyar Z, Amini R, Johnson JL, Suleiman MS. (2017) 
Functional and cardioprotective effects of simultaneous and individual activation of 
protein kinase A and Epac. Br J Pharmacol. 174(6):438-453. 
Kim SJ, Peppas A, Hong SK, Yang G, Huang Y, Diaz G, Sadoshima J, Vatner DE, 
Vatner SF. (2003) Persistent stunning induces myocardial hibernation and 
protection:flow/function and metabolic mechanisms. Circ Res. 92(11):1233-9. 
Kim SY, Grant P, Lee JH, Pant HC, Steinert PM. (1999) Differential expression of 
multiple transglutaminases in human brain. Increased expression and cross-linking 
by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem. 
274(43):30715-21. 
Kimes BW, Brandt BL. (1976) Properties of a clonal muscle cell line from rat heart. 
Exp Cell Res. 98(2):367-81. 
Kingwell K. (2016) Receptor pharmacology: The many faces of G protein-coupled 
receptors. Nat Rev Drug Discov. 15(9):602-3. 
Király R, Demény M, Fésüs L. (2011) Protein transamidation by transglutaminase 2 
in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J. 
278(24):4717-39. 
Kojima S, Kuo TF, Tatsukawa H, Hirose S. (2010) Induction of cross-linking and 
silencing of Sp1 by transglutaminase during liver injury in ASH and NASH via 
different ER stress pathways. Dig Dis. 28(6):715-21. 
Kolwicz SC Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. 
(2012) Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic 
remodeling during pressure-overload hypertrophy. Circ Res. 111(6):728-38. 
Kolwicz SC Jr, Purohit S, Tian R. (2013) Cardiac metabolism and its interactions 
with contraction, growth, and survival of cardiomyocytes. Circ Res. 113(5):603-16. 
Kong L, Korthuis RJ. (1997) Melanoma cell adhesion to injured arterioles: 
mechanisms of stabilized tethering. Clin Exp Metastasis. 15(4):426-31. 
Konkar AA, Zhai Y, Granneman JG. (2000) beta1-adrenergic receptors mediate 
beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol 
Pharmacol. 57(2):252-8. 
Korge P, Ping P, Weiss JN. (2008) Reactive oxygen species production in energized 
cardiac mitochondria during hypoxia/reoxygenation: modulation by nitric oxide. 
Circ Res. 103(8):873-80. 
243 
 
Kozłowska H, Szymska U, Schlicker E, Malinowska B. (2003) Atypical beta-
adrenoceptors, different from beta 3-adrenoceptors and probably from the low-
affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery. Br J 
Pharmacol. 140(1):3-12. 
Kranias EG, Hajjar RJ. (2012) Modulation of cardiac contractility by the 
phospholamban/SERCA2a regulatome. Circ Res. 110(12):1646-60. 
Krasnikov BF, Kim SY, McConoughey SJ, Ryu H, Xu H, Stavrovskaya I, Iismaa SE, 
Mearns BM, Ratan RR, Blass JP, Gibson GE, Cooper AJ. (2005) Transglutaminase 
activity is present in highly purified nonsynaptosomal mouse brain and liver 
mitochondria. Biochemistry. 44(21):7830-43. 
Kudo M, Wang Y, Xu M, Ayub A, Ashraf M. (2002) Adenosine A(1) receptor 
mediates late preconditioning via activation of PKC-delta signaling pathway. Am J 
Physiol Heart Circ Physiol. 283(1):H296-301.  
Kull B, Svenningsson P, Fredholm BB. (2000) Adenosine A(2A) receptors are 
colocalized with and activate g(olf) in rat striatum. Mol Pharmacol. 58(4):771-7. 
Kuncio GS, Tsyganskaya M, Zhu J, Liu SL, Nagy L, Thomazy V, Davies PJ, Zern MA. 
(1998) TNF-alpha modulates expression of the tissue transglutaminase gene in 
liver cells. Am J Physiol. 274(2 Pt 1):G240-5.  
Kuno A, Critz SD, Cui L, Solodushko V, Yang XM, Krahn T, Albrecht B, Philipp S, 
Cohen MV, Downey JM. (2007) Protein kinase C protects preconditioned rabbit 
hearts by increasing sensitivity of adenosine A2b-dependent signaling during early 
reperfusion. J Mol Cell Cardiol. 43(3):262-71. 
Kuo TF, Tatsukawa H, Matsuura T, Nagatsuma K, Hirose S, Kojima S. (2012) Free 
fatty acids induce transglutaminase 2-dependent apoptosis in hepatocytes via ER 
stress-stimulated PERK pathways. J Cell Physiol. 227(3):1130-7. 
Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen Y, Lakatta EG, Xiao RP. (1999) G(i) 
protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic 
signaling. J Biol Chem. 274(31):22048-52. 
Kuschel M, Zhou YY, Spurgeon HA, Bartel S, Karczewski P, Zhang SJ, Krause EG, 
Lakatta EG, Xiao RP. (1999) beta2-adrenergic cAMP signaling is uncoupled from 
phosphorylation of cytoplasmic proteins in canine heart. Circulation. 99(18):2458-
65. 
Kuznetsov V, Pak E, Robinson RB, Steinberg SF. (1995) Beta 2-adrenergic receptor 
actions in neonatal and adult rat ventricular myocytes. Circ Res. 76(1):40-52. 
244 
 
Kuznetsov AV, Javadov S, Sickinger S, Frotschnig S, Grimm M. (2015) H9c2 and 
HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial 
function and sensitivity to hypoxia-reoxygenation. Biochim Biophys Acta. 
1853(2):276-84. 
Lader AS, Xiao YF, Ishikawa Y, Cui Y, Vatner DE, Vatner SF, Homcy CJ, Cantiello 
HF. (1998) Cardiac Gsalpha overexpression enhances L-type calcium channels 
through an adenylyl cyclase independent pathway. Proc Natl Acad Sci U S A. 
95(16):9669-74. 
Laemmli UK, Mölbert E, Showe M, Kellenberger E. (1970) Form-determining 
function of the genes required for the assembly of the head of bacteriophage T4. J 
Mol Biol. 49(1):99-113. 
Lai TS, Bielawska A, Peoples KA, Hannun YA, Greenberg CS. (1997) 
Sphingosylphosphocholine reduces the calcium ion requirement for activating 
tissue transglutaminase. J Biol Chem. 272(26):16295-300. 
Lai TS, Greenberg CS. (2013) TGM2 and implications for human disease: role of 
alternative splicing. Front Biosci (Landmark Ed). 18:504-19.  
Lambert JP, Ivosev G, Couzens AL, Larsen B, Taipale M, Lin ZY, Zhong Q, Lindquist 
S, Vidal M, Aebersold R, Pawson T, Bonner R, Tate S, Gingras AC. (2013) Mapping 
differential interactomes by affinity purification coupled with data-independent 
mass spectrometry acquisition. Nat Methods. 10(12):1239-45. 
Lange M, Smul TM, Blomeyer CA, Redel A, Klotz KN, Roewer N, Kehl F. (2006) Role 
of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning 
against myocardial infarction in the rabbit heart in vivo. Anesthesiology. 
105(3):503-10. 
Leblais V, Jo SH, Chakir K, Maltsev V, Zheng M, Crow MT, Wang W, Lakatta EG, 
Xiao RP. (2004) Phosphatidylinositol 3-kinase offsets cAMP-mediated positive 
inotropic effect via inhibiting Ca2+ influx in cardiomyocytes. Circ Res. 
95(12):1183-90. 
Lee KH, Lee N, Lim S, Jung H, Ko YG, Park HY, Jang Y, Lee H, Hwang KC. (2003) 
Calreticulin inhibits the MEK1,2-ERK1,2 pathway in alpha 1-adrenergic 
receptor/Gh-stimulated hypertrophy of neonatal rat cardiomyocytes. J Steroid 
Biochem Mol Biol. 84(1):101-7. 
Lee KN, Arnold SA, Birckbichler PJ, Patterson MK Jr, Fraij BM, Takeuchi Y, Carter 
HA. (1993) Site-directed mutagenesis of human tissue transglutaminase: Cys-277 
245 
 
is essential for transglutaminase activity but not for GTPase activity. Biochim 
Biophys Acta. 1202(1):1-6. 
Lee MY, Chung S, Bang HW, Baek KJ, Uhm D. (1997) Modulation of large 
conductance Ca2+-activated K+ channel by Galphah (transglutaminase II) in the 
vascular smooth muscle cell. Pflugers Arch. 433(5):671-3. 
Lerner A, Neidhöfer S, Matthias T (2015) Transglutaminase 2 and Anti 
Transglutaminase 2 Autoantibodies in Celiac Disease and Beyond: Anti- 
Transglutaminase 2 Autoantibodies: Friends or Enemies. Immunome Res 11: 100. 
Lewis CJ, Gong H, Brown MJ, Harding SE. (2004) Overexpression of beta 1-
adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A 
cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology. Br 
J Pharmacol. 141(5):813-24. 
Lewis TE, Milam TD, Klingler DW, Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji 
KC. (2005) Tissue transglutaminase interacts with protein kinase A anchor protein 
13 in prostate cancer. Urol Oncol. 23(6):407-12. 
Li J, Bai C, Guo J, Liang W, Long J. (2017) NDUFA4L2 protects against 
ischaemia/reperfusion-induced cardiomyocyte apoptosis and mitochondrial 
dysfunction by inhibiting complex I. Clin Exp Pharmacol Physiol. 44(7):779-786. 
Li DY, Tao L, Liu H, Christopher TA, Lopez BL, Ma XL. (2006) Role of ERK1/2 in the 
anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia 
and reperfusion. Apoptosis. 11(6):923-30. 
Li F, Zhang J, Cao X, Wang L, Li D, Song S, Ye B, Fan C. (2009) Adenosine 
detection by using gold nanoparticles and designed aptamer sequences. Analyst. 
134(7):1355-60. 
Li X, Wei XL, Meng LL, Chi MG, Yan JQ, Ma XY, Jia YS, Liang L, Yan HT, Zheng JQ. 
(2009) Involvement of tissue transglutaminase in endothelin 1-induced 
hypertrophy in cultured neonatal rat cardiomyocytes. Hypertension. 54(4):839-44. 
Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, Cheng H, Wang Y, Xiao 
RP. (2002) p38 Mitogen-activated protein kinase mediates a negative inotropic 
effect in cardiac myocytes. Circ Res. 90(2):190-6.  
Lilley GR, Skill J, Griffin M, Bonner PL. (1998) Detection of Ca2+-dependent 
transglutaminase activity in root and leaf tissue of monocotyledonous and 
dicotyledonous plants. Plant Physiol. 117(3):1115-23. 
246 
 
Linden J, Thai T, Figler H, Jin X, Robeva AS. (1999) Characterization of human 
A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to 
G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 
56(4):705-13. 
Linden J. (1994) Cloned adenosine A3 receptors: pharmacological properties, 
species differences and receptor functions. Trends Pharmacol Sci. 15(8):298-306. 
Linden J. (2001) Molecular approach to adenosine receptors: receptor-mediated 
mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 41:775-87. 
Lindsay MA, Bungay PJ, Griffin M. (1990) Transglutaminase involvement in the 
secretion of insulin from electropermeabilised rat islets of Langerhans. Biosci Rep. 
10(6):557-61. 
Liu GS, Cohen MV, Mochly-Rosen D, Downey JM. (1999) Protein kinase C-epsilon is 
responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol 
Cell Cardiol. 31(10):1937-48. 
Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. (1991) 
Protection against infarction afforded by preconditioning is mediated by A1 
adenosine receptors in rabbit heart. Circulation. 84(1):350-6. 
Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. (2012) Biased signalling 
pathways in β2-adrenergic receptor characterized by 19F-NMR. Science. 
335(6072):1106-10. 
Liu Q, Hofmann PA. (2003) Modulation of protein phosphatase 2a by adenosine A1 
receptors in cardiomyocytes: role for p38 MAPK. Am J Physiol Heart Circ Physiol. 
285(1):H97-103. 
Liu R, Ramani B, Soto D, De Arcangelis V, Xiang Y. (2009) Agonist dose-dependent 
phosphorylation by protein kinase A and G protein-coupled receptor kinase 
regulates beta2 adrenoceptor coupling to G(i) proteins in cardiomyocytes. J Biol 
Chem. 284(47):32279-87. 
Liu J, Sui H, Zhao J, Wang Y. (2017) Osmotin Protects H9c2 Cells from Simulated 
Ischemia-Reperfusion Injury through AdipoR1/PI3K/AKT Signaling Pathway. Front 
Physiol. 8:611. 
Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. (1999) Ischemic 
preconditioning and the beta-adrenergic signal transduction pathway. Circulation. 
100(9):958-66. 
247 
 
Long X, Boluyt MO, Hipolito ML, Lundberg MS, Zheng JS, O'Neill L, Cirielli C, 
Lakatta EG, Crow MT. (1997) p53 and the hypoxia-induced apoptosis of cultured 
neonatal rat cardiac myocytes. J Clin Invest. 99(11):2635-43. 
López-Neblina F, Toledo-Pereyra LH. (2006) Phosphoregulation of signal 
transduction pathways in ischemia and reperfusion. J Surg Res. 134(2):292-9. 
Lorand L, Conrad SM. (1984) Transglutaminases. Mol Cell Biochem. 58(1-2):9-35. 
Lorand L, Graham RM. (2003) Transglutaminases: crosslinking enzymes with 
pleiotropic functions. Nat Rev Mol Cell Biol. 4(2):140-56.  
Lundby A, Secher A, Lage K, Nordsborg NB, Dmytriyev A, Lundby C, Olsen JV. 
(2012) Quantitative maps of protein phosphorylation sites across 14 different rat 
organs and tissues. Nat Commun. 3:876. 
Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. (2006) 
Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and 
dissociation from Bcl-XL. BMC Cell Biol. 7:1. 
MacDonald, M. E., Ambrose, C. M., Dujao, M. P. and et al. (1993). A novel gene 
containing a trinucleotide repeat that is expanded and unstable on Huntington's 
disease chromosomes. Cell 72:971-983. 
Macdougall DA, Agarwal SR, Stopford EA, Chu H, Collins JA, Longster AL, Colyer J, 
Harvey RD, Calaghan S. (2012) Caveolae compartmentalise β2-adrenoceptor 
signals by curtailing cAMP production and maintaining phosphatase activity in the 
sarcoplasmic reticulum of the adult ventricular myocyte. J Mol Cell Cardiol. 
52(2):388-400. 
Mackintosh C. (2004) Dynamic interactions between 14-3-3 proteins and 
phosphoproteins regulate diverse cellular processes. Biochem J. 381(Pt 2):329-42. 
Maillet M, van Berlo JH, Molkentin JD. (2013) Molecular basis of physiological heart 
growth: fundamental concepts and new players. Nat Rev Mol Cell Biol. 14(1):38-
48. 
Majno G, Joris I. (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. 
Am J Pathol. 146(1):3-15. 
Makaula S, Lochner A, Genade S, Sack MN, Awan MM, Opie LH. (2005) H-89, a 
non-specific inhibitor of protein kinase A, promotes post-ischemic cardiac 
contractile recovery and reduces infarct size. J Cardiovasc Pharmacol. 45(4):341-7. 
248 
 
Mäkitie LT, Kanerva K, Andersson LC. (2009) Ornithine decarboxylase regulates 
the activity and localization of rhoA via polyamination. Exp Cell Res. 315(6):1008-
14. 
Malhotra R, Lin Z, Vincenz C, Brosius FC 3rd. (2001) Hypoxia induces apoptosis via 
two independent pathways in Jurkat cells: differential regulation by glucose. Am J 
Physiol Cell Physiol. 281(5):C1596-603. 
Malorni W, Farrace MG, Matarrese P, Tinari A, Ciarlo L, Mousavi-Shafaei P, D'Eletto 
M, Di Giacomo G, Melino G, Palmieri L, Rodolfo C, Piacentini M. (2009) The adenine 
nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications 
for mitochondrial-dependent apoptosis. Cell Death Differ. 16(11):1480-92. 
Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. (2007) Tissue 
transglutaminase expression promotes cell attachment, invasion and survival in 
breast cancer cells. Oncogene. 26(17):2459-70.  
Mangano DT, Goldman L. (1995) Preoperative assessment of patients with known 
or suspected coronary disease. N Engl J Med. 333(26):1750-6. 
Mangoni ME, Barrère-Lemaire S. (2004) Adenosine receptors, heart rate, and 
cardioprotection. Cardiovasc Res. 62(3):447-9. 
Manni S, Mauban JH, Ward CW, Bond M. (2008) Phosphorylation of the cAMP-
dependent protein kinase (PKA) regulatory subunit modulates PKA-AKAP 
interaction, substrate phosphorylation, and calcium signaling in cardiac cells. J Biol 
Chem. 283(35):24145-54. 
Marais E, Genade S, Strijdom H, Moolman JA, Lochner A. (2001) p38 MAPK 
activation triggers pharmacologically-induced beta-adrenergic preconditioning, but 
not ischaemic preconditioning. J Mol Cell Cardiol. 33(12):2157-77. 
Marques MA, de Oliveira GA. (2016) Cardiac Troponin and Tropomyosin: Structural 
and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. 
Front Physiol. 7:429. 
Martel C, Wang Z, Brenner C. (2014) VDAC phosphorylation, a lipid sensor 
influencing the cell fate. Mitochondrion. 19(Pt A):69-77. 
Martens D, Lohse MJ, Rauch B, Schwabe U. (1987) Pharmacological 
characterization of A1 adenosine receptors in isolated rat ventricular myocytes. 
Naunyn Schmiedebergs Arch Pharmacol. 336(3):342-8. 
249 
 
Martin A, De Vivo G, Gentile V. (2011) Possible role of the transglutaminases in the 
pathogenesis of Alzheimer's disease and other neurodegenerative diseases. Int J 
Alzheimers Dis. 1:865432. 
Martin NP, Whalen EJ, Zamah MA, Pierce KL, Lefkowitz RJ. (2004) PKA-mediated 
phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. Cell 
Signal. 16(12):1397-403. 
Mastroberardino PG, Farrace MG, Viti I, Pavone F, Fimia GM, Melino G, Rodolfo C, 
Piacentini M. (2006) "Tissue" transglutaminase contributes to the formation of 
disulphide bridges in proteins of mitochondrial respiratory complexes. Biochim 
Biophys Acta. 1757(9-10):1357-65. 
Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino 
G, Moreno S, Pavone F, Oliverio S, Fesus L, Piacentini M. (2002) 'Tissue' 
transglutaminase ablation reduces neuronal death and prolongs survival in a 
mouse model of Huntington's disease. Cell Death Differ. 9(9):873-80. 
Mastroberardino PG, Piacentini M. (2010) Type 2 transglutaminase in Huntington's 
disease: a double-edged sword with clinical potential. J Intern Med. 268(5):419-
31. 
Matlung HL, Neele AE, Groen HC, van Gaalen K, Tuna BG, van Weert A, de Vos J, 
Wentzel JJ, Hoogenboezem M, van Buul JD, VanBavel E, Bakker EN. (2012) 
Transglutaminase activity regulates atherosclerotic plaque composition at locations 
exposed to oscillatory shear stress. Atherosclerosis. 224(2):355-62. 
McCommis KS, Baines CP. (2012) The role of VDAC in cell death: friend or foe? 
Biochim Biophys Acta. 1818(6):1444-50. 
McGrath JC. (2015) Localization of α-adrenoceptors: JR Vane Medal Lecture. Br J 
Pharmacol. 172(5):1179-94. 
Medina DL, Toro MJ, Santisteban P. (2000) Somatostatin interferes with 
thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase 
and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E x cyclin-
dependent kinase 2 complexes. J Biol Chem. 275(20):15549-56. 
Mehta K, Fok J, Miller FR, Koul D, Sahin AA. (2004) Prognostic significance of 
tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer 
Res. 10(23):8068-76. 
Mehta K, Fok JY, Mangala LS. (2006) Tissue transglutaminase: from biological glue 
to cell survival cues. Front Biosci. 11:173-85. 
250 
 
Mehta K, Kumar A, Kim HI. (2010) Transglutaminase 2: a multi-tasking protein in 
the complex circuitry of inflammation and cancer. Biochem Pharmacol. 
80(12):1921-9.  
Messerli FH, Bangalore S, Yao SS, Steinberg JS. (2009) Cardioprotection with 
beta-blockers: myths, facts and Pascal's wager. J Intern Med. 266(3):232-41. 
Métrich M, Lucas A, Gastineau M, Samuel JL, Heymes C, Morel E, Lezoualc'h F. 
(2008) Epac mediates beta-adrenergic receptor-induced cardiomyocyte 
hypertrophy. Circ Res. 102(8):959-65. 
Mhaouty-Kodja S. (2004) Ghalpha/tissue transglutaminase 2: an emerging G 
protein in signal transduction. Biol Cell. 96(5):363-7. 
Milakovic T, Tucholski J, McCoy E, Johnson GV. (2004) Intracellular localization and 
activity state of tissue transglutaminase differentially impacts cell death. J Biol 
Chem. 279(10):8715-22. 
Miller-Fleming L, Olin-Sandoval V, Campbell K, Ralser M. (2015) Remaining 
Mysteries of Molecular Biology: The Role of Polyamines in the Cell. J Mol Biol. 
427(21):3389-406. 
Milligan G, Kostenis E. (2006) Heterotrimeric G-proteins: a short history. Br J 
Pharmacol. 147 Suppl 1:S46-55. 
Min B, Kwon YC, Choe KM, Chung KC. (2015) PINK1 phosphorylates 
transglutaminase 2 and blocks its proteasomal degradation. J Neurosci Res. 
93(5):722-35. 
Minneman KP. (1988) Alpha 1-adrenergic receptor subtypes, inositol phosphates, 
and sources of cell Ca2+. Pharmacol Rev. 40(2):87-119. 
Mishra S, Melino G, Murphy LJ. (2007) Transglutaminase 2 kinase activity 
facilitates protein kinase A-induced phosphorylation of retinoblastoma protein. J 
Biol Chem 282(25):18108-15. 
Mishra S, Murphy LJ. (2006) Phosphorylation of transglutaminase 2 by PKA at 
Ser216 creates 14-3-3 binding sites. Biochem Biophys Res Commun. 
347(4):1166-70. 
Mishra S, Murphy LJ. (2006) The p53 oncoprotein is a substrate for tissue 
transglutaminase kinase activity. Biochem Biophys Res Commun. 339(2):726-30. 
251 
 
Mishra S, Murphy LJ. (2004) Tissue transglutaminase has intrinsic kinase activity: 
identification of transglutaminase 2 as an insulin-like growth factor-binding 
protein-3 kinase. J Biol Chem. 279(23):23863-8. 
Mishra S, Saleh A, Espino PS, Davie JR, Murphy LJ. (2006) Phosphorylation of 
histones by tissue transglutaminase. J Biol Chem. 281(9):5532-8. 
Mitchell CH, Peterson-Yantorno K, Carré DA, McGlinn AM, Coca-Prados M, Stone RA, 
Civan MM. (1999) A3 adenosine receptors regulate Cl- channels of nonpigmented 
ciliary epithelial cells. Am J Physiol. 276(3 Pt 1):C659-66. 
Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. (2000) The p38 MAPK inhibitor, 
SB203580, abrogates ischaemic preconditioning in rat heart but timing of 
administration is critical. Basic Res Cardiol. 95(6):472-8. 
Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. (2005) Myocardial 
ischemia/reperfusion-injury, a clinical view on a complex pathophysiological 
process. Int J Cardiol. 100(2):179-90.  
Monaco G, Decrock E, Arbel N, van Vliet AR, La Rovere RM, De Smedt H, Parys JB, 
Agostinis P, Leybaert L, Shoshan-Barmatz V, Bultynck G. (2015) The BH4 domain 
of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-
dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ 
signals to mitochondria. J Biol Chem. 290(14):9150-61. 
Moolman JA, Hartley S, Van Wyk J, Marais E, Lochner A. (2006a) Inhibition of 
myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is 
dependent on p38 MAPK. Cardiovasc Drugs Ther. 20(1):13-25. 
Moolman, JA, Salie, R, Lochner, A (2006c) The mechanism of 0-adrenergic 
preconditioning (fJPC) depends on activation of adenosine A(3) receptors by 
endogenous adenosine and involves the PI3-K/PKB signal transduction pathway. 
Journal of Molecular and Cellular Cardiology 41(4): 741-742. 
Morisco C, Zebrowski DC, Vatner DE, Vatner SF, Sadoshima J. (2001) Beta-
adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the 
rat heart. J Mol Cell Cardiol. 33(3):561-73. 
Morgan AJ, Murray KJ, Challiss RA. (1993) Comparison of the effect of 
isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels 
in SH-SY5Y neuroblastoma cells. Biochem Pharmacol. 45(12):2373-80. 
252 
 
Motomura S, Reinhard-Zerkowski H, Daul A, Brodde OE. (1990) On the physiologic 
role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am 
Heart J. 119(3 Pt 1):608-19. 
Munshi R, Pang IH, Sternweis PC, Linden J. (1991) A1 adenosine receptors of 
bovine brain couple to guanine nucleotide-binding proteins Gi1, Gi2, and Go. J Biol 
Chem. 266(33):22285-9. 
Münzel T, Gori T, Keaney JF Jr, Maack C, Daiber A. (2015) Pathophysiological role 
of oxidative stress in systolic and diastolic heart failure and its therapeutic 
implications. Eur Heart J. 36(38):2555-64. 
Murry CE, Jennings RB, Reimer KA. (1986) Preconditioning with ischemia: a delay 
of lethal cell injury in ischemic myocardium. Circulation. 74(5):1124-36. 
Murthy KS, Makhlouf GM. (1995) Adenosine A1 receptor-mediated activation of 
phospholipase C-beta 3 in intestinal muscle: dual requirement for alpha and beta 
gamma subunits of Gi3. Mol Pharmacol. 47(6):1172-9. 
Murthy, S.N., Iismaa, S., Begg, G., Freymann, D.M., Graham, R.M., and Lorand, L. 
(2002). Conserved tryptophan in the core domain of transglutaminase is essential 
for catalytic activity. Proc Natl Acad Sci U S A 99: 2738-2742. 
MYCEK MJ, CLARKE DD, NEIDLE A, WAELSCH H. (1959) Amine incorporation into 
insulin as catalyzed by transglutaminase. Arch Biochem Biophys. 84:528-40. 
Myneni VD, Hitomi K, Kaartinen MT. (2014) Factor XIII-A transglutaminase acts as 
a switch between preadipocyte proliferation and differentiation. Blood. 
124(8):1344-53. 
Myrsky E, Kaukinen K, Syrjänen M, Korponay-Szabó IR, Mäki M, Lindfors K. (2008) 
Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb 
angiogenesis. Clin Exp Immunol. 152(1):111-9. 
Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA. (2005) Protein kinase 
activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor 
endocytosis. Nat Cell Biol. 7(8):785-96. 
Nagarkatti DS, Sha'afi RI. (1998) Role of p38 MAP kinase in myocardial stress. J 
Mol Cell Cardiol. 30(8):1651-64. 
Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM. 
(1994) Gh: a GTP-binding protein with transglutaminase activity and receptor 
signalling function. Science. 264(5165):1593-6. 
253 
 
Nardacci R, Lo Iacono O, Ciccosanti F, Falasca L, Addesso M, Amendola A, 
Antonucci G, Craxì A, Fimia GM, Iadevaia V, Melino G, Ruco L, Tocci G, Ippolito G, 
Piacentini M. (2003) Transglutaminase type II plays a protective role in hepatic 
injury. Am J Pathol. 162(4):1293-303. 
Nasa Y, Yabe K, Takeo S. (1997) Beta-adrenoceptor stimulation-mediated 
preconditioning-like cardioprotection in perfused rat hearts. J Cardiovasc 
Pharmacol. 29(4):436-43. 
Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, Ashcroft F, 
Tepikin A, Neoptolemos JP, Costello E. (2009) S100A6 binds to annexin 2 in 
pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 
101(7):1145-54. 
Nelson TE, Gruol DL. (2004) The chemokine CXCL10 modulates excitatory activity 
and intracellular calcium signaling in cultured hippocampal neurons. J 
Neuroimmunol. 156(1-2):74-87. 
Neves SR, Ram PT, Iyengar R. (2002) G protein pathways. Science. 
296(5573):1636-9. 
Nichols M, Townsend N, Scarborough P, Rayner M. (2014) Cardiovascular disease 
in Europe 2014: epidemiological update. Eur Heart J. 35(42):2950-9. 
Nikolaev VO, Bünemann M, Schmitteckert E, Lohse MJ, Engelhardt S. (2006) Cyclic 
AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but 
locally confined beta2-adrenergic receptor-mediated signaling. Circ Res. 
99(10):1084-91. 
Nikolaev VO, Bünemann M, Schmitteckert E, Lohse MJ, Engelhardt S. (2006) Cyclic 
AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but 
locally confined beta2-adrenergic receptor-mediated signaling. Circ Res. 
99(10):1084-91. 
Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev 
YE, Harding SE, Gorelik J. (2010) Beta2-adrenergic receptor redistribution in heart 
failure changes cAMP compartmentation. Science. 327(5973):1653-7. 
Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, 
Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA. (2012) 
Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal 
nitric oxide synthase. J Am Coll Cardiol. 59(22):1979-87. 
254 
 
Nurminskaya M, Magee C, Faverman L, Linsenmayer TF. (2003) Chondrocyte-
derived transglutaminase promotes maturation of preosteoblasts in periosteal bone. 
Dev Biol. 263(1):139-52. 
Nurminskaya MV, Belkin AM. (2012) Cellular functions of tissue transglutaminase. 
Int Rev Cell Mol Biol. 294:1-97. 
Odii BO, Coussons P. (2014) Biological functionalities of transglutaminase 2 and 
the possibility of its compensation by other members of the transglutaminase 
family. Scientific World Journal. 1:714561. 
Oertel K, Hunfeld A, Specker E, Reiff C, Seitz R, Pasternack R, Dodt J. (2007) A 
highly sensitive fluorometric assay for determination of human coagulation factor 
XIII in plasma. Anal Biochem. 367(2):152-8. 
Oestreich EA, Malik S, Goonasekera SA, Blaxall BC, Kelley GG, Dirksen RT, Smrcka 
AV. (2009) Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by 
activation of protein kinase Cepsilon and calcium-calmodulin kinase II. J Biol Chem. 
284(3):1514-22. 
Offermanns S, Simon MI. (1995) G alpha 15 and G alpha 16 couple a wide variety 
of receptors to phospholipase C. J Biol Chem. 270(25):15175-80. 
Okamoto T, Murayama Y, Hayashi Y, Inagaki M, Ogata E, Nishimoto I. (1991) 
Identification of a Gs activator region of the beta 2-adrenergic receptor that is 
autoregulated via protein kinase A-dependent phosphorylation. Cell. 67(4):723-30. 
Olah ME, Stiles GL. (1995) Adenosine receptor subtypes: characterization and 
therapeutic regulation. Annu Rev Pharmacol Toxicol. 35:581-606. 
Oliverio S, Amendola A, Di Sano F, Farrace MG, Fesus L, Nemes Z, Piredda L, 
Spinedi A, Piacentini M. (1997) Tissue transglutaminase-dependent 
posttranslational modification of the retinoblastoma gene product in promonocytic 
cells undergoing apoptosis. Mol Cell Biol. 17(10):6040-8. 
Onaran HO, Ambrosio C, Uğur Ö, Madaras Koncz E, Grò MC, Vezzi V, Rajagopal S, 
Costa T. (2017) Systematic errors in detecting biased agonism: Analysis of current 
methods and development of a new model-free approach. Sci Rep. 7:44247. 
Orre LM, Pernemalm M, Lengqvist J, Lewensohn R, Lehtiö J. (2007) Up-regulation, 
modification, and translocation of S100A6 induced by exposure to ionizing 
radiation revealed by proteomics profiling. Mol Cell Proteomics. 6(12):2122-31. 
255 
 
Osaki M, Oshimura M, Ito H. (2004) PI3K-Akt pathway: its functions and 
alterations in human cancer. Apoptosis. 9(6):667-76. 
Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, Insel PA. (2001) 
Receptor number and caveolar co-localization determine receptor coupling 
efficiency to adenylyl cyclase. J Biol Chem. 276(45):42063-9. 
Otani H, Matsuhisa S, Akita Y, Kyoi S, Enoki C, Tatsumi K, Fujiwara H, Hattori R, 
Imamura H, Iwasaka T. (2006) Role of mechanical stress in the form of 
cardiomyocyte death during the early phase of reperfusion. Circ J. 70(10):1344-55. 
Ou H, Haendeler J, Aebly MR, Kelly LA, Cholewa BC, Koike G, Kwitek-Black A, 
Jacob HJ, Berk BC, Miano JM. (2000) Retinoic acid-induced tissue transglutaminase 
and apoptosis in vascular smooth muscle cells. Circ Res. 87(10):881-7. 
Pac-Soo CK, Mathew H, Ma D. (2015) Ischaemic conditioning strategies reduce 
ischaemia/reperfusion-induced organ injury. Br J Anaesth. 114(2):204-16. 
Palacios-Moreno J, Foltz L, Guo A, Stokes MP, Kuehn ED, George L, Comb M, 
Grimes ML. (2015) Neuroblastoma tyrosine kinase signaling networks involve FYN 
and LYN in endosomes and lipid rafts. PLoS Comput Biol. 11(4):e1004130. 
Palczewski K. (2006) G protein-coupled receptor rhodopsin. Annu Rev Biochem. 
75:743-67. 
Palmer TM, Gettys TW, Stiles GL. (1995) Differential interaction with and 
regulation of multiple G-proteins by the rat A3 adenosine receptor. J Biol Chem. 
270(28):16895-902. 
Palmiter KA, Kitada Y, Muthuchamy M, Wieczorek DF, Solaro RJ. (1996) Exchange 
of beta- for alpha-tropomyosin in hearts of transgenic mice induces changes in thin 
filament response to Ca2+, strong cross-bridge binding, and protein 
phosphorylation. J Biol Chem. 271(20):11611-4. 
Park ES, Won JH, Han KJ, Suh PG, Ryu SH, Lee HS, Yun HY, Kwon NS, Baek KJ. 
(1998) Phospholipase C-delta1 and oxytocin receptor signalling: evidence of its 
role as an effector. Biochem J. 331 ( Pt 1):283-9. 
Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM. (2010) 
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J 
Cancer Res Clin Oncol. 136(4):493-502. 
256 
 
Parsons M, Young L, Lee JE, Jacobson KA, Liang BT. (2000) Distinct 
cardioprotective effects of adenosine mediated by differential coupling of receptor 
subtypes to phospholipases C and D. FASEB J. 14(10):1423-31. 
Pastorino JG, Hoek JB. (2008) Regulation of hexokinase binding to VDAC. J 
Bioenerg Biomembr. 40(3):171-82. 
Patel HH, Murray F, Insel PA. (2008) Caveolae as organizers of pharmacologically 
relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 48:359-91. 
Peart JN, Headrick JP. (2007) Adenosinergic cardioprotection: multiple receptors, 
multiple pathways. Pharmacol Ther. 114(2):208-21. 
Penumatsa K, Abualkhair S, Wei L, Warburton R, Preston I, Hill NS, Watts 
SW,Fanburg BL, Toksoz D. (2014) Tissue transglutaminase promotes serotonin-
induced AKT signaling and mitogenesis in pulmonary vascular smooth muscle cells. 
Cell Signal. 26(12):2818-25. 
Pereira L, Cheng H, Lao DH, Na L, van Oort RJ, Brown JH, Wehrens XH, Chen J, 
Bers DM. (2013) Epac2 mediates cardiac β1-adrenergic-dependent sarcoplasmic 
reticulum Ca2+ leak and arrhythmia. Circulation. 127(8):913-22. 
Perry MJ, Mahoney SA, Haynes LW. (1995) Transglutaminase C in cerebellar 
granule neurons: regulation and localization of substrate cross-linking. 
Neuroscience. 65(4):1063-76. 
Peter AK, Bjerke MA, Leinwand LA. (2016) Biology of the cardiac myocyte in heart 
disease. Molecular Biology of the Cell 27(14):2149-2160. 
Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. (2006) 
Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b 
receptor cascade. Cardiovasc Res. 70(2):308-14. 
Phillips AB, Ko W. (2007) Effects of ischemic preconditioning and adenosine 
pretreatment on myocardial function and energetics in a clinically relevant model. 
Life Sci. 81(17-18):1355-61. 
Piacentini M, Farrace MG, Piredda L, Matarrese P, Ciccosanti F, Falasca L, Rodolfo C, 
Giammarioli AM, Verderio E, Griffin M, Malorni W. (2002) Transglutaminase 
overexpression sensitizes neuronal cell lines to apoptosis by increasing 
mitochondrial membrane potential and cellular oxidative stress. J Neurochem. 
81(5):1061-72. 
257 
 
Pierce KD, Furlong TJ, Selbie LA, Shine J. (1992) Molecular cloning and expression 
of an adenosine A2b receptor from human brain. Biochem Biophys Res Commun. 
187(1):86-93. 
Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. (2015) Acetyl 
coenzyme A: a central metabolite and second messenger. Cell Metab. 21(6):805-
21. 
Piper HM, Kasseckert S, Abdallah Y. (2006) The sarcoplasmic reticulum as the 
primary target of reperfusion protection. Cardiovasc Res. 70(2):170-3.  
Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, 
Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. (1999) The effect of 
bisoprolol on perioperative mortality and myocardial infarction in high-risk patients 
undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation 
Applying Stress Echocardiography Study Group. N Engl J Med. 341(24):1789-94. 
Porter GW, Khuri FR, Fu H. (2006) Dynamic 14-3-3/client protein interactions 
integrate survival and apoptotic pathways. Semin Cancer Biol. 16(3):193-202. 
Porzio O, Massa O, Cunsolo V, Colombo C, Malaponti M, Bertuzzi F, Hansen T, 
Johansen A, Pedersen O, Meschi F, Terrinoni A, Melino G, Federici M, Decarlo N, 
Menicagli M, Campani D, Marchetti P, Ferdaoussi M, Froguel P, Federici G, 
Vaxillaire M, Barbetti F. (2007) Missense mutations in the TGM2 gene encoding 
transglutaminase 2 are found in patients with early-onset type 2 diabetes. 
Mutation in brief no. 982. Online. Hum Mutat. 28(11):1150. 
Prezma T, Shteinfer A, Admoni L, Raviv Z, Sela I, Levi I, Shoshan-Barmatz V. 
(2013) VDAC1-based peptides: novel pro-apoptotic agents and potential 
therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis. 4:e809. 
Przedborski S, Vila M, Jackson-Lewis V. (2003) Neurodegeneration: what is it and 
where are we? J Clin Invest. 111(1):3-10. 
Qin Q, Downey JM, Cohen MV. (2003) Acetylcholine but not adenosine triggers 
preconditioning through PI3-kinase and a tyrosine kinase. Am J Physiol Heart Circ 
Physiol. 284(2):H727-34. 
Quan G, Choi JY, Lee DS, Lee SC. (2005) TGF-beta1 up-regulates 
transglutaminase two and fibronectin in dermal fibroblasts: a possible mechanism 
for the stabilization of tissue inflammation. Arch Dermatol Res. 297(2):84-90. 
258 
 
Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, 
Violin JD, Lefkowitz RJ. (2011) Quantifying ligand bias at seven-transmembrane 
receptors. Mol Pharmacol. 80(3):367-77. 
Rajagopal S. (2013) Quantifying biased agonism: understanding the links between 
affinity and efficacy. Nat Rev Drug Discov. 12(6):483. 
Ralevic V, Burnstock G. (1998) Receptors for purines and pyrimidines. Pharmacol 
Rev. 50(3):413-92. 
Randhawa PK, Jaggi AS. (2016) Unraveling the role of adenosine in remote 
ischemic preconditioning-induced cardioprotection. Life Sci. 155:140-6. 
Rankovic Z, Brust TF, Bohn LM. (2016) Biased agonism: An emerging paradigm in 
GPCR drug discovery. Bioorg Med Chem Lett. 26(2):241-50. 
Rauhavirta T, Hietikko M, Salmi T, Lindfors K. (2016) Transglutaminase 2 and 
Transglutaminase 2 Autoantibodies in Celiac Disease: a Review. Clin Rev Allergy 
Immunol. [Epub ahead of print]. 
Rebecchi MJ, Pentyala SN. (2000) Structure, function, and control of 
phosphoinositide-specific phospholipase C. Physiol Rev. 80(4):1291-335. 
Regan SE, Broad M, Byford AM, Lankford AR, Cerniway RJ, Mayo MW, Matherne GP. 
(2003) A1 adenosine receptor overexpression attenuates ischemia-reperfusion-
induced apoptosis and caspase 3 activity. Am J Physiol Heart Circ Physiol. 
284(3):H859-66. 
Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. (2012) Molecular mechanism of β-
arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol 
Toxicol. 52:179-97. 
Reiter MJ. (2004) Cardiovascular drug class specificity: beta-blockers. Prog 
Cardiovasc Dis. 47(1):11-33. 
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, 
Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, 
Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu 
TL, Polakiewicz RD, Rush J, Comb MJ. (2007) Global survey of phosphotyrosine 
signaling identifies oncogenic kinases in lung cancer. Cell. 131(6):1190-203. 
Risso G, Blaustein M, Pozzi B, Mammi P, Srebrow A. (2015) Akt/PKB: one kinase, 
many modifications. Biochem J. 468(2):203-14. 
259 
 
Roberts SJ, Molenaar P, Summers RJ. (1993) Characterization of propranolol-
resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle. Br J 
Pharmacol. 109(2):344-52. 
Roberts SJ, Russell FD, Molenaar P, Summers RJ. (1995) Characterization and 
localization of atypical beta-adrenoceptors in rat ileum. Br J Pharmacol. 
116(6):2549-56. 
Robinet A, Hoizey G, Millart H. (2005) PI 3-kinase, protein kinase C, and protein 
kinase A are involved in the trigger phase of beta1-adrenergic preconditioning. 
Cardiovasc Res. 66(3):530-42. 
Robinson AJ, Dickenson JM. (2001) Regulation of p42/p44 MAPK and p38 MAPK by 
the adenosine A(1) receptor in DDT(1)MF-2 cells. Eur J Pharmacol. 413(2-3):151-
61.  
Rocha-Singh KJ, Honbo NY, Karliner JS. (1991) Hypoxia and glucose independently 
regulate the beta-adrenergic receptor-adenylate cyclase system in cardiac 
myocytes. J Clin Invest. 88(1):204-13. 
Rodolfo C, Mormone E, Matarrese P, Ciccosanti F, Farrace MG, Garofano E, Piredda 
L, Fimia GM, Malorni W, Piacentini M. (2004) Tissue transglutaminase is a 
multifunctional BH3-only protein. J Biol Chem. 279(52):54783-92.  
Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP Jr, Barsh GS, Bernstein D, 
Kobilka BK. (1996) Targeted disruption of the mouse beta1-adrenergic receptor 
gene: developmental and cardiovascular effects. Proc Natl Acad Sci U S A. 
93(14):7375-80. 
Rosa JC, César MC. (2016) Role of Hexokinase and VDAC in Neurological Disorders. 
Curr Mol Pharmacol. 9(4):320-331. 
Rosenbaum DM, Rasmussen SG, Kobilka BK. (2009) The structure and function of 
G-protein-coupled receptors. Nature. 459(7245):356-63. 
Rozec B, Gauthier C. (2006) beta3-adrenoceptors in the cardiovascular system: 
putative roles in human pathologies. Pharmacol Ther. 111(3):652-73.  
Ruan Q, Quintanilla RA, Johnson GV. (2007) Type 2 transglutaminase differentially 
modulates striatal cell death in the presence of wild type or mutant huntingtin. J 
Neurochem. 102(1):25-36. 
260 
 
Ruan Q, Tucholski J, Gundemir S, Johnson Voll GV. (2008) The Differential Effects 
of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human 
Type 2 Transglutaminase. Int J Clin Exp Med. 1(3):248-59.  
Sabourin J, Antigny F, Robin E, Frieden M, Raddatz E. (2012) Activation of 
transient receptor potential canonical 3 (TRPC3)-mediated Ca2+ entry by A1 
adenosine receptor in cardiomyocytes disturbs atrioventricular conduction. J Biol 
Chem. 287(32):26688-701. 
Safran N, Shneyvays V, Balas N, Jacobson KA, Nawrath H, Shainberg A. (2001) 
Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia 
in isolated rat cardiac myocytes. Mol Cell Biochem. 217(1-2):143-52. 
Sailer A, Houlden H. (2012) Recent advances in the genetics of cerebellar ataxias. 
Curr Neurol Neurosci Rep. 12(3):227-36. 
Salie R, Moolman JA, Lochner A. (2012) The mechanism of beta-adrenergic 
preconditioning: roles for adenosine and ROS during triggering and mediation. 
Basic Res Cardiol. 107(5):281. 
Salie R, Moolman JA, Lochner A. (2011) The role of β-adrenergic receptors in the 
cardioprotective effects of beta-preconditioning (βPC). Cardiovasc Drugs Ther. 
25(1):31-46. 
Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. (2000) 
Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated 
inflammatory cells. J Biol Chem. 275(6):4429-34. 
Sanada S, Kitakaze M. (2004) Ischemic preconditioning: emerging evidence, 
controversy, and translational trials. Int J Cardiol. 97(2):263-76. 
Sane DC, Kontos JL, Greenberg CS. (2007) Roles of transglutaminases in cardiac 
and vascular diseases. Front Biosci. 12:2530-45. 
Santhanam L, Tuday EC, Webb AK, Dowzicky P, Kim JH, Oh YJ, Sikka G, Kuo M, 
Halushka MK, Macgregor AM, Dunn J, Gutbrod S, Yin D, Shoukas A, Nyhan D, 
Flavahan NA, Belkin AM, Berkowitz DE. (2010) Decreased S-nitrosylation of tissue 
transglutaminase contributes to age-related increases in vascular stiffness. Circ 
Res. 107(1):117-25.  
Sarang Z, Molnár P, Németh T, Gomba S, Kardon T, Melino G, Cotecchia S, Fésüs L, 
Szondy Z. (2005) Tissue transglutaminase (TG2) acting as G protein protects 
hepatocytes against Fas-mediated cell death in mice. Hepatology. 42(3):578-87.  
261 
 
Sarang Z, Tóth B, Balajthy Z, Köröskényi K, Garabuczi E, Fésüs L, Szondy Z. (2009) 
Some lessons from the tissue transglutaminase knockout mouse. Amino Acids. 
36(4):625-31. 
Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. (1997) 
Apoptosis in human acute myocardial infarction. Circulation. 95(2):320-3. 
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005) Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science. 307(5712):1098-101. 
Sarsero D, Molenaar P, Kaumann AJ, Freestone NS. (1999) Putative beta 4-
adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: 
comparison with atrial receptors and relationship to (-)-[3H]-CGP 12177 binding. 
Br J Pharmacol. 128(7):1445-60. 
Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D. (2007) 
Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. 
Cancer Res. 67(15):7194-202. 
Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE, 
Courtney S, Scheel A, Macdonald D. (2010) A profiling platform for the 
characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen. 
15(5):478-87. 
Schäfer M, Pönicke K, Heinroth-Hoffmann I, Brodde OE, Piper HM, Schlüter KD. 
(2001) Beta-adrenoceptor stimulation attenuates the hypertrophic effect of alpha-
adrenoceptor stimulation in adult rat ventricular cardiomyocytes. J Am Coll Cardiol. 
37(1):300-7. 
Schaper J, Kostin S. (2005) Cell death and adenosine triphosphate: the paradox. 
Circulation. 112(1):6-8. 
Schmidt A, Beck M, Malmström J, Lam H, Claassen M, Campbell D, Aebersold R. 
(2011) Absolute quantification of microbial proteomes at different states by 
directed mass spectrometry. Mol Syst Biol. 7:510. 
Schmitt JM, Stork PJ. (2000) beta 2-adrenergic receptor activates extracellular 
signal-regulated kinases (ERKs) via the small G protein rap1 and the 
serine/threonine kinase B-Raf. J Biol Chem. 275(33):25342-50. 
Schneider G, Filipek A. (2011) S100A6 binding protein and Siah-1 interacting 
protein (CacyBP/SIP): spotlight on properties and cellular function. Amino Acids. 
41(4):773-80. 
262 
 
Scholz KP, Miller RJ. (1991) GABAB receptor-mediated inhibition of Ca2+ currents 
and synaptic transmission in cultured rat hippocampal neurones. J Physiol. 
444:669-86. 
Schömig A. (1990) Catecholamines in myocardial ischemia. Systemic and cardiac 
release. Circulation. 82(3 Suppl):II13-22. 
Schreiber KL, Paquet L, Allen BG, Rindt H. (2001) Protein kinase C isoform 
expression and activity in the mouse heart. Am J Physiol Heart Circ Physiol. 
281(5):H2062-71.  
Schulte G, Fredholm BB. (2003) Signalling from adenosine receptors to mitogen-
activated protein kinases. Cell Signal. 15(9):813-27. 
Schuppan D, Hahn EG. (2002) Biomedicine. Gluten and the gut-lessons for 
immune regulation. Science. 297(5590):2218-20. 
Schwartz DD. (1997) Activation of alpha-2 adrenergic receptors inhibits 
norepinephrine release by a pertussis toxin-insensitive pathway independent of 
changes in cytosolic calcium in cultured rat sympathetic neurons. J Pharmacol Exp 
Ther. 282(1):248-55. 
Schwartz LM, Lagranha CJ. (2006) Ischemic postconditioning during reperfusion 
activates Akt and ERK without protecting against lethal myocardial ischemia-
reperfusion injury in pigs. Am J Physiol Heart Circ Physiol. 290(3):H1011-8. 
Schwarzer C, Barnikol-Watanabe S, Thinnes FP, Hilschmann N. (2002) Voltage-
dependent anion-selective channel (VDAC) interacts with the dynein light chain 
Tctex1 and the heat-shock protein PBP74. Int J Biochem Cell Biol. 34(9):1059-70. 
Sener A, Dunlop ME, Gomis R, Mathias PC, Malaisse-Lagae F, Malaisse WJ. (1985) 
Role of transglutaminase in insulin release. Study with glycine and sarcosine 
methylesters. Endocrinology. 117(1):237-42. 
Seurin D, Lombet A, Babajko S, Godeau F, Ricort JM. (2013) Insulin-like growth 
factor binding proteins increase intracellular calcium levels in two different cell 
lines. PLoS One. 8(3):e59323. 
Shafiei M, Mahmoudian M. (1999) Atypical beta-adrenoceptors of rat thoracic aorta. 
Gen Pharmacol. 32(5):557-62. 
Shcherbakova OG, Hurt CM, Xiang Y, Dell'Acqua ML, Zhang Q, Tsien RW, Kobilka 
BK. (2007) Organization of beta-adrenoceptor signaling compartments by 
sympathetic innervation of cardiac myocytes. J Cell Biol. 176(4):521-33. 
263 
 
Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, 
Premont RT, Lichtarge O, Lefkowitz RJ. (2006) beta-arrestin-dependent, G protein-
independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 
281(2):1261-73. 
Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V. (2014) Adenosine 
receptors: expression, function and regulation. Int J Mol Sci. 15(2):2024-52. 
Shin DM, Kang J, Ha J, Kang HS, Park SC, Kim IG, Kim SJ. (2008) Cystamine 
prevents ischemia-reperfusion injury by inhibiting polyamination of RhoA. Biochem 
Biophys Res Commun. 365(3):509-14. 
Shizukuda Y, Buttrick PM. (2002) Subtype specific roles of beta-adrenergic 
receptors in apoptosis of adult rat ventricular myocytes. J Mol Cell Cardiol. 
34(7):823-31. 
Shoshan-Barmatz V, Keinan N, Abu-Hamad S, Tyomkin D, Aram L. (2010) 
Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC 
oligomerization: release of cytochrome c, AIF and Smac/Diablo. Biochim Biophys 
Acta. 1797(6-7):1281-91. 
Shoshan-Barmatz V, Zakar M, Rosenthal K, Abu-Hamad S. (2009) Key regions of 
VDAC1 functioning in apoptosis induction and regulation by hexokinase. Biochim 
Biophys Acta. 1787(5):421-30. 
Shrestha R, Tatsukawa H, Shrestha R, Ishibashi N, Matsuura T, Kagechika H, Kose 
S, Hitomi K, Imamoto N, Kojima S. (2015) Molecular mechanism by which acyclic 
retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular 
carcinoma cells. Cell Death Dis. 6:e2002. 
Shryock JC, Belardinelli L. (1997) Adenosine and adenosine receptors in the 
cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol. 
79(12A):2-10. 
Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, 
Chatziantoniou C, Ronco P, Boffa JJ. (2008) Tissue transglutaminase contributes to 
interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-
beta activation and cell infiltration. Am J Pathol. 173(3):631-42. 
Siedlecka U, Arora M, Kolettis T, Soppa GK, Lee J, Stagg MA, Harding SE, Yacoub 
MH, Terracciano CM. (2008) Effects of clenbuterol on contractility and Ca2+ 
homeostasis of isolated rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 
295(5):H1917-26. 
264 
 
Siegel M, Khosla C. (2007) Transglutaminase 2 inhibitors and their therapeutic role 
in disease states. Pharmacol Ther. 115(2):232-45. 
Sileno S, D'Oria V, Stucchi R, Alessio M, Petrini S, Bonetto V, Maechler P, Bertuzzi 
F, Grasso V, Paolella K, Barbetti F, Massa O. (2014) A possible role of 
transglutaminase 2 in the nucleus of INS-1E and of cells of human pancreatic islets. 
J Proteomics. 96:314-27. 
Simonis G, Briem SK, Schoen SP, Bock M, Marquetant R, Strasser RH. (2007) 
Protein kinase C in the human heart: differential regulation of the isoforms in 
aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem. 305(1-2):103-11. 
Simpson P. (1983) Norepinephrine-stimulated hypertrophy of cultured rat 
myocardial cells is an alpha 1 adrenergic response. J Clin Invest. 72(2):732-8. 
Singh RN, McQueen T, Mehta K. (1995) Detection of the amine acceptor protein 
substrates of transglutaminase with 5-(biotinamido) pentylamine. Anal Biochem. 
231(1):261-3. 
Singh US, Kunar MT, Kao YL, Baker KM. (2001) Role of transglutaminase II in 
retinoic acid-induced activation of RhoA-associated kinase-2. EMBO J. 
20(10):2413-23. 
Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM. (2003) Tissue 
transglutaminase mediates activation of RhoA and MAP kinase pathways during 
retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem. 
278(1):391-9. 
Sivaramakrishnan M, Shooter GK, Upton Z, Croll TI. (2013) Transglutaminases and 
receptor tyrosine kinases. Amino Acids. 44(1):19-24. 
Sivaraman V, Hausenloy DJ, Kolvekar S, Hayward M, Yap J, Lawrence D, Di Salvo 
C, Yellon DM. (2009) The divergent roles of protein kinase C epsilon and delta in 
simulated ischaemia-reperfusion injury in human myocardium. J Mol Cell Cardiol. 
46(5):758-64. 
Skeberdis VA, Jurevicius J, Fischmeister aR. (1997) Beta-2 adrenergic activation of 
L-type Ca++ current in cardiac myocytes. J Pharmacol Exp Ther. 283(2):452-61. 
Skeberdis VA, Jurevicius J, Fischmeister R. (1997) Pharmacological 
characterization of the receptors involved in the beta-adrenoceptor-mediated 
stimulation of the L-type Ca2+ current in frog ventricular myocytes. Br J 
Pharmacol. 121(7):1277-86. 
265 
 
Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS. (1992) A microtiter plate 
transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal 
Biochem. 205(1):166-71. 
Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, Dorn GW 2nd, Liggett SB. 
(1999) Cardiac specific overexpression of transglutaminase II (G(h)) results in a 
unique hypertrophy phenotype independent of phospholipase C activation. J Biol 
Chem. 274(30):21291-6. 
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, 
Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. (1985) Measurement of protein using 
bicinchoninic acid. Anal Biochem. 150(1):76-85. Erratum in: Anal Biochem 1985 
May 15;163(1):279. 
Smrcka AV, Sternweis PC. (1993) Regulation of purified subtypes of 
phosphatidylinositol-specific phospholipase C beta by G protein alpha and beta 
gamma subunits. J Biol Chem. 268(13):9667-74. 
Sneddon WB, Magyar CE, Willick GE, Syme CA, Galbiati F, Bisello A, Friedman PA. 
(2004) Ligand-selective dissociation of activation and internalization of the 
parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments. 
Endocrinology. 145(6):2815-23. 
Solaini G, Harris DA. (2005) Biochemical dysfunction in heart mitochondria 
exposed to ischaemia and reperfusion. Biochem J. 390(Pt 2):377-94.  
Solenkova NV, Solodushko V, Cohen MV, Downey JM. (2006) Endogenous 
adenosine protects preconditioned heart during early minutes of reperfusion by 
activating Akt. Am J Physiol Heart Circ Physiol. 290(1):H441-9. 
Sollid LM, Scott H. (1998) New tool to predict celiac disease on its way to the 
clinics. Gastroenterology. 115(6):1584-6. 
Soltis AR, Saucerman JJ. (2010) Synergy between CaMKII substrates and β-
adrenergic signaling in regulation of cardiac myocyte Ca(2+) handling. Biophys J. 
99(7):2038-47. 
Somvanshi RK, Qiu X, Kumar U. (2013) Isoproterenol induced hypertrophy and 
associated signaling pathways are modulated by somatostatin in H9c2 cells. Int J 
Cardiol. 167(3):1012-22. 
Somvanshi RK, War SA, Chaudhari N, Qiu X, Kumar U. (2011) Receptor specific 
crosstalk and modulation of signaling upon heterodimerization between β1-
adrenergic receptor and somatostatin receptor-5. Cell Signal. 23(5):794-811. 
266 
 
Soto D, De Arcangelis V, Zhang J, Xiang Y. (2009) Dynamic protein kinase a 
activities induced by beta-adrenoceptors dictate signaling propagation for 
substrate phosphorylation and myocyte contraction. Circ Res. 104(6):770-9. 
Southworth R, Davey KA, Warley A, Garlick PB. (2007) A reevaluation of the roles 
of hexokinase I and II in the heart. Am J Physiol Heart Circ Physiol. 292(1):H378-
86. 
Spear JF, Prabu SK, Galati D, Raza H, Anandatheerthavarada HK, Avadhani NG. 
(2007) beta1-Adrenoreceptor activation contributes to ischemia-reperfusion 
damage as well as playing a role in ischemic preconditioning. Am J Physiol Heart 
Circ Physiol. 292(5):H2459-66. 
Stahl EL, Zhou L, Ehlert FJ, Bohn LM. (2015) A novel method for analyzing 
extremely biased agonism at G protein-coupled receptors. Mol Pharmacol. 
87(5):866-77. 
Stamnaes J, Fleckenstein B, Sollid LM. (2008) The propensity for deamidation and 
transamidation of peptides by transglutaminase 2 is dependent on substrate 
affinity and reaction conditions. Biochim Biophys Acta. 1784(11):1804-11. 
Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C, Sollid LM. (2010) Redox 
regulation of transglutaminase 2 activity. J Biol Chem. 285(33):25402-9. 
Staus DP, Wingler LM, Strachan RT, Rasmussen SG, Pardon E, Ahn S, Steyaert J, 
Kobilka BK, Lefkowitz RJ. (2014) Regulation of β2-adrenergic receptor function by 
conformationally selective single-domain intrabodies. Mol Pharmacol. 85(3):472-
81. 
Steinberg SF. (1999) The molecular basis for distinct beta-adrenergic receptor 
subtype actions in cardiomyocytes. Circ Res. 85(11):1101-11. 
Steinberg SF. (2012) Cardiac actions of protein kinase C isoforms. Physiology 
(Bethesda). 27(3):130-9. 
Stephens P, Grenard P, Aeschlimann P, Langley M, Blain E, Errington R, Kipling D, 
Thomas D, Aeschlimann D. (2004) Crosslinking and G-protein functions of 
transglutaminase 2 contribute differentially to fibroblast wound healing responses. 
J Cell Sci. 117(Pt 15):3389-403. 
Steppan J, Bergman Y, Viegas K, Armstrong D, Tan S, Wang H, Melucci S, Hori D, 
Park SY, Barreto SF, Isak A, Jandu S, Flavahan N, Butlin M, An SS, Avolio A, 
Berkowitz DE, Halushka MK, Santhanam L. (2017) Tissue Transglutaminase 
267 
 
Modulates Vascular Stiffness and Function Through Crosslinking-Dependent and 
Crosslinking-Independent Functions. J Am Heart Assoc. 6(2). 
Steppan J, Sikka G, Jandu S, Barodka V, Halushka MK, Flavahan NA, Belkin AM, 
Nyhan D, Butlin M, Avolio A, Berkowitz DE, Santhanam L. (2014) Exercise, 
vascular stiffness, and tissue transglutaminase. J Am Heart Assoc. 3(2):e000599. 
Sterin-Borda L, Gómez RM, Borda E. (2002) Role of nitric oxide/cyclic GMP in 
myocardial adenosine A1 receptor-inotropic response. Br J Pharmacol. 
135(2):444-50. 
Stockwell J, Jakova E, Cayabyab FS. (2017) Adenosine A1 and A2A Receptors in 
the Brain: Current Research and Their Role in Neurodegeneration. Molecules. 
22(4). pii: E676. 
Straiker AJ, Borden CR, Sullivan JM. (2002) G-protein alpha subunit isoforms 
couple differentially to receptors that mediate presynaptic inhibition at rat 
hippocampal synapses. J Neurosci. 22(7):2460-8. 
Strasser, RH, Krimmer, J, Braun-Duallaeus, R, Marquetant, R, Kubler, W (1990) 
Dual sensitization of the adrenergic system in early myocardial ischemia: 
Independent regulation of the P-adrenergic receptors and the adenylyl cyclase. 
Journal of Molecular and Cellular Cardiology 22(12): 1405-1423. 
Sun L, Fan H, Yang L, Shi L, Liu Y. (2015) Tyrosol prevents ischemia/reperfusion-
induced cardiac injury in H9c2 cells: involvement of ROS, Hsp70, JNK and ERK, 
and apoptosis. Molecules. 20(3):3758-75. 
Sun L, Zhao M, Yang Y, Xue RQ, Yu XJ, Liu JK, Zang WJ. (2016) Acetylcholine 
Attenuates Hypoxia/Reoxygenation Injury by Inducing Mitophagy Through 
PINK1/Parkin Signal Pathway in H9c2 Cells. J Cell Physiol. 231(5):1171-81. 
Sunahara RK, Insel PA. (2016) The Molecular Pharmacology of G Protein Signaling 
Then and Now: A Tribute to Alfred G. Gilman. Mol Pharmacol. 89(5):585-92. 
Suto N, Ikura K, Sasaki R. (1993) Expression induced by interleukin-6 of tissue-
type transglutaminase in human hepatoblastoma HepG2 cells. J Biol Chem. 
268(10):7469-73. 
Swaminathan PD, Purohit A, Hund TJ, Anderson ME. (2012) Calmodulin-dependent 
protein kinase II: linking heart failure and arrhythmias. Circ Res. 110(12):1661-77. 
Syrovatkina V, Alegre KO, Dey R, Huang XY. (2016) Regulation, Signaling, and 
Physiological Functions of G-Proteins. J Mol Biol. 428(19):3850-68. 
268 
 
Szondy Z, Mastroberardino PG, Váradi J, Farrace MG, Nagy N, Bak I, Viti I, 
Wieckowski MR, Melino G, Rizzuto R, Tósaki A, Fesus L, Piacentini M. (2006) Tissue 
transglutaminase (TG2) protects cardiomyocytes against ischemia/reperfusion 
injury by regulating ATP synthesis. Cell Death Differ. 13(10):1827-9. 
Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe 
M. (1994) Hypoxia induces apoptosis with enhanced expression of Fas antigen 
messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 75(3):426-33. 
Tatsukawa H, Furutani Y, Hitomi K, Kojima S. (2016) Transglutaminase 2 has 
opposing roles in the regulation of cellular functions as well as cell growth and 
death. Cell Death Dis. 7(6):e2244. 
Tatsukawa H, Kojima S. (2010) Recent advances in understanding the roles of 
transglutaminase 2 in alcoholic steatohepatitis. Cell Biol Int. 34(3):325-34. 
Tatsukawa H, Sano T, Fukaya Y, Ishibashi N, Watanabe M, Okuno M, Moriwaki H, 
Kojima S. (2011) Dual induction of caspase 3- and transglutaminase-dependent 
apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer. 10:4. 
Tatsumi T, Shiraishi J, Keira N, Akashi K, Mano A, Yamanaka S, Matoba S, Fushiki 
S, Fliss H, Nakagawa M. (2003) Intracellular ATP is required for mitochondrial 
apoptotic pathways in isolated hypoxic rat cardiac myocytes. Cardiovasc Res. 
59(2):428-40. 
Tchivileva IE, Tan KS, Gambarian M, Nackley AG, Medvedev AV, Romanov S, Flood 
PM, Maixner W, Makarov SS, Diatchenko L. (2009) Signaling pathways mediating 
beta3-adrenergic receptor-induced production of interleukin-6 in adipocytes. Mol 
Immunol. 46(11-12):2256-66. 
Tee AE, Marshall GM, Liu PY, Xu N, Haber M, Norris MD, Iismaa SE, Liu T. (2010) 
Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma 
cell differentiation. J Biol Chem. 285(6):3561-7. 
Telci D, Wang Z, Li X, Verderio EA, Humphries MJ, Baccarini M, Basaga H, Griffin M. 
(2008) Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell 
adhesion through syndecan-4 and beta1 integrin co-signaling. J Biol Chem. 
283(30):20937-47. 
Terzic A, Pucéat M, Vassort G, Vogel SM. (1993) Cardiac alpha 1-adrenoceptors: 
an overview. Pharmacol Rev. 45(2):147-75. 
269 
 
Thangaraju K, Biri B, Schlosser G, Kiss B, Nyitray L, Fésüs L, Király R. (2016) Real-
time kinetic method to monitor isopeptidase activity of transglutaminase 2 on 
protein substrate. Anal Biochem. 505:36-42. 
Thomas H, Beck K, Adamczyk M, Aeschlimann P, Langley M, Oita RC, Thiebach L, 
Hils M, Aeschlimann D. (2013) Transglutaminase 6: a protein associated with 
central nervous system development and motor function. Amino Acids. 44(1):161-
77. 
Thornton JD, Liu GS, Olsson RA, Downey JM. (1992) Intravenous pretreatment 
with A1-selective adenosine analogues protects the heart against infarction. 
Circulation. 85(2):659-65. 
Toker A, Marmiroli S. (2014) Signaling specificity in the Akt pathway in biology and 
disease. Adv Biol Regul. 55:28-38. 
Tolentino PJ, Waghray A, Wang KK, Hayes RL. (2004) Increased expression of 
tissue-type transglutaminase following middle cerebral artery occlusion in rats. J 
Neurochem. 89(5):1301-7. 
Tomura H, Itoh H, Sho K, Sato K, Nagao M, Ui M, Kondo Y, Okajima F. (1997) 
Betagamma subunits of pertussis toxin-sensitive G proteins mediate A1 adenosine 
receptor agonist-induced activation of phospholipase C in collaboration with 
thyrotropin. A novel stimulatory mechanism through the cross-talk of two types of 
receptors. J Biol Chem. 272(37):23130-7. 
Tong H, Bernstein D, Murphy E, Steenbergen C. (2005) The role of beta-adrenergic 
receptor signaling in cardioprotection. FASEB J. 19(8):983-5. 
Toone, E. (2011). Advances in Enzymology and Related Areas of Molecular Biology. 
1st ed. Hoboken: John Wiley & Sons, Incorporated. 78:PMID22220470 
Tota B, Angelone T, Cerra MC. (2014) The surging role of Chromogranin A in 
cardiovascular homeostasis. Front Chem. 2:64. 
Tota B, Gentile S, Pasqua T, Bassino E, Koshimizu H, Cawley NX, Cerra MC, Loh YP, 
Angelone T. (2012) The novel chromogranin A-derived serpinin and 
pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes. 
FASEB J. 26(7):2888-98. 
Tóth B, Garabuczi E, Sarang Z, Vereb G, Vámosi G, Aeschlimann D, Blaskó B, Bécsi 
B, Erdõdi F, Lacy-Hulbert A, Zhang A, Falasca L, Birge RB, Balajthy Z, Melino G, 
Fésüs L, Szondy Z. (2009) Transglutaminase 2 is needed for the formation of an 
270 
 
efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol. 
182(4):2084-92. 
Towbin H, Staehelin T, Gordon J. (1979) Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 
Proc Natl Acad Sci U S A. 76(9):4350-4. 
Tracey, W. (1998) "Selective activation of adenosine A3 receptors with N6-(3-
chlorobenzyl)-5′-N-methylcarboxamidoadenosine (CB-MECA) provides 
cardioprotection via KATP channel activation." Cardiovascular Research 40(1): 
138-45. 
Trigwell SM, Lynch PT, Griffin M, Hargreaves AJ, Bonner PL. (2004) An improved 
colorimetric assay for the measurement of transglutaminase (type II)-(gamma-
glutamyl) lysine cross-linking activity. Anal Biochem. 330(1):164-6. 
Trump BF, Berezesky IK. (1996) The role of altered [Ca2+]i regulation in apoptosis, 
oncosis, and necrosis. Biochim Biophys Acta. 1313(3):173-8. 
Tsoporis JN, Izhar S, Parker TG. (2008) Expression of S100A6 in cardiac myocytes 
limits apoptosis induced by tumor necrosis factor-alpha. J Biol Chem. 
283(44):30174-83. 
Tucholski J, Johnson GV. (2003) Tissue transglutaminase directly regulates 
adenylyl cyclase resulting in enhanced cAMP-response element-binding protein 
(CREB) activation. J Biol Chem. 278(29):26838-43. 
Tutor AS, Penela P, Mayor F Jr. (2007) Anti-beta1-adrenergic receptor 
autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. 
Cardiovasc Res. 76(1):51-60. 
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch 
JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. 
(2007) Functional selectivity and classical concepts of quantitative pharmacology. J 
Pharmacol Exp Ther. 320(1):1-13. 
Urmaliya VB, Church JE, Coupar IM, Rose'Meyer RB, Pouton CW, White PJ. (2009) 
Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell 
ischemia model involves cooperative activation of adenosine A2A and A2B 
receptors by endogenous adenosine. J Cardiovasc Pharmacol. 53(5):424-33. 
Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, Tajik 
AJ, Gersh BJ. (2002) Prevalence and severity of "benign" mutations in the beta-
271 
 
myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in 
hypertrophic cardiomyopathy. Circulation. 106(24):3085-90. 
Vanhaesebroeck B, Alessi DR. (2000) The PI3K-PDK1 connection: more than just a 
road to PKB. Biochem J. 346 Pt 3:561-76. 
Velasco CE, Turner M, Cobb MA, Virmani R, Forman MB. (1991) Myocardial 
reperfusion injury in the canine model after 40 minutes of ischemia: effect of 
intracoronary adenosine. Am Heart J. 122(6):1561-70. 
Verderio EA, Johnson T, Griffin M. (2004) Tissue transglutaminase in normal and 
abnormal wound healing: review article. Amino Acids. 26(4):387-404. 
Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-
Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. (2008) 
Therapeutic significance of elevated tissue transglutaminase expression in 
pancreatic cancer. Clin Cancer Res. 14(8):2476-83. 
Verma A, Guha S, Wang H, Fok JY, Koul D, Abbruzzese J, Mehta K. (2008) Tissue 
transglutaminase regulates focal adhesion kinase/AKT activation by modulating 
PTEN expression in pancreatic cancer cells. Clin Cancer Res. 14(7):1997-2005. 
Verma A, Mehta K. (2007) Tissue transglutaminase-mediated chemoresistance in 
cancer cells. Drug Resist Updat. 10(4-5):144-51. 
Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K. (2006) 
Increased expression of tissue transglutaminase in pancreatic ductal 
adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 
66(21):10525-33. 
Vezza R, Habib A, FitzGerald GA. (1999) Differential signaling by the thromboxane 
receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem. 
274(18):12774-9. 
Wallace AW, Au S, Cason BA. (2011) Perioperative β-blockade: atenolol is 
associated with reduced mortality when compared to metoprolol. Anesthesiology. 
114(4):824-36. 
Wallukat G. (2002) The beta-adrenergic receptors. Herz. 27(7):683-90. 
Walther DJ, Peter JU, Winter S, Höltje M, Paulmann N, Grohmann M, Vowinckel J, 
Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, Bader M. (2003) 
Serotonylation of small GTPases is a signal transduction pathway that triggers 
platelet alpha-granule release. Cell. 115(7):851-62. 
272 
 
Wang JL, Yang X, Xia K, Hu ZM, Weng L, Jin X, Jiang H, Zhang P, Shen L, Guo JF, 
Li N, Li YR, Lei LF, Zhou J, Du J, Zhou YF, Pan Q, Wang J, Wang J, Li RQ, Tang BS. 
(2010) TGM6 identified as a novel causative gene of spinocerebellar ataxias using 
exome sequencing. Brain. 133(Pt 12):3510-8. 
Wang Y, Ande SR, Mishra S. (2012) Phosphorylation of transglutaminase 2 (TG2) 
at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and 
in the downregulation of PTEN. BMC Cancer. 12:277. 
Wang Y, De Arcangelis V, Gao X, Ramani B, Jung YS, Xiang Y. (2008) 
Norepinephrine- and epinephrine-induced distinct beta2-adrenoceptor signaling is 
dictated by GRK2 phosphorylation in cardiomyocytes. J Biol Chem. 283(4):1799-
807. 
Wang Z, Telci D, Griffin M. (2011) Importance of syndecan-4 and syndecan -2 in 
osteoblast cell adhesion and survival mediated by a tissue transglutaminase-
fibronectin complex. Exp Cell Res. 317(3):367-81. 
Wang, Jing, Quanhu Sheng, and Yu Shyr. (2015) "SWATH-MS in proteomics: 
current status." International Journal of Computational Biology and Drug 
Design 8(3):192. 
Wang M, Sun GB, Du YY, Tian Y, Liao P, Liu XS, Ye JX, Sun XB. (2017) Myricitrin 
Protects Cardiomyocytes from Hypoxia/Reoxygenation Injury: Involvement of Heat 
Shock Protein 90. Front Pharmacol. 8:353. 
Watkins SJ, Borthwick GM, Arthur HM. (2011) The H9C2 cell line and primary 
neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro 
Cell Dev Biol Anim. 47(2):125-31. 
Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B, Bishopric NH. (1999) 
Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a Ph 
shift and is independent of p53. J Clin Invest. 104(3):239-52. 
Wettschureck N, Offermanns S. (2005) Mammalian G proteins and their cell type 
specific functions. Physiol Rev. 85(4):1159-204. 
White TE, Dickenson JM, Alexander SP, Hill SJ. (1992) Adenosine A1-receptor 
stimulation of inositol phospholipid hydrolysis and calcium mobilisation in DDT1 
MF-2 cells. Br J Pharmacol. 106(1):215-21. 
Wieczorek DF, Jagatheesan G, Rajan S. (2008) The role of tropomyosin in heart 
disease. Adv Exp Med Biol. 644:132-42. 
273 
 
Wieczorek, DF. (2016) Tropomyosin: an effector of cardiac 
remodeling. International Journal of Medical and Biological Frontiers. 22(1), 1-17. 
Williams H, Pease RJ, Newell LM, Cordell PA, Graham RM, Kearney MT, Jackson CL, 
Grant PJ. (2010) Effect of transglutaminase 2 (TG2) deficiency on atherosclerotic 
plaque stability in the apolipoprotein E deficient mouse. Atherosclerosis. 
210(1):94-9. 
Woo AY, Xiao RP. (2012) β-Adrenergic receptor subtype signaling in heart: from 
bench to bedside. Acta Pharmacol Sin. 33(3):335-41. 
Wu D, Jiang H, Simon MI. (1995) Different alpha 1-adrenergic receptor sequences 
required for activating different G alpha subunits of Gq class of G proteins. J Biol 
Chem. 270(17):9828-32. 
Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, Trimble R, Roden DM, Passier R, 
Olson EN, Colbran RJ, Anderson ME. (2002) Calmodulin kinase II and arrhythmias 
in a mouse model of cardiac hypertrophy. Circulation. 106(10):1288-93. 
Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. (2002) Ischemic 
preconditioning suppresses ventricular tachyarrhythmias after myocardial 
revascularization. Circulation. 106(24):3091-6. 
Xi L, Das A, Zhao ZQ, Merino VF, Bader M, Kukreja RC. (2008) Loss of myocardial 
ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene 
knockout mice. Circulation. 118(14 Suppl):S32-7. 
Xia Z, Li H, Irwin MG. (2016) Myocardial ischaemia reperfusion injury: the 
challenge of translating ischaemic and anaesthetic protection from animal models 
to humans. Br J Anaesth. 117 Suppl 2:ii44-ii62. 
Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ. (2009) 
Direct activation of protein kinases by unanchored polyubiquitin chains. Nature. 
461(7260):114-9. 
Xiang F, Huang YS, Zhang DX, Chu ZG, Zhang JP, Zhang Q. (2010) Adenosine A1 
receptor activation reduces opening of mitochondrial permeability transition pores 
in hypoxic cardiomyocytes. Clin Exp Pharmacol Physiol. 37(3):343-9. 
Xiang Y, Kobilka B. (2003) The PDZ-binding motif of the beta2-adrenoceptor is 
essential for physiologic signaling and trafficking in cardiac myocytes. Proc Natl 
Acad Sci U S A. 100(19):10776-81. 
274 
 
Xiang Y, Kobilka BK. (2003) Myocyte adrenoceptor signaling pathways. Science. 
300(5625):1530-2.  
Xiang Y, Rybin VO, Steinberg SF, Kobilka B. (2002) Caveolar localization dictates 
physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. J Biol 
Chem. 277(37):34280-6. 
Xiang YK. (2011) Compartmentalization of beta-adrenergic signals in 
cardiomyocytes. Circ Res. 109(2):231-44. 
Xiao RP, Hohl C, Altschuld R, Jones L, Livingston B, Ziman B, Tantini B, Lakatta EG. 
(1994) Beta 2-adrenergic receptor-stimulated increase in cAMP in rat heart cells is 
not coupled to changes in Ca2+ dynamics, contractility, or phospholamban 
phosphorylation. J Biol Chem. 269(29):19151-6. 
Xiao RP, Ji X, Lakatta EG. (1995) Functional coupling of the beta 2-adrenoceptor to 
a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 
47(2):322-9. 
Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, Balke CW, Lakatta EG, 
Cheng H. (2003) Enhanced G(i) signaling selectively negates beta2-adrenergic 
receptor(AR)--but not beta1-AR-mediated positive inotropic effect in myocytes 
from failing rat hearts. Circulation. 108(13):1633-9. 
Xiao RP. (2001) Beta-adrenergic signaling in the heart: dual coupling of the beta2-
adrenergic receptor to G(s) and G(i) proteins. Sci STKE. 104:re15. 
Xiao, R. P., and E. G. Lakatta. (1993) "Beta 1-adrenoceptor stimulation and beta 
2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2 , and 
Ca2 current in single rat ventricular cells." Circulation Research 73(2): 286-300. 
Xin W, Tran TM, Richter W, Clark RB, Rich TC. (2008) Roles of GRK and PDE4 
activities in the regulation of beta2 adrenergic signaling. J Gen Physiol. 
131(4):349-64. 
Xu Z, Downey JM, Cohen MV. (2001) Amp 579 reduces contracture and limits 
infarction in rabbit heart by activating adenosine A2 receptors. J Cardiovasc 
Pharmacol. 38(3):474-81. 
Xu Y, Gu Q, Tang J, Qian Y, Tan X, Yu Z, Qu C. (2017) Substance P Attenuates 
Hypoxia/Reoxygenation-Induced Apoptosis Via the Akt Signalling Pathway and the 
NK1-Receptor in H9C2Cells. Heart Lung Circ 17(pii):31420-8. 
275 
 
Yabe K, Ishishita H, Tanonaka K, Takeo S. (1998) Pharmacologic preconditioning 
induced by beta-adrenergic stimulation is mediated by activation of protein kinase 
C. J Cardiovasc Pharmacol. 32(6):962-8. 
Yanagawa Y, Hiraide S, Matsumoto M, Shimamura K, Togashi H. (2014) Enhanced 
transglutaminase 2 expression in response to stress-related catecholamines in 
macrophages. Immunobiology. 219(9):680-6. 
Yang H, Raymer K, Butler R, Parlow J, Roberts R. (2006) The effects of 
perioperative beta-blockade: results of the Metoprolol after Vascular Surgery 
(MaVS) study, a randomized controlled trial. Am Heart J. 152(5):983-90. 
Yang X, Zheng J, Xiong Y, Shen H, Sun L, Huang Y, Sun C, Li Y, He J. (2010) Beta-
2 adrenergic receptor mediated ERK activation is regulated by interaction with 
MAGI-3. FEBS Lett. 584(11):2207-12. 
Yang Z, Sun W, Hu K. (2009) Adenosine A(1) receptors selectively target protein 
kinase C isoforms to the caveolin-rich plasma membrane in cardiac myocytes. 
Biochim Biophys Acta. 1793(12):1868-75. 
Yano N, Ianus V, Zhao TC, Tseng A, Padbury JF, Tseng YT. (2007) A novel 
signalling pathway for beta-adrenergic receptor-mediated activation of 
phosphoinositide 3-kinase in H9c2 cardiomyocytes. Am J Physiol Heart Circ Physiol. 
293(1):H385-93. 
Yates, L, Mardon, HL, Broadley, KJ (2003) Preconditioning against myocardial 
stunning by betaadrenoceptor stimulation with isoprenaline. 11th Meeting on 
Adrenergic Mechanisms, Porto, Portugal. Autonomic andAutacoid Pharmacology 23: 
P7. 
Yellon DM, Hausenloy DJ. (2005) Realizing the clinical potential of ischemic 
preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med. 2(11):568-75. 
Yeung PK, Kolathuru SS (2015) Therapeutic Potential of Adenosine Transport 
Modulators for Cardiovascular Protection. Cardiol Pharmacol 4:e127. 
Yu CH, Chou CC, Lee YJ, Khoo KH, Chang GD. (2015) Uncovering protein 
polyamination by the spermine-specific antiserum and mass spectrometric analysis. 
Amino Acids. 47(3):469-81. 
Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich 
KM. (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in 
the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. 
Oncogene. 26(18):2563-73. 
276 
 
Zainelli GM, Ross CA, Troncoso JC, Fitzgerald JK, Muma NA. (2004) Calmodulin 
regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci. 24(8):1954-
61. 
Zatta AJ, Kin H, Lee G, Wang N, Jiang R, Lust R, Reeves JG, Mykytenko J, Guyton 
RA, Zhao ZQ, Vinten-Johansen J. (2006) Infarct-sparing effect of myocardial 
postconditioning is dependent on protein kinase C signalling. Cardiovasc Res. 
70(2):315-24. 
Zaugg M, Schaub MC. (2008) Beta3-adrenergic receptor subtype signaling in 
senescent heart: nitric oxide intoxication or "endogenous" beta blockade for 
protection? Anesthesiology. 109(6):956-9. 
Zaugg M, Schaub MC. (2004) Cellular mechanisms in sympatho-modulation of the 
heart. Br J Anaesth. 93(1):34-52. 
Zaugg M, Schaub MC. (2005) Genetic modulation of adrenergic activity in the 
heart and vasculature: implications for perioperative medicine. Anesthesiology. 
102(2):429-46. 
Zhang J, Antonyak MA, Singh G, Cerione RA. (2013) A mechanism for the 
upregulation of EGF receptor levels in glioblastomas. Cell Rep. 3(6):2008-20. 
Zhang J, Lesort M, Guttmann RP, Johnson GV. (1998) Modulation of the in situ 
activity of tissue transglutaminase by calcium and GTP. J Biol Chem. 273(4):2288-
95. 
Zhang J, Zhi HY, Ding F, Luo AP, Liu ZH. (2005) Transglutaminase 3 expression in 
C57BL/6J mouse embryo epidermis and the correlation with its differentiation. Cell 
Res. 15(2):105-10. 
Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, 
Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, 
Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. (2005) Calmodulin 
kinase II inhibition protects against structural heart disease. Nat Med. 11(4):409-
17. 
Zhang W, Yano N, Deng M, Mao Q, Shaw SK, Tseng YT. (2011) β-Adrenergic 
receptor-PI3K signaling crosstalk in mouse heart: elucidation of immediate 
downstream signalling cascades. PLoS One. 6(10):e26581. 
Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-
Johansen J. (2003) Inhibition of myocardial injury by ischemic postconditioning 
277 
 
during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart 
Circ Physiol. 285(2):H579-88. 
Zhou P, Zhao YT, Guo YB, Xu SM, Bai SH, Lakatta EG, Cheng H, Hao XM, Wang SQ. 
(2009) Beta-adrenergic signaling accelerates and synchronizes cardiac ryanodine 
receptor response to a single L-type Ca2+ channel. Proc Natl Acad Sci U S A. 
106(42):18028-33. 
Zhou, T., Zhou, Z., Zhou, S., & Huang, F. (2016) Real-time monitoring of 
contractile properties of H9C2 cardiomyoblasts by using a quartz crystal 
microbalance. Analytical Methods  8(3), 488-495 
Zhou YY, Cheng H, Bogdanov KY, Hohl C, Altschuld R, Lakatta EG, Xiao RP. (1997) 
Localized cAMP-dependent signaling mediates beta 2-adrenergic modulation of 
cardiac excitation-contraction coupling. Am J Physiol. 273(3 Pt2):H1611-8. 
Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, Devic E, Kobilka BK, 
Cheng H, Xiao RP. (2003) Linkage of beta1-adrenergic stimulation to apoptotic 
heart cell death through protein kinase A-independent activation of 
Ca2+/calmodulin kinase II. J Clin Invest. 111(5):617-25. 
Zhu HL, Wei X, Qu SL, Zhang C, Zuo XX, Feng YS, Luo Q, Chen GW, Liu MD, Jiang 
L, Xiao XZ, Wang KK. (2011) Ischemic postconditioning protects cardiomyocytes 
against ischemia/reperfusion injury by inducing MIP2. Exp Mol Med. 43(8):437-45. 
Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. (2001) Dual 
modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult 
mouse cardiac myocytes. Proc Natl Acad Sci U S A. 98(4):1607-12. 
Zordoky BN, El-Kadi AO. (2007) H9c2 cell line is a valuable in vitro model to study 
the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods. 
56(3):317-22. 
 
 
 
 
 
 
 
278 
 
Appendix 
Transfection with siRNAs: 
H9c2 cells were seeded in 6-well flat-bottomed plates (45,000 cells/well) and cultured 
for 24 h in fully supplemented DMEM. Cells were transfected using the Accell siRNA 
delivery system (Dharmacon, Lafayette, CO). Briefly, the medium was removed and 
replaced with Accell delivery medium containing either TG2-specific siRNA targeting 
ORF of rat TG2 mRNA, positive control (GAPDH-targeting siRNA) or negative control 
(non-targeting control siRNA; Dharmacon, Lafayette, CO). Cells were incubated for 24, 
48 and 72 h in the same media and following incubation, cells were lysed and 
subjected to western blotting as described in chapter II section 2.6 to detect TG2 and 
GAPDH. β-actin was used as loading control in these experiments. 
Western blot analysis revealed that at 72 h, 39.25 ± 4.29 knockdown of TG2 protein 
expression was achieved (figure A.1) and therefore this time point would be suitable 
for future experiments. GAPDH siRNA was used as a positive control to check if the 
siRNA delivery mechanism was working. At 72 h, 36.57 ± 3.76 knockdown of GAPDH 
protein expression was achieved (figure A.1). It should also be noted that there was 
no significant difference between growth media and delivery media for either TG2 (84% 
of control) or GAPDH (92% of control) protein expression and the β-actin expression 
was unaltered in all conditions. 
 
 
 
 
 
 
 
 
 
 
Fig A.1: Protein expression of TG2 and GAPDH in H9c2 cells. Cell lysates (15 μg) from 
mitotic H9c2 cells treated with growth media (GM), delivery media (DM), negative 
control siRNA (NC), TG2 specific (A) and GAPDH specific (B) siRNAs for 72 h were 
analysed for TG2 and GAPDH protein expression by western blotting. Quantified data 
are expressed as percentage of control for TG2 and GAPDH protein expression relative 
to β-actin and represent the mean  S.E.M. from three independent experiments.  
